US9642809B2 - Controlled release pharmaceutical compositions for prolonged effect - Google Patents

Controlled release pharmaceutical compositions for prolonged effect Download PDF

Info

Publication number
US9642809B2
US9642809B2 US14/446,234 US201414446234A US9642809B2 US 9642809 B2 US9642809 B2 US 9642809B2 US 201414446234 A US201414446234 A US 201414446234A US 9642809 B2 US9642809 B2 US 9642809B2
Authority
US
United States
Prior art keywords
active substance
release
composition
daltons
inner layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US14/446,234
Other versions
US20150024048A1 (en
Inventor
Pernille Hoyrup Hemmingsen
Anders Vagno Pedersen
Daniel Bar-Shalom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egalet Ltd
Original Assignee
Egalet Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egalet Ltd filed Critical Egalet Ltd
Priority to US14/446,234 priority Critical patent/US9642809B2/en
Publication of US20150024048A1 publication Critical patent/US20150024048A1/en
Assigned to U.S. BANK NATIONAL ASSOCIATION reassignment U.S. BANK NATIONAL ASSOCIATION SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EGALET CORPORATION, EGALET LTD, EGALET US, INC.
Assigned to EGALET LTD. reassignment EGALET LTD. CHANGE OF ADDRESS Assignors: EGALET LTD.
Application granted granted Critical
Publication of US9642809B2 publication Critical patent/US9642809B2/en
Assigned to ZYLA LIFE SCIENCES, F/K/A EGALET CORPORATION, EGALET LIMITED, ZYLA LIFE SCIENCES US INC., F/K/A EGALET US, INC. reassignment ZYLA LIFE SCIENCES, F/K/A EGALET CORPORATION RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: U.S. BANK NATIONAL ASSOCIATION
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/2853Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Definitions

  • the present invention relates to a technology that is especially suitable for designing oral pharmaceutical compositions that are useful in the treatment of diseases where absorption e.g. takes place over a large part of the gastrointestinal tract (e.g. in stomach, the small intestine as well as in the colon). Accordingly, the present invention provides a composition that enables a first release of the active substance (e.g. a burst or a controlled release) followed by a second release of the same active substance (e.g. a burst or a controlled release).
  • the design of the composition takes into account the fact that different conditions are present in different parts of the gastrointestinal system. Thus, e.g.
  • compositions of the present invention may also be suitable in the treatment of diseases in which circadian rhythm or biorhythm effects can influence the condition being treated or when an effective therapy is desired e.g. in the early morning before awakening or when the active substance have a narrow absorption window or the absorption is poor e.g. in the colon or for local effect/treatment.
  • compositions are periodically produced in vivo at certain time intervals and it may accordingly be desirable to administer such substances in a controlled release formulation which periodically releases the active substance at predetermined time intervals to obtain certain fluctuation in the drug level which may be desirable in connection with the treatment of various diseases.
  • the present technology provides a means for designing such compositions and moreover, such compositions may be combined with an initiated burst release and/or zero order controlled release of the active substance.
  • the active substance may exert its effect locally in the colon or other parts of the gastrointestinal system, such as for treatment of cancer, inflammation, gastrointestinal diseases and treatment with anthelmintic agents.
  • FIG. 1 illustrate double burst unit, with a delay between the two bursts.
  • FIG. 2 illustrate simple combination formulation
  • FIG. 3 releases of Hydrocodone and Morphine with burst-controlled release behaviour see preparation 4.
  • FIG. 4 releases of Oxycodone and Morphine with controlled-controlled release behaviour see preparation 5.
  • FIG. 5 illustrate double burst unit, with a delay between the two bursts.
  • FIG. 6 release of Paracetamol with double burst release behaviour see example 2.
  • FIG. 7 illustrate unit exhibiting controlled-burst or burst-burst release behaviour.
  • FIG. 8 release of Morphine with controlled-burst release behaviour see example 3.
  • FIG. 9 release of Morphine with controlled-burst release behaviour see example 4.
  • FIG. 10 illustrate unit exhibiting controlled-controlled or burst-controlled release behaviour.
  • FIG. 11 release of Morphine with controlled-controlled release behaviour see example 5.
  • FIG. 12 release of Morphine pellets see example 5.
  • FIG. 13 release of Morphine with controlled-controlled release behaviour see example 6.
  • FIG. 14 release of Morphine with burst-controlled release behaviour see example 7.
  • FIG. 15 illustrate burst-lag-burst release characteristics.
  • FIG. 16 illustrate burst-controlled-burst release characteristics.
  • FIG. 17 illustrate burst-controlled release characteristics.
  • FIG. 18 illustrate controlled-burst release characteristics.
  • FIG. 19 illustrate lag-burst release characteristics.
  • FIG. 20 illustrate controlled-controlled release characteristic
  • FIG. 21 illustrate controlled-controlled release characteristic
  • FIG. 22 illustrate releases of two active substances with the same release characteristics.
  • FIG. 23 illustrate releases of two active substances with different release characteristics.
  • FIG. 24 illustrate releases of two active substances with sequential release characteristics.
  • a further advantage could be a technology that enables variation in the design in a relatively easy manner such that the composition also includes e.g. a burst dose or controlled release dose (of different active substance).
  • the present invention provides such a technology.
  • the technology is a further development of the Applicant's proprietary technology described in WO 99/51208, WO 03/24426, WO 03/24429, WO 03/24430, WO 2004/41252, WO 2004/84869, WO 2005/107713, WO2006/128471 that is based on matrix compositions comprising a substantially water soluble and/or crystalline polymer.
  • WO 2006/128471 that relates to a composition having an inner part of a composition that liquefies at body temperature sandwiched between two matrix compositions.
  • the liquefied inner part is designed to flow out of the shell that surrounds the cylindrical part of a cylindrical shaped composition (i.e. the shell (or coating) covers the cylindrical surface, but not the end surfaces).
  • the active substance in the inner part should be immediately released once the matrix parts are eroded.
  • the present inventors have observed that the outflow of the liquefied inner part is not that easy, e.g. in situations where the composition reaches the large intestine or the colon.
  • the present invention provides an extended release composition for prolonged effect and a way to ensure prolonged effect e.g. once daily administration is to ensure optimal absorption of the active substance though the gastrointestinal tract i.e. from the stomach to rectum.
  • a relatively fast release of the active substance is an advantage when the controlled release composition enter this part of the tract and especially in those cases where the active substance is poorly absorbed in the distal part of the small intestine or in ascending and first part of the transverse colon.
  • a release composition having controlled release follow by immediate release behavior is desirable for optimal absorption and effect.
  • a composition having controlled release follow by immediate release of the active substance is also an advantage when the active substance is poorly soluble and therefore requires a substantial amount of water/fluid to dissolve in the distal part of the small intestine before it enters colon for absorption.
  • Controlling the release of the active substance from the composition and thereby the absorption of the active substance makes it possible to control the blood level of the active substance and maintain the concentration within the therapeutic range over an extended period of time without high peak trough fluctuation which improve the therapeutic effect and reduced incidence of side effects.
  • Another advantage relating to the present invention is the possibility of administering the two active substances at the same time and advantageous in the same pharmaceutical composition.
  • a combination treatment is expected to have optimized effect with respect to each of the two substances at different points in time it is important to incorporate the two active substances in the composition in such a manner that
  • the present invention relates to a layered pharmaceutical composition
  • a layered pharmaceutical composition comprising A) a solid inner layer comprising
  • each outer layer comprising
  • layer A comprises
  • the present invention is a further development of the Applicant's proprietary technology, namely preparation of pharmaceutical compositions based on a water soluble and/or crystalline polymer or mixture of such polymers involving a step of melting or softening the polymer by means of injection moulding, extrusion or the like.
  • the injection moulding technique has the advantage of simultaneous mixing and heating the components during increased pressure in a one step procedure without exposure to air and moisture because the injection moulding is performed in a single closed compartment from the time a blend of the components has entered the machine to the final pharmaceutical units are ejected ready for packaging. More details regarding the preparation method are given below and in the experimental section.
  • the invention concerns a layered pharmaceutical composition having an inner layer with the active substance sandwiched between two lag-time providing layers, i.e. layers that enable a delay in the release of the active substance contained in the inner layer.
  • the layered composition is coated in such a manner that only a surface layer from the outer layer(s) is free of coating material.
  • the composition has a cylindrical shape and then the cylindrical surface is coated leaving one or two of the end surfaces without any coating (normally both end surfaces are without coating).
  • the present inventor's have found that the following two properties are important, namely the geometry and dimensions of the composition and the present of a disintegrant and/or an effervescent agent (or couple).
  • the first parameter ensures that the distance to travel for the inner layer is not too big compared with the size of the opening (i.e. the end surface) and the other one ensures that a driving force activates the mobility of the active substance in layer A) when it comes into contact with a body liquid.
  • a further parameter has also a positive influence in order to enable a release of the active substance from layer A), namely the incorporation of the active substance in readily flowable multiple units.
  • the lag-time mechanisms (and the release mechanics of any active substance contained in the outer layers) described above depends on the geometry of the composition.
  • erosion based release from a matrix depends on the exposed area of the matrix.
  • the area may be manipulated by employment of a coat that is not subject to erosion and thus covering the areas of the matrix that hence will not be a releasing site.
  • a cylindrical composition with the two ends exposing the eroding matrix will give rise to zero order release because the releasing area is constant.
  • the geometric form of the composition is very important for the obtainment of the above-mentioned controlled release.
  • the pharmaceutical composition has a geometric shape, which enables a substantially constant surface area to become exposed during erosion of the matrix.
  • the present inventors have found that the proportions between the surface area of the end surface and the length of the cylinder are important in order to ensure that the active substance (or, if relevant, of the multiple unit formulation containing the active substance) can be released from the inner part. Specific examples appear from the examples herein.
  • the following ratio between the surface area of one end surface and the length of the cylinder has been found to be suitable in order to ensure a proper release: from about 0.02 to about 45 mm such as, e.g., from about 0.1 to about 10 mm or from about 0.5 to about 8 mm.
  • the composition of the invention has two end surfaces, and, if the ratio is calculated on the total surface area of the end surfaces, then the ratio is from about 0.02 to about 85 mm such as, e.g., from about 0.1 to about 10 mm or from about 1.3 to about 14 mm.
  • the compositions employed are coated in such a manner that the surface has a substantially constant or controlled surface area during release or erosion.
  • controlled surface area relates to a predetermined surface area typically predicted from the shape of the coat of the unit dosage system. It may have a simple uniform cylindrical shape or the cylindrical form can have one or more tapered ends in order to decrease (or increase) the initial release period.
  • the release will furthermore depend on the thickness of the diffusion layer and in this case the release will depend both on the diffusion area and thickness of the diffusion system.
  • the release mechanism of dissolving/solubilization also depend on the releasing area and the release rate may be controlled by covering parts of the releasing matrix by a coat. Controlling the coverage of the matrix by the coat hence refers to covering from 0 to 100% of the matrix by a coat.
  • the object of the present invention is to design a composition comprising an active substance that is released after a certain period of time (e.g. burst release followed by controlled release, controlled release followed by burst release, controlled release followed by controlled release, burst release followed by burst release).
  • a certain period of time e.g. burst release followed by controlled release, controlled release followed by burst release, controlled release followed by controlled release, burst release followed by burst release.
  • aqueous medium e.g. the gastrointestinal fluids after oral administration
  • various types of release of the active substance can be obtained ranging from immediate release (e.g. the active substance is readily available for release such as e.g. present in dissolved form in a form that is easily dissolvable) to controlled release (e.g. in the form of pellets designed to controlled release or other well-known types of formulations including beads, flakes, mini-tablets, granules, microspheres, nanoparticles, crystals or the like).
  • the shell (coating) has properties that ensure exposure of a well-defined (normally constant or substantially constant) surface area of the composition to the surrounding medium so that the outer layer(s) can be eroded with a constant rate until the layer(s) are eroded away, it is important that the shell remains intact until the outer layer(s) have eroded.
  • the inner layer may be formulated such that it disintegrates upon contact with water.
  • the disintegration may be by a mechanism of exploding, by effervescence, by swelling, by rapid erosion or combinations thereof.
  • the disintegration by exploding may be governed by rapid water influx into- and swelling of one or several of the matrix components leading to a collapse of the inner layer structure (normally a matrix structure) such that the active substance may be released or such that e.g. multiple units, crystals etc. containing the active substance may be released.
  • the multiple units may be designed as quick release (/burst release/immediate release) multiple units or controlled release multiple units for release of the active substance in the small intestine and/or colon.
  • the disintegration may be by means of swelling.
  • the inner layer comprises an excipient (here a disintegrant), which swells rapidly upon contact with aqueous media makes it possible to push the active substance or active multiple units out of the shell.
  • the detachment of the active matrix should be in smaller lumps with a large area-to-volume ratio.
  • the “release” of the inner layer may be aided by incorporation of e.g. a disintegrant also called swelling and/or exploding agent.
  • a disintegrant typically swells upon contact with water and enable disruption of the inner layer to agglomerates or particle.
  • Suitable disintegrants include Sodium starch glycolate, Povidone, Sodium alginate, Alginic acid, Calcium alginate, Carboxymethylcellulose calcium, Carboxymethylcellulose sodium, Powdered cellulose, Chitosan, Croscarmellose sodium, Crospovidone, Hydroxypropyl starch, Hydroxypropyl cellulose low-substituted, Magnesium aluminium silicate, Methylcellulose, Microcrystalline cellulose, pregelatinized starch, Docusae sodium, Guar gum, Polacrilin potassium.
  • the disintegration may also be due to an effervescent effect, whereby gas such as CO 2 is released from the inner layer upon contact with water and a rapid dissolving system is formed.
  • gas such as CO 2
  • the formation of gas bubbles will push the inner layer out in small lumps and thereby manifold increase the exposed area of the inner layer (e.g. containing active substance, active multiple units or the like) to the medium.
  • active substance active multiple units or the like
  • sodium bicarbonate releases CO 2 by reaction with water in an acidic environment. It is possible to develop a more pH-robust formulation by adding an acidic excipient to the formulation. The rate of which the gas formation occurs depends on the rate of hydration and diffusion of water into the matrix.
  • “Release” of the inner layer may also take place by means of gas formation using effervescent substances or effervescent couples.
  • suitable effervescent agent include Effer-Soda, Citric acid, monohydrate, Dextrates, Fumaric acid, Potassium bicarbonate, Sodium bicarbonate, Sodium citrate dehydrate, Tartaric acid.
  • Disintegration may also take place by rapid erosion, which can be obtained by employing for example short chained polymers in the matrix, such that the matrix is readily wetted and dissolved exposing either the active multiple units or the matrix component(s) containing the active substance.
  • disintegration might be facilitated by facilitating water transport through the matrix by for example open pores.
  • the inner layer A) without B) and C) disintegrates within at the most 60 min such as, e.g., at the most about 30 min or at the most about 15 min, when subjected to a disintegration test according to Ph. Eur.
  • the concentration of the one or more disintegrants, exploding agent and/or effervescent agent in the inner layer is from about 5% w/w to about 80% w/w such as, e.g., from about 10% w/w to about 70% w/w, from about 15% w/w to about 60% w/w or from about 20% w/w to about 50% w/w.
  • One or more pharmaceutically acceptable excipients or additives may also be present in inner layer A) (see the section “Pharmaceutically acceptable excipients”)
  • the inner layer A) may also contain a polymer.
  • the layer A may also contain a polymeric substance (as a dispersion medium for the active substance), but in this case, it is important that the polymeric substance has different properties from that used in layer B).
  • a polymeric substance as a dispersion medium for the active substance
  • the notation “matrix polymer” is used to indicate that the polymer is suitable for use in layer B) and in multiple units
  • the notation “layer A polymer” is used to indicate that the polymer is suitable for use as a dispersion medium or excipient in layer A.
  • Suitable polymers for use according to the invention typically comprises a polyglycol, e.g. in the form of a homopolymer and/or a copolymer.
  • the polymer is substantially water soluble, thermoplastic, crystalline, semi-crystalline or amorphous or a mixture of substantially water soluble, crystalline, semi-crystalline or amorphous polymers.
  • Suitable polymers for use in a composition according to the invention are polyethylene glycols, including derivatives such as mono and dimethoxypolyethylene glycols (mPEGs) polyethylene oxides and/or block copolymers of ethylene oxide and propylene oxide.
  • Polyethylene glycols are linear polydisperse polymers composed of repeating units of ethylene glycol. Their chemical formula is HOCH 2 [CH 2 OCH 2 ] m CH 2 OH where m represents the average number of repeating units.
  • H[OCH 2 CH 2 ] n OH may be used to represent polyethylene glycol, where n is a number m in the previous formula+1. See the structural presentations of polyethylene glycol below. n is the average number of oxyethylene groups. n equals m+1.
  • Polyethylene oxides are linear polydisperse nonionic polymers composed of repeating units of ethylene oxide. Their chemical formula is HO[CH 2 CH 2 O] n H where n represents the average number of oxyethylene groups. See the structural presentation of polyethylene oxide below. n is the average number of oxyethylene groups. Depending on preparation method high molecular weigh PEO may have one terminal methyl group.
  • Polyethylene glycols are mixtures of addition of ethylene glycol.
  • PEG refers to polymers chains with molecular weights below 20,000
  • PEO refers to higher molecular weights polymers.
  • PEO refers to higher molecular weights polymers.
  • Poloxamers are copolymers or block copolymers and are a range of non-ionic surfactants of polyethylene glycol (PEG) and polypropylene glycol (PPG).
  • Diol EO/PO block copolymers are described under the scientific name—hydroxy-hydroxypoly(oxyethylene)poly(oxypropylene)-poly(oxyethylene)-block copolymer in combination with the CAS register number.
  • a suitable poloxamer for use in a composition of the invention has a HLB value of at least about 18 such as, e.g., at least about 20.
  • the mean molecular weight of a suitable poloxamer is typically at least about 2,000.
  • the polymer has a melting point higher than the body temperature of the human in which the composition is to be used.
  • the polymer(s) employed in the matrix composition will suitably have a melting point of about 20-120° C. such as, e.g. from about 30 to about 100° C. or from about 40 to about 80° C.
  • polymers of a polyglycol type as described above may be suitable for use in a pharmaceutical composition provided that the solubility and/or release rate of the active substance from the composition in water is higher than or equal to the solubility of the matrix in 40% w/w ethanol in water.
  • the polymer or an additional polymer to the polyglycol may be selected from one or more of the following polymers: modified or unmodified water soluble natural polymers such as glucomannan, galactan, glucan, polygalacturonic acid, polyxylane, polygalactomannans, rhamnogalacturonan, polyxyloglycan, arabinogalactan, and starch, cellulose, chitosan, alginate, fibrin, collagen, gelatin, hyaluronic acid, amylopectin, pectin including low methylated or methoxylated pectins, dextran and fatty acids and alcohols; synthetic polymers such as polyvinylpyrrolidone (PVP), PVA, PVB, Eudragit L methyl ester, Eudragit L, Eudragit RL, Eudragit E, Eudragit S, PHPV, PHA, PCL, PLGA and PLA; and hydrogels made from the following polymers: modified or unmodified
  • layer A) comprises v) a substantially water soluble and/or crystalline polymer or a mixture of substantially water soluble and/or crystalline polymers, the polymer being a polyglycol in the from of one of c) a homopolymer having a MW of at the most about 16,000 daltons, and d) a copolymer having a MW of at the most about 30,000 daltons.
  • the polymer comprises a homopolymer having a MW of at least about 1,000 daltons such as, e.g., a homopolymer having a MW in a range from about 1,000 to about 15,000 daltons, from about 1,000 to about 12,000 daltons, from about 1,500 to about 10,000 daltons, from about 1,500 to about 8,000 daltons.
  • the polymer may also comprise a co-polymer having a MW of at the most about 25,000 daltons such as, e.g., at the most about 20,000 daltons, at the most about 15,000 daltons, at the most about 10,000 daltons, at the most about 5,000 daltons, at the most about 2,000 daltons.
  • Polyethylene glycols and/or polyethylene oxides which are suitable for use in the matrix composition are those having a molecular weights of from about 20,000 daltons, such as, e.g., from about 20,000 to about 700,000 daltons, from about 20,000 to about 600,000 daltons, from about 35,000 to about 500,000 daltons, from about 35,000 to about 400,000 daltons, from about 35,000 to about 300,000 daltons, from about 50,000 to about 300,000 daltons, such as, e.g. about 35,000 daltons, about 50,000 daltons, about 75,000 daltons, about 100,000 daltons, about 150,000 daltons, about 200,000 daltons, about 250,000 daltons, about 300,000 daltons or about 400,000 daltons.
  • 20,000 daltons such as, e.g., from about 20,000 to about 700,000 daltons, from about 20,000 to about 600,000 daltons, from about 35,000 to about 500,000 daltons, from about 35,000
  • the matrix polymer is a polyethylene oxide or a polyethylene glycol that has a molecular weight of about 20,000 daltons, about 35,000 daltons, about 50,000 daltons, about 100,000 daltons, about 200,000 daltons, about 300,000 daltons and about 400,000 daltons.
  • PEG is commercially available with average molecular weights up to 35 000.
  • PEO is commercially available with average molecular weights up to 8,000,000.
  • the polymer is a PEO having a molecular weight of at least about 100,000 such as, e.g., from about 100,000 to about 8,000,000, from about 100,000 to about 7,000,000, from about 100,000 to about 5,000,000, from about 100,000 to about 4,000,000, from about 100,000 to about 2,000,000, from about 100,000 to about 1,000,000, form about 100,000 to about 900,000.
  • PEO typically has a molecular weight as mentioned in the preceding paragraph.
  • Commercially available PEOs with a molecular weight in the higher end have typically the following molecular weights: about 900,000, about 1,000,000, about 2,000,000, about 4,000,000, about 5,000,000, about 7,000,000, about 8,000,000.
  • Typical block copolymers of ethylene oxide and propylene oxide have a molecular weight of from about 2,000 daltons, typically about 3,000 to about 30,000 daltons such as, e.g. from about 4,000 to about 15,000 daltons. If the copolymer is the sole thermoplastic polymer present in the composition it must not bee too brittle in order to avoid abuse by crushing of the composition, i.e. it must have an HLB value of about 18 to about 24.
  • the polymer may also be a mixture of the above-mentioned polymers.
  • concentration of the polymer(s) in layer A) when applied is from about 1 to about 99.9% w/w dependent on the desired release properties relating to the release of the active substance from the inner layer.
  • a relative fast release of the active substance or multiple units e.g. a pellet composition or the like containing the active substance
  • a relative low concentration of the polymer may be of interest such as, e.g.
  • the concentration of the polymer in layer A) may be such as from about 10 to about 95% w/w, from about 15% to about 90% w/w, such as from 20 to 85%, such as from 30% to 85% from about 30 to about 99% w/w such as, e.g., from about 35 to about 95% w/w, from about 35 to about 90% w/w, from about 35 to about 85% w/w, from about 35 to about 80% w/w, from about 40 to about 75% w/w, from about 45 to about 70% w/w, from about 45 to about 65% w/w. from about 55 to about 85% w/w or from about 60 to about 85% w/w.
  • One or more polymers are typically present in a composition of the invention in a concentration amount of from 5 to 99.9% w/w such as from 10 to 95% such as from 15% to 90%, such as from 20 to 85%, such as from 30% to 85% calculated as w/w % of the composition.
  • the concentration of an individual polymer in the composition may typically be from about 0% to about 95% w/w such as, e.g., from about 0.5% to about 90% w/w, from about 1% to about 90% w/w, from about 5% to about 90% w/w, from about 10% to about 90% w/w, from about 10% to about 80% w/w, from about 10% to about 70% w/w, from about 10% to about 60%, from about 10% to about 50%, from about 15% to about 50% w/w, from about 15% to about 45% w/w, from about 15% to about 40% w/w, from about 20% to about 40% w/w, from about 20% to about 35% w/w or from about 20% to about 30% w/w.
  • the concentration is even lower such as from about 1% to about 15% w/w or from about 5% to about 15% w/w.
  • the total concentration of the polymers (notably the sum of homo- and copolymers of the polyglycol type) in the composition is typically from about 5 to about 99.9% w/w such as from about 10 to about 95% w/w, from about 15% to about 90% w/w, such as from 20 to 85%, such as from 30% to 85% from about 30 to about 99% w/w such as, e.g., from about 35 to about 95% w/w, from about 35 to about 90% w/w, from about 35 to about 85% w/w, from about 35 to about 80% w/w, from about 40 to about 75% w/w, from about 45 to about 70% w/w, from about 45 to about 65% w/w.
  • the concentration is even lower such as from about 5% to about 40% w/w or from about 5% to about 35% w/w.
  • the concentration of the polyglycol homopolymer is typically from about 0.5 to about 99.9% w/w such as from 5 to about 99.9% w/w, from about 0.5% to about 90% w/w, from about 1% to about 90% w/w, from about 5% to about 90% w/w, from about 20 to about 90% w/w, from about to about 90% w/w, and, in those cases where the homopolymer is the only thermoplastic polymer present in the composition, then the concentration is normally from about 50 to about 95% w/w such as, e.g. from about 55 to about 90% w/w, from about 60 to about 90%, from about 65 to about 90%, from about 70% to about 90% or from about 70 to about 85% w/w. In specific embodiments, the concentration is even lower such as from about 1% to about 15% w/w or from about 5% to about 15% w/w.
  • the concentration of the polyglycol copolymer, if present in combination with a polyglycol homopolymer, is typically from about 1 to about 60% w/w such as, e.g. from about 2.5 to about 50% w/w, from about 5 to about 45% w/w. If the copolymer is the sole thermoplastic polymer in the composition the concentration may be from about 5 to about 99.5% w/w such as those ranges described above and described for the homopolymer. In specific embodiments, the concentration is even lower such as from about 1% to about 15% w/w or from about 5% to about 15% w/w.
  • the weight ratio (PEO/poloxamer) is normally in a range from about 10:0.1 to about 0.1:10 such as, e.g., from about 10:1 to about 1:10, from about 5:1 to about 1:5 or from about 3:1 to about 1:3.
  • the one or more, the same or different active substance in the inner layer may be designed to various types of release once the inner layer is “released” from the shell.
  • the inner layer contains the active substance incorporated into a multiple unit formulation or it may be present in the form of relatively large crystals (i.e. 100 ⁇ m or more).
  • the active substance may be present in many forms in the inner layer. Thus, it may be present in dissolved form, e.g. dissolved in the ingredients of the inner layer such as in the form of a solid dispersion or solid solution. It may also be present in solid form e.g. in the form of particles or crystals of the active substance. Moreover, the active substance may be incorporated into a formulation before it is incorporation into the inner layer. Such formulations are described in the following including multiple units. In such a formulation, the active substance may be present in solid or dissolved form as well.
  • the multiple units for use according to the invention may be crystals of an active substance, inert cores coated with active substance—inert cores like e.g.
  • the shape of the multiple units may be any suitable shape including a rounded or oval shape as well as a polygonal or rod-like or flake-like shape.
  • the mean particle size of the multiple units is at the most about 1400 ⁇ m.
  • the particle size of the multiple units is at the most about 1200 ⁇ m such as, e.g., at the most about 1100 ⁇ m, at the most about 1000 ⁇ m, at the most about 900 ⁇ m, at the most about 800 ⁇ m, at the most about 750 ⁇ m, at the most about 700 ⁇ m, at the most about 650 ⁇ m, at the most about 600 ⁇ m, at the most about 550 ⁇ m or at the most about 500 ⁇ m; such as, e.g., from about 150 ⁇ m to about 1200 ⁇ m, from about 200 ⁇ m to about 1200 ⁇ m, from about 200 ⁇ m to about 1000 ⁇ m, from about 250 ⁇ m to about 800 ⁇ m or from about 300 ⁇ m to about 750 ⁇ m.
  • the particle size of the multiple units is at the most about 500 ⁇ m to about 1000 ⁇ m, or from about 350 ⁇ m to about 500 ⁇ m. In some cases, the particle size of the multiple units may be even higher. Thus, in some cases the particle size may be at the most about 2 mm.
  • the release of the active substance may take place by diffusion by which the rate of release depends on several mechanisms, for example: the concentration difference between the matrix active substance concentration and the bulk concentration, the release surface area and the diffusion constant of the drug substance in the matrix. In special cases diffusion controlled release may be zero order.
  • the release of the active substance may take place.
  • the release of the active substance from the inner layer may follow a kinetic that is different from a zero order release.
  • the present formulation principle is designed to delay the release not necessarily to enable a zero order release or other types of release kinetics that are relevant when designing controlled or modified release compositions.
  • the basic formulation principle of the present invention may be combined with known formulation principles e.g. if an active substance also is included in the matrix of the outer layer B), then this active substance can be released by zero order kinetics, i.e. in a controlled manner, and the active substance contained in the first fraction is released once exposed to the gastrointestinal fluids (or another aqueous medium) or in a controlled manner, but once the release of active substance or active multiple units from the first fraction starts it may be relatively fast.
  • the outer layers of a composition according to the invention are typically based on the matrix principle disclosed in WO 99/51208, WO 03/24426, WO 03/24429, WO 03/24430, WO 2004/41252, WO 2004/84869, WO 2005/107713, WO2006/128471 (to the same applicant).
  • Such matrices have unique properties in that they erode, i.e. it does not disintegrate into smaller particles or conglomerates of particles upon exposure to the gastrointestinal fluid. Simplified, erosion means that a layer is eroded from the composition into the surrounding medium almost as if a slice of the matrix is cut off.
  • the outer layers contain the same active substance as the inner layer A) to ensure optimal absorption of the active substance though the gastrointestinal tract a way to prolong the effect of e.g. a once-daily dosage form.
  • each of the outer layers B1) and B2) comprises iii) a substantially water soluble and/or crystalline polymer or a mixture of substantially water soluble and/or crystalline polymers, the polymer being a polyglycol in the from of one of a) a homopolymer having a MW of at least about 100,000 daltons, and b) a copolymer having a MW of at least about 2,000 daltons,
  • the layers B1) and B2) may have the same or different composition and in a cylindrical shaped composition they may have the same or different size. In a preferred embodiment, the composition and size of the two B) layers are the same.
  • Suitable polymers for use in the outer layers are described in detail in the section above. However, with respect to the outer layer, it is important to ensure a control of the rate with which the outer layer disappears from the composition once it is exposed to an aqueous medium.
  • the outer layers are composed in such a manner that the outer layer leaves the composition with a constant rate (corresponding to a zero order release rate in the event that a drug substance was present in the layer).
  • a constant rate can be achieved by use of one or more polyglycols, but in contrast to the polymers suitable for used in the inner layer A), the homopolymer should preferably have a much higher molecular weight in order to ensure a constant erosion rate of the outer layer.
  • a co-polymer is employed preferably one or more of another polymer is included in the outer layer in order to obtain a suitable constant erosion rate.
  • the polymer composition of the outer layer(s) B is different from the polymer composition of the inner layer A).
  • One or more pharmaceutically acceptable excipients or additives may also be incorporated into the outer layer(s), see the section herein. However, it is important that such excipients or additives do not significantly change the manner in which the outer layer disappears from the composition, i.e. it is important that this disappearance still is by a substantially constant rate e.g. by erosion or diffusion; addition of such substances may have impact on the rate (e.g. slow down or increase the rate), but it must not significantly change the properties of the outer layer B) so that the function as a “controlled lag-time layer provider” is destroyed.
  • the outer layer B) may also contain one or more second active substances.
  • a second active substance in layer B) will be a different substance from that contained in layer A) in order to achieve a suitable combination treatment with two of more different active substance, one of which with a desired controlled release following a zero order release (the one contained in the outer layer B)) and the other one contained in the inner layer and designed for immediate release (or, alternatively, as detailed described under the section “Inner layer”, as a controlled release composition e.g. with zero or 1st order release).
  • the layered composition is provided with a coating C) that has at least one opening exposing at least one surface of said outer layer (layer B), the coating being substantially insoluble in and impermeable to fluids and comprising a polymer.
  • a composition according to the invention may be provided with a coating that can be applied in such a manner that it leaves a well-defined surface area free of coating while the remaining surface is covered and at the same time ensuring that the coating fulfils the requirement that no transport of water into the matrix (or other parts of the composition) takes place through the coating (or, if any water should enter, then it does not result in a transport of dissolved active substance out through the coating).
  • a coating that does not leave an uncontrollable surface area of the matrix exposed to the aqueous environment and that has suitable properties compared to the matrix, i.e.
  • the coating dissolves or otherwise disappears then it should only take place after the matrix has eroded or dissolved away (during the release period, the coating may of course also partly dissolve or disappear provided that the part it concerns covered a part of the matrix that has already been subject to erosion or diffusion, thus, leaving the remaining composition “intact” with a matrix that is surrounded by the coating apart from the open end from which erosion or diffusion of the matrix takes place).
  • the composition may be partly or fully covered by a coat with specific properties in such a way that the exposed area of the matrix may be controlled by the use of a coat.
  • the coat is substantially insoluble, non-erodible and non-permeable to water leaving only the exposed areas of the composition for release.
  • a coat may be composed of a polymer that has thermoplastic properties. Examples of such materials are mentioned below including cellulose derivative which has thermoplastic properties, plasticizer or plasticizers and/other functional excipients.
  • the coating may also be a coating, which is substantially soluble in and permeable to fluids such as body fluids during the intended release period provided that the coating dissolves so much slower than the matrix composition that the coating remains intact until the matrix has eroded and/or released the inner layer containing an active substance.
  • suitable polymers include polyglycols as described herein.
  • the coating may further comprise any of the mentioned matrix materials (i.e. polymeric material suitable for use in the outer layers B) in a form, which erodes at a substantially slower rate than the rest of the matrix.
  • the coating may thus comprise a matrix of one or more substantially water soluble crystalline polymers and, optionally, a non-ionic emulsifier, the coating being one which is eroded in the aqueous phase at a substantially slower rate than the outer layer B, whereby a substantially controlled area of the outer layer B matrix composition (in some cases also comprising a second active substance) is exposed during erosion of the matrix composition and/or during release of the active substance, and whereby the coating is substantially eroded upon erosion of the matrix composition and/or during release of the active substance.
  • Such a coating will be designed so that its longitudinal erosion rate is substantially the same as the longitudinal erosion rate of the matrix, whereby the matrix and the coating will erode longitudinally towards the centre of the composition at substantially the same rate.
  • the coating will also be substantially completely eroded.
  • a matrix composition having such a coating has the obvious advantage of being completely biodegraded upon release of the active substance.
  • the coating may impart delayed properties for releasing the active substance or it may be a film-coating or a coating containing the active substance for immediate release prior to the controlled release or other kinds of coatings that does not delay the release but e.g. make it easier to swallow the composition or it may e.g. mask a bad taste.
  • Materials suitable for such coatings are well-known for a person skilled in the art and information can be found e.g. in the latest editions of handbooks like Handbook of Pharmaceutical Excipients or in Remington's Pharmaceutical Sciences.
  • the coating is one, which biodegrades, disintegrates crumbles or dissolves after erosion of the matrix and/or during the release of the active substance.
  • a coating applied for an erosion matrix will remain intact as long as it is supported by the matrix containing the active substance, but it lacks the ability to remain intact after erosion of the matrix, because it then biodegrades, disintegrates or crumbles, so that it will not remain in e.g. a human for any significant amount of time after the complete erosion of the outer matrix layer B and the release of the inner layer A.
  • the composition of the invention further comprises a coating having at least one opening exposing at least one surface of the matrix, the coating being one which crumbles and/or erodes upon exposure to the aqueous medium at a rate which is equal to or slower than the rate at which the matrix erodes in the aqueous medium, allowing exposure of said surface of the matrix to the aqueous medium to be controlled.
  • Polymers useful as coatings are such as e.g. cellulose derivative e.g. ethylcellulose, cellulose acetate, cellulose propionate, cellulose nitrate, cellulose derivative selected from the group consisting of methylcellulose, carboxymethylcellulose and salts thereof, cellulose acetate phthalate, microcrystalline cellulose, ethylhydroxyethylcellulose, ethylmethylcellulose, hydroxyethylcellulose, hydroxyethylmethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxymethylcellulose and hydroxymethylpropylcellulose, cellulose acetate, Eudragit L methyl ester, Eudragit RL, Eudragit E, polyamide, polyethylene, polyethylene terephthalate, polypropylene polyurethane, polyvinyl acetate, polyvinyl chloride, silicone rubber, latex, polyhydroxybutyrate, polyhydroxyvalerate, polytetrafluoroethylene, polylactic acid or polyglycolic acid and copo
  • the coating may also be copolymers of polylactic acid and polyglycolic acid.
  • the coating may also be an enteric coating employing methacrylates Eudragit L, Eudragit S, Eudragit FS, a co-polymer of methacrylate-galactomannan etc.
  • the controlled release composition of the invention further comprises a coating having at least one opening exposing at least one surface of the matrix, the coating being one which crumbles and/or erodes upon exposure to the aqueous medium at a rate which is equal to or slower than the rate at which the matrix erodes in the aqueous medium, allowing exposure of said surface of the matrix to the aqueous medium to be controlled.
  • a coating having at least one opening exposing at least one surface of the matrix, the coating being one which crumbles and/or erodes upon exposure to the aqueous medium at a rate which is equal to or slower than the rate at which the matrix erodes in the aqueous medium, allowing exposure of said surface of the matrix to the aqueous medium to be controlled.
  • the first cellulose derivative (a) such as, e.g., ethylcellulose is typically contained in the coating in a concentration of from about 10 to about 99% w/w such as, e.g., from about 20 to about 95% w/w, from about 30 to about 90% w/w, from about 40 to about 90% w/w, from about 45 to about 90% w/w, from about 50 to about 85% w/w or from about 50 to about 80% w/w.
  • the concentration of the polymer in the coating is from about 60% w/w to about 100% w/w. 0-40% w/w of one or more of a plasticizer, a colouring agent, a stabilizer, a glidants or the like may also be present in the coating.
  • a further active substance may be incorporated in the coating or the composition may be provided with a second coating comprising the further active substance.
  • a coating may be designed to release the active substance from the coating immediately after oral administration or a composition of the invention may be subject to enteric coating such that release will be pH dependent.
  • compositions wherein a coating contains an active substance may be of interest in those situations where a fast onset of action is desired, i.e. a fast release of an active substance is desired in order to quickly obtain a therapeutically effective plasma concentration of the active substance.
  • an active substance may be the same or different from that contained in layer B and/or the inner layer A dependent on the particular disease or condition to be treated.
  • such a coating is generally a film-coating and it is normally applied in a separate manufacturing step (e.g. not by injection moulding, but using processes generally applicable for film-coating of tablets such as, e.g., pan coating, fluid bed coating, spray coating, dip coating etc.).
  • the invention is based on controlled release compositions comprising polymer or a mixture of polymers, more specifically a polyglycol, an active substance and optionally one or more pharmaceutically acceptable excipients in layer B.
  • Polymers and pharmaceutically acceptable excipients suitable for use in such a composition as well as relevant active substances are described herein.
  • Such compositions have proved to mitigate the risk of alcohol induced dose dumping. “Dose dumping” is unintended, rapid drug release in a short period of time of the entire amount or a significant fraction of the active substance retained in a controlled release dosage.
  • the release mechanism is primarily erosion or diffusion from layer B composed of a polymer matrix, an active substance and if necessary one or more excipients.
  • the mechanism of erosion enables the composition to release with a rate depending on the exposed area.
  • Inner layer A of the invention contains active substance or active multiple units (e.g. pellets or mini tablets) in such a form that the active substance or individual active units will be made available upon disintegration of the composition in the stomach, small intestine and/or colon after erosion of layer B.
  • the individual units are of a size, which allows them to be incorporated into such a composition.
  • the matrix composition of layer B and active multiple units according to the invention has (in total) a lower (or equal) solubility and/or release rate in alcohol containing media (e.g. ethanol) than in aqueous media (e.g. water, buffer).
  • alcohol containing media e.g. ethanol
  • aqueous media e.g. water, buffer
  • the active substance in the above mention matrix composition optionally comprising chosen polymers and excipients in a suitable ratio attains an unchanged or lower dissolution rate when tested in alcohol containing media as compared to aqueous media.
  • compositions to avoid alcohol dose dumping can be of relevance for any active substance.
  • compositions potentially will be subject to alcohol induced dose dumping are to subject the composition to an dissolution test using a dissolution medium with and without alcohol and investigate whether there are any differences in the release pattern under the two different conditions.
  • the harshest conditions are in a dissolution medium containing 40% (v/v) ethanol. If the dissolution rate of the composition is substantially unaffected or slower, then it is likely to assume that no alcohol induced dose dumping will take place in vivo.
  • a composition according to the invention comprises one or more active substances. At least one active substance is included in the inner layer and outer layer(s) of the composition, which are the same, but the outer layer(s) may also contain one or more active substances that is different from the active substance contained in the inner layer.
  • the amount of each active substance in the composition if the same active substance is present in the inner layer and/or outer layer and/or in the coating corresponds to a daily or part of a daily therapeutic dose.
  • a pharmaceutical composition according to the invention is suitable for use for both water soluble as well as slightly soluble or insoluble active substances.
  • a pharmaceutical composition according to the invention may comprise one or more active substances, i.e. substances, which are therapeutically, prophylactically, diagnostically and/or biologically active substance.
  • active substance as used herein broadly includes any compound, or mixture thereof, that can be delivered from the composition to produce a beneficial result.
  • the active substance or substances included in a pharmaceutical composition of the invention may be selected from many therapeutic categories, in particular from substances which may advantageously be administered orally, rectally, vaginally, or administered to a body cavity (e.g. the urinary bladder, kidney pelvis, the gall bladder, the uterus, a central nervous system cavity, infectious/malignant/post-operative cavities, etc.).
  • a body cavity e.g. the urinary bladder, kidney pelvis, the gall bladder, the uterus, a central nervous system cavity, infectious/malignant/post-operative cavities, etc.
  • Examples of specific active substances suitable for use in a composition of the invention are: Stomatological active substances; Epinephrine, Benzydamine, Acetylsalicylic acid, Adrenalone, Amlexanox, Sodium fluoride, Sodium monofluorophosphate, Olaflur, Stannous fluoride, Sodium fluoride, Hydrogen peroxide, Chlorhexidine, Amphotericin B, Polynoxylin, Domiphen, Oxyquinoline, Neomycin, Miconazole, Natamycin, Hexetidine, Tetracycline, Benzoxonium chloride, Tibezonium iodide, Mepartricin, Metronidazole, Clotrimazole, Sodium perborate, Chlortetracycline, Doxycycline, Minocycline, Triamcinolone, Dexamethasone, Hydrocortisone, Prednisolone.
  • Active substances for functional gastrointestinal disorders Oxyphencyclimine, Camylofin, Mebeverine, Trimebutine, Rociverine, Dicycloverine, Dihexyverine, Difemerine, Piperidolate, Metoclopramide, Cisapride, Domperidone, Bromopride, Alizapride, Clebopride.
  • Antiemetic and antinauseant active substances Serotonin (5HT3) antagonists, Ondansetron, Granisetron, Tropisetron, Dolasetron, Palonosetron, Scopolamine, Cerium oxalate, Chlorobutanol, Metopimazine, Dronabinol, Nabilone, Aprepitant.
  • Bile acid preparations Chenodeoxycholic acid, Ursodeoxycholic acid, Nicotinyl methylamide, Piprozolin, Hymecromone, Cyclobutyrol, Arginine glutamate, Silymarin, Citiolone, Epomediol, Ornithine oxoglurate, Tidiacic arginine.
  • Laxative active substances Softeners, Emollients, Liquid paraffin, Docusate sodium, Liquid paraffin, Contact laxatives, Oxyphenisatine, Bisacodyl, Dantron, Phenolphthalein, Castor oil, Senna glycosides, Cascara, Sodium picosulfate, Bisoxatin, Belladonna alkaloids, Bisacodyl, Dantron, Senna glycosides, Cascara, Sodium picosulfate, Ispaghula ( psylla seeds), Ethulose, Sterculia, Linseed, Methylcellulose, Triticum (wheat fibre), Polycarbophil calcium, Magnesium carbonate, Magnesium oxide, Magnesium peroxide, Magnesium sulfate, Lactulose, Lactitol, Sodium sulfate, Pentaerithrityl, Macrogol, Mannitol, Sodium phosphate, Sorbito
  • Antidiarrheal, intestinal, anti-inflammatory/antiinfective active substances Antibiotics, Neomycin, Nystatin, Natamycin, Streptomycin, Polymyxin B, Paromomycin, Amphotericin B, Kanamycin, Vancomycin, Colistin, Rifaximin, Sulfonamides, Phthalylsulfathiazole, Sulfaguanidine, Succinylsulfathiazole, Imidazole derivatives, Miconazole, Broxyquinoline, Acetarsol, Nifuroxazide, Nifurzide, Medicinal charcoal, Bismuth, Pectin, Kaolin, Crospovidone, Attapulgite, Diosmectite, Diphenoxylate, Opium, Loperamide, Difenoxin, Loperamide oxide, Morphine, Prednisolone, Hydrocortisone, Prednisone, Betamethasone, Tixocortol, Budesonide, Beclometas
  • corticosteroids corticosteroids, Cromoglicic acid, Aminosalicylic acid and similar agents, Sulfasalazine, Mesalazine, Olsalazine, Balsalazide, Antidiarrheal microorganisms, Lactic acid producing organisms, Saccharomyces boulardii , Lactic acid producing organisms, Albumin tannate, Ceratonia , Calcium compounds, Racecadotril.
  • Antiobesity active substances Phentermine, Fenfluramine, Amfepramone, Dexfenfluramine, Mazindol, Etilamfetamine, Cathine, Clobenzorex, Mefenorex, Sibutramine, Ephedrine, Orlistat, Rimonabant. Digestiveactive substances; Enzyme preparations, Diastase, Multienzymes (lipase, protease etc.), Pepsin, Tilactase, Acid preparations, Glutamic acid hydrochloride, Betaine hydrochloride, Hydrochloric acid, Citric acid.
  • Diabetes active substances Insulins and analogues, Biguanides, Phenformin, Metformin, Buformin, Sulfonamides, urea derivatives, Glibenclamide, Chlorpropamide, Tolbutamide, Glibornuride, Tolazamide, Carbutamide, Glipizide, Gliquidone, Gliclazide, Metahexamide, Glisoxepide, Glimepiride, Acetohexamide, Sulfonamides (heterocyclic), Glymidine, Combinations of oral blood glucose lowering drugs, Alpha glucosidase inhibitors, Acarbose, Miglitol, Voglibose, Thiazolidinediones, Troglitazone, Rosiglitazone, Pioglitazone, Dipeptidyl peptidase 4 (DPP-4) inhibitors, Sitagliptin, Vildagliptin, Guar gum, Repaglinide, Nateglinide, Exenatide
  • Anabolic active substances Androstan derivatives, Androstanolone, Stanozolol, Metandienone, Metenolone, Oxymetholone, Quinbolone, Prasterone, Oxandrolone, Norethandrolone, Estren derivatives, Nandrolone, Ethylestrenol, Oxabolone cipionate.
  • Metabolism active substances Amino acids and derivatives, Levocarnitine, Ademetionine, Glutamine, Mercaptamine, Carglumic acid, Betaine, Enzymes, Alglucerase, Imiglucerase, Agalsidase alfa, Agalsidase beta, Laronidase, Sacrosidase, Alglucosidase alfa, Galsulfase, Idursulfase, Tioctic acid, Anethole trithione, Sodium phenylbutyrate, Nitisinone, Zinc acetate, Miglustat, Sapropterin.
  • Vitamin K antagonists Dicoumarol, Phenindione, Warfarin, Phenprocoumon, Acenocoumarol, Ethyl biscoumacetate, Clorindione, Diphenadione, Tioclomarol, Heparin, Antithrombin III, Dalteparin, Enoxaparin, Nadroparin, Parnaparin, Reviparin, Danaparoid, Tinzaparin, Sulodexide, Bemiparin, Platelet aggregation inhibitors excl.
  • Antihemorrhagics active substances Amino acids, Aminocaproic acid, Tranexamic acid, Aminomethylbenzoic acid, Proteinase inhibitors, Aprotinin, Alfa1 antitrypsin, C1-inhibitor, Camostat, Vitamin K, Phytomenadione, Menadione, Fibrinogen, Local hemostatics, Absorbable gelatin sponge, Oxidized cellulose, Tetragalacturonic acid hydroxymethylester, Adrenalone, Thrombin, Collagen, Calcium alginate, Epinephrine, Blood coagulation factors, Coagulation factor IX, II, VII and X in combination, Coagulation factor VIII, Factor VIII inhibitor bypassing activity, Coagulation factor IX, Coagulation factor VII, Von Willebrand factor and coagulation factor VIII in combination, Coagulation factor XIII, Eptacog alfa (activated), Nonacog alfa, Thrombin, Etams
  • Antianemic active substances Ferrous glycine sulfate, Ferrous fumarate, Ferrous gluconate, Ferrous carbonate, Ferrous chloride, Ferrous succinate, Ferrous sulfate, Ferrous tartrate, Ferrous aspartate, Ferrous ascorbate, Ferrous iodine, Ferric sodium citrate, Saccharated iron oxide, Sodium feredetate, Ferric hydroxide, Dextriferron, Ferric citrate, Chondroitin sulfate-iron complex, Ferric acetyl transferrin, Ferric proteinsuccinylate, Dextriferron, Vitamin B12 (cyanocobalamin and analogues), Cyanocobalamin, Cyanocobalamin tannin complex, Hydroxocobalamin, Cobamamide, Mecobalamin, Folic acid and derivatives, Erythropoietin, Darbepoetin alfa, Methoxy polyethylene glycol-epoetin beta.
  • Fibrinolysin and desoxyribonuclease Hematological active subtances; Fibrinolysin and desoxyribonuclease, Hyaluronidase, Chymotrypsin, Trypsin, Desoxyribonuclease, Bromelains, Streptokinase, combinations, Hematin.
  • Cardiac stimulant active substances Cardiac stimulant active substances; Cardiac glycosides, Digitalis glycosides, Acetyldigitoxin, Acetyldigoxin, Digitalis leaves, Digitoxin, Digoxin, Lanatoside C, Deslanoside, Metildigoxin, Gitoformate, Scilla glycosides, Proscillaridin, Strophantus glycosides, G-strophanthin, Cymarin, Peruvoside, Adrenergic and dopaminergic agents, Etilefrine, Isoprenaline, Norepinephrine, Dopamine, Norfenefrine, Phenylephrine, Dobutamine, Oxedrine, Metaraminol, Methoxamine, Mephentermine, Dimetofrine, Prenalterol, Dopexamine, Gepefrine, Ibopamine, Midodrine, Octopamine, Fenoldopam, cafedrine, Arbutamine, Theodrenaline,
  • Antiarrhythmics active subtances class Ia, Quinidine, Procainamide, Disopyramide, Sparteine, Ajmaline, Prajmaline, Lorajmine, Antiarrhythmics, class Ib, Lidocaine, Mexiletine, Tocainide, Aprindine, Antiarrhythmics, class Ic, Propafenone, Flecainide, Lorcainide, Encainide, Antiarrhythmics, class III, Amiodarone, Bretylium tosilate, Bunaftine, Dofetilide, Ibutilide, Other class I antiarrhythmics, Moracizine, Cibenzoline.
  • Active substances for vasodilation Organic nitrates, Glyceryl trinitrate, Methylpropylpropanediol dinitrate, Pentaerithrityl tetranitrate, Propatylnitrate, Isosorbide dinitrate, Trolnitrate, Eritrityl tetranitrate, Isosorbide mononitrate, Tenitramine, Flosequinan, Itramin tosilate, Prenylamine, Oxyfedrine, Benziodarone, Carbocromen, Hexobendine, Etafenone, Heptaminol, Imolamine, Dilazep, Trapidil, Molsidomine, Efloxate, Cinepazet, Cloridarol, Nicorandil, Linsidomine, Nesiritide.
  • Cardiac active substances Prostaglandins, Alprostadil, Other cardiac preparations, Camphora , Indometacin, Crataegus glycosides, Creatinolfosfate, Fosfocreatine, Fructose 1,6-diphosphate, Ubidecarenone, Adenosine, Tiracizine, Tedisamil, Acadesine, Trimetazidine, Ibuprofen, Ivabradine, Ranolazine.
  • Antihypertensive active substances Rauwolfia alkaloids, Rescinnamine, Reserpine, Deserpidine, Methoserpidine, Bietaserpine, Methyldopa, Imidazoline receptor agonists, Clonidine, Guanfacine, Tolonidine, Moxonidine, Rilmenidine, Sulfonium derivatives, Trimetaphan, Secondary and tertiary amines, Mecamylamine, Bisquaternary ammonium compounds, Alpha-adrenoreceptor antagonists, Prazosin, Indoramin, Trimazosin, Doxazosin, Urapidil, Guanidine derivatives, Betanidine, Guanethidine, Guanoxan, Debrisoquine, Guanoclor, Guanazodine, Guanoxabenz, Thiazide derivatives, Diazoxide, Hydrazinophthalazine derivatives, Dihydralazine, Hydralazine, Endralazine, Cad
  • Diuretic active substances Thiazides, Bendroflumethiazide, Hydroflumethiazide, Hydrochlorothiazide, Chlorothiazide, Polythiazide, Trichlormethiazide, Cyclopenthiazide, Methyclothiazide, Cyclothiazide, Mebutizide, Sulfonamides, Quinethazone, Clopamide, Chlortalidone, Mefruside, Clofenamide, Metolazone, Meticrane, Xipamide, Indapamide, Clorexolone, Fenquizone, Mercurial diuretics, Mersalyl, Xanthine derivatives, Theobromine, Cicletanine, Furosemide, Bumetanide, Piretanide, Torasemide, Aryloxyacetic acid derivatives, Etacrynic acid, Tienilic acid, Pyrazolone derivatives, Muzolimine, Etozolin, Aldosterone antagonist
  • Active substances for peripheral vasodilation 2-amino-1-phenylethanol derivatives, Isoxsuprine, Buphenine, Bamethan, Imidazoline derivatives, Phentolamine, Tolazoline, Nicotinic acid, Nicotinyl alcohol (pyridylcarbinol), Inositol nicotinate, Ciclonicate, Purine derivatives, Pentifylline, Xantinol nicotinate, Pentoxifylline, Etofylline nicotinate, Ergot alkaloids, Ergoloid mesylates, Nicergoline, Dihydroergocristine, Kallidinogenase, Cycelelate, Phenoxybenzamine, Vincamine, Moxisylyte, Bencyclane, Vinburnine, Suloctidil, Buflomedil, Naftidrofuryl, Butalamine, Visnadine, Cetiedil, Cinepazide, Ifenprodil, Az
  • Vasoprotective active substances Heparinoid, Sodium apolate, Heparin, Pentosan polysulfate sodium, Monoethanolamine oleate, Polidocanol, Invert sugar, Sodium tetradecyl sulfate, Phenol, Glucose, Calcium dobesilate, Bioflavonoids, Rutoside, Monoxerutin, Diosmin, Troxerutin, Hidrosmin, Tribenoside.
  • Beta blocking active substances Beta blocking agents, non-selective, Alprenolol, Oxprenolol, Pindolol, Propranolol, Timolol, Sotalol, Nadolol, Mepindolol, Carteolol, Tertatolol, Bopindolol, Bupranolol, Penbutolol, Cloranolol, Beta blocking agents, selective, Practolol, Metoprolol, Atenolol, Acebutolol, Betaxolol, Bevantolol, Bisoprolol, Celiprolol, Esmolol, Epanolol, S-atenolol, Nebivolol, Talinolol, Alpha and beta blocking agents, Labetalol, Carvedilol.
  • Calium channel blockers Dihydropyridine derivatives, Amlodipine, Felodipine, Isradipine, Nicardipine, Nifedipine, Nimodipine, Nisoldipine, Nitrendipine, Lacidipine, Nilvadipine, Manidipine, Barnidipine, Lercanidipine, Cilnidipine, Benidipine, Mibefradil, Phenylalkylamine derivatives, Verapamil, Gallopamil, Benzothiazepine derivatives, Diltiazem, Phenylalkylamine derivatives, Fendiline, Bepridil, Lidoflazine, Perhexiline.
  • ACE inhibitors Active substances acting on the renin-angiotensin system; ACE inhibitors, Captopril, Enalapril, Lisinopril, Perindopril, Ramipril, Quinapril, Benazepril, Cilazapril, Fosinopril, Trandolapril, Spirapril, Delapril, Moexipril, Temocapril, Zofenopril, Imidapril, Other, Renin-inhibitors, Remikiren, Aliskiren, Angiotensin II antagonists, Losartan, Eprosartan, Valsartan, Irbesartan, Candesartan, Telmisartan, Olmesartan.
  • Lipid modifying active substances HMG CoA reductase inhibitors, Simvastatin, Lovastatin, Pravastatin, Fluvastatin, Atorvastatin, Cerivastatin, Rosuvastatin, Pitavastatin, Fibrates, Clofibrate, Bezafibrate, Aluminium clofibrate, Gemfibrozil, Fenofibrate, Simfibrate, Ronifibrate, Ciprofibrate, Etofibrate, Clofibride, Bile acid sequestrants, Colestyramine, Colestipol, Colextran, Colesevelam, Nicotinic acid and derivatives, Niceritrol, Nicofuranose, Aluminium nicotinate, Nicotinyl alcohol (pyridylcarbinol), Acipimox, Other lipid modifying agents, Dextrothyroxine, Probucol, Tiadenol, Benfluorex, Meglutol, Omega-3-triglycerides, Magnesium
  • Dermatological active substances for system use Antifungals, Griseofulvin, Terbinafine, Protectives against UV-radiation for systemic use, Betacarotene, Antipsoriatics, Psoralens, Trioxysalen, Methoxsalen, Bergapten, Retinoids, Etretinate, Acitretin, Anti-acne, Isotretinoin, Ichtasol.
  • Antiinfective and antiseptic active substances Antibiotics, Nystatin, Natamycin, Amphotericin B, Candicidin, Chloramphenicol, Azidamfenicol, Hachimycin, Oxytetracycline, Carfecillin, Mepartricin, Clindamycin, Pentamycin, Arsenic compounds, Acetarsol, Quinoline derivatives, Diiodohydroxyquinoline, Clioquinol, Chlorquinaldol, Dequalinium, Broxyquinoline, Oxyquinoline, Organic acids, Lactic acid, Acetic acid, Ascorbic acid, Sulfonamides, Sulfatolamide, Combinations of sulfonamides, Imidazole derivatives, Metronidazole, Clotrimazole, Miconazole, Econazole, Ornidazole, Isoconazole, Tioconazole, Ketoconazole, Fenticonazole, Azanidazole, Propenidazole, But
  • Gynecological active substances Ergot alkaloids, Methylergometrine, Ergot alkaloids, Ergometrine, Oxytocin, Prostaglandins, Dinoprost, Dinoprostone, Gemeprost, Carboprost, Sulprostone, Misoprostol, Ritodrine, Buphenine, Fenoterol, Prolactine inhibitors, Bromocriptine, Lisuride, Cabergoline, Quinagolide, Metergoline.
  • Urological active substances Acidifiers, Ammonium chloride, Calcium chloride, Urinary concrement solvents, Urinary antispasmodics, Emepronium, Flavoxate, Meladrazine, Oxybutynin, Terodiline, Propiverine, Tolterodine, Solifenacin, Trospium, Darifenacin, Fesoterodine, Drugs used in erectile dysfunction, Alprostadil, Papaverine, Sildenafil, Yohimbin, Phentolamine, Moxisylyte, Apomorphine, Tadalafil, Vardenafil, Combinations, Papaverine, combinations, Magnesium hydroxide, Acetohydroxamic acid, Phenazopyridine, Succinimide, Collagen, Phenyl salicylate, Dimethyl sulfoxide, Alpha-adrenoreceptor antagonists, Alfuzosin, Tamsulosin, Terazosin, Testosterone-5-alpha
  • Corticosteroids Mineralocorticoids, Aldosterone, Fludrocortisone, Desoxycortone, Glucocorticoids, Betamethasone, Dexamethasone, Fluocortolone, Methylprednisolone, Paramethasone, Prednisolone, Prednisone, Triamcinolone, Hydrocortisone, Cortisone, Prednylidene, Rimexolone, Deflazacort, Cloprednol, Meprednisone, Cortivazol, Anticorticosteroids, Trilostane.
  • Thyroid and antithyroid active substances Thyroid hormones, Levothyroxine sodium, Liothyronine sodium, Tiratricol, Thiouracils, Methylthiouracil, Propylthiouracil, Benzylthiouracil, Sulfur-containing imidazole derivatives, Carbimazole, Thiamazole, Perchlorates, Potassium perchlorate, Diiodotyrosine, Dibromotyrosine, Iodine.
  • Antiinfective active substances Demeclocycline, Doxycycline, Chlortetracycline, Lymecycline, Metacycline, Oxytetracycline, Tetracycline, Minocycline, Rolitetracycline, Penimepicycline, Clomocycline, Tigecycline, Amphenicols, Chloramphenicol, Thiamphenicol, Ampicillin, Pivampicillin, Carbenicillin, Amoxicillin, Carindacillin, Bacampicillin, Epicillin, Pivmecillinam, Azlocillin, Mezlocillin, Mecillinam, Piperacillin, Ticarcillin, Metampicillin, Talampicillin, Sulbenicillin, Temocillin, Hetacillin, Benzylpenicillin, Phenoxymethylpenicillin, Propicillin, Azidocillin, Pheneticillin, Penamecillin, Clometocillin, Benzathine, benzylpenicillin, Procaine benzylpenicillin,
  • Antimycotic active substances Antibiotics, Amphotericin B, Hachimycin, Imidazole derivatives, Miconazole, Ketoconazole, Triazole derivatives, Fluconazole, Itraconazole, Voriconazole, Posaconazole, Flucytosine, Caspofungin, Micafungin, Anidulafungin.
  • Antimycobacterial active substances Aminosalicylic acid and derivatives, Sodium aminosalicylate, Calcium aminosalicylate, Antibiotics, Cycloserine, Rifampicin, Rifamycin, Rifabutin, Rifapentine, Capreomycin, Hydrazides, Isoniazid, Isoniazid, Thiocarbamide derivatives, Protionamide, Tiocarlide, Ethionamide, Pyrazinamide, Ethambutol, Terizidone, Morinamide, Clofazimine, Dapsone, Aldesulfone sodium.
  • Antiviral active substances Thiosemicarbazones, Metisazone, Nucleosides and nucleotides, Aciclovir, Idoxuridine, Vidarabine, Ribavirin, Ganciclovir, Famciclovir, Valaciclovir, Cidofovir, Penciclovir, Valganciclovir, Brivudine, Cyclic amines, Rimantadine, Tromantadine, Phosphonic acid derivatives, Foscarnet, Fosfonet, Protease inhibitors, Saquinavir, Indinavir, Ritonavir, Nelfinavir, Amprenavir, Lopinavir, Fosamprenavir, Atazanavir, Tipranavir, Darunavir, Zidovudine, Didanosine, Zalcitabine, Stavudine, Lamivudine, Abacavir, Tenofovir disoproxil, Adefovir dipivoxil, Emtricita
  • Vaccines Bacterial vaccines, Anthrax vaccines, Anthrax antigen, Brucellosis vaccines, Brucella antigen, Cholera vaccines, Diphtheria vaccines, Diphtheria toxoid, Hemophilus influenzae B vaccines, Meningococcal vaccines, Meningococcus A, Meningococcus B, Meningococcus C, Pertussis vaccines, Plague vaccines, Pneumococcal vaccines, Pneumococcus, Tetanus vaccines, Tuberculosis vaccines, Typhoid vaccines, Typhus (exanthematicus) vaccines, Other bacterial vaccines, viral vaccines, Encephalitis vaccines, Influenza vaccines, Hepatitis vaccines, Measles vaccines, Mumps vaccines, Poliomyelitis vaccines, Rabies vaccines, Rota virus vaccines, Rubella vaccines, Varicella zoster vaccines, Yellow fever vaccines, Papillomavirus
  • Antineoplastic and immunomodulating active substances Nitrogen mustard analogues, Cyclophosphamide, Chlorambucil, Melphalan, Chlormethine, Ifosfamide, Trofosfamide, Prednimustine, Alkyl sulfonates, Busulfan, Treosulfan, Mannosulfan, Ethylene imines, Thiotepa, Triaziquone, Carboquone, Nitrosoureas, Carmustine, Lomustine, Semustine, Streptozocin, Fotemustine, Nimustine, Ranimustine, Epoxides, Etoglucid, Other alkylating agents, Mitobronitol, Pipobroman, Temozolomide, dacarbazine.
  • Antimetabolite active substances Folic acid analogues, Methotrexate, Raltitrexed, Pemetrexed, Purine analogues, Mercaptopurine, Tioguanine, Cladribine, Fludarabine, Clofarabine, Nelarabine, Pyrimidine analogues, Cytarabine, Fluorouracil, Tegafur, Carmofur, Gemcitabine, Capecitabine, Vinca alkaloids and analogues, Vinblastine, Vincristine, Vindesine, Vinorelbine, Podophyllotoxin derivatives, Etoposide, Teniposide, Colchicine derivatives, Demecolcine, Taxanes, Paclitaxel, Docetaxel, Other plant alkaloids and natural products, Trabectedin.
  • Cytotoxic antibiotic and related active substances Actinomycines, Dactinomycin, Anthracyclines and related substances, Doxorubicin, Daunorubicin, Epirubicin, Aclarubicin, Zorubicin, Idarubicin, Mitoxantrone, Pirarubicin, Valrubicin, Other cytotoxic antibiotics, Bleomycin, Plicamycin, Mitomycin, Ixabepilone.
  • Antineoplastic active substances Platinum compounds, Cisplatin, Carboplatin, Oxaliplatin, Methylhydrazines, Procarbazine, Monoclonal antibodies, Edrecolomab, Rituximab, Trastuzumab, Alemtuzumab, Gemtuzumab, Cetuximab, Bevacizumab, Panitumumab, Sensitizers used in photodynamic/radiation therapy, Porfimer sodium, Methyl aminolevulinate, Aminolevulinic acid, Temoporfin, Efaproxiral, Protein kinase inhibitors, Imatinib, Gefitinib, Erlotinib, Sunitinib, Sorafenib, Dasatinib, Lapatinib, Nilotinib, Other antineoplastic agents, Amsacrine, Asparaginase, Altretamine, Hydroxycarbamide, Lonidamine, Pentostatin
  • Estrogens Diethylstilbestrol, Polyestradiol phosphate, Ethinylestradiol, Fosfestrol, Progestogens, Megestrol, Medroxyprogesterone, Medroxyprogesterone, Gestonorone, Gonadotropin releasing hormone analogues, Buserelin, Leuprorelin, Goserelin, Triptorelin, hormones antagonists, Anti-estrogens, Tamoxifen, Toremifene, Fulvestrant, Anti-androgens, Flutamide, Nilutamide, Bicalutamide, Enzyme inhibitors, Aminogluthetimide, Formestane, Anastrozole, Letrozole, Vorozole, Exemestane, Abarelix.
  • Immunostimulant active substances Cytokines and immunomodulators, Colony stimulating factors, Filgrastim, Molgramostim, Sargramostim, Lenograstim, Ancestim, Pegfilgrastim, Interferons, Peginterferons, Interleukins, Aldesleukin, Oprelvekin, Lentinan, Roquinimex, BCG vaccine, Pegademase, Pidotimod, Poly I:C, Poly ICLC, Thymopentin, Immunocyanin, Tasonermin, Melanoma vaccine, Glatiramer acetate, Histamine dihydrochloride, Mifamurtide.
  • Immunosuppressive active substances Ciclosporin, Muromonab-CD3, Antilymphocyte immunoglobulin, Antithymocyte immunoglobulin, Tacrolimus, Mycophenolic acid, Daclizumab, Basiliximab, Sirolimus, Etanercept, Infliximab, Leflunomide, Anakinra, Alefacept, Afelimomab, Adalimumab, Everolimus, Gusperimus, Efalizumab, Abetimus, Natalizumab, Abatacept, Eculizumab, Certolizumab pegol, Other immunosuppressive agents, Azathioprine, Thalidomide, Methotrexate, Lenalidomide.
  • Muscle relaxant active substances Peripherally acting agents, Curare alkaloids, Alcuronium, Tubocurarine, Dimethyltubocurarine, Choline derivatives, Suxamethonium, Other quaternary ammonium compounds, Pancuronium, Gallamine, Vecuronium, Atracurium, Hexafluronium, Pipecuronium bromide, Doxacurium chloride, Fazadinium bromide, Rocuronium bromide, Mivacurium chloride, Cisatracurium, Botulinum toxin, Centrally acting agents, Carbamic acid esters, Phenprobamate, Carisoprodol, Methocarbamol, Styramate, Febarbamate, Oxazol, thiazine, and triazine derivatives, Chlormezanone, Chlorzoxazone, Ethers, chemically close to antihistamines, Orphenadrine (citrate), Other centrally acting agents, Baclofen, Tizanidine, Pri
  • Antigout active substances Preparations inhibiting uric acid production, Allopurinol, Tisopurine, Febuxostat, Preparations increasing uric acid excretion, Probenecid, Sulfinpyrazone, Benzbromarone, Isobromindione, Preparations with no effect on uric acid metabolism, Colchicine, Cinchophen, Other antigout preparations, Urate oxidase.
  • Active substances affecting bone struture and mineralization Bisphosphonates, Etidronic acid, Clodronic acid, Pamidronic acid, Alendronic acid, Tiludronic acid, Ibandronic acid, Risedronic acid, Zoledronic acid, Bone morphogenetic proteins, Dibotermin alfa, Eptotermin alfa, Other drugs affecting bone structure and mineralization, Ipriflavone, Aluminium chlorohydrate, Strontium ranelate, Quinine and derivatives, Hydroquinine, Enzymes, Chymopapain, Trypsin, Hyaluronic acid. Colecalciferol.
  • Analgesics Opioids, Natural opium alkaloids, Morphine, Opium, Hydromorphone, Nicomorphine, Oxycodone, Dihydrocodeine, Diamorphine, Papaveretum, Codeine, Phenylpiperidine derivatives, Ketobemidone, Pethidine, Fentanyl, Diphenylpropylamine derivatives, Dextromoramide, Piritramide, Dextropropoxyphene, Bezitramide, Methadone, Benzomorphan derivatives, Pentazocine, Phenazocine, Oripavine derivatives, Buprenorphine, Morphinan derivatives, Butorphanol, Nalbuphine, Tilidine, Tramadol, Dezocine, Salicylic acid and derivatives, Acetylsalicylic acid, Aloxiprin, Choline salicylate, Sodium salicylate, Salicylamide, Salsalate, Ethenzamide, Morpholine salicylate, Dipyrocetyl, Benorilate, Di
  • Antimigraine active substances Ergot alkaloids, Dihydroergotamine, Ergotamine, Methysergide, Lisuride, Corticosteroid derivatives, Flumedroxone, Selective serotonin (5HT1) agonists, Sumatriptan, Naratriptan, Zolmitriptan, Rizatriptan, Almotriptan, Eletriptan, Frovatriptan, Other antimigraine preparations, Pizotifen, Clonidine, Iprazochrome, Dimetotiazine, Oxetorone.
  • Antiepileptic active substances Barbiturates and derivatives, Methylphenobarbital, Phenobarbital, Primidone, Barbexaclone, Metharbital, Hydantoin derivatives, Ethotoin, Phenytoin,
  • Amino(diphenylhydantoin) valeric acid Mephenytoin, Fosphenytoin, Oxazolidine derivatives, Paramethadione, Trimethadione, Ethadione, Succinimide derivatives, Ethosuximide, Phensuximide, Mesuximide, Benzodiazepine derivatives, Clonazepam, Carboxamide derivatives, Carbamazepine, Oxcarbazepine, Rufinamide, Fatty acid derivatives, Valproic acid, Valpromide, Aminobutyric acid, Vigabatrin, Progabide, Tiagabine, Other antiepileptics, Sultiame, Phenacemide, Lamotrigine, Felbamate, Topiramate, Gabapentin, Pheneturide, Levetiracetam, Zonisamide, Pregabalin, Stiripentol, Lacosamide, Beclamide.
  • Anticholinergic active substances Tertiary amines, Trihexyphenidyl, Biperiden, Metixene, Procyclidine, Profenamine, Dexetimide, Phenglutarimide, Mazaticol, Bornaprine, Tropatepine, Ethers chemically close to antihistamines, Etanautine, Orphenadrine (chloride), Ethers of tropine or tropine derivatives, Benzatropine, Etybenzatropine.
  • Dopaminergic ative substances Dopa and dopa derivatives, Levodopa, Melevodopa, Etilevodopa, Adamantane derivatives, Amantadine, Dopamine agonists, Bromocriptine, Pergolide, Dihydroergocryptine mesylate, Ropinirole, Pramipexole, Cabergoline, Apomorphine, Piribedil, Rotigotine, Monoamine, oxidase B inhibitors, Selegiline, Rasagiline, Other dopaminergic agents, Tolcapone, Entacapone, Budipine.
  • Phenothiazines with aliphatic side-chain Chlorpromazine, Levomepromazine, Promazine, Acepromazine, Triflupromazine, Cyamemazine, Chlorproethazine, Phenothiazines with piperazine structure, Dixyrazine, Fluphenazine, Perphenazine, Prochlorperazine, Thiopropazate, Trifluoperazine, Acetophenazine, Thioproperazine, Butaperazine, Perazine, Phenothiazines with piperidine structure, Periciazine, Thioridazine, Mesoridazine, Pipotiazine, Butyrophenone derivatives, Haloperidol, Trifluperidol, Melperone, Moperone, Pipamperone, Bromperidol, Benperidol, Droperidol, Fluanisone, Indole derivatives, Oxypertine, Molindone, Sert
  • Anxiolytic active substances Benzodiazepine derivatives, Diazepam, Chlordiazepoxide, Medazepam, Oxazepam, Potassium clorazepate, Lorazepam, Adinazolam, Bromazepam, Clobazam, Ketazolam, Prazepam, Alprazolam, Halazepam, Pinazepam, Camazepam, Nordazepam, Fludiazepam, Ethyl loflazepate, Etizolam, Clotiazepam, Cloxazolam, Tofisopam, Diphenylmethane derivatives, Hydroxyzine, Captodiame, Carbamates, Meprobamate, Emylcamate, Mebutamate, Dibenzo-bicyclo-octadiene derivatives, Benzoctamine, Azaspirodecanedione derivatives, Buspirone, Other anxiolytics, Mepheno
  • Hypnotic and sedative active substances Barbiturates, Pentobarbital, Amobarbital, Butobarbital, Barbital, Aprobarbital, Secobarbital, Talbutal, Vinylbital, Vinbarbital, Cyclobarbital, Heptabarbital, Reposal, Methohexital, Hexobarbital, Thiopental, Etallobarbital, Allobarbital, Proxibarbal, Aldehydes and derivatives, Chloral hydrate, Chloralodol, Acetylglycinamide chloral hydrate, Dichloralphenazone, Paraldehyde, Benzodiazepineemepronium derivatives, Flurazepam, Nitrazepam, Flunitrazepam, Estazolam, Triazolam, Lormetazepam, Temazepam, Midazolam, Brotizolam, Quazepam, Loprazolam, Doxefazepam, Cin
  • Non-selective monoamine reuptake inhibitors Desipramine, Imipramine, Imipramine oxide, Clomipramine, Opipramol, Trimipramine, Lofepramine, Dibenzepin, Amitriptyline, Nortriptyline, Protriptyline, Doxepin, Iprindole, Melitracen, Butriptyline, Dosulepin, Amoxapine, Dimetacrine, Amineptine, Maprotiline, Quinupramine, Selective serotonin reuptake inhibitors, Zimeldine, Fluoxetine, Citalopram, Paroxetine, Sertraline, Alaproclate, Fluvoxamine, Etoperidone, Escitalopram, Monoamine oxidase inhibitors, non-selective, Isocarboxazid, Nialamide, Phenelzine, Tranylcypromine, Iproniazide, Iproclozide, Monoamine oxidase inhibitor
  • Anti-dementia active subtances Anticholinesterases, Tacrine, Donepezil, Rivastigmine, Galantamine, Other anti-dementia drugs, Memantine, Ginkgo biloba .
  • Other nervous system active substances Parasympathomimetics, Anticholinesterases, Neostigmine, Pyridostigmine, Distigmine, Ambenonium, Choline esters, Carbachol, Bethanechol, Other parasympathomimetics, Pilocarpine, Choline alfoscerate.
  • Active substances used in addictive disorders Drugs used in nicotine dependence, Nicotine, Bupropion, Varenicline, Drugs used in alcohol dependence, Disulfiram, Calcium carbimide, Acamprosate, Naltrexone, Drugs used in opioid dependence, Buprenorphine, Methadone, Levacetylmethadol, Lofexidine. Antivertigo active subtances; Betahistine, Cinnarizine, Flunarizine, Acetylleucine, other nervous system drugs, Gangliosides and ganglioside derivatives, Tirilazad, Riluzole, Xaliproden, Hydroxybutyric acid, Amifampridine.
  • Hydroxyquinoline derivatives Broxyquinoline, Clioquinol, Chlorquinaldol, Tilbroquinol, Nitroimidazole derivatives, Metronidazole, Tinidazole, Ornidazole, Azanidazole, Propenidazole, Nimorazole, Secnidazole, Dichloroacetamide derivatives, Diloxanide, Clefamide, Etofamide, Teclozan, Arsenic compounds, Arsthinol, Difetarsone, Glycobiarsol, Chiniofon, Emetine, Phanquinone, Mepacrine, Atovaquone, Trimetrexate, Tenonitrozole, Dihydroemetine, Fumagillin, Nitazoxanide.
  • Antimalarial active substances Aminoquinolines, Chloroquine, Hydroxychloroquine, Primaquine, Amodiaquine, Biguanides, Proguanil, Cycloguanil embonate, Methanolquinolines, Quinine, Mefloquine, Diaminopyrimidines, Pyrimethamine, Artemisinin and derivatives, Artemether, Artesunate, Artemotil, Artenimol, Halofantrine.
  • Active substances against leishmaniasis and trypanosomiasis Nitroimidazole derivatives, Benznidazole, Antimony compounds, Meglumine antimonate, Sodium stibogluconate, Nitrofuran derivatives, Nifurtimox, Nitrofural, Arsenic compounds, Melarsoprol, Acetarsol, Pentamidine isethionate, Suramin sodium, Eflornithine.
  • Antinematodal active substances Benzimidazole derivatives, Mebendazole, Tiabendazole, Albendazole, Ciclobendazole, Flubendazole, Fenbendazole, Piperazine and derivatives, Diethylcarbamazine, Tetrahydropyrimidine derivatives, Pyrantel, Oxantel, Imidazothiazole derivatives, Levamisole, Avermectines, Ivermectin, Pyrvinium, Bephenium, anticestodal active substance; Salicylic acid derivatives, Niclosamide, Desaspidin, Dichlorophen.
  • Ectoparasiticide active substances Sulfur containing products, Dixanthogen, Potassium polysulfide, Mesulfen, Disulfiram, Thiram, Chlorine containing products, Clofenotane, Lindane, Pyrethrines, incl. synthetic compounds, Pyrethrum, Bioallethrin, Phenothrin, Permethrin, Benzyl benzoate, Copper oleinate, Malathion, Quassia.
  • Insecticide and repellent active substances Pyrethrines, Cyfluthrin, Cypermethrin, Decamethrin, Tetramethrin, Diethyltoluaide, Dimethylphthalate, Dibutylphthalate, Dibutylsuccinate, Dimethylcarbate, Etohexadiol.
  • Decongestant active substances Sympathomimetics, Cyclopentamine, Ephedrine, Phenylephrine, Oxymetazoline, Tetryzoline, Xylometazoline, Naphazoline, Tramazoline, Metizoline, Tuaminoheptane, Fenoxazoline, Tymazoline, Epinephrine, Cromoglicic acid, Levocabastine, Azelastine, Antazoline, Spaglumic acid, Thonzylamine, Nedocromil, Olopatadine, Corticosteroids, Beclometasone, Prednisolone, Dexamethasone, Flunisolide, Budesonide, Betamethasone, Tixocortol, Fluticasone, Mometasone, Triamcinolone, Fluticasone furoate, Hydrocortisone, Calcium hexamine thiocyanate, Retinol, Ipratropium bromide, Ritiometan, Mupirocin, He
  • Throat active substances Antiseptics, Ambazone, Dequalinium, Dichlorobenzyl alcohol, Chlorhexidine, Cetylpyridinium, Benzethonium, Myristyl-benzalkonium, Chlorquinaldol, Hexylresorcinol, Acriflavinium chloride, Oxyquinoline, Povidone-iodine, Benzalkonium, Cetrimonium, Hexamidine, Phenol, Antibiotics, Neomycin, Tyrothricin, Fusafungine, Bacitracin, Gramicidin, Benzocaine, Lidocaine, Cocaine, Dyclonine.
  • Active substances for obstructive airway diseases include Orciprenaline, Salbutamol, Terbutaline, Fenoterol, Rimiterol, Hexoprenaline, Isoetarine, Pirbuterol, Tretoquinol, Carbuterol, Tulobuterol, Salmeterol, Formoterol, Clenbuterol, Reproterol, Procaterol, Bitolterol, Glucocorticoids, Beclometasone, Budesonide, Flunisolide, Betamethasone, Fluticasone, Triamcinolone, Mometasone, Ciclesonide, Ipratropium bromide, Oxitropium bromide, Stramoni preparations, Tiotropium bromide, Cromoglicic acid, Nedocromil, Fenspiride, Methoxyphenamine, Bambuterol, Xanthines, Diprophylline, Choline theophyllinate, Proxyphylline, Theophylline, Aminophylline, Etamiphy
  • Antihistamine active substances Aminoalkyl ethers, Bromazine, Diphenhydramine, Clemastine, Chlorphenoxamine, Diphenylpyraline, Carbinoxamine, Doxylamine, Substituted alkylamines, Brompheniramine, Dexchlorpheniramine, Dimetindene, Chlorphenamine, Pheniramine, Dexbrompheniramine, Talastine, Substituted ethylene diamines, Mepyramine, Histapyrrodine, Chloropyramine, Tripelennamine, Methapyrilene, Thonzylamine, Phenothiazine derivatives, Alimemazine, Promethazine, Thiethylperazine, Methdilazine, Hydroxyethylpromethazine, Thiazinam, Mequitazine, Oxomemazine, Isothipendyl, Piperazine derivatives, Buclizine, Cyclizine, Chlorcyclizine
  • the active substance is for cardiac therapy including e.g. cardiac glycosides, antiarrhythmics, cardiac stimulants, vasodilators, antihypertensives, diuretics, vasoprotectives, beta blockers, calcium channel blockers, agents acting on the rennin-angiotensin system, lipid modifying agents.
  • cardiac therapy including e.g. cardiac glycosides, antiarrhythmics, cardiac stimulants, vasodilators, antihypertensives, diuretics, vasoprotectives, beta blockers, calcium channel blockers, agents acting on the rennin-angiotensin system, lipid modifying agents.
  • the active substance is from the therapeutic classes including antiemetics, antinauseants, antiobesity and anabolic agents.
  • the active substance is from the therapeutic classes including antiinflammatory and antiinfective agents, corticosteroids, non-steroids anti-inflammatory and antirheumatic agents.
  • the active substance is from the therapeutic classes including decongestants, adrenergics, expectorants, cough suppressant and antihistamines.
  • the active substance is from the therapeutic classes including anesthetics, analgesics, opioids, antipyretics, antimigraine agents, antiepileptics, anti-parkinson agents, dopaminergic agents, antipsychotics, anxiolytics, sedatives, antidepressants, psychostimulants agents used for ADHD and nootropics, agents used in addictive disorders.
  • anesthetics including anesthetics, analgesics, opioids, antipyretics, antimigraine agents, antiepileptics, anti-parkinson agents, dopaminergic agents, antipsychotics, anxiolytics, sedatives, antidepressants, psychostimulants agents used for ADHD and nootropics, agents used in addictive disorders.
  • the active substance is from the therapeutic classes including anaesthetics, centrally-acting analgesics, sedative-hypnotics, anxiolytics; appetite suppressants, decongestants, antitussives, antihistamines, antiemetics, antidiarrheals, and drugs used to treat narcolepsy and attention deficit hyperactivity disorder.
  • the active substance is associated with abuse syndromes include opioids, CNS depressants, CNS stimulants, cannabinoids, nicotine-like compounds, glutamate antagonists and N-methyl-D-aspartate (NMDA) antagonists.
  • opioids include opioids, CNS depressants, CNS stimulants, cannabinoids, nicotine-like compounds, glutamate antagonists and N-methyl-D-aspartate (NMDA) antagonists.
  • the active substance is buprenorphine, codeine, dextromoramide, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, morphine, pentazocine, oxycodeine, oxycodone, oxymorphone and tramadol.
  • the active substance can be in various forms, such as uncharged or charged molecules, molecular complexes, crystalline forms, amorphous form, polyamorphous form, polymorphous form, complexes, solvates, anhydrates, if relevant isomers, enantiomers, racemic mixtures and pharmacologically acceptable salts such as e.g. hydrochloride, hydrobromide, sulfate, laurylate, palmitate, phosphate, nitrite, nitrate, citrate, borate, acetate, maleate, tartrate, oleate, and salicylate.
  • salts of metals e.g.
  • alkali metal salts such as, e.g., sodium or potassium salts
  • alkaline earth metal salts such as, e.g., calcium and magnesium salts
  • amines amino acids or organic cations quaternary ammoniums
  • Derivatives of active substances such as esters, ethers and amides which have solubility characteristics suitable for use herein can be used alone or mixed with other drugs. After release of the derivative from the drug delivery system it may be converted by enzymes, hydrolysed by body pH or other metabolic processes to the parent drug or to another biologically active form.
  • a pharmaceutical composition of the invention may in addition be suitable for the delivery of peptides, polypeptides or proteins, for example hormones, enzymes such as lipases, proteases, carbohydrates, amylases, lactoferrin, lactoperoxidases, lysozymes, nanoparticles, etc., and antibodies.
  • the composition may also be employed for the delivery of microorganisms, either living, attenuated or dead, for example bacteria, e.g. gastrointestinal bacteria such as streptococci, e.g. S. faecium, Bacillus spp. such as B. subtilis and B.
  • licheniformis lactobacteria, Aspergillus spp., bifidogenic factors, or viruses such as indigenous vira, enterovira, bacteriophages, e.g. as vaccines, and fungi such as baker's yeast, Saccharomyces cerevisiae and fungi imperfecti.
  • the active substance is a pharmaceutically active powder.
  • the powder typically has a particle size of from about 0.1 ⁇ m to about 500 ⁇ m, typically from about 0.5 ⁇ m to about 300 ⁇ m, more typically from about 1 ⁇ m to about 200 ⁇ m, especially from about 5 ⁇ m to about 100 ⁇ m.
  • the active substance is a pharmaceutically active crystal.
  • the crystal typically has a particle size of from about 0.1 ⁇ m to about 1000 ⁇ m such as, e.g., about 0.1 ⁇ m to about 750 ⁇ m, about 0.1 ⁇ m to about 500 ⁇ m, typically from about 0.5 ⁇ m to about 500 ⁇ m, more typically from about 1 ⁇ m to about 500 ⁇ m, especially from about 5 ⁇ m to about 500 ⁇ m.
  • a composition comprises active substance that at least partially is present in amorphous form with a mean particle size of at least about 0.01 ⁇ m such as, e.g., from about 0.01 ⁇ m to about 500 ⁇ m, from about 0.05 ⁇ m to about 500 ⁇ m, from about 0.1 ⁇ m to about 500 ⁇ m, from about 0.5 ⁇ m to about 500 ⁇ m, about 1 ⁇ m to about 500 ⁇ m, typically from about 0.5 ⁇ m to about 300 ⁇ m, more typically from about 1 ⁇ m to about 200 ⁇ m, especially from about 1 ⁇ m to about 100 ⁇ m.
  • a mean particle size such as, e.g., from about 0.01 ⁇ m to about 500 ⁇ m, from about 0.05 ⁇ m to about 500 ⁇ m, from about 0.1 ⁇ m to about 500 ⁇ m, from about 0.5 ⁇ m to about 500 ⁇ m, about 1 ⁇ m to about 500 ⁇ m, typically from about 0.5 ⁇ m to about 300 ⁇ m, more
  • the at least one therapeutically, prophylactically and/or diagnostically and/or biologically active substance will suitably be present in an amount of up to about 80%, typically up to about 70%, up to about 60% or up to about 50%, such as, e.g., from 0.1% to 80%, such as from 0.25% to 75%, such as from 0.5% to 60%, such as from 0.75% to 50%, such as from 1% to 40%, such as from 1.5% to 35%, such as from 1.75% to 30% by weight of the composition or layer.
  • a content of about 60-80% w/w is contemplated to be the maximum content, which still allows for a sufficient content of the polymer and, when relevant, a pharmaceutically acceptable excipient in the composition.
  • the active substance may, on the other hand, be present in the composition in much smaller amounts, depending on the nature and potency of the active substance in question.
  • a composition according to the invention containing a drug substance is typically for oral administration. Due to the possibility of controlling the release rate of the active substance the composition may be adapted for oral administration 1-6 times a day, normally 1-4 times daily such as 1-3 times, 1-2 times or 1 times daily.
  • the technology may also provide compositions for administration only once or twice daily.
  • once daily is intended to mean that it is only necessary to administer the pharmaceutical composition once a day in order to obtain a suitable therapeutic and/or prophylactic response; however, any administration may comprise co-administration of more than one dosage unit, such as, e.g. 2-4 dosage units if the amount of active substance required may not be formulated in only one composition or if a composition of a smaller size is preferred.
  • the dosage of the active substance depends on the particular substance, the age, weight condition etc. of the human or animal that will be treated with the composition etc. All such factors are well known to a person skilled in the art.
  • the active substance or substances maybe stabilized in the dosage form in its amorphous form.
  • the amorphous state and/or the solid dispersion is stabilized either by a very careful choice of the concentration of the active substance in the composition and/or by addition of suitable stabilizing agents acting by stabilizing one or more of the conditions mentioned above under items 1) to 5).
  • condition 4 the stability may be retrieved by several mechanisms of which the most important are
  • a stabilizing agent may serve more than one purpose, it may stabilize the amorphous state of the active substance in the composition in order to avoid, reduce or delay any recrystallization, it may stabilize the active substance or other ingredients towards proteolytic or oxidative degradation or it may have an anti-plasticizing effect.
  • a stabilizing agent may also contribute to an improved solubility of the active substance. Without being bound to any theory it may be assumed that the stabilizing agent together with the polyethylene glycol and/or polyethylene oxide represent the dispersion medium wherein the solubility of the active substance may be higher than in the polyethylene glycol and/or polyethylene oxide alone. The same may apply with respect to the stability of the amorphous form of the active substance.
  • composition may also contain other excipients as well, e.g. in order to improve the technical properties of the composition so that it may be easier to produce or in order to improve the properties of the composition such as release rate of the active substance, stability of the active substance or of the composition itself etc.
  • a suitable pharmaceutically acceptable excipient for use in a composition of the invention may be selected from the group consisting of fillers, diluents, disintegrants, glidants, pH-adjusting agents, viscosity adjusting agents, solubility increasing or decreasing agents, osmotically active agents and solvents.
  • Suitable excipients include conventional tablet or capsule excipients. These excipients may be, for example, diluents such as dicalcium phosphate, calcium sulfate, lactose or sucrose or other disaccharides, cellulose, cellulose derivatives, kaolin, mannitol, dry starch, glucose or other monosaccharides, dextrin or other polysaccharides, sorbitol, inositol or mixtures thereof; binders such as alginic acid, calcium alginate, sodium alginate, starch, gelatin, saccharides (including glucose, sucrose, dextrose and lactose), molasses, panwar gum, ghatti gum, mucilage of isapol husk, carboxymethylcellulose, methylcellulose, veegum, larch arabolactan, polyethylene glycols, ethylcellulose, water, alcohols, waxes, polyvinylpyrrolidone such
  • sodium hydrogencarbonate/tartaric acid or citric acid crosprovidone, sodium starch glycolate, agar, alginic acid, calcium alginate, sodium alginate, chitosan, colloidal silicon dioxide, docusate sodium, guar gum, low-substituted hydroxypropyl cellulose, hydroxypropyl starch, magnesium aluminium silicate, polacrilin potassium, povidone, sodium starch glycolate, pregelatinized starch, cation exchange resins, citrus pulp, veegum, glycollate, natural sponge, bentonite, sucralfate, calcium hydroxyl-apatite or mixtures thereof, effervescent agents (carbonate release) such as citric acid, anhydrous, citric acid, monohydrate, dextrates, fumaric acid, potassium bicarbonate, sodium bicarbonate, sodium citrate, dehydrate, tartaric acid or mixtures thereof.
  • effervescent agents carbonate release
  • composition may comprise one or more agents selected from the group consisting of sweetening agents, flavouring agents and colouring agents, in order to provide an elegant and palatable preparation.
  • agents selected from the group consisting of sweetening agents, flavouring agents and colouring agents, in order to provide an elegant and palatable preparation.
  • sweetening agents examples are maltol, citric acid, water soluble FD&C dyes and mixtures thereof with corresponding lakes and direct compression sugars such as Di-Pac from Amstar.
  • coloured dye migration inhibitors such as tragacanth, acacia or attapulgite talc may be added.
  • Specific examples include Calcium carbonate, 1,3,5-trihydroxybenzene, Chromium-cobalt-aluminium oxide, ferric ferrocyanide, Ferric oxide, Iron ammonium citrate, Iron (III) oxide hydrated, Iron oxides, Carmine red, Magnesium carbonate and Titanium dioxide.
  • Plasticizer may be incorporated in the composition.
  • a suitable plasticizer is selected from such as e.g. mono- and di-acetylated monoglycerides, diacetylated monoglycerides, acetylated hydrogenated cottonseed glyceride, glyceryl cocoate, Polyethylene glycols or polyethylene oxides (e.g.
  • dipropylene glycol salicylate glycerin dipropylene glycol salicylate glycerin, fatty acids and esters, phthalate esters, phosphate esters, amides, diocyl phthalate, phthalyl glycolate, mineral oils, hydrogenated vegetable oils, vegetable oils, acetylated hydrogenated soybean oil glycerides, Castor oil, acetyl tributyl citrate, acetyl triethyl citrate, methyl abietate, nitrobenzene, carbon disulfide, ⁇ -naphtyl salicylate, sorbitol, sorbitol glyceryl tricitrate, fatty alcohols, cetostearyl alcohol, cetyl alcohol, stearyl alcohol, oleyl alcohol, myristyl alcohol, sucrose octaacetate, alfa-tocopheryl polyethylene glycol succinate (TPGS), tocopheryl derivative, diacetylene
  • the use of a plasticizer will often be desirable in order to improve the processibility of the coating.
  • the plasticizer may also be a non-ionic surfactant, e.g. a non-ionic surfactant as the one mentioned above.
  • Preferred stabilizers include TPG e.g. in the form of TPGS due to surfactant properties, BHA, BHT, t-butyl hydroquinone, calcium ascorbate, gallic acid, hydroquinone, maltol, octyl gallate, sodium bisulfite, sodium metabisulfite, tocopherol and derivates thereof, citric acid, tartaric acid, and ascorbic acid.
  • Other stabilisers include trivalent phosphorous like e.g. phosphite, phenolic antioxidants, hydroxylamines, lactones such as substituted benzofuranones.
  • Modifier may be incorporated in the composition.
  • a suitable modifier is selected from such as e.g. fatty acids and esters, fatty alcohols, cetyl alcohol, stearyl alcohol, mineral oils, hydrogenated vegetable oils, vegetable oils, acetylated hydrogenated soybean oil glycerides, Castor oil, phosphate esters, amides, phthalate esters, glyceryl cocoate oleyl alcohol, myristyl alcohol, sucrose octaacetate, diacetylated monoglycerides, diethylene glycol monostearate, ethylene glycol monostearate, glyceryl monooleate, glyceryl monostearate, propylene glycol monostearate, macrogol esters, macrogol stearate 400, macrogol stearate 2000, polyoxyethylene 50 stearate, macrogol ethers, cetomacrogol 1000, lauromacrogols, poloxamers, polyvinyl alcohols, sorbitan mono
  • suitable modifier may be selected from the group consisting of inorganic acids, inorganic bases, inorganic salts, organic acids or bases and pharmaceutically acceptable salts thereof, saccharides, oligosaccharides, polysaccharides, polyethylene glycol derivatives and cellulose and cellulose derivatives.
  • suitable organic acids include acetic acid/ethanoic acid, adipic acid, angelic acid, ascorbic acid/vitamin C, carbamic acid, cinnamic acid, citramalic acid, formic acid, fumaric acid, gallic acid, gentisic acid, glutaconic acid, glutaric acid, glyceric acid, glycolic acid, glyoxylic acid, lactic acid, levulinic acid, malonic acid, mandelic acid, oxalic acid, oxamic acid, pimelic acid, and pyruvic acid.
  • suitable inorganic acids include pyrophosphoric, glycerophosphoric, phosphoric such as ortho and meta phosphoric, boric acid, hydrochloric acid, and sulfuric acid.
  • suitable inorganic compounds include aluminium.
  • Suitable pharmaceutically acceptable salts of an organic acid is e.g. an alkali metal salt or an alkaline earth metal salt such as, e.g. sodium phosphate, sodium dihydrogenphosphate, disodium hydrogenphosphate etc., potassium phosphate, potassium dihydrogenphosphate, potassium hydrogenphosphate etc., calcium phosphate, dicalcium phosphate etc., sodium sulfate, potassium sulfate, calcium sulfate, sodium carbonate, sodium hydrogencarbonate, potassium carbonate, potassium hydrogencarbonate, calcium carbonate, magnesium carbonate etc., sodium acetate, potassium acetate, calcium acetate, sodium succinate, potassium succinate, calcium succinate, sodium citrate, potassium citrate, calcium citrate, sodium tartrate, potassium tartrate, calcium tartrate etc.
  • an alkali metal salt or an alkaline earth metal salt such as, e.g. sodium phosphate, sodium dihydrogenphosphate, disodium hydrogenphosphate etc., potassium phosphate, potassium dihydrogenphosphate, potassium hydrogenphosphat
  • a suitable inorganic salt for use in a matrix composition of the invention is sodium chloride, potassium chloride, calcium chloride, magnesium chloride etc.
  • Saccharides such as glucose, ribose, arabinose, xylose, lyxose, xylol, allose, altrose, inosito, glucose, sorbitol, mannose, gulose, Glycerol, idose, galactose, talose, mannitol, erythritol, ribitol, xylitol, maltitol, isomalt, lactitol, sucrose, fructose, lactose, dextrin, dextran, amylose, xylan.
  • Polyethylene glycol derivatives such as e.g. polyethylene glycol di(2-ethyl hexoate), polyethylene glycols (200-600 daltons) or polyethylene oxides, e.g. with a molecular weight of about 800-500,000 daltons, typically about 1,000-100,000 daltons, more typically 1,000-50,000 daltons, especially about 1,000-10,000 daltons, in particular about 1,500-5,000 daltons, and mixtures thereof.
  • Cellulose and cellulose derivative selected from the group consisting of methylcellulose, carboxymethylcellulose and salts thereof, microcrystalline cellulose, ethylhydroxyethylcellulose, ethylcellulose, cellulose acetate, cellulose proprionate, cellulose nitrate, cellulose acetate phthalate, ethylmethylcellulose, hydroxyethylcellulose, hydroxyethylmethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxymethylcellulose and hydroxymethylpropylcellulose.
  • a composition of the invention may be produced by various methods which are either known per se in the pharmaceutical industry or which, for example, are used in the production of polymer-based materials, depending upon the desired embodiment and the materials employed in the composition in question.
  • One advantage of the composition according to the invention is that it may be produced by methods, which are relatively simple and inexpensive.
  • compositions according to the invention include extrusion, injection moulding, tabletting, capsule filling, thermoforming, spray coating, micro encapsulation and other methods suitable for preparation of controlled release compositions.
  • Compositions according to the invention may be prepared in numerous ways giving rise to different release mechanisms. Particularly the composition may be prepared by 1, 2 or multiple component injection mouldings, by conventional tablet compression, by tablet compression and afterward temperature curing, by micro encapsulation, by 1, 2 or multiple component extrusions, by capsule filling or by thermoforming.
  • the preparation may also comprise separate steps as for example wet granulation, dry granulation, melt granulation, pelletizing, roller compaction, spray coating, electrostatic coating or other forms of controlled release preparation methods.
  • the composition is prepared by two/three component injection moulding of a matrix and a coat partly covering the matrix and exposing two ends of the composition for erosion governed release.
  • separately prepared components e.g. tablets, pellets etc. can be assembled in a separate, automated assembly process.
  • a composition may also be produced by, for example, injection moulding, co-extrusion of the coating with the matrix composition and the active substance, extrusion and dip coating, injection moulding and dip coating, or by extrusion or injection moulding and solvent coating by spraying or dipping, electrostatic coating. Multiple component injection moulding, or a combination of these methods.
  • the injection moulding technique have the advantage of simultaneous mixing and heating the components during increased pressure in a one step procedure without exposure to air and moisture because the injection moulding is performed in a single closed compartment from the time the blend has entered the machine to the final pharmaceutical units are ejected ready for packaging.
  • the blending process may be followed by an extrusion step for obtaining pellets suitable for feeding of the injection moulding machines.
  • the extruding step may secure a more intimate blending and thereby higher reproducibility of the final pharmaceutical product.
  • the present technology also can be applied when it is desired to have an amorphous form of the active substance in the composition, because the most convenient process for the preparation of a composition of the invention involves heating of the polymer together with the active substance and the conversion from the crystalline state to the amorphous state requires addition of energy (heating).
  • heating is employed for e.g. an injection moulding process.
  • PEO in various qualities forms free radicals that results in the formation of inter alia formaldehyde and formic acid. These products may often lead to further degradation e.g. of the active substance present in the composition and it is therefore necessary to take the necessary precautions in this respect.
  • Oxidative free radicals degradation by hydroperoxides can be catalysed by certain transition metal ions, especially those of copper, cobalt and manganese.
  • employment of PEO qualities devoid of or only containing a very small amount of such transition metal ions may improve stability.
  • ком ⁇ онент in a quality that ensures that free radicals formed, if any, do not significantly increase the degradation of the active substance in the composition.
  • a quality could e.g. be a quality containing an antioxidant that functions by preventing the formation of free radical during heating or by scavenging any free radicals formed.
  • Another possibility is to add such antioxidant to the formulation before any heating takes place.
  • a composition according to the invention may therefore further comprise one or more antioxidants that inhibits the formation of peroxides and/or inactivates any peroxides present.
  • Suitable antioxidants for use includes beta-caroten (a vitamin A precursor), ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, monothioglycerol, potassium metabisulfite, sodium metabisulfite, propyl gallate, sodium formaldehylde sulfoxylate, sodium thiosulfate, sulfur dioxide, tocopherol, tocopherol acetate, tocopherol hemisuccinate, TPGS or other tocopherol derivatives, sulfides, phosphine etc.
  • Other suitable antioxidants are described herein.
  • the amorphous state of the active substance is furthermore favoured by the processing procedures of the preparation of the product according to the present invention, which in a preferred embodiment involves injection moulding of the pharmaceutical units.
  • a composition of the present invention can be designed to have release properties including burst release (very fast release of substantially the whole content in that part of the composition), controlled release (typically prolonged or extended release), delayed release (i.e. release only after a certain lag time) and immediate release (relatively fast release).
  • burst release very fast release of substantially the whole content in that part of the composition
  • controlled release typically prolonged or extended release
  • delayed release i.e. release only after a certain lag time
  • immediate release relatively fast release
  • the present invention provides a composition for controlled delivery of at least one active substance. It is possible to include two or more different active substances in the composition of the invention, adapted to enable release at different concentrations, intervals and/or release rates.
  • the same and/or a different active substance can be substantially homogeneously dispersed in the outer layer (the polymer matrix), in which case a substantially zero order release of the second active substance is obtained.
  • a burst release of the same or a different active substance may be obtained in a composition of the invention which comprises alternating layers.
  • the alternating layers may comprise, respectively, none, one, two or more different active substances.
  • an inner layer comprises a quick release function obtained by e.g. fast disintegration, exploding and/or effervescent effects.
  • the first fraction comprises
  • the outer layers comprise
  • a third component may also be present comprising
  • composition of the invention Due to the nature of the composition of the invention, it is possible to obtain a substantially controlled pulsatile/burst release, optionally in combination with a constant rate of release of the active substance over a specific period of time.
  • the amount of drug release corresponds to the dosage necessary for the treatment in question, so that adherence to a strict dosage regimen, e.g. requiring administration of a drug at set intervals up to several times a day, may be dispensed with. It is possible to combine two or more active substances each following and independent release pattern however the release pattern of such substances may also be identical.
  • the matrix of the outer layer of a pharmaceutical composition of the invention may be designed to release an active substance, if any, in a controlled manner such as by a zero order release mechanism. Accordingly, the composition is also suitable for controlled release of an active substance, i.e. first a controlled release of an active substance (from the matrix, layer B) and then a relatively fast release of the same or different active substance (from the Layer A) or other suitable release combinations.
  • controlled release is used to designate a release a desired rate during a predetermined release period. Terms like “modified”, “delayed”, “sustained”, “prolonged”, “extended” etc. release are in the present context synonyms to the term “controlled release”. Normally, the term relates to compositions that have a slower release of the active ingredient than that of a plain tablet or a tablet designed for immediate release. A person skilled in the art knows of these terms.
  • a double burst unit is presented by having a layered composition placed inside an immediate release tablet matrix in such a way that the outer matrix is eroded or disintegrated, exposing the layered composition, as shown in FIG. 1 .
  • the inner layer of a composition according to the invention comprises an active substance.
  • the release of the active substance is delayed because the outer layer must erode before the first fraction is exposed to the gastrointestinal fluids after oral administration.
  • a substantially controlled burst release optionally in combination with a constant rate of release over a specific period of time. It is possible to combine two or more active substances each following and independent release pattern however the release pattern of such substances may also be identical. It may in certain cases be desirable to incorporate a mixture of two active substances into the matrix in order to release both active substances in the matrix with the same release rate. In other cases it is desirable to have different release rates of the two active substances. In such cases the composition may be composed of two different matrixes, each with different release characteristics. In yet another case the release of the active substances may be sequential, such that during the initial dissolution phase one active substance S1 is released and then the other S2. In this case the second release is onset after a lag defined by the first release.
  • any combination of layers A) and B) is contemplated (i.e. any of the layer B) of 1, 2, 5-9 may be combined with any of layer A) 3, 4, 10-14, and the multiple unit formulations 15 or 16 may be part of either layer A) or B), and the coat formulations 17 or 18 may be applied to any of the combined formulations):
  • FIGS. 15-24 are given release profiles obtainable by compositions of the present invention.
  • Dissolution testing is performed according to USP 30, NF 25 (711), and apparatus 2 (paddle method).
  • the dissolution medium may consist of 0.1 M HCl or phosphate buffer e.g. pH 6.8, pH 6.8 & 40% ethanol or pH 7.2.
  • the volume of dissolution medium is typically 900 ml or 1000 ml and the paddle speed is 50 rpm. Samples are withdrawn at suitable time points and analysed for content of active substance by means of on-line UV detection or HPLC with UV detection.
  • An accurate amount of the polymer is loaded into a MTI mixer followed by an accurate amount of the active substance and of the pharmaceutically acceptable excipients(s), if any.
  • the mixing is performed at 900-2000 rpm and at a time period up to 20 min. At the start of the mixing the temperature is about 19-21° C. and the final temperature of the mixture is about 30-50° C. The mixture is then allowed to cool to room temperature and is ready to be fed into an injection moulding machine.
  • the coating composition is prepared by first adding the Ethylcellulose then Cetostearyl alcohol, and finally the Titanium dioxide to an MTI-Mixer at a temperature about 19-21° C. Mixing rate is 1000 rpm. The mixer is stopped when the temperature reaches 40-50° C. and the adhered material is manually incorporated into the mixture. The mixture is left to cool for about 10 minutes. The mixing is then finalized with a short high-speed mix in order to minimize lumps formation. The mixture is then allowed to cool to room temperature, after which it has a suitable consistency for being fed into an injection moulding machine.
  • a mixture may be prepared by simple volumetric mixing of the components. 3 g of the mixture is then feeded into a table top injection molding machine (Haake MiniJet II, Thermo Electron, Düsseldorf, Germany) and molded directly into a pre-molden shell and/or matrix. Typical settings in the MiniJet are: Temperature 90-120° C. and pressure 600-800 bar.
  • the final dosage units may be prepared according to two different methods.
  • the coat and the matrix are moulded individually followed by a manually incorporation of the moulded matrix plug into the moulded coat.
  • the injection moulding machine used is an Arburg Allrounder 220 S 250/60.
  • the coat and matrix are moulded in one process where the coat is moulded in a first step and the matrix is moulded directly into the coat in a second step (co-moulding or 2-component moulding).
  • the injection moulding machine used is Arburg Allrounder 420 V 800-60/35.
  • Pellets were prepared by mixing Poloxamer 188 (48% w/w), Eudragit RL (24% w/w) and Hydrocortisone (28% w/w) in a beaker on a heat stage set at 150° C. The melt was applied to a punched plate (hole size 1 mm) and pellets of diameter 1 mm was formed. The pellets disintegrated in cold MQ water in less than 1 h.
  • Pellets (batch 108-009-05-001C) comprising Hydrocortison (55% w/w), PEG 8000 (40% w/w) and PVP C15 (5% w/w) was prepared by hot melt extrusion followed by grinding. The pellets were sieved to reach a final size of 1000 ⁇ m-1200 ⁇ m. 35-37 mg pellets were mixed with 206-230 mg filler material comprising Lactose (StarLac®). The material was placed in an IR-tablet preparing device and compressed at a pressure of 5 metric tons.
  • Dissolution shows that the tablet is completely disintegrated after 18 minutes leaving the pellets for slower dissolution.
  • Pellets (batch 108-009-05-001C) comprising Hydrocortison (55% w/w), PEG 8000 (40% w/w) and PVP C15 (5% w/w) was prepared by hot melt extrusion followed by grinding. The pellets were sieved to reach a final size of 1000 ⁇ m-1200 ⁇ m. 35-37 mg pellets were mixed with 165-336 mg filler material comprising Lactose (StarLac®):NaHCO 3 :Citric Acid (1497:333:272% w/w). The material was placed in an IR-tablet preparing device and compressed at a pressure of 5 metric tons.
  • Dissolution shows that the tablet disintegrates immediately leaving the pellets for slower dissolution.
  • a dosage unit exhibiting Burst-controlled behaviour (MQV batch 1047-041, 1047-042 & 1047-044), see FIG. 2 .
  • Morphine and Hydrocodone absorb at the same wave length, it has been necessary to conduct two parallel experiments—each experiment applying a dosage unit with active substance combined with placebo.
  • the dosage units consisted of two plugs, one containing the active substance, one being a placebo-formulation. Finally the results from the two experiments were pooled, thereby simulating one dosage unit consisting of the two active substances, one plug which exhibits burst release of Hydrocodone and the other controlled release of Morphine.
  • the shell was produced by injection moulding.
  • the plugs were injection moulded using the mini jet at applying a temperature 110° C., a pressure of 800 bar and a cycle time of 20 s.
  • the thickness and the diameter of the plug was 4.5 mm diameter.
  • the exposed area of the matrix (i.e. two ends) is 35.04 mm 2 and the length of the dosage unit is 9 mm.
  • the active plug comprised: PoloXamer 188, PEO 300 000, Morphine Sulphate pentahydrate and Mannitol, which were mixed. Afterwards the powder mixture fed to the injection moulding machine.
  • the inactive (placebo) plug comprised: PoloXamer 407, PEO 300 000, which were mixed. Then the powder mixture was fed to the injection moulding machine.
  • the active plug comprised: Hydrocodone bitartarte, PEG 3350S, Sodium hydrogen carbonate and Citric acid, which were mixed. Afterwards the powder mixture fed to the injection moulding machine.
  • the inactive (placebo) plug comprised: PEG 3350S, Sodium hydrogen carbonate and Citric acid, which were mixed. Then the powder mixture was fed to the injection moulding machine.
  • the Controlled Release Plug has the Composition:
  • the Burst Release Plug has the Composition:
  • a dosage unit exhibiting Controlled-controlled behaviour (MQV batch 1047-041), see FIG. 2 .
  • Morphine and Oxycodone absorb at the same wave length, it has been necessary to conduct two parallel experiments—each experiment applying a dosage unit with active substance combined with placebo.
  • the dosage units consisted of two plugs, one containing the active substances, one being a placebo-formulation. Finally the results from the two experiments were pooled, thereby simulating one dosage unit consisting of Morphine and Oxycodone, both exhibiting controlled release beheveour.
  • the shell was produced by injection moulding.
  • the plugs were injection moulded using the mini jet at applying a temperature 110° C., a pressure of 800 bar and a cycle time of 20 s.
  • the thickness and the diameter of the plug was 4.5 mm diameter.
  • the exposed area of the matrix (i.e. two ends) is 35.04 mm 2 and the length of the dosage unit is 9 mm.
  • the active plug comprised: PoloXamer 188, PEO 300 000, Morphine Sulphate pentahydrate and Mannitol, which were mixed. Afterwards the powder mixture fed to the injection moulding machine.
  • the active plug comprised: Oxycodone hydrochloride, PEO 200 000, Mannitol, PoloXamer 407, which were mixed. Afterwards the powder mixture fed to the injection moulding machine.
  • the inactive (placebo) plug comprised: PoloXamer 407, PEO 300 000, which were mixed. Then the powder mixture was fed to the injection moulding machine.
  • the dosage form (controlled release) consists of an active plug and a placebo plug, the composition is given below:
  • Units were prepared by the following procedure: Pellets comprising Hydrocortison (55% w/w), PEG 8000 (40% w/w) and PVP C15 (5% w/w) was prepared by hot melt extrusion followed by grinding. The pellets were sieved to reach a uniform size. 36-38 mg pellets were mixed with 170-175 mg filler material comprising lactose (StarLac®), NaHCO 3 and Citric Acid (18500:825:675% w/w). Shell comprising Ethyl cellulose (89% w/w), Cetostearyl alcohol (10% w/w) and Titanium dioxide (1% w/w) (batch 06-0010-058) was prepared by injection moulding.
  • the dosage unit was hand assembled first with a 2 mm thick delay plug comprising PEO 200 000, the pellet/filler blend was added and then another 2 mm thick delay plug comprising PEO 200 000.
  • the exposed area of the matrix is 77 mm 2 and the length of the shell is 22.7 mm.
  • Dosage Unit According to the Invention Exhibiting Double Burst Behaviours (Batch 05-0126-110/05-0134-110), See FIG. 5 .
  • the exposed area of the matrix is 77 mm 2 (i.e. sum of surface area of the two ends) and the length of the shell is 22.7 mm.
  • the shell was produced by injection moulding.
  • the injection moulding machine used is a Haake Minijet II. End plugs and centre plug were prepared by hand and hand assembled. Each plug had a thickness of 3 mm.
  • PoloXamer 338, PEO 200 000, Morphine Sulphate pentahydrate and Mannitol were mixed. Afterwards the powder mixture was heated to approximately 110° C. The melt was moulded into a 3 mm thick, and a 4.5 mm diameter, hole metal filter to attain the plugs.
  • the exposed area of the matrix is 34.72 mm 2 (i.e. two ends) and the length of the dosage unit is 9 mm.
  • the shell was produced by injection moulding.
  • the injection moulding machine used is a Haake Minijet II. End plugs and centre plug were prepared by hand and hand assembled. Each plug had a thickness of 3 mm.
  • PoloXamer 338, PEO 200 000, Morphine Sulphate pentahydrate and Mannitol were mixed. Afterwards the powder mixture was heated to approximately 110° C. The melt was moulded into a 3 mm thick, and a 4.5 mm diameter, hole metal filter to attain the plugs.
  • the exposed area of the matrix (i.e. two ends) is 34.72 mm 2 and the length of the dosage unit is 9 mm.
  • the shell was produced by injection moulding. End plugs and centre plug, comprising pellets, were prepared by hand and hand assembled. Each plug had a thickness of 3 mm.
  • PoloXamer 188, PEO 300 000, Mannitol and Morphine sulphate pentahydrate were mixed.
  • the material was melted to approximately 110° C., and the melt was moulded into a 3 mm thick, and a 4.5 mm diameter, hole metal filter to attain the plugs.
  • PoloXamer 188, PEO 300 000, Mannitol and Morphine sulphate pentahydrate were mixed and processed on a melt extruder.
  • the extruded strings were cooled and cut into pellets.
  • the pellets were sieved to reach a uniform size.
  • Pellets were mixed with CrosPovidone to attain a centre plug of approximately 3 mm thickness and a 4.5 mm diameter.
  • the exposed area of the matrix (i.e. two ends) is 34.72 mm 2 and the length of the dosage unit is 9 mm.
  • a Dosage Unit According to the Invention Exhibiting Controlled-controlled Behaviour (MQV Batch 1047-047, See FIG. 10 .
  • the shell was produced by injection moulding. End plugs and centre plug, comprising pellets, were prepared by hand and hand assembled. Each plug had a thickness of 3 mm.
  • Morphine, PEO and PoloXamer 407 were mixed thoroughly and melted to approximately 110° C., and the melt was moulded into a 2 mm thick, and a 4.5 mm diameter, hole metal filter to attain the plugs.
  • PoloXamer 188, PEO 300 000, Mannitol and Morphine sulphate pentahydrate were mixed and processed on a melt extruder.
  • the extruded strings were cooled and cut into pellets.
  • the pellets were sieved to reach a uniform size.
  • Pellets were mixed with CrosPovidone to attain a centre plug of approximately 3 mm thickness and a 4.5 mm diameter.
  • the Dosage form has the Composition:
  • the exposed area of the matrix (i.e. two ends) is 34.72 mm 2 and the length of the dosage unit is 9 mm.
  • a Dosage Unit According to the Invention Exhibiting Burst-controlled Behaviour (MQV Batch 1047-046), See FIG. 10 .
  • the shell was produced by injection moulding. End plugs and centre plug, comprising pellets, were prepared by hand and hand assembled. Each plug had a thickness of 3 mm.
  • Morphine sulphate pentahydrate, PEG 3350S, Sodium hydrogen carbonate and Citric acid were mixed and melted to approximately 110° C., and the melt was moulded into a 3 mm thick, and a 4.5 mm diameter, hole metal filter to attain the plugs.
  • PoloXamer 188, PEO 300 000, Mannitol and Morphine sulphate pentahydrate were mixed and processed on a melt extruder.
  • the extruded strings were cooled and cut into pellets.
  • the pellets were sieved to reach a uniform size.
  • Pellets were mixed with CrosPovidone to attain a centre plug of approximately 3 mm thickness and a 4.5 mm diameter.
  • the exposed area of the matrix (i.e. two ends) is 34.72 mm 2 and the length of the dosage unit is 9 mm.

Abstract

Layered pharmaceutical composition suitable for oral use in the treatment of diseases where absorption takes place over a large part of the gastrointestinal tract. The composition comprising A) a solid inner layer comprising
  • i) an active substance, and
  • ii) one or more disintegrants/exploding agents, one of more effervescent agents or a mixture thereof.
The solid inner layer being sandwiched between two outer layers B1) and B2), each outer layer comprising
  • iii) a substantially water soluble and/or crystalline polymer or a mixture of substantially water soluble and/or crystalline polymers, the polymer being a polyglycol in the form of one of a) a homopolymer having a MW of at least about 100,000 daltons, and b) a copolymer having a MW of at least about 2,000 daltons, or a mixture thereof, and
  • iv) an active substance, which is the same as in said solid inner layer A), and layer A being different from layer B,
    the layered composition being coated with a coating C) that has at least one opening exposing at least one surface of said outer layer, the coating being substantially insoluble in and impermeable to fluids and comprising a polymer, and the composition having a cylindrical form optionally with one or more tapered ends, wherein the ratio between the surface area of one end surface of the cylinder and the length of the cylinder is in a range of from 0.02 to 45 mm.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of U.S. patent application Ser. No. 12/602,953, filed Jun. 7, 2010, which is a National Stage of International Application No. PCT/EP2002/056910, filed Jun. 4, 2008, which claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Patent Application No. 60/941,848, filed Jun. 4, 2007, these applications are incorporated herein by reference in their entireties.
INTRODUCTION
The present invention relates to a technology that is especially suitable for designing oral pharmaceutical compositions that are useful in the treatment of diseases where absorption e.g. takes place over a large part of the gastrointestinal tract (e.g. in stomach, the small intestine as well as in the colon). Accordingly, the present invention provides a composition that enables a first release of the active substance (e.g. a burst or a controlled release) followed by a second release of the same active substance (e.g. a burst or a controlled release). The design of the composition takes into account the fact that different conditions are present in different parts of the gastrointestinal system. Thus, e.g. in the colon, the surface area of the mucosal surface through which the active substance must be absorbed is much smaller than in the small intestine and, moreover, the amount of body liquid present is also much smaller. The compositions of the present invention may also be suitable in the treatment of diseases in which circadian rhythm or biorhythm effects can influence the condition being treated or when an effective therapy is desired e.g. in the early morning before awakening or when the active substance have a narrow absorption window or the absorption is poor e.g. in the colon or for local effect/treatment. Some physiologically active substances are periodically produced in vivo at certain time intervals and it may accordingly be desirable to administer such substances in a controlled release formulation which periodically releases the active substance at predetermined time intervals to obtain certain fluctuation in the drug level which may be desirable in connection with the treatment of various diseases. The present technology provides a means for designing such compositions and moreover, such compositions may be combined with an initiated burst release and/or zero order controlled release of the active substance.
BACKGROUND OF THE INVENTION
In the past decades many controlled release technologies have appeared. However, for drug substances that can be absorbed through many segments of the gastrointestinal (GI) tract, there is still a need for developing compositions that enable sufficient absorption of the drug substance over broader range of segment of the gastrointestinal (GI) tract in order to enable a less frequent dosage of the drug and/or in order to avoid excretion of unabsorbed drug via the faeces.
Pharmacodynamics and pharmacokinetics challenges might enforce the need for special release patters (such as paracetamol in which the first pass metabolism makes it difficult to make a constant release unit work). Furthermore, the passage of material through the gastrointestinal tract is carefully controlled by several mechanisms. This “house-keeping” (intestinal peristalsis) might lead to anomalies in the effect of solid oral dosage forms which might be compensated by the formulation.
Furthermore, the active substance may exert its effect locally in the colon or other parts of the gastrointestinal system, such as for treatment of cancer, inflammation, gastrointestinal diseases and treatment with anthelmintic agents.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1, illustrate double burst unit, with a delay between the two bursts.
FIG. 2, illustrate simple combination formulation.
FIG. 3, releases of Hydrocodone and Morphine with burst-controlled release behaviour see preparation 4.
FIG. 4, releases of Oxycodone and Morphine with controlled-controlled release behaviour see preparation 5.
FIG. 5, illustrate double burst unit, with a delay between the two bursts.
FIG. 6, release of Paracetamol with double burst release behaviour see example 2.
FIG. 7, illustrate unit exhibiting controlled-burst or burst-burst release behaviour.
FIG. 8, release of Morphine with controlled-burst release behaviour see example 3.
FIG. 9, release of Morphine with controlled-burst release behaviour see example 4.
FIG. 10, illustrate unit exhibiting controlled-controlled or burst-controlled release behaviour.
FIG. 11, release of Morphine with controlled-controlled release behaviour see example 5.
FIG. 12, release of Morphine pellets see example 5.
FIG. 13, release of Morphine with controlled-controlled release behaviour see example 6.
FIG. 14, release of Morphine with burst-controlled release behaviour see example 7.
FIG. 15, illustrate burst-lag-burst release characteristics.
FIG. 16, illustrate burst-controlled-burst release characteristics.
FIG. 17, illustrate burst-controlled release characteristics.
FIG. 18, illustrate controlled-burst release characteristics.
FIG. 19, illustrate lag-burst release characteristics.
FIG. 20, illustrate controlled-controlled release characteristic.
FIG. 21, illustrate controlled-controlled release characteristic.
FIG. 22, illustrate releases of two active substances with the same release characteristics.
FIG. 23, illustrate releases of two active substances with different release characteristics.
FIG. 24, illustrate releases of two active substances with sequential release characteristics.
DETAILED DESCRIPTION OF THE INVENTION
However, to the best of our knowledge there is still a need to develop a technology that enables preparation of pharmaceutical compositions useful for the above-mentioned therapies (including chronotherapy) in a relatively simple manner, preferably in a procedure involving relatively few steps and relatively simple equipment, and in an economical feasible manner. Moreover, it is desired to obtain a technology that is suitable for use for many different drug substances, i.e. a technology that is relatively flexible with respect to how to obtain a desired release pattern of the active substance. Thus, a relatively simple technology is desired that enables combination of e.g. delayed release followed by controlled (extended) release, delayed release followed by immediate release, burst release followed by delayed release followed by either controlled or immediate release, burst release followed by controlled release, controlled release followed by controlled release or immediate release. A further advantage could be a technology that enables variation in the design in a relatively easy manner such that the composition also includes e.g. a burst dose or controlled release dose (of different active substance).
The present invention provides such a technology. The technology is a further development of the Applicant's proprietary technology described in WO 99/51208, WO 03/24426, WO 03/24429, WO 03/24430, WO 2004/41252, WO 2004/84869, WO 2005/107713, WO2006/128471 that is based on matrix compositions comprising a substantially water soluble and/or crystalline polymer. Moreover it is a further development of the technology described in WO 2006/128471 that relates to a composition having an inner part of a composition that liquefies at body temperature sandwiched between two matrix compositions. In this manner a delay is obtained with respect to release of the active substance contained in the inner part and once, the matrix compositions are eroded away, the liquefied inner part is designed to flow out of the shell that surrounds the cylindrical part of a cylindrical shaped composition (i.e. the shell (or coating) covers the cylindrical surface, but not the end surfaces). In this manner the active substance in the inner part should be immediately released once the matrix parts are eroded. However, in some situations the present inventors have observed that the outflow of the liquefied inner part is not that easy, e.g. in situations where the composition reaches the large intestine or the colon. In these situations, a limited amount of water is present and, accordingly, the flow is limited and moreover, in the colon lumps of faeces may block the open ends of the shell leading to limited release of the active substance. Accordingly, the present inventors have developed compositions that substantially overcome the above-mentioned problems.
The present invention provides an extended release composition for prolonged effect and a way to ensure prolonged effect e.g. once daily administration is to ensure optimal absorption of the active substance though the gastrointestinal tract i.e. from the stomach to rectum.
When absorption of the active substance is limited or do not proceed substantially good in the distal part of the small intestine and/or in colon a relatively fast release of the active substance is an advantage when the controlled release composition enter this part of the tract and especially in those cases where the active substance is poorly absorbed in the distal part of the small intestine or in ascending and first part of the transverse colon. A release composition having controlled release follow by immediate release behavior is desirable for optimal absorption and effect.
A composition having controlled release follow by immediate release of the active substance is also an advantage when the active substance is poorly soluble and therefore requires a substantial amount of water/fluid to dissolve in the distal part of the small intestine before it enters colon for absorption.
If absorption of the active substance is unchanged through the gastrointestinal tract a better absorption of the active substance in the colon can be achieved if a relatively fast release of controlled release multiple units is released from the controlled release composition in the distal part of the small intestine to prevent limited absorption of the active substance due to block of the open ends of the shell in the colon lumps of faeces. A composition having controlled release follow by controlled release behavior in the shape of controlled release multiple units is desirable.
The opposite is the case (i.e. a composition having burst release follow by delay and/or controlled release behavior) if there is absorption problem in the first part of the gastrointestinal tract e.g. the stomach. It is also the case if fast effect follow by maintenance of the effect is desirable.
Controlling the release of the active substance from the composition and thereby the absorption of the active substance, makes it possible to control the blood level of the active substance and maintain the concentration within the therapeutic range over an extended period of time without high peak trough fluctuation which improve the therapeutic effect and reduced incidence of side effects.
It is an object of certain embodiments of the present invention to provide bioavailable formulations suitable for once daily administration which substantially improve efficiency and quality of the treatment.
It is an object of certain embodiments of the present invention to provide oral controlled release composition suitable for once daily administration which provide an early onset of therapeutic effect and which, after rising to a maximum concentration during the dosage interval, provide a relatively flat plasma profile, meaning that the plasma level pf the active substance provides a peak trough ratio of about 0.5 to about 1.0, and which provides effective treatment.
Another advantage relating to the present invention is the possibility of administering the two active substances at the same time and advantageous in the same pharmaceutical composition. However, as such a combination treatment is expected to have optimized effect with respect to each of the two substances at different points in time it is important to incorporate the two active substances in the composition in such a manner that
  • i) it is possible to incorporate a suitable amount of each active substance (notably an amount corresponding to a daily dose and should be present in a specific weight ratio that is optimized with respect to therapeutic effect),
  • ii) it is possible to avoid any negative interaction of the two active substances in the composition,
  • iii) it is possible to avoid an excessive degree of oxidation of the active substances (however, levels corresponding to normally accepted levels are acceptable),
  • iii) it is possible to obtain release patterns of both substances that are optimized with respect to therapeutic effect (see iv)-vi) for more specific details),
  • iv) it is possible to control the release pattern of the two active substances from the composition in such a manner that the release of S1 is independent of the release of S2; this applies for the release mechanism as well as the release rate and time for 80-100% w/w release,
  • v) it is possible to e.g. obtain a zero order release for one or both of the active substance, zero order release for one of the active substances and another order of release for the other active substance or the like,
  • vi) it is possible to obtain e.g. a relatively slow release followed by a faster release of one of the active substance without impact on the release of the other active substance, and/or
  • vii) it is possible to use a formulation technique that potentially may improve the bioavailability of at least one of the active substances and, preferably, of both of the active substance (due to the fact that both active substances generally have a low bioavailability).
In one aspect, the present invention relates to a layered pharmaceutical composition comprising A) a solid inner layer comprising
  • i) an active substance, and
  • ii) one or more disintegrants/exploding agents, one of more effervescent agents or a mixture thereof.
The solid inner layer being sandwiched between two outer layers B1) and B2), each outer layer comprising
  • iii) a substantially water soluble and/or crystalline polymer or a mixture of substantially water soluble and/or crystalline polymers, the polymer being a polyglycol in the form of one of a) a homopolymer having a MW of at least about 100,000 daltons, and b) a copolymer having a MW of at least about 2,000 daltons, or a mixture thereof, and
  • iv) an active substance, which is the same as in said solid inner layer A), and layer A being different from layer B,
    the layered composition being coated with a coating C) that has at least one opening exposing at least one surface of said outer layer, the coating being substantially insoluble in and impermeable to fluids and comprising a polymer, and the composition having a cylindrical form optionally with one or more tapered ends, wherein the ratio between the surface area of one end surface of the cylinder and the length of the cylinder is in a range of from 0.02 to 45 mm.
In a specific embodiment of the present invention, layer A) comprises
  • v) a substantially water soluble and/or crystalline polymer or a mixture of substantially water soluble and/or crystalline polymers, the polymer being a polyglycol in the from of one of c) a homopolymer having a MW of at the most about 16,000 daltons, and d) a copolymer having a MW of at the most about 30,000 daltons.
As mentioned above, the present invention is a further development of the Applicant's proprietary technology, namely preparation of pharmaceutical compositions based on a water soluble and/or crystalline polymer or mixture of such polymers involving a step of melting or softening the polymer by means of injection moulding, extrusion or the like. The injection moulding technique has the advantage of simultaneous mixing and heating the components during increased pressure in a one step procedure without exposure to air and moisture because the injection moulding is performed in a single closed compartment from the time a blend of the components has entered the machine to the final pharmaceutical units are ejected ready for packaging. More details regarding the preparation method are given below and in the experimental section.
As appears from the above, the invention concerns a layered pharmaceutical composition having an inner layer with the active substance sandwiched between two lag-time providing layers, i.e. layers that enable a delay in the release of the active substance contained in the inner layer. The layered composition is coated in such a manner that only a surface layer from the outer layer(s) is free of coating material. In a preferred embodiment, the composition has a cylindrical shape and then the cylindrical surface is coated leaving one or two of the end surfaces without any coating (normally both end surfaces are without coating). In order to ensure a sufficient release of the active substance contained in layer A) of the composition, the present inventor's have found that the following two properties are important, namely the geometry and dimensions of the composition and the present of a disintegrant and/or an effervescent agent (or couple). The first parameter ensures that the distance to travel for the inner layer is not too big compared with the size of the opening (i.e. the end surface) and the other one ensures that a driving force activates the mobility of the active substance in layer A) when it comes into contact with a body liquid. Moreover, as will be explained below, a further parameter has also a positive influence in order to enable a release of the active substance from layer A), namely the incorporation of the active substance in readily flowable multiple units.
Geometry
The lag-time mechanisms (and the release mechanics of any active substance contained in the outer layers) described above depends on the geometry of the composition. For example erosion based release from a matrix depends on the exposed area of the matrix. In this case the area may be manipulated by employment of a coat that is not subject to erosion and thus covering the areas of the matrix that hence will not be a releasing site. In particular, a cylindrical composition with the two ends exposing the eroding matrix will give rise to zero order release because the releasing area is constant.
The geometric form of the composition is very important for the obtainment of the above-mentioned controlled release. Thus, in one embodiment of the invention, the pharmaceutical composition has a geometric shape, which enables a substantially constant surface area to become exposed during erosion of the matrix. As explained above, the present inventors have found that the proportions between the surface area of the end surface and the length of the cylinder are important in order to ensure that the active substance (or, if relevant, of the multiple unit formulation containing the active substance) can be released from the inner part. Specific examples appear from the examples herein. In general, the following ratio between the surface area of one end surface and the length of the cylinder has been found to be suitable in order to ensure a proper release: from about 0.02 to about 45 mm such as, e.g., from about 0.1 to about 10 mm or from about 0.5 to about 8 mm. In most cases, the composition of the invention has two end surfaces, and, if the ratio is calculated on the total surface area of the end surfaces, then the ratio is from about 0.02 to about 85 mm such as, e.g., from about 0.1 to about 10 mm or from about 1.3 to about 14 mm.
In a specific example, the compositions employed are coated in such a manner that the surface has a substantially constant or controlled surface area during release or erosion. In the present context controlled surface area relates to a predetermined surface area typically predicted from the shape of the coat of the unit dosage system. It may have a simple uniform cylindrical shape or the cylindrical form can have one or more tapered ends in order to decrease (or increase) the initial release period.
As another example, in diffusion based systems the release will furthermore depend on the thickness of the diffusion layer and in this case the release will depend both on the diffusion area and thickness of the diffusion system.
As yet another example the release mechanism of dissolving/solubilization also depend on the releasing area and the release rate may be controlled by covering parts of the releasing matrix by a coat. Controlling the coverage of the matrix by the coat hence refers to covering from 0 to 100% of the matrix by a coat.
Inner Layer A)
The object of the present invention is to design a composition comprising an active substance that is released after a certain period of time (e.g. burst release followed by controlled release, controlled release followed by burst release, controlled release followed by controlled release, burst release followed by burst release). However, as explained above one of the problems the inventors were faced with was how to ensure that the inner layer exits the shell (coating) once the outer layers have disappeared. As explained above, two parameters are of importance. Firstly, incorporation of a pharmaceutically acceptable excipient that aids in disintegrating the inner layer seems to be of relevance. Accordingly, the inner layer may also contain one or more disintegration/exploding agents, one of more effervescent agents or a mixture thereof.
It is important to note that once the inner layer is “released” from the shell and brought into direct contact with an aqueous medium (e.g. the gastrointestinal fluids after oral administration) then various types of release of the active substance can be obtained ranging from immediate release (e.g. the active substance is readily available for release such as e.g. present in dissolved form in a form that is easily dissolvable) to controlled release (e.g. in the form of pellets designed to controlled release or other well-known types of formulations including beads, flakes, mini-tablets, granules, microspheres, nanoparticles, crystals or the like).
As the shell (coating) has properties that ensure exposure of a well-defined (normally constant or substantially constant) surface area of the composition to the surrounding medium so that the outer layer(s) can be eroded with a constant rate until the layer(s) are eroded away, it is important that the shell remains intact until the outer layer(s) have eroded. This normally means that the shell is left when the inner layer is the only layer left of the composition. Accordingly, the difficulty of the problem is to ensure a “release” of the inner layer from the shell or, in other words, a delivery of the inner layer material from the inside of the shell to the outside.
Disintegrants, Swelling Agents, Exploding Agents, Effervescent Agents
The inner layer may be formulated such that it disintegrates upon contact with water. The disintegration may be by a mechanism of exploding, by effervescence, by swelling, by rapid erosion or combinations thereof. The disintegration by exploding may be governed by rapid water influx into- and swelling of one or several of the matrix components leading to a collapse of the inner layer structure (normally a matrix structure) such that the active substance may be released or such that e.g. multiple units, crystals etc. containing the active substance may be released. The multiple units may be designed as quick release (/burst release/immediate release) multiple units or controlled release multiple units for release of the active substance in the small intestine and/or colon.
The disintegration may be by means of swelling. The inner layer comprises an excipient (here a disintegrant), which swells rapidly upon contact with aqueous media makes it possible to push the active substance or active multiple units out of the shell. Preferably, the detachment of the active matrix should be in smaller lumps with a large area-to-volume ratio.
As mentioned above, the “release” of the inner layer (or delivery of the inner layer material to the outside of the shell) may be aided by incorporation of e.g. a disintegrant also called swelling and/or exploding agent. A disintegrant typically swells upon contact with water and enable disruption of the inner layer to agglomerates or particle. Examples of suitable disintegrants include Sodium starch glycolate, Povidone, Sodium alginate, Alginic acid, Calcium alginate, Carboxymethylcellulose calcium, Carboxymethylcellulose sodium, Powdered cellulose, Chitosan, Croscarmellose sodium, Crospovidone, Hydroxypropyl starch, Hydroxypropyl cellulose low-substituted, Magnesium aluminium silicate, Methylcellulose, Microcrystalline cellulose, pregelatinized starch, Docusae sodium, Guar gum, Polacrilin potassium.
The disintegration may also be due to an effervescent effect, whereby gas such as CO2 is released from the inner layer upon contact with water and a rapid dissolving system is formed. The formation of gas bubbles will push the inner layer out in small lumps and thereby manifold increase the exposed area of the inner layer (e.g. containing active substance, active multiple units or the like) to the medium. For example sodium bicarbonate releases CO2 by reaction with water in an acidic environment. It is possible to develop a more pH-robust formulation by adding an acidic excipient to the formulation. The rate of which the gas formation occurs depends on the rate of hydration and diffusion of water into the matrix.
NaHCO3(s)
Figure US09642809-20170509-P00001
Na+(aq)+HCO3 (aq)  (1)
HCO3 (aq)+H3O+(aq)
Figure US09642809-20170509-P00001
H2CO3(aq)+H2O(l)  (2)
H2CO3(aq)
Figure US09642809-20170509-P00001
CO2(g)+H2O(l)  (3)
“Release” of the inner layer may also take place by means of gas formation using effervescent substances or effervescent couples. Examples of suitable effervescent agent include Effer-Soda, Citric acid, monohydrate, Dextrates, Fumaric acid, Potassium bicarbonate, Sodium bicarbonate, Sodium citrate dehydrate, Tartaric acid.
Disintegration may also take place by rapid erosion, which can be obtained by employing for example short chained polymers in the matrix, such that the matrix is readily wetted and dissolved exposing either the active multiple units or the matrix component(s) containing the active substance.
Furthermore, disintegration might be facilitated by facilitating water transport through the matrix by for example open pores.
In order to ensure suitable properties of the inner layer A, the inner layer A) without B) and C) disintegrates within at the most 60 min such as, e.g., at the most about 30 min or at the most about 15 min, when subjected to a disintegration test according to Ph. Eur.
Normally, the concentration of the one or more disintegrants, exploding agent and/or effervescent agent in the inner layer is from about 5% w/w to about 80% w/w such as, e.g., from about 10% w/w to about 70% w/w, from about 15% w/w to about 60% w/w or from about 20% w/w to about 50% w/w.
One or more pharmaceutically acceptable excipients or additives may also be present in inner layer A) (see the section “Pharmaceutically acceptable excipients”)
The inner layer A) may also contain a polymer. The same applies to the outer layers B) and in the following is given a general description of suitable polymers for the two (three) layers A) and B). It is important to note that in those cases where the active substance in layer A) is present in the form of multiple units, then the multiple units may be in the form of e.g. pellets, beads or the like, and in such cases one or more polymer may be employed in the preparation of the multiple units. In such cases, the polymers mentioned in the following are suitable and such polymers may appropriately be of the same nature as the polymers employed in the B) layers. In contrast hereto, the layer A may also contain a polymeric substance (as a dispersion medium for the active substance), but in this case, it is important that the polymeric substance has different properties from that used in layer B). To differentiate between the individual polymers, the notation “matrix polymer” is used to indicate that the polymer is suitable for use in layer B) and in multiple units, whereas the notation “layer A polymer” is used to indicate that the polymer is suitable for use as a dispersion medium or excipient in layer A.
Suitable polymers for use according to the invention typically comprises a polyglycol, e.g. in the form of a homopolymer and/or a copolymer. In a specific embodiment the polymer is substantially water soluble, thermoplastic, crystalline, semi-crystalline or amorphous or a mixture of substantially water soluble, crystalline, semi-crystalline or amorphous polymers. Suitable polymers for use in a composition according to the invention are polyethylene glycols, including derivatives such as mono and dimethoxypolyethylene glycols (mPEGs) polyethylene oxides and/or block copolymers of ethylene oxide and propylene oxide.
Polyethylene glycols (PEGs) are linear polydisperse polymers composed of repeating units of ethylene glycol. Their chemical formula is HOCH2[CH2OCH2]mCH2OH where m represents the average number of repeating units. Alternatively, the general formula H[OCH2CH2]nOH may be used to represent polyethylene glycol, where n is a number m in the previous formula+1. See the structural presentations of polyethylene glycol below. n is the average number of oxyethylene groups. n equals m+1.
Figure US09642809-20170509-C00001
Polyethylene oxides (PEOs) are linear polydisperse nonionic polymers composed of repeating units of ethylene oxide. Their chemical formula is HO[CH2CH2O]nH where n represents the average number of oxyethylene groups. See the structural presentation of polyethylene oxide below. n is the average number of oxyethylene groups. Depending on preparation method high molecular weigh PEO may have one terminal methyl group.
Figure US09642809-20170509-C00002
Polyethylene glycols are mixtures of addition of ethylene glycol. In general PEG refers to polymers chains with molecular weights below 20,000, while PEO refers to higher molecular weights polymers. However, because of the similarities between PEO and PEG, the terms are often used interchangeably for the same compound.
Poloxamers are copolymers or block copolymers and are a range of non-ionic surfactants of polyethylene glycol (PEG) and polypropylene glycol (PPG).
In chemical abstracts Diol EO/PO block copolymers are described under the scientific name—hydroxy-hydroxypoly(oxyethylene)poly(oxypropylene)-poly(oxyethylene)-block copolymer in combination with the CAS register number.
In specific embodiments a suitable poloxamer for use in a composition of the invention has a HLB value of at least about 18 such as, e.g., at least about 20. The mean molecular weight of a suitable poloxamer is typically at least about 2,000.
Mixtures of PEO with different average molecular weights can be used in order to obtain a PEO with a desirable average molecular weight. The same applies to PEG.
The polymer has a melting point higher than the body temperature of the human in which the composition is to be used. Thus, the polymer(s) employed in the matrix composition will suitably have a melting point of about 20-120° C. such as, e.g. from about 30 to about 100° C. or from about 40 to about 80° C.
In addition to a polymer of a polyglycol type as described above other polymers may be suitable for use in a pharmaceutical composition provided that the solubility and/or release rate of the active substance from the composition in water is higher than or equal to the solubility of the matrix in 40% w/w ethanol in water. Thus, in other embodiments of the invention, the polymer or an additional polymer to the polyglycol may be selected from one or more of the following polymers: modified or unmodified water soluble natural polymers such as glucomannan, galactan, glucan, polygalacturonic acid, polyxylane, polygalactomannans, rhamnogalacturonan, polyxyloglycan, arabinogalactan, and starch, cellulose, chitosan, alginate, fibrin, collagen, gelatin, hyaluronic acid, amylopectin, pectin including low methylated or methoxylated pectins, dextran and fatty acids and alcohols; synthetic polymers such as polyvinylpyrrolidone (PVP), PVA, PVB, Eudragit L methyl ester, Eudragit L, Eudragit RL, Eudragit E, Eudragit S, PHPV, PHA, PCL, PLGA and PLA; and hydrogels made from the polymers or combined polymers mentioned above and or from polymers originated from: HEMA, HEEMA, MEMA, MEEMA, EDGMA, NVP, VAc, AA, acrylamide, MAA, HPMA, PEGA, PEGMA, PEGDMA, PEGDA, and PEGDMA.
Polymers in Layer A)
In one embodiment of the invention, layer A) comprises v) a substantially water soluble and/or crystalline polymer or a mixture of substantially water soluble and/or crystalline polymers, the polymer being a polyglycol in the from of one of c) a homopolymer having a MW of at the most about 16,000 daltons, and d) a copolymer having a MW of at the most about 30,000 daltons.
In specific embodiments, the polymer comprises a homopolymer having a MW of at least about 1,000 daltons such as, e.g., a homopolymer having a MW in a range from about 1,000 to about 15,000 daltons, from about 1,000 to about 12,000 daltons, from about 1,500 to about 10,000 daltons, from about 1,500 to about 8,000 daltons.
The polymer may also comprise a co-polymer having a MW of at the most about 25,000 daltons such as, e.g., at the most about 20,000 daltons, at the most about 15,000 daltons, at the most about 10,000 daltons, at the most about 5,000 daltons, at the most about 2,000 daltons.
Polymers in Layers B) or Used in Multiple Units Containing the Active Substance and Incorporated in Layer A)
Polyethylene glycols and/or polyethylene oxides, which are suitable for use in the matrix composition are those having a molecular weights of from about 20,000 daltons, such as, e.g., from about 20,000 to about 700,000 daltons, from about 20,000 to about 600,000 daltons, from about 35,000 to about 500,000 daltons, from about 35,000 to about 400,000 daltons, from about 35,000 to about 300,000 daltons, from about 50,000 to about 300,000 daltons, such as, e.g. about 35,000 daltons, about 50,000 daltons, about 75,000 daltons, about 100,000 daltons, about 150,000 daltons, about 200,000 daltons, about 250,000 daltons, about 300,000 daltons or about 400,000 daltons.
In a specific embodiment the matrix polymer is a polyethylene oxide or a polyethylene glycol that has a molecular weight of about 20,000 daltons, about 35,000 daltons, about 50,000 daltons, about 100,000 daltons, about 200,000 daltons, about 300,000 daltons and about 400,000 daltons. PEG is commercially available with average molecular weights up to 35 000. PEO is commercially available with average molecular weights up to 8,000,000. In specific embodiment, the polymer is a PEO having a molecular weight of at least about 100,000 such as, e.g., from about 100,000 to about 8,000,000, from about 100,000 to about 7,000,000, from about 100,000 to about 5,000,000, from about 100,000 to about 4,000,000, from about 100,000 to about 2,000,000, from about 100,000 to about 1,000,000, form about 100,000 to about 900,000. When PEO is employed with a molecular weight in the lower end, the PEO typically has a molecular weight as mentioned in the preceding paragraph. Commercially available PEOs with a molecular weight in the higher end have typically the following molecular weights: about 900,000, about 1,000,000, about 2,000,000, about 4,000,000, about 5,000,000, about 7,000,000, about 8,000,000. It should be noted that when PEO with a molecular weight of up to about 700,000 is used, it is possible to obtain a matrix composition (prepared e.g. by injection molding) that releases the active substance contained in the matrix with a zero order release (erosion of a constant surface area). However, the applicant has indications that employment of PEO with a molecular weight of 1,000,000 or higher leads to a slower release and a different release pattern. However, zero order release may not always be required from the layer B), but a slow release may be important. In such cases, the high molecular weight PEOs are suitable for use in a composition of the invention.
Typical block copolymers of ethylene oxide and propylene oxide have a molecular weight of from about 2,000 daltons, typically about 3,000 to about 30,000 daltons such as, e.g. from about 4,000 to about 15,000 daltons. If the copolymer is the sole thermoplastic polymer present in the composition it must not bee too brittle in order to avoid abuse by crushing of the composition, i.e. it must have an HLB value of about 18 to about 24.
Concentration of Polymers in Layer A and/or B
The polymer may also be a mixture of the above-mentioned polymers. Normally, the concentration of the polymer(s) in layer A) when applied is from about 1 to about 99.9% w/w dependent on the desired release properties relating to the release of the active substance from the inner layer. In those cases where a relative fast release of the active substance (or multiple units e.g. a pellet composition or the like containing the active substance) is desired or there is a relatively high concentration of active substance in layer A), a relative low concentration of the polymer may be of interest such as, e.g. from about 1 to about 30% w/w such as, e.g., from about 5 to about 25% w/w, from about 5 to about 20% w/w or from about 10 to about 20% w/w. In other cases, the concentration of the polymer in layer A) may be such as from about 10 to about 95% w/w, from about 15% to about 90% w/w, such as from 20 to 85%, such as from 30% to 85% from about 30 to about 99% w/w such as, e.g., from about 35 to about 95% w/w, from about 35 to about 90% w/w, from about 35 to about 85% w/w, from about 35 to about 80% w/w, from about 40 to about 75% w/w, from about 45 to about 70% w/w, from about 45 to about 65% w/w. from about 55 to about 85% w/w or from about 60 to about 85% w/w.
One or more polymers are typically present in a composition of the invention in a concentration amount of from 5 to 99.9% w/w such as from 10 to 95% such as from 15% to 90%, such as from 20 to 85%, such as from 30% to 85% calculated as w/w % of the composition.
In those cases, where mixture of polymers are present in the composition, the concentration of an individual polymer in the composition may typically be from about 0% to about 95% w/w such as, e.g., from about 0.5% to about 90% w/w, from about 1% to about 90% w/w, from about 5% to about 90% w/w, from about 10% to about 90% w/w, from about 10% to about 80% w/w, from about 10% to about 70% w/w, from about 10% to about 60%, from about 10% to about 50%, from about 15% to about 50% w/w, from about 15% to about 45% w/w, from about 15% to about 40% w/w, from about 20% to about 40% w/w, from about 20% to about 35% w/w or from about 20% to about 30% w/w. In specific embodiments, the concentration is even lower such as from about 1% to about 15% w/w or from about 5% to about 15% w/w.
The total concentration of the polymers (notably the sum of homo- and copolymers of the polyglycol type) in the composition is typically from about 5 to about 99.9% w/w such as from about 10 to about 95% w/w, from about 15% to about 90% w/w, such as from 20 to 85%, such as from 30% to 85% from about 30 to about 99% w/w such as, e.g., from about 35 to about 95% w/w, from about 35 to about 90% w/w, from about 35 to about 85% w/w, from about 35 to about 80% w/w, from about 40 to about 75% w/w, from about 45 to about 70% w/w, from about 45 to about 65% w/w. from about 55 to about 85% w/w or from about 60 to about 85% w/w. In specific embodiments (e.g. for burst layer (may be layer A) and/or layer B)), the concentration is even lower such as from about 5% to about 40% w/w or from about 5% to about 35% w/w.
The concentration of the polyglycol homopolymer is typically from about 0.5 to about 99.9% w/w such as from 5 to about 99.9% w/w, from about 0.5% to about 90% w/w, from about 1% to about 90% w/w, from about 5% to about 90% w/w, from about 20 to about 90% w/w, from about to about 90% w/w, and, in those cases where the homopolymer is the only thermoplastic polymer present in the composition, then the concentration is normally from about 50 to about 95% w/w such as, e.g. from about 55 to about 90% w/w, from about 60 to about 90%, from about 65 to about 90%, from about 70% to about 90% or from about 70 to about 85% w/w. In specific embodiments, the concentration is even lower such as from about 1% to about 15% w/w or from about 5% to about 15% w/w.
The concentration of the polyglycol copolymer, if present in combination with a polyglycol homopolymer, is typically from about 1 to about 60% w/w such as, e.g. from about 2.5 to about 50% w/w, from about 5 to about 45% w/w. If the copolymer is the sole thermoplastic polymer in the composition the concentration may be from about 5 to about 99.5% w/w such as those ranges described above and described for the homopolymer. In specific embodiments, the concentration is even lower such as from about 1% to about 15% w/w or from about 5% to about 15% w/w.
In embodiments where the outer layer matrix composition comprises a PEO and a poloxamer the weight ratio (PEO/poloxamer) is normally in a range from about 10:0.1 to about 0.1:10 such as, e.g., from about 10:1 to about 1:10, from about 5:1 to about 1:5 or from about 3:1 to about 1:3.
The one or more, the same or different active substance in the inner layer may be designed to various types of release once the inner layer is “released” from the shell.
In one embodiment of the invention, the inner layer contains the active substance incorporated into a multiple unit formulation or it may be present in the form of relatively large crystals (i.e. 100 μm or more).
Inner Layer—Active Substance in Multiple Units
As mentioned above, the active substance may be present in many forms in the inner layer. Thus, it may be present in dissolved form, e.g. dissolved in the ingredients of the inner layer such as in the form of a solid dispersion or solid solution. It may also be present in solid form e.g. in the form of particles or crystals of the active substance. Moreover, the active substance may be incorporated into a formulation before it is incorporation into the inner layer. Such formulations are described in the following including multiple units. In such a formulation, the active substance may be present in solid or dissolved form as well. The multiple units for use according to the invention may be crystals of an active substance, inert cores coated with active substance—inert cores like e.g. calcium alginate beads, cellulose spheres, charged resin spheres, glass beads, polystyrene spheres, sand silica beads or units, sodium hydroxide beads, sucrose spheres. Cores containing active substance like e.g. beads, pellets, flake, pieces, granules, granulates (also denoted agglomerates), spheres, tablets, especially minitablets etc.
The shape of the multiple units may be any suitable shape including a rounded or oval shape as well as a polygonal or rod-like or flake-like shape.
The mean particle size of the multiple units is at the most about 1400 μm. In particular embodiments, the particle size of the multiple units is at the most about 1200 μm such as, e.g., at the most about 1100 μm, at the most about 1000 μm, at the most about 900 μm, at the most about 800 μm, at the most about 750 μm, at the most about 700 μm, at the most about 650 μm, at the most about 600 μm, at the most about 550 μm or at the most about 500 μm; such as, e.g., from about 150 μm to about 1200 μm, from about 200 μm to about 1200 μm, from about 200 μm to about 1000 μm, from about 250 μm to about 800 μm or from about 300 μm to about 750 μm. In a specific embodiment of the invention the particle size of the multiple units is at the most about 500 μm to about 1000 μm, or from about 350 μm to about 500 μm. In some cases, the particle size of the multiple units may be even higher. Thus, in some cases the particle size may be at the most about 2 mm.
The release of the active substance may take place by diffusion by which the rate of release depends on several mechanisms, for example: the concentration difference between the matrix active substance concentration and the bulk concentration, the release surface area and the diffusion constant of the drug substance in the matrix. In special cases diffusion controlled release may be zero order.
Once the inner layer is exposed to the gastrointestinal fluids (or another aqueous medium) the release of the active substance may take place. In contrast to a release from a matrix that erodes (i.e. a matrix like the one of the outer layer), the release of the active substance from the inner layer may follow a kinetic that is different from a zero order release. The present formulation principle is designed to delay the release not necessarily to enable a zero order release or other types of release kinetics that are relevant when designing controlled or modified release compositions. However, the basic formulation principle of the present invention may be combined with known formulation principles e.g. if an active substance also is included in the matrix of the outer layer B), then this active substance can be released by zero order kinetics, i.e. in a controlled manner, and the active substance contained in the first fraction is released once exposed to the gastrointestinal fluids (or another aqueous medium) or in a controlled manner, but once the release of active substance or active multiple units from the first fraction starts it may be relatively fast.
Outer Layers B1) and B2)
The outer layers of a composition according to the invention are typically based on the matrix principle disclosed in WO 99/51208, WO 03/24426, WO 03/24429, WO 03/24430, WO 2004/41252, WO 2004/84869, WO 2005/107713, WO2006/128471 (to the same applicant). Such matrices have unique properties in that they erode, i.e. it does not disintegrate into smaller particles or conglomerates of particles upon exposure to the gastrointestinal fluid. Simplified, erosion means that a layer is eroded from the composition into the surrounding medium almost as if a slice of the matrix is cut off. Only the outer surface is exposed to erosion and from this outer layer the active substance will be released and/or dissolved provided that an active substance is present in the matrix. This means that if it is possible to control the size of the surface area by maintaining a constant size, it is possible to control the size of the release rate and, furthermore, a zero order release rate can be obtained.
The outer layers contain the same active substance as the inner layer A) to ensure optimal absorption of the active substance though the gastrointestinal tract a way to prolong the effect of e.g. a once-daily dosage form.
As mentioned above, each of the outer layers B1) and B2) comprises iii) a substantially water soluble and/or crystalline polymer or a mixture of substantially water soluble and/or crystalline polymers, the polymer being a polyglycol in the from of one of a) a homopolymer having a MW of at least about 100,000 daltons, and b) a copolymer having a MW of at least about 2,000 daltons,
The layers B1) and B2) may have the same or different composition and in a cylindrical shaped composition they may have the same or different size. In a preferred embodiment, the composition and size of the two B) layers are the same.
Suitable polymers for use in the outer layers are described in detail in the section above. However, with respect to the outer layer, it is important to ensure a control of the rate with which the outer layer disappears from the composition once it is exposed to an aqueous medium. As described above, the outer layers are composed in such a manner that the outer layer leaves the composition with a constant rate (corresponding to a zero order release rate in the event that a drug substance was present in the layer). Such a constant rate can be achieved by use of one or more polyglycols, but in contrast to the polymers suitable for used in the inner layer A), the homopolymer should preferably have a much higher molecular weight in order to ensure a constant erosion rate of the outer layer. Moreover, it is contemplated that when a co-polymer is employed preferably one or more of another polymer is included in the outer layer in order to obtain a suitable constant erosion rate.
As the function of the outer layers is different from the function of the inner layer, the polymer composition of the outer layer(s) B is different from the polymer composition of the inner layer A).
One or more pharmaceutically acceptable excipients or additives may also be incorporated into the outer layer(s), see the section herein. However, it is important that such excipients or additives do not significantly change the manner in which the outer layer disappears from the composition, i.e. it is important that this disappearance still is by a substantially constant rate e.g. by erosion or diffusion; addition of such substances may have impact on the rate (e.g. slow down or increase the rate), but it must not significantly change the properties of the outer layer B) so that the function as a “controlled lag-time layer provider” is destroyed.
In some embodiments of the invention, the outer layer B) may also contain one or more second active substances. Normally, such a second active substance in layer B) will be a different substance from that contained in layer A) in order to achieve a suitable combination treatment with two of more different active substance, one of which with a desired controlled release following a zero order release (the one contained in the outer layer B)) and the other one contained in the inner layer and designed for immediate release (or, alternatively, as detailed described under the section “Inner layer”, as a controlled release composition e.g. with zero or 1st order release).
In the section “Other embodiments of the invention” examples of various combinations are described.
Coating
As described above, the layered composition is provided with a coating C) that has at least one opening exposing at least one surface of said outer layer (layer B), the coating being substantially insoluble in and impermeable to fluids and comprising a polymer.
A composition according to the invention may be provided with a coating that can be applied in such a manner that it leaves a well-defined surface area free of coating while the remaining surface is covered and at the same time ensuring that the coating fulfils the requirement that no transport of water into the matrix (or other parts of the composition) takes place through the coating (or, if any water should enter, then it does not result in a transport of dissolved active substance out through the coating). In other words, it has been the object to develop a coating that does not leave an uncontrollable surface area of the matrix exposed to the aqueous environment and that has suitable properties compared to the matrix, i.e. if the coating dissolves or otherwise disappears then it should only take place after the matrix has eroded or dissolved away (during the release period, the coating may of course also partly dissolve or disappear provided that the part it concerns covered a part of the matrix that has already been subject to erosion or diffusion, thus, leaving the remaining composition “intact” with a matrix that is surrounded by the coating apart from the open end from which erosion or diffusion of the matrix takes place).
The composition may be partly or fully covered by a coat with specific properties in such a way that the exposed area of the matrix may be controlled by the use of a coat. In a specific example the coat is substantially insoluble, non-erodible and non-permeable to water leaving only the exposed areas of the composition for release. Such a coat may be composed of a polymer that has thermoplastic properties. Examples of such materials are mentioned below including cellulose derivative which has thermoplastic properties, plasticizer or plasticizers and/other functional excipients.
The coating may also be a coating, which is substantially soluble in and permeable to fluids such as body fluids during the intended release period provided that the coating dissolves so much slower than the matrix composition that the coating remains intact until the matrix has eroded and/or released the inner layer containing an active substance. Examples of suitable polymers include polyglycols as described herein.
The coating may further comprise any of the mentioned matrix materials (i.e. polymeric material suitable for use in the outer layers B) in a form, which erodes at a substantially slower rate than the rest of the matrix. The coating may thus comprise a matrix of one or more substantially water soluble crystalline polymers and, optionally, a non-ionic emulsifier, the coating being one which is eroded in the aqueous phase at a substantially slower rate than the outer layer B, whereby a substantially controlled area of the outer layer B matrix composition (in some cases also comprising a second active substance) is exposed during erosion of the matrix composition and/or during release of the active substance, and whereby the coating is substantially eroded upon erosion of the matrix composition and/or during release of the active substance. Such a coating will be designed so that its longitudinal erosion rate is substantially the same as the longitudinal erosion rate of the matrix, whereby the matrix and the coating will erode longitudinally towards the centre of the composition at substantially the same rate. Thus, when the outer layer matrix composition has been completely eroded and/or dissolved by the aqueous medium and the inner layer has been released from the shell (i.e. the coating), the coating will also be substantially completely eroded. A matrix composition having such a coating has the obvious advantage of being completely biodegraded upon release of the active substance.
The coating may impart delayed properties for releasing the active substance or it may be a film-coating or a coating containing the active substance for immediate release prior to the controlled release or other kinds of coatings that does not delay the release but e.g. make it easier to swallow the composition or it may e.g. mask a bad taste. Materials suitable for such coatings are well-known for a person skilled in the art and information can be found e.g. in the latest editions of handbooks like Handbook of Pharmaceutical Excipients or in Remington's Pharmaceutical Sciences.
In an embodiment of the invention, the coating is one, which biodegrades, disintegrates crumbles or dissolves after erosion of the matrix and/or during the release of the active substance. A coating applied for an erosion matrix will remain intact as long as it is supported by the matrix containing the active substance, but it lacks the ability to remain intact after erosion of the matrix, because it then biodegrades, disintegrates or crumbles, so that it will not remain in e.g. a human for any significant amount of time after the complete erosion of the outer matrix layer B and the release of the inner layer A.
In an interesting embodiment, the composition of the invention further comprises a coating having at least one opening exposing at least one surface of the matrix, the coating being one which crumbles and/or erodes upon exposure to the aqueous medium at a rate which is equal to or slower than the rate at which the matrix erodes in the aqueous medium, allowing exposure of said surface of the matrix to the aqueous medium to be controlled.
Polymers useful as coatings are such as e.g. cellulose derivative e.g. ethylcellulose, cellulose acetate, cellulose propionate, cellulose nitrate, cellulose derivative selected from the group consisting of methylcellulose, carboxymethylcellulose and salts thereof, cellulose acetate phthalate, microcrystalline cellulose, ethylhydroxyethylcellulose, ethylmethylcellulose, hydroxyethylcellulose, hydroxyethylmethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxymethylcellulose and hydroxymethylpropylcellulose, cellulose acetate, Eudragit L methyl ester, Eudragit RL, Eudragit E, polyamide, polyethylene, polyethylene terephthalate, polypropylene polyurethane, polyvinyl acetate, polyvinyl chloride, silicone rubber, latex, polyhydroxybutyrate, polyhydroxyvalerate, polytetrafluoroethylene, polylactic acid or polyglycolic acid and copolymers thereof, copolymers such as ethylene vinyl acetate (EVA), styrene-butadienestyrene (SBS) and styrene-isoprene-styrene (SIS). The coating may also be copolymers of polylactic acid and polyglycolic acid. The coating may also be an enteric coating employing methacrylates Eudragit L, Eudragit S, Eudragit FS, a co-polymer of methacrylate-galactomannan etc.
In one embodiment, the controlled release composition of the invention further comprises a coating having at least one opening exposing at least one surface of the matrix, the coating being one which crumbles and/or erodes upon exposure to the aqueous medium at a rate which is equal to or slower than the rate at which the matrix erodes in the aqueous medium, allowing exposure of said surface of the matrix to the aqueous medium to be controlled. Coatings of this type are described in WO 95/22962, to which reference is made and which is incorporated herein by reference. These coatings comprise:
    • (a) a first cellulose derivative which has thermoplastic properties and which is substantially insoluble in the aqueous medium in which the composition is to be used, e.g. an ethylcellulose such as ethylcellulose having an ethoxyl content in the range of 44.5-52.5%, or cellulose acetate, cellulose propionate or cellulose nitrate;
      and at least one of:
    • (b) a second cellulose derivative which is soluble or dispersible in water, e.g. a cellulose derivative selected from the group consisting of methylcellulose, carboxymethylcellulose and salts thereof, cellulose acetate phthalate, microcrystalline cellulose, ethylhydroxyethylcellulose, ethylmethylcellulose, hydroxyethylcellulose, hydroxyethylmethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxymethylcellulose and hydroxymethylpropylcellulose;
    • (c) a plasticizer, e.g. selected from the group consisting of phosphate esters; phthalate esters; amides; mineral oils; fatty acids and esters thereof; polyethylene glycol, glycerin or sugars; fatty alcohols and ethers thereof; vegetable oils; or a non-ionic surfactant; and
    • (d) a filler, e.g. selected from conventional tablet or capsule excipients such as diluents, binders, lubricants and disintegrants.
The first cellulose derivative (a) such as, e.g., ethylcellulose is typically contained in the coating in a concentration of from about 10 to about 99% w/w such as, e.g., from about 20 to about 95% w/w, from about 30 to about 90% w/w, from about 40 to about 90% w/w, from about 45 to about 90% w/w, from about 50 to about 85% w/w or from about 50 to about 80% w/w.
In general, the concentration of the polymer in the coating is from about 60% w/w to about 100% w/w. 0-40% w/w of one or more of a plasticizer, a colouring agent, a stabilizer, a glidants or the like may also be present in the coating.
Moreover, in some embodiments of the invention a further active substance may be incorporated in the coating or the composition may be provided with a second coating comprising the further active substance. Such a coating may be designed to release the active substance from the coating immediately after oral administration or a composition of the invention may be subject to enteric coating such that release will be pH dependent.
Such compositions wherein a coating contains an active substance may be of interest in those situations where a fast onset of action is desired, i.e. a fast release of an active substance is desired in order to quickly obtain a therapeutically effective plasma concentration of the active substance. Such an active substance may be the same or different from that contained in layer B and/or the inner layer A dependent on the particular disease or condition to be treated.
In such cases where a second coating is provided on the composition such a coating is generally a film-coating and it is normally applied in a separate manufacturing step (e.g. not by injection moulding, but using processes generally applicable for film-coating of tablets such as, e.g., pan coating, fluid bed coating, spray coating, dip coating etc.).
Dose Dumping
In one aspect, the invention is based on controlled release compositions comprising polymer or a mixture of polymers, more specifically a polyglycol, an active substance and optionally one or more pharmaceutically acceptable excipients in layer B. Polymers and pharmaceutically acceptable excipients suitable for use in such a composition as well as relevant active substances are described herein. Such compositions have proved to mitigate the risk of alcohol induced dose dumping. “Dose dumping” is unintended, rapid drug release in a short period of time of the entire amount or a significant fraction of the active substance retained in a controlled release dosage.
In a specific embodiment of the invention the release mechanism is primarily erosion or diffusion from layer B composed of a polymer matrix, an active substance and if necessary one or more excipients. The mechanism of erosion enables the composition to release with a rate depending on the exposed area. Inner layer A of the invention contains active substance or active multiple units (e.g. pellets or mini tablets) in such a form that the active substance or individual active units will be made available upon disintegration of the composition in the stomach, small intestine and/or colon after erosion of layer B. The individual units are of a size, which allows them to be incorporated into such a composition.
The matrix composition of layer B and active multiple units according to the invention has (in total) a lower (or equal) solubility and/or release rate in alcohol containing media (e.g. ethanol) than in aqueous media (e.g. water, buffer).
The active substance in the above mention matrix composition optionally comprising chosen polymers and excipients in a suitable ratio attains an unchanged or lower dissolution rate when tested in alcohol containing media as compared to aqueous media.
In principle, the use of a composition to avoid alcohol dose dumping can be of relevance for any active substance.
An easy manner to investigate whether a composition potentially will be subject to alcohol induced dose dumping is to subject the composition to an dissolution test using a dissolution medium with and without alcohol and investigate whether there are any differences in the release pattern under the two different conditions. The harshest conditions are in a dissolution medium containing 40% (v/v) ethanol. If the dissolution rate of the composition is substantially unaffected or slower, then it is likely to assume that no alcohol induced dose dumping will take place in vivo.
Active Substances for Use in a Composition of the Invention
A composition according to the invention comprises one or more active substances. At least one active substance is included in the inner layer and outer layer(s) of the composition, which are the same, but the outer layer(s) may also contain one or more active substances that is different from the active substance contained in the inner layer.
Typically, the amount of each active substance in the composition if the same active substance is present in the inner layer and/or outer layer and/or in the coating) corresponds to a daily or part of a daily therapeutic dose.
A pharmaceutical composition according to the invention is suitable for use for both water soluble as well as slightly soluble or insoluble active substances.
Thus, a pharmaceutical composition according to the invention may comprise one or more active substances, i.e. substances, which are therapeutically, prophylactically, diagnostically and/or biologically active substance. The term “active substance” as used herein broadly includes any compound, or mixture thereof, that can be delivered from the composition to produce a beneficial result.
The active substance or substances included in a pharmaceutical composition of the invention may be selected from many therapeutic categories, in particular from substances which may advantageously be administered orally, rectally, vaginally, or administered to a body cavity (e.g. the urinary bladder, kidney pelvis, the gall bladder, the uterus, a central nervous system cavity, infectious/malignant/post-operative cavities, etc.).
Examples of specific active substances suitable for use in a composition of the invention are: Stomatological active substances; Epinephrine, Benzydamine, Acetylsalicylic acid, Adrenalone, Amlexanox, Sodium fluoride, Sodium monofluorophosphate, Olaflur, Stannous fluoride, Sodium fluoride, Hydrogen peroxide, Chlorhexidine, Amphotericin B, Polynoxylin, Domiphen, Oxyquinoline, Neomycin, Miconazole, Natamycin, Hexetidine, Tetracycline, Benzoxonium chloride, Tibezonium iodide, Mepartricin, Metronidazole, Clotrimazole, Sodium perborate, Chlortetracycline, Doxycycline, Minocycline, Triamcinolone, Dexamethasone, Hydrocortisone, Prednisolone. Active substances for acid related disorders; Magnesium carbonate, Magnesium oxide, Magnesium peroxide, Magnesium hydroxide, Magnesium silicate, Aluminium hydroxide, Algeldrate, Aluminium phosphate, Dihydroxialumini sodium carbonate, Aluminium acetoacetate, Aloglutamol, Aluminium glycinate, Calcium carbonate, Calcium silicate, Ordinary salt combinations, Magaldrate, Almagate, Hydrotalcite, Almasilate, Magaldrate, Cimetidine, Ranitidine, Famotidine, Nizatidine, Niperotidine, Roxatidine, Ranitidine bismuth citrate, Lafutidine, Cimetidine, Famotidine, Misoprostol, Enprostil, Omeprazole, Pantoprazole, Lansoprazole, Rabeprazole, Esomeprazole, Carbenoxolone, Sucralfate, Pirenzepine, Methiosulfonium chloride, Bismuth subcitrate, Proglumide, Gefarnate, Sulglicotide, Acetoxolone, Zolimidine, Troxipide, Bismuth subnitrate, Alginic acid. Active substances for functional gastrointestinal disorders; Oxyphencyclimine, Camylofin, Mebeverine, Trimebutine, Rociverine, Dicycloverine, Dihexyverine, Difemerine, Piperidolate, Metoclopramide, Cisapride, Domperidone, Bromopride, Alizapride, Clebopride. Antiemetic and antinauseant active substances; Serotonin (5HT3) antagonists, Ondansetron, Granisetron, Tropisetron, Dolasetron, Palonosetron, Scopolamine, Cerium oxalate, Chlorobutanol, Metopimazine, Dronabinol, Nabilone, Aprepitant. Active substances for bile and liver therapy; Bile acid preparations, Chenodeoxycholic acid, Ursodeoxycholic acid, Nicotinyl methylamide, Piprozolin, Hymecromone, Cyclobutyrol, Arginine glutamate, Silymarin, Citiolone, Epomediol, Ornithine oxoglurate, Tidiacic arginine. Laxative active substances; Softeners, Emollients, Liquid paraffin, Docusate sodium, Liquid paraffin, Contact laxatives, Oxyphenisatine, Bisacodyl, Dantron, Phenolphthalein, Castor oil, Senna glycosides, Cascara, Sodium picosulfate, Bisoxatin, Belladonna alkaloids, Bisacodyl, Dantron, Senna glycosides, Cascara, Sodium picosulfate, Ispaghula (psylla seeds), Ethulose, Sterculia, Linseed, Methylcellulose, Triticum (wheat fibre), Polycarbophil calcium, Magnesium carbonate, Magnesium oxide, Magnesium peroxide, Magnesium sulfate, Lactulose, Lactitol, Sodium sulfate, Pentaerithrityl, Macrogol, Mannitol, Sodium phosphate, Sorbitol, Magnesium citrate, Sodium tartrate, Enemas, Sodium phosphate, Bisacodyl, Glycerol, Oil, Laurilsulfate, Carbon dioxide producing drugs. Antidiarrheal, intestinal, anti-inflammatory/antiinfective active substances; Antibiotics, Neomycin, Nystatin, Natamycin, Streptomycin, Polymyxin B, Paromomycin, Amphotericin B, Kanamycin, Vancomycin, Colistin, Rifaximin, Sulfonamides, Phthalylsulfathiazole, Sulfaguanidine, Succinylsulfathiazole, Imidazole derivatives, Miconazole, Broxyquinoline, Acetarsol, Nifuroxazide, Nifurzide, Medicinal charcoal, Bismuth, Pectin, Kaolin, Crospovidone, Attapulgite, Diosmectite, Diphenoxylate, Opium, Loperamide, Difenoxin, Loperamide oxide, Morphine, Prednisolone, Hydrocortisone, Prednisone, Betamethasone, Tixocortol, Budesonide, Beclometasone, Antiallergic agents, excl. corticosteroids, Cromoglicic acid, Aminosalicylic acid and similar agents, Sulfasalazine, Mesalazine, Olsalazine, Balsalazide, Antidiarrheal microorganisms, Lactic acid producing organisms, Saccharomyces boulardii, Lactic acid producing organisms, Albumin tannate, Ceratonia, Calcium compounds, Racecadotril. Antiobesity active substances; Phentermine, Fenfluramine, Amfepramone, Dexfenfluramine, Mazindol, Etilamfetamine, Cathine, Clobenzorex, Mefenorex, Sibutramine, Ephedrine, Orlistat, Rimonabant. Digestiveactive substances; Enzyme preparations, Diastase, Multienzymes (lipase, protease etc.), Pepsin, Tilactase, Acid preparations, Glutamic acid hydrochloride, Betaine hydrochloride, Hydrochloric acid, Citric acid. Diabetes active substances; Insulins and analogues, Biguanides, Phenformin, Metformin, Buformin, Sulfonamides, urea derivatives, Glibenclamide, Chlorpropamide, Tolbutamide, Glibornuride, Tolazamide, Carbutamide, Glipizide, Gliquidone, Gliclazide, Metahexamide, Glisoxepide, Glimepiride, Acetohexamide, Sulfonamides (heterocyclic), Glymidine, Combinations of oral blood glucose lowering drugs, Alpha glucosidase inhibitors, Acarbose, Miglitol, Voglibose, Thiazolidinediones, Troglitazone, Rosiglitazone, Pioglitazone, Dipeptidyl peptidase 4 (DPP-4) inhibitors, Sitagliptin, Vildagliptin, Guar gum, Repaglinide, Nateglinide, Exenatide, Aldose reductase inhibitors, Tolrestat. Anabolic active substances; Androstan derivatives, Androstanolone, Stanozolol, Metandienone, Metenolone, Oxymetholone, Quinbolone, Prasterone, Oxandrolone, Norethandrolone, Estren derivatives, Nandrolone, Ethylestrenol, Oxabolone cipionate. Metabolism active substances; Amino acids and derivatives, Levocarnitine, Ademetionine, Glutamine, Mercaptamine, Carglumic acid, Betaine, Enzymes, Alglucerase, Imiglucerase, Agalsidase alfa, Agalsidase beta, Laronidase, Sacrosidase, Alglucosidase alfa, Galsulfase, Idursulfase, Tioctic acid, Anethole trithione, Sodium phenylbutyrate, Nitisinone, Zinc acetate, Miglustat, Sapropterin.
Antithrombotic active substances; Vitamin K antagonists, Dicoumarol, Phenindione, Warfarin, Phenprocoumon, Acenocoumarol, Ethyl biscoumacetate, Clorindione, Diphenadione, Tioclomarol, Heparin, Antithrombin III, Dalteparin, Enoxaparin, Nadroparin, Parnaparin, Reviparin, Danaparoid, Tinzaparin, Sulodexide, Bemiparin, Platelet aggregation inhibitors excl. heparin, Ditazole, Cloricromen, Picotamide, Clopidogrel, Ticlopidine, Acetylsalicylic acid, Dipyridamole, Carbasalate calcium, Epoprostenol, Indobufen, Iloprost, Abciximab, Aloxiprin, Eptifibatide, Tirofiban, Triflusal, Beraprost, Treprostinil, Enzymes, Streptokinase, Alteplase, Anistreplase, Urokinase, Fibrinolysin, Brinase, Reteplase, Saruplase, Ancrod, Drotrecogin alfa (activated), Tenecteplase, Protein C, Direct thrombin inhibitors, Desirudin, Lepirudin, Argatroban, Melagatran, Ximelagatran, Bivalirudin, Dabigatran etexilate, Defibrotide, Dermatan sulfate, Fondaparinux. Antihemorrhagics active substances; Amino acids, Aminocaproic acid, Tranexamic acid, Aminomethylbenzoic acid, Proteinase inhibitors, Aprotinin, Alfa1 antitrypsin, C1-inhibitor, Camostat, Vitamin K, Phytomenadione, Menadione, Fibrinogen, Local hemostatics, Absorbable gelatin sponge, Oxidized cellulose, Tetragalacturonic acid hydroxymethylester, Adrenalone, Thrombin, Collagen, Calcium alginate, Epinephrine, Blood coagulation factors, Coagulation factor IX, II, VII and X in combination, Coagulation factor VIII, Factor VIII inhibitor bypassing activity, Coagulation factor IX, Coagulation factor VII, Von Willebrand factor and coagulation factor VIII in combination, Coagulation factor XIII, Eptacog alfa (activated), Nonacog alfa, Thrombin, Etamsylate, Carbazochrome, Batroxobin. Antianemic active substances; Ferrous glycine sulfate, Ferrous fumarate, Ferrous gluconate, Ferrous carbonate, Ferrous chloride, Ferrous succinate, Ferrous sulfate, Ferrous tartrate, Ferrous aspartate, Ferrous ascorbate, Ferrous iodine, Ferric sodium citrate, Saccharated iron oxide, Sodium feredetate, Ferric hydroxide, Dextriferron, Ferric citrate, Chondroitin sulfate-iron complex, Ferric acetyl transferrin, Ferric proteinsuccinylate, Dextriferron, Vitamin B12 (cyanocobalamin and analogues), Cyanocobalamin, Cyanocobalamin tannin complex, Hydroxocobalamin, Cobamamide, Mecobalamin, Folic acid and derivatives, Erythropoietin, Darbepoetin alfa, Methoxy polyethylene glycol-epoetin beta. Hematological active subtances; Fibrinolysin and desoxyribonuclease, Hyaluronidase, Chymotrypsin, Trypsin, Desoxyribonuclease, Bromelains, Streptokinase, combinations, Hematin.
Cardiac stimulant active substances; Cardiac glycosides, Digitalis glycosides, Acetyldigitoxin, Acetyldigoxin, Digitalis leaves, Digitoxin, Digoxin, Lanatoside C, Deslanoside, Metildigoxin, Gitoformate, Scilla glycosides, Proscillaridin, Strophantus glycosides, G-strophanthin, Cymarin, Peruvoside, Adrenergic and dopaminergic agents, Etilefrine, Isoprenaline, Norepinephrine, Dopamine, Norfenefrine, Phenylephrine, Dobutamine, Oxedrine, Metaraminol, Methoxamine, Mephentermine, Dimetofrine, Prenalterol, Dopexamine, Gepefrine, Ibopamine, Midodrine, Octopamine, Fenoldopam, Cafedrine, Arbutamine, Theodrenaline, Epinephrine, Phosphodiesterase inhibitors, Amrinone, Milrinone, Enoximone, Bucladesine, Other cardiac stimulants, Angiotensinamide, Xamoterol, Levosimendan. Antiarrhythmics active subtances; class Ia, Quinidine, Procainamide, Disopyramide, Sparteine, Ajmaline, Prajmaline, Lorajmine, Antiarrhythmics, class Ib, Lidocaine, Mexiletine, Tocainide, Aprindine, Antiarrhythmics, class Ic, Propafenone, Flecainide, Lorcainide, Encainide, Antiarrhythmics, class III, Amiodarone, Bretylium tosilate, Bunaftine, Dofetilide, Ibutilide, Other class I antiarrhythmics, Moracizine, Cibenzoline. Active substances for vasodilation; Organic nitrates, Glyceryl trinitrate, Methylpropylpropanediol dinitrate, Pentaerithrityl tetranitrate, Propatylnitrate, Isosorbide dinitrate, Trolnitrate, Eritrityl tetranitrate, Isosorbide mononitrate, Tenitramine, Flosequinan, Itramin tosilate, Prenylamine, Oxyfedrine, Benziodarone, Carbocromen, Hexobendine, Etafenone, Heptaminol, Imolamine, Dilazep, Trapidil, Molsidomine, Efloxate, Cinepazet, Cloridarol, Nicorandil, Linsidomine, Nesiritide. Cardiac active substances; Prostaglandins, Alprostadil, Other cardiac preparations, Camphora, Indometacin, Crataegus glycosides, Creatinolfosfate, Fosfocreatine, Fructose 1,6-diphosphate, Ubidecarenone, Adenosine, Tiracizine, Tedisamil, Acadesine, Trimetazidine, Ibuprofen, Ivabradine, Ranolazine. Antihypertensive active substances; Rauwolfia alkaloids, Rescinnamine, Reserpine, Deserpidine, Methoserpidine, Bietaserpine, Methyldopa, Imidazoline receptor agonists, Clonidine, Guanfacine, Tolonidine, Moxonidine, Rilmenidine, Sulfonium derivatives, Trimetaphan, Secondary and tertiary amines, Mecamylamine, Bisquaternary ammonium compounds, Alpha-adrenoreceptor antagonists, Prazosin, Indoramin, Trimazosin, Doxazosin, Urapidil, Guanidine derivatives, Betanidine, Guanethidine, Guanoxan, Debrisoquine, Guanoclor, Guanazodine, Guanoxabenz, Thiazide derivatives, Diazoxide, Hydrazinophthalazine derivatives, Dihydralazine, Hydralazine, Endralazine, Cadralazine, Pyrimidine derivatives, Minoxidil, Nitroferricyanide derivatives, Nitroprusside, Guanidine derivatives, Pinacidil, Veratrum, Tyrosine hydroxylase inhibitors, Metirosine, MAO inhibitors, Pargyline, Serotonin antagonists, Ketanserin, http://www.whocc.no/atcddd/indexdatabase/index.php?query=C02KX Bosentan, Ambrisentan, Sitaxentan. Diuretic active substances; Thiazides, Bendroflumethiazide, Hydroflumethiazide, Hydrochlorothiazide, Chlorothiazide, Polythiazide, Trichlormethiazide, Cyclopenthiazide, Methyclothiazide, Cyclothiazide, Mebutizide, Sulfonamides, Quinethazone, Clopamide, Chlortalidone, Mefruside, Clofenamide, Metolazone, Meticrane, Xipamide, Indapamide, Clorexolone, Fenquizone, Mercurial diuretics, Mersalyl, Xanthine derivatives, Theobromine, Cicletanine, Furosemide, Bumetanide, Piretanide, Torasemide, Aryloxyacetic acid derivatives, Etacrynic acid, Tienilic acid, Pyrazolone derivatives, Muzolimine, Etozolin, Aldosterone antagonists, Spironolactone, Potassium canrenoate, Canrenone, Eplerenone, Amiloride, Triamterene. Active substances for peripheral vasodilation; 2-amino-1-phenylethanol derivatives, Isoxsuprine, Buphenine, Bamethan, Imidazoline derivatives, Phentolamine, Tolazoline, Nicotinic acid, Nicotinyl alcohol (pyridylcarbinol), Inositol nicotinate, Ciclonicate, Purine derivatives, Pentifylline, Xantinol nicotinate, Pentoxifylline, Etofylline nicotinate, Ergot alkaloids, Ergoloid mesylates, Nicergoline, Dihydroergocristine, Kallidinogenase, Cyclandelate, Phenoxybenzamine, Vincamine, Moxisylyte, Bencyclane, Vinburnine, Suloctidil, Buflomedil, Naftidrofuryl, Butalamine, Visnadine, Cetiedil, Cinepazide, Ifenprodil, Azapetine, Fasudil. Vasoprotective active substances; Heparinoid, Sodium apolate, Heparin, Pentosan polysulfate sodium, Monoethanolamine oleate, Polidocanol, Invert sugar, Sodium tetradecyl sulfate, Phenol, Glucose, Calcium dobesilate, Bioflavonoids, Rutoside, Monoxerutin, Diosmin, Troxerutin, Hidrosmin, Tribenoside. Beta blocking active substances; Beta blocking agents, non-selective, Alprenolol, Oxprenolol, Pindolol, Propranolol, Timolol, Sotalol, Nadolol, Mepindolol, Carteolol, Tertatolol, Bopindolol, Bupranolol, Penbutolol, Cloranolol, Beta blocking agents, selective, Practolol, Metoprolol, Atenolol, Acebutolol, Betaxolol, Bevantolol, Bisoprolol, Celiprolol, Esmolol, Epanolol, S-atenolol, Nebivolol, Talinolol, Alpha and beta blocking agents, Labetalol, Carvedilol. Calium channel blockers; Dihydropyridine derivatives, Amlodipine, Felodipine, Isradipine, Nicardipine, Nifedipine, Nimodipine, Nisoldipine, Nitrendipine, Lacidipine, Nilvadipine, Manidipine, Barnidipine, Lercanidipine, Cilnidipine, Benidipine, Mibefradil, Phenylalkylamine derivatives, Verapamil, Gallopamil, Benzothiazepine derivatives, Diltiazem, Phenylalkylamine derivatives, Fendiline, Bepridil, Lidoflazine, Perhexiline. Active substances acting on the renin-angiotensin system; ACE inhibitors, Captopril, Enalapril, Lisinopril, Perindopril, Ramipril, Quinapril, Benazepril, Cilazapril, Fosinopril, Trandolapril, Spirapril, Delapril, Moexipril, Temocapril, Zofenopril, Imidapril, Other, Renin-inhibitors, Remikiren, Aliskiren, Angiotensin II antagonists, Losartan, Eprosartan, Valsartan, Irbesartan, Candesartan, Telmisartan, Olmesartan. Lipid modifying active substances; HMG CoA reductase inhibitors, Simvastatin, Lovastatin, Pravastatin, Fluvastatin, Atorvastatin, Cerivastatin, Rosuvastatin, Pitavastatin, Fibrates, Clofibrate, Bezafibrate, Aluminium clofibrate, Gemfibrozil, Fenofibrate, Simfibrate, Ronifibrate, Ciprofibrate, Etofibrate, Clofibride, Bile acid sequestrants, Colestyramine, Colestipol, Colextran, Colesevelam, Nicotinic acid and derivatives, Niceritrol, Nicofuranose, Aluminium nicotinate, Nicotinyl alcohol (pyridylcarbinol), Acipimox, Other lipid modifying agents, Dextrothyroxine, Probucol, Tiadenol, Benfluorex, Meglutol, Omega-3-triglycerides, Magnesium pyridoxal 5-phosphate glutamate, Policosanol, Ezetimibe
Dermatological active substances for system use; Antifungals, Griseofulvin, Terbinafine, Protectives against UV-radiation for systemic use, Betacarotene, Antipsoriatics, Psoralens, Trioxysalen, Methoxsalen, Bergapten, Retinoids, Etretinate, Acitretin, Anti-acne, Isotretinoin, Ichtasol. Antiinfective and antiseptic active substances; Antibiotics, Nystatin, Natamycin, Amphotericin B, Candicidin, Chloramphenicol, Azidamfenicol, Hachimycin, Oxytetracycline, Carfecillin, Mepartricin, Clindamycin, Pentamycin, Arsenic compounds, Acetarsol, Quinoline derivatives, Diiodohydroxyquinoline, Clioquinol, Chlorquinaldol, Dequalinium, Broxyquinoline, Oxyquinoline, Organic acids, Lactic acid, Acetic acid, Ascorbic acid, Sulfonamides, Sulfatolamide, Combinations of sulfonamides, Imidazole derivatives, Metronidazole, Clotrimazole, Miconazole, Econazole, Ornidazole, Isoconazole, Tioconazole, Ketoconazole, Fenticonazole, Azanidazole, Propenidazole, Butoconazole, Omoconazole, Oxiconazole, Flutrimazole, Triazole derivatives, Terconazole, Clodantoin, Inosine, Policresulen, Nifuratel, Furazolidone, Methylrosaniline, Povidone-iodine, Ciclopirox, Protiofate, Lactobacillus fermentum, Copper usnate, Octenidine
Gynecological active substances; Ergot alkaloids, Methylergometrine, Ergot alkaloids, Ergometrine, Oxytocin, Prostaglandins, Dinoprost, Dinoprostone, Gemeprost, Carboprost, Sulprostone, Misoprostol, Ritodrine, Buphenine, Fenoterol, Prolactine inhibitors, Bromocriptine, Lisuride, Cabergoline, Quinagolide, Metergoline. Hormones; Norgestrel, Gestodene, Norgestimate, Drospirenone, Norelgestromin, Progestogens, Norethisterone, Lynestrenol, Levonorgestrel, Quingestanol, Megestrol, Medroxyprogesterone, Norgestrienone, Etonogestrel, Desogestrel, 3-oxoandrosten (4) derivatives, Fluoxymesterone, Methyltestosterone, Testosterone, 5-androstanon (3) derivatives, Mesterolone, Androstanolone, Ethinylestradiol, Estradiol, Estriol, Chlorotrianisene, Estrone, Promestriene, Conjugated estrogens, Dienestrol, Diethylstilbestrol, Methallenestril, Moxestrol, Dienestrol, Methallenestril, Estrone, Diethylstilbestrol, Pregnen (4) derivatives, Gestonorone, Medroxyprogesterone, Hydroxyprogesterone, Progesterone, Pregnadien derivatives, Dydrogesterone, Megestrol, Medrogestone, Nomegestrol, Demegestone, Chlormadinone, Promegestone, Estren derivatives, Allylestrenol, Norethisterone, Lynestrenol, Ethisterone, Tibolone, Etynodiol, Methylestrenolone, Methyltestosterone, Methylnortestosterone, Noretynodrel, Dienogest, Trimegeston, Gonadotropins, Urofollitropin, Follitropin alfa, Follitropin beta, Lutropin alfa, Choriogonadotropin alfa, Cyclofenil, Clomifene, Epimestrol, Cyproterone, Danazol, Gestrinone, Antiprogestogens, Mifepristone, Raloxifene, Corticotropin, Tetracosactide, Thyrotropin, Thyrotropin, Somatropin and somatropin agonists, Somatropin, Somatrem, Mecasermin, Sermorelin, Mecasermin rinfabate, Pegvisomant, Vasopressin and analogues, Vasopressin, Desmopressin, Lypressin, Terlipressin, Ornipressin, Argipressin, Oxytocin and analogues, Demoxytocin, Oxytocin, Carbetocin, Gonadotropin-releasing hormones, Gonadorelin, Nafarelin, Histrelin, Antigrowth hormone, Somatostatin, Octreotide, Lanreotide, Vapreotide, Anti-gonadotropin-releasing hormones, Ganirelix, Cetrorelix, Glycogenolytic hormones, Glucagon, Parathyroid hormones and analogues, Teriparatide, Parathyroid hormone, Calcitonin, http://www.whocc.no/atcddd/indexdatabase/index.php?query=H05BA01 Elcatonin, Cinacalcet. Urological active substances; Acidifiers, Ammonium chloride, Calcium chloride, Urinary concrement solvents, Urinary antispasmodics, Emepronium, Flavoxate, Meladrazine, Oxybutynin, Terodiline, Propiverine, Tolterodine, Solifenacin, Trospium, Darifenacin, Fesoterodine, Drugs used in erectile dysfunction, Alprostadil, Papaverine, Sildenafil, Yohimbin, Phentolamine, Moxisylyte, Apomorphine, Tadalafil, Vardenafil, Combinations, Papaverine, combinations, Magnesium hydroxide, Acetohydroxamic acid, Phenazopyridine, Succinimide, Collagen, Phenyl salicylate, Dimethyl sulfoxide, Alpha-adrenoreceptor antagonists, Alfuzosin, Tamsulosin, Terazosin, Testosterone-5-alpha reductase inhibitors, Finasteride, Dutasteride, Pygeum africanum, Serenoa repens, Mepartricin. Corticosteroids; Mineralocorticoids, Aldosterone, Fludrocortisone, Desoxycortone, Glucocorticoids, Betamethasone, Dexamethasone, Fluocortolone, Methylprednisolone, Paramethasone, Prednisolone, Prednisone, Triamcinolone, Hydrocortisone, Cortisone, Prednylidene, Rimexolone, Deflazacort, Cloprednol, Meprednisone, Cortivazol, Anticorticosteroids, Trilostane. Thyroid and antithyroid active substances; Thyroid hormones, Levothyroxine sodium, Liothyronine sodium, Tiratricol, Thiouracils, Methylthiouracil, Propylthiouracil, Benzylthiouracil, Sulfur-containing imidazole derivatives, Carbimazole, Thiamazole, Perchlorates, Potassium perchlorate, Diiodotyrosine, Dibromotyrosine, Iodine.
Antiinfective active substances; Demeclocycline, Doxycycline, Chlortetracycline, Lymecycline, Metacycline, Oxytetracycline, Tetracycline, Minocycline, Rolitetracycline, Penimepicycline, Clomocycline, Tigecycline, Amphenicols, Chloramphenicol, Thiamphenicol, Ampicillin, Pivampicillin, Carbenicillin, Amoxicillin, Carindacillin, Bacampicillin, Epicillin, Pivmecillinam, Azlocillin, Mezlocillin, Mecillinam, Piperacillin, Ticarcillin, Metampicillin, Talampicillin, Sulbenicillin, Temocillin, Hetacillin, Benzylpenicillin, Phenoxymethylpenicillin, Propicillin, Azidocillin, Pheneticillin, Penamecillin, Clometocillin, Benzathine, benzylpenicillin, Procaine benzylpenicillin, Benzathine phenoxymethylpenicillin, Dicloxacillin, Cloxacillin, Meticillin, Oxacillin, Flucloxacillin, Sulbactam, Tazobactam, Sultamicillin, Cefalexin, Cefaloridine, Cefalotin, Cefazolin, Cefadroxil, Cefazedone, Cefatrizine, Cefapirin, Cefradine, Cefacetrile, Cefroxadine, Ceftezole, Cefoxitin, Cefuroxime, Cefamandole, Cefaclor, Cefotetan, Cefonicide, Cefotiam, Loracarbef, Cefmetazole, Cefprozil, Ceforanide, Cefotaxime, Ceftazidime, Cefsulodin, Ceftriaxone, Cefmenoxime, Latamoxef, Ceftizoxime, Cefixime, Cefodizime, Cefetamet, Cefpiramide, Cefoperazone, Cefpodoxime, Ceftibuten, Cefdinir, Cefditoren, Ceftriaxone, Cefepime, Cefpirome, Monobactams, Aztreonam, Carbapenems, Meropenem, Ertapenem, Imipenem, Trimethoprim, Brodimoprim, Sulfaisodimidine, Sulfamethizole, Sulfadimidine, Sulfapyridine, Sulfafurazole, Sulfanilamide, Sulfathiazole, Sulfathiourea, Sulfamethoxazole, Sulfadiazine, Sulfamoxole, Sulfadimethoxine, Sulfalene, Sulfametomidine, Sulfametoxydiazine, Sulfamethoxypyridazine, Sulfaperin, Sulfamerazine, Sulfaphenazole, Sulfamazone, Macrolides, Erythromycin, Spiramycin, Midecamycin, Oleandomycin, Roxithromycin, Josamycin, Troleandomycin, Clarithromycin, Azithromycin, Miocamycin, Rokitamycin, Dirithromycin, Flurithromycin, Telithromycin, Lincosamides, Clindamycin, Lincomycin, Streptogramins, Pristinamycin,
Quinupristin/dalfopristin, Streptomycins, Streptomycin, Streptoduocin, Other aminoglycosides, Tobramycin, Gentamicin, Kanamycin, Azithromycin, Neomycin, Amikacin, Retapamulin, Netilmicin, Sisomicin, Dibekacin, Ribostamycin, Isepamicin, Fluoroquinolones, Ofloxacin, Ciprofloxacin, Pefloxacin, Enoxacin, Temafloxacin, Norfloxacin, Lomefloxacin, Fleroxacin, Sparfloxacin, Rufloxacin, Grepafloxacin, Levofloxacin, Trovafloxacin, Moxifloxacin, Gemifloxacin, Gatifloxacin, Prulifloxacin, Pazufloxacin, Garenoxacin, Other quinolones, Rosoxacin, Nalidixic acid, Piromidic acid, Pipemidic acid, Oxolinic acid, Cinoxacin, Flumequine, Glycopeptide antibacterials, Vancomycin, Teicoplanin, Telavancin, Polymyxins, Colistin, Polymyxin B, Steroid antibacterials, Fusidic acid, Imidazole derivatives, Metronidazole, Tinidazole, Ornidazole, Nitrofuran derivatives, Nitrofurantoin, Nifurtoinol, Fosfomycin, Xibornol, Clofoctol, Spectinomycin, Methenamine, Mandelic acid, Nitroxoline, Linezolid, Daptomycin. Antimycotic active substances; Antibiotics, Amphotericin B, Hachimycin, Imidazole derivatives, Miconazole, Ketoconazole, Triazole derivatives, Fluconazole, Itraconazole, Voriconazole, Posaconazole, Flucytosine, Caspofungin, Micafungin, Anidulafungin. Antimycobacterial active substances; Aminosalicylic acid and derivatives, Sodium aminosalicylate, Calcium aminosalicylate, Antibiotics, Cycloserine, Rifampicin, Rifamycin, Rifabutin, Rifapentine, Capreomycin, Hydrazides, Isoniazid, Isoniazid, Thiocarbamide derivatives, Protionamide, Tiocarlide, Ethionamide, Pyrazinamide, Ethambutol, Terizidone, Morinamide, Clofazimine, Dapsone, Aldesulfone sodium. Antiviral active substances; Thiosemicarbazones, Metisazone, Nucleosides and nucleotides, Aciclovir, Idoxuridine, Vidarabine, Ribavirin, Ganciclovir, Famciclovir, Valaciclovir, Cidofovir, Penciclovir, Valganciclovir, Brivudine, Cyclic amines, Rimantadine, Tromantadine, Phosphonic acid derivatives, Foscarnet, Fosfonet, Protease inhibitors, Saquinavir, Indinavir, Ritonavir, Nelfinavir, Amprenavir, Lopinavir, Fosamprenavir, Atazanavir, Tipranavir, Darunavir, Zidovudine, Didanosine, Zalcitabine, Stavudine, Lamivudine, Abacavir, Tenofovir disoproxil, Adefovir dipivoxil, Emtricitabine, Entecavir, Telbivudine, Nevirapine, Delavirdine, Efavirenz, Zanamivir, Oseltamivir, Moroxydine, Lysozyme, Inosine pranobex, Pleconaril, Enfuvirtide, Raltegravir, Maraviroc. Immune sera and immunoglobulin; Diphtheria antitoxin, Tetanus antitoxin, Snake venom antiserum, Botulinum antitoxin, Gas-gangrene sera, Rabies serum, Immunoglobulins from human, Anti-D (rh) immunoglobulin, Tetanus immunoglobulin, Varicella/zoster immunoglobulin, Hepatitis B immunoglobulin, Rabies immunoglobulin, Rubella immunoglobulin, Vaccinia immunoglobulin, Staphylococcus immunoglobulin, Cytomegalovirus immunoglobulin, Diphtheria immunoglobulin, Hepatitis A immunoglobulin, Encephalitis, tick borne immunoglobulin, Pertussis immunoglobulin, Measles immunoglobulin, Mumps immunoglobulin, Palivizumab, Nebacumab. Vaccines; Bacterial vaccines, Anthrax vaccines, Anthrax antigen, Brucellosis vaccines, Brucella antigen, Cholera vaccines, Diphtheria vaccines, Diphtheria toxoid, Hemophilus influenzae B vaccines, Meningococcal vaccines, Meningococcus A, Meningococcus B, Meningococcus C, Pertussis vaccines, Plague vaccines, Pneumococcal vaccines, Pneumococcus, Tetanus vaccines, Tuberculosis vaccines, Typhoid vaccines, Typhus (exanthematicus) vaccines, Other bacterial vaccines, viral vaccines, Encephalitis vaccines, Influenza vaccines, Hepatitis vaccines, Measles vaccines, Mumps vaccines, Poliomyelitis vaccines, Rabies vaccines, Rota virus vaccines, Rubella vaccines, Varicella zoster vaccines, Yellow fever vaccines, Papillomavirus vaccines, Other viral vaccines.
Antineoplastic and immunomodulating active substances; Nitrogen mustard analogues, Cyclophosphamide, Chlorambucil, Melphalan, Chlormethine, Ifosfamide, Trofosfamide, Prednimustine, Alkyl sulfonates, Busulfan, Treosulfan, Mannosulfan, Ethylene imines, Thiotepa, Triaziquone, Carboquone, Nitrosoureas, Carmustine, Lomustine, Semustine, Streptozocin, Fotemustine, Nimustine, Ranimustine, Epoxides, Etoglucid, Other alkylating agents, Mitobronitol, Pipobroman, Temozolomide, Dacarbazine. Antimetabolite active substances; Folic acid analogues, Methotrexate, Raltitrexed, Pemetrexed, Purine analogues, Mercaptopurine, Tioguanine, Cladribine, Fludarabine, Clofarabine, Nelarabine, Pyrimidine analogues, Cytarabine, Fluorouracil, Tegafur, Carmofur, Gemcitabine, Capecitabine, Vinca alkaloids and analogues, Vinblastine, Vincristine, Vindesine, Vinorelbine, Podophyllotoxin derivatives, Etoposide, Teniposide, Colchicine derivatives, Demecolcine, Taxanes, Paclitaxel, Docetaxel, Other plant alkaloids and natural products, Trabectedin. Cytotoxic antibiotic and related active substances; Actinomycines, Dactinomycin, Anthracyclines and related substances, Doxorubicin, Daunorubicin, Epirubicin, Aclarubicin, Zorubicin, Idarubicin, Mitoxantrone, Pirarubicin, Valrubicin, Other cytotoxic antibiotics, Bleomycin, Plicamycin, Mitomycin, Ixabepilone. Antineoplastic active substances; Platinum compounds, Cisplatin, Carboplatin, Oxaliplatin, Methylhydrazines, Procarbazine, Monoclonal antibodies, Edrecolomab, Rituximab, Trastuzumab, Alemtuzumab, Gemtuzumab, Cetuximab, Bevacizumab, Panitumumab, Sensitizers used in photodynamic/radiation therapy, Porfimer sodium, Methyl aminolevulinate, Aminolevulinic acid, Temoporfin, Efaproxiral, Protein kinase inhibitors, Imatinib, Gefitinib, Erlotinib, Sunitinib, Sorafenib, Dasatinib, Lapatinib, Nilotinib, Other antineoplastic agents, Amsacrine, Asparaginase, Altretamine, Hydroxycarbamide, Lonidamine, Pentostatin, Miltefosine, Masoprocol, Estramustine, Tretinoin, Mitoguazone, Topotecan, Tiazofurine, Irinotecan, Alitretinoin, Mitotane, Pegaspargase, Bexarotene, Arsenic trioxide, Denileukin diftitox, Bortezomib, Celecoxib, Anagrelide, Oblimersen, Sitimagene ceradenovec, Combinations of antineoplastic agents. Endocrine active substances; Estrogens, Diethylstilbestrol, Polyestradiol phosphate, Ethinylestradiol, Fosfestrol, Progestogens, Megestrol, Medroxyprogesterone, Medroxyprogesterone, Gestonorone, Gonadotropin releasing hormone analogues, Buserelin, Leuprorelin, Goserelin, Triptorelin, hormones antagonists, Anti-estrogens, Tamoxifen, Toremifene, Fulvestrant, Anti-androgens, Flutamide, Nilutamide, Bicalutamide, Enzyme inhibitors, Aminogluthetimide, Formestane, Anastrozole, Letrozole, Vorozole, Exemestane, Abarelix. Immunostimulant active substances; Cytokines and immunomodulators, Colony stimulating factors, Filgrastim, Molgramostim, Sargramostim, Lenograstim, Ancestim, Pegfilgrastim, Interferons, Peginterferons, Interleukins, Aldesleukin, Oprelvekin, Lentinan, Roquinimex, BCG vaccine, Pegademase, Pidotimod, Poly I:C, Poly ICLC, Thymopentin, Immunocyanin, Tasonermin, Melanoma vaccine, Glatiramer acetate, Histamine dihydrochloride, Mifamurtide. Immunosuppressive active substances; Ciclosporin, Muromonab-CD3, Antilymphocyte immunoglobulin, Antithymocyte immunoglobulin, Tacrolimus, Mycophenolic acid, Daclizumab, Basiliximab, Sirolimus, Etanercept, Infliximab, Leflunomide, Anakinra, Alefacept, Afelimomab, Adalimumab, Everolimus, Gusperimus, Efalizumab, Abetimus, Natalizumab, Abatacept, Eculizumab, Certolizumab pegol, Other immunosuppressive agents, Azathioprine, Thalidomide, Methotrexate, Lenalidomide.
Antiinflammatory and antirheumatic active substances; Butylpyrazolidines, Phenylbutazone, Mofebutazone, Oxyphenbutazone, Clofezone, Kebuzone, Acetic acid derivatives and related substances, Indometacin, Sulindac, Tolmetin, Zomepirac, Diclofenac, Alclofenac, Bumadizone, Etodolac, Lonazolac, Fentiazac, Acemetacin, Difenpiramide, Oxametacin, Proglumetacin, Ketorolac, Aceclofenac, Bufexamac, Oxicams, Piroxicam, Tenoxicam, Droxicam, Lornoxicam, Meloxicam, Propionic acid derivatives, Ibuprofen, Naproxen, Ketoprofen, Fenoprofen, Fenbufen, Benoxaprofen, Suprofen, Pirprofen, Flurbiprofen, Indoprofen, Tiaprofenic acid, Oxaprozin, Ibuproxam, Dexibuprofen, Flunoxaprofen, Alminoprofen, Dexketoprofen, Fenamates, Mefenamic acid, Tolfenamic acid, Flufenamic acid, Meclofenamic acid, Coxibs, Celecoxib, Rofecoxib, Valdecoxib, Parecoxib, Etoricoxib, Lumiracoxib, Nabumetone, Niflumic acid, Azapropazone, Glucosamine, Benzydamine, Glucosaminoglycan polysulfate, Proquazone, Orgotein, Nimesulide, Feprazone, Diacerein, Morniflumate, Tenidap, Oxaceprol, Chondroitin sulfate, Feprazone, Dipyrocetyl, Acetylsalicylic acid, Quinolines, Oxycinchophen, Gold preparations, Sodium aurothiomalate, Sodium aurotiosulfate, Auranofin, Aurothioglucose, Aurotioprol, Penicillamine and similar agents, Bucillamine. Muscle relaxant active substances; Peripherally acting agents, Curare alkaloids, Alcuronium, Tubocurarine, Dimethyltubocurarine, Choline derivatives, Suxamethonium, Other quaternary ammonium compounds, Pancuronium, Gallamine, Vecuronium, Atracurium, Hexafluronium, Pipecuronium bromide, Doxacurium chloride, Fazadinium bromide, Rocuronium bromide, Mivacurium chloride, Cisatracurium, Botulinum toxin, Centrally acting agents, Carbamic acid esters, Phenprobamate, Carisoprodol, Methocarbamol, Styramate, Febarbamate, Oxazol, thiazine, and triazine derivatives, Chlormezanone, Chlorzoxazone, Ethers, chemically close to antihistamines, Orphenadrine (citrate), Other centrally acting agents, Baclofen, Tizanidine, Pridinol, Tolperisone, Thiocolchicoside, Mephenesin, Tetrazepam, Cyclobenzaprine, Fenyramidol, Directly acting agents, Dantrolene and derivatives. Antigout active substances; Preparations inhibiting uric acid production, Allopurinol, Tisopurine, Febuxostat, Preparations increasing uric acid excretion, Probenecid, Sulfinpyrazone, Benzbromarone, Isobromindione, Preparations with no effect on uric acid metabolism, Colchicine, Cinchophen, Other antigout preparations, Urate oxidase. Active substances affecting bone struture and mineralization; Bisphosphonates, Etidronic acid, Clodronic acid, Pamidronic acid, Alendronic acid, Tiludronic acid, Ibandronic acid, Risedronic acid, Zoledronic acid, Bone morphogenetic proteins, Dibotermin alfa, Eptotermin alfa, Other drugs affecting bone structure and mineralization, Ipriflavone, Aluminium chlorohydrate, Strontium ranelate, Quinine and derivatives, Hydroquinine, Enzymes, Chymopapain, Trypsin, Hyaluronic acid. Colecalciferol.
Analgesics; Opioids, Natural opium alkaloids, Morphine, Opium, Hydromorphone, Nicomorphine, Oxycodone, Dihydrocodeine, Diamorphine, Papaveretum, Codeine, Phenylpiperidine derivatives, Ketobemidone, Pethidine, Fentanyl, Diphenylpropylamine derivatives, Dextromoramide, Piritramide, Dextropropoxyphene, Bezitramide, Methadone, Benzomorphan derivatives, Pentazocine, Phenazocine, Oripavine derivatives, Buprenorphine, Morphinan derivatives, Butorphanol, Nalbuphine, Tilidine, Tramadol, Dezocine, Salicylic acid and derivatives, Acetylsalicylic acid, Aloxiprin, Choline salicylate, Sodium salicylate, Salicylamide, Salsalate, Ethenzamide, Morpholine salicylate, Dipyrocetyl, Benorilate, Diflunisal, Potassium salicylate, Guacetisal, Carbasalate calcium, Imidazole salicylate, Pyrazolones, Phenazone, Metamizole sodium, Aminophenazone, Propyphenazone, Nifenazone, Anilides, Paracetamol, Phenacetin, Bucetin, Propacetamol, Other analgesics and antipyretics, Rimazolium, Glafenine, Floctafenine, Viminol, Nefopam, Flupirtine, Ziconotide. Anesthetics; Ethers, Diethyl ether, Vinyl ether, Halogenated hydrocarbons, Halothane, Chloroform, Methoxyflurane, Enflurane, Trichloroethylene, Isoflurane, Desflurane, Sevoflurane, Barbiturates, Methohexital, Hexobarbital, Thiopental, Narcobarbital, Opioid anesthetics, Fentanyl, Alfentanil, Sufentanil, Phenoperidine, Anileridine, Remifentanil, Other general anesthetics, Droperidol, Ketamine, Propanidid, Alfaxalone, Etomidate, Propofol, Hydroxybutyric acid, Nitrous oxide, Esketamine, Xenon, Esters of aminobenzoic acid, Metabutethamine, Procaine, Tetracaine, Chloroprocaine, Benzocaine, Amides, Bupivacaine, Lidocaine, Mepivacaine, Prilocaine, Butanilicaine, Cinchocaine, Etidocaine, Articaine, Ropivacaine, Levobupivacaine, Esters of benzoic acid, Cocaine, Other local anesthetics, Ethyl chloride, Dyclonine, Phenol, Capsaicin. Antimigraine active substances; Ergot alkaloids, Dihydroergotamine, Ergotamine, Methysergide, Lisuride, Corticosteroid derivatives, Flumedroxone, Selective serotonin (5HT1) agonists, Sumatriptan, Naratriptan, Zolmitriptan, Rizatriptan, Almotriptan, Eletriptan, Frovatriptan, Other antimigraine preparations, Pizotifen, Clonidine, Iprazochrome, Dimetotiazine, Oxetorone. Antiepileptic active substances; Barbiturates and derivatives, Methylphenobarbital, Phenobarbital, Primidone, Barbexaclone, Metharbital, Hydantoin derivatives, Ethotoin, Phenytoin,
Amino(diphenylhydantoin) valeric acid, Mephenytoin, Fosphenytoin, Oxazolidine derivatives, Paramethadione, Trimethadione, Ethadione, Succinimide derivatives, Ethosuximide, Phensuximide, Mesuximide, Benzodiazepine derivatives, Clonazepam, Carboxamide derivatives, Carbamazepine, Oxcarbazepine, Rufinamide, Fatty acid derivatives, Valproic acid, Valpromide, Aminobutyric acid, Vigabatrin, Progabide, Tiagabine, Other antiepileptics, Sultiame, Phenacemide, Lamotrigine, Felbamate, Topiramate, Gabapentin, Pheneturide, Levetiracetam, Zonisamide, Pregabalin, Stiripentol, Lacosamide, Beclamide. Anticholinergic active substances; Tertiary amines, Trihexyphenidyl, Biperiden, Metixene, Procyclidine, Profenamine, Dexetimide, Phenglutarimide, Mazaticol, Bornaprine, Tropatepine, Ethers chemically close to antihistamines, Etanautine, Orphenadrine (chloride), Ethers of tropine or tropine derivatives, Benzatropine, Etybenzatropine. Dopaminergic ative substances; Dopa and dopa derivatives, Levodopa, Melevodopa, Etilevodopa, Adamantane derivatives, Amantadine, Dopamine agonists, Bromocriptine, Pergolide, Dihydroergocryptine mesylate, Ropinirole, Pramipexole, Cabergoline, Apomorphine, Piribedil, Rotigotine, Monoamine, oxidase B inhibitors, Selegiline, Rasagiline, Other dopaminergic agents, Tolcapone, Entacapone, Budipine. Antipsychotic active substances; Phenothiazines with aliphatic side-chain, Chlorpromazine, Levomepromazine, Promazine, Acepromazine, Triflupromazine, Cyamemazine, Chlorproethazine, Phenothiazines with piperazine structure, Dixyrazine, Fluphenazine, Perphenazine, Prochlorperazine, Thiopropazate, Trifluoperazine, Acetophenazine, Thioproperazine, Butaperazine, Perazine, Phenothiazines with piperidine structure, Periciazine, Thioridazine, Mesoridazine, Pipotiazine, Butyrophenone derivatives, Haloperidol, Trifluperidol, Melperone, Moperone, Pipamperone, Bromperidol, Benperidol, Droperidol, Fluanisone, Indole derivatives, Oxypertine, Molindone, Sertindole, Ziprasidone, Thioxanthene derivatives, Flupentixol, Clopenthixol, Chlorprothixene, Tiotixene, Zuclopenthixol, Diphenylbutylpiperidine derivatives, Fluspirilene, Pimozide, Penfluridol, Diazepines, oxazepines and thiazepines, Loxapine, Clozapine, Olanzapine, Quetiapine, Neuroleptics, in tardive dyskinesia, Tetrabenazine, Benzamides, Sulpiride, Sultopride, Tiapride, Remoxipride, Amisulpride, Veralipride, Levosulpiride, Lithium, Other antipsychotics, Prothipendyl, Risperidone, Clotiapine, Mosapramine, Zotepine, Aripiprazole, Paliperidone. Anxiolytic active substances; Benzodiazepine derivatives, Diazepam, Chlordiazepoxide, Medazepam, Oxazepam, Potassium clorazepate, Lorazepam, Adinazolam, Bromazepam, Clobazam, Ketazolam, Prazepam, Alprazolam, Halazepam, Pinazepam, Camazepam, Nordazepam, Fludiazepam, Ethyl loflazepate, Etizolam, Clotiazepam, Cloxazolam, Tofisopam, Diphenylmethane derivatives, Hydroxyzine, Captodiame, Carbamates, Meprobamate, Emylcamate, Mebutamate, Dibenzo-bicyclo-octadiene derivatives, Benzoctamine, Azaspirodecanedione derivatives, Buspirone, Other anxiolytics, Mephenoxalone, Gedocarnil, Etifoxine. Hypnotic and sedative active substances; Barbiturates, Pentobarbital, Amobarbital, Butobarbital, Barbital, Aprobarbital, Secobarbital, Talbutal, Vinylbital, Vinbarbital, Cyclobarbital, Heptabarbital, Reposal, Methohexital, Hexobarbital, Thiopental, Etallobarbital, Allobarbital, Proxibarbal, Aldehydes and derivatives, Chloral hydrate, Chloralodol, Acetylglycinamide chloral hydrate, Dichloralphenazone, Paraldehyde, Benzodiazepineemepronium derivatives, Flurazepam, Nitrazepam, Flunitrazepam, Estazolam, Triazolam, Lormetazepam, Temazepam, Midazolam, Brotizolam, Quazepam, Loprazolam, Doxefazepam, Cinolazepam, Piperidinedione derivatives, Glutethimide, Methyprylon, Pyrithyldione, Benzodiazepine related drugs, Zopiclone, Zolpidem, Zaleplon, Ramelteon, Other hypnotics and sedatives, Methaqualone, Clomethiazole, Bromisoval, Carbromal, Scopolamine, Propiomazine, Triclofos, Ethchlorvynol, Valerian, Hexapropymate, Bromides, Apronal, Valnoctamide, Methylpentynol, Niaprazine, Melatonin, Dexmedetomidine, Dipiperonylaminoethanol. Antidepressant active substances; Non-selective monoamine reuptake inhibitors, Desipramine, Imipramine, Imipramine oxide, Clomipramine, Opipramol, Trimipramine, Lofepramine, Dibenzepin, Amitriptyline, Nortriptyline, Protriptyline, Doxepin, Iprindole, Melitracen, Butriptyline, Dosulepin, Amoxapine, Dimetacrine, Amineptine, Maprotiline, Quinupramine, Selective serotonin reuptake inhibitors, Zimeldine, Fluoxetine, Citalopram, Paroxetine, Sertraline, Alaproclate, Fluvoxamine, Etoperidone, Escitalopram, Monoamine oxidase inhibitors, non-selective, Isocarboxazid, Nialamide, Phenelzine, Tranylcypromine, Iproniazide, Iproclozide, Monoamine oxidase A inhibitors, Moclobemide, Toloxatone, Other antidepressants, Oxitriptan, Tryptophan, Mianserin, Nomifensine, Trazodone, Nefazodone, Minaprine, Bifemelane, Viloxazine, Oxaflozane, Mirtazapine, Medifoxamine, Tianeptine, Pivagabine, Venlafaxine, Milnacipran, Reboxetine, Gepirone, Duloxetine, Agomelatine, Desvenlafaxine, Centrally acting sympathomimetics, Amfetamine, Dexamfetamine, Metamfetamine, Methylphenidate, Pemoline, Fencamfamin, Modafinil, Fenozolone, Atomoxetine, Fenetylline, Xanthine derivatives, Caffeine, Propentofylline, Other psychostimulants and nootropics, Meclofenoxate, Pyritinol, Piracetam, Deanol, Fipexide, Citicoline, Oxiracetam, Pirisudanol, Linopirdine, Nizofenone, Aniracetam, Acetylcarnitine, Idebenone, Prolintane, Pipradrol, Pramiracetam, Adrafinil, Vinpocetine. Anti-dementia active subtances; Anticholinesterases, Tacrine, Donepezil, Rivastigmine, Galantamine, Other anti-dementia drugs, Memantine, Ginkgo biloba. Other nervous system active substances; Parasympathomimetics, Anticholinesterases, Neostigmine, Pyridostigmine, Distigmine, Ambenonium, Choline esters, Carbachol, Bethanechol, Other parasympathomimetics, Pilocarpine, Choline alfoscerate. Active substances used in addictive disorders; Drugs used in nicotine dependence, Nicotine, Bupropion, Varenicline, Drugs used in alcohol dependence, Disulfiram, Calcium carbimide, Acamprosate, Naltrexone, Drugs used in opioid dependence, Buprenorphine, Methadone, Levacetylmethadol, Lofexidine. Antivertigo active subtances; Betahistine, Cinnarizine, Flunarizine, Acetylleucine, other nervous system drugs, Gangliosides and ganglioside derivatives, Tirilazad, Riluzole, Xaliproden, Hydroxybutyric acid, Amifampridine.
Active substances against amoebiasis and other protozoal diseases; Hydroxyquinoline derivatives, Broxyquinoline, Clioquinol, Chlorquinaldol, Tilbroquinol, Nitroimidazole derivatives, Metronidazole, Tinidazole, Ornidazole, Azanidazole, Propenidazole, Nimorazole, Secnidazole, Dichloroacetamide derivatives, Diloxanide, Clefamide, Etofamide, Teclozan, Arsenic compounds, Arsthinol, Difetarsone, Glycobiarsol, Chiniofon, Emetine, Phanquinone, Mepacrine, Atovaquone, Trimetrexate, Tenonitrozole, Dihydroemetine, Fumagillin, Nitazoxanide. Antimalarial active substances; Aminoquinolines, Chloroquine, Hydroxychloroquine, Primaquine, Amodiaquine, Biguanides, Proguanil, Cycloguanil embonate, Methanolquinolines, Quinine, Mefloquine, Diaminopyrimidines, Pyrimethamine, Artemisinin and derivatives, Artemether, Artesunate, Artemotil, Artenimol, Halofantrine. Active substances against leishmaniasis and trypanosomiasis; Nitroimidazole derivatives, Benznidazole, Antimony compounds, Meglumine antimonate, Sodium stibogluconate, Nitrofuran derivatives, Nifurtimox, Nitrofural, Arsenic compounds, Melarsoprol, Acetarsol, Pentamidine isethionate, Suramin sodium, Eflornithine. Antitrematodal active substances; Quinoline derivatives and related substances, Praziquantel, Oxamniquine, Organophosphorous compounds, Metrifonate, Bithionol, Niridazole, Stibophen, Triclabendazole. Antinematodal active substances; Benzimidazole derivatives, Mebendazole, Tiabendazole, Albendazole, Ciclobendazole, Flubendazole, Fenbendazole, Piperazine and derivatives, Diethylcarbamazine, Tetrahydropyrimidine derivatives, Pyrantel, Oxantel, Imidazothiazole derivatives, Levamisole, Avermectines, Ivermectin, Pyrvinium, Bephenium, anticestodal active substance; Salicylic acid derivatives, Niclosamide, Desaspidin, Dichlorophen. Ectoparasiticide active substances; Sulfur containing products, Dixanthogen, Potassium polysulfide, Mesulfen, Disulfiram, Thiram, Chlorine containing products, Clofenotane, Lindane, Pyrethrines, incl. synthetic compounds, Pyrethrum, Bioallethrin, Phenothrin, Permethrin, Benzyl benzoate, Copper oleinate, Malathion, Quassia. Insecticide and repellent active substances; Pyrethrines, Cyfluthrin, Cypermethrin, Decamethrin, Tetramethrin, Diethyltoluaide, Dimethylphthalate, Dibutylphthalate, Dibutylsuccinate, Dimethylcarbate, Etohexadiol.
Decongestant active substances; Sympathomimetics, Cyclopentamine, Ephedrine, Phenylephrine, Oxymetazoline, Tetryzoline, Xylometazoline, Naphazoline, Tramazoline, Metizoline, Tuaminoheptane, Fenoxazoline, Tymazoline, Epinephrine, Cromoglicic acid, Levocabastine, Azelastine, Antazoline, Spaglumic acid, Thonzylamine, Nedocromil, Olopatadine, Corticosteroids, Beclometasone, Prednisolone, Dexamethasone, Flunisolide, Budesonide, Betamethasone, Tixocortol, Fluticasone, Mometasone, Triamcinolone, Fluticasone furoate, Hydrocortisone, Calcium hexamine thiocyanate, Retinol, Ipratropium bromide, Ritiometan, Mupirocin, Hexamidine, Framycetin, Phenylpropanolamine, Pseudoephedrine, Phenylephrine. Throat active substances; Antiseptics, Ambazone, Dequalinium, Dichlorobenzyl alcohol, Chlorhexidine, Cetylpyridinium, Benzethonium, Myristyl-benzalkonium, Chlorquinaldol, Hexylresorcinol, Acriflavinium chloride, Oxyquinoline, Povidone-iodine, Benzalkonium, Cetrimonium, Hexamidine, Phenol, Antibiotics, Neomycin, Tyrothricin, Fusafungine, Bacitracin, Gramicidin, Benzocaine, Lidocaine, Cocaine, Dyclonine. Active substances for obstructive airway diseases; Orciprenaline, Salbutamol, Terbutaline, Fenoterol, Rimiterol, Hexoprenaline, Isoetarine, Pirbuterol, Tretoquinol, Carbuterol, Tulobuterol, Salmeterol, Formoterol, Clenbuterol, Reproterol, Procaterol, Bitolterol, Glucocorticoids, Beclometasone, Budesonide, Flunisolide, Betamethasone, Fluticasone, Triamcinolone, Mometasone, Ciclesonide, Ipratropium bromide, Oxitropium bromide, Stramoni preparations, Tiotropium bromide, Cromoglicic acid, Nedocromil, Fenspiride, Methoxyphenamine, Bambuterol, Xanthines, Diprophylline, Choline theophyllinate, Proxyphylline, Theophylline, Aminophylline, Etamiphylline, Theobromine, Bamifylline, Acefylline piperazine, Bufylline, Doxofylline, Zafirlukast, Pranlukast, Montelukast, Ibudilast, Amlexanox, Eprozinol, Fenspiride, Omalizumab, Seratrodast, Roflumilast. Cough and cold active substances; Expectorants, Tyloxapol, Potassium iodide, Guaifenesin, Ipecacuanha, Althea root, Senega, Antimony pentasulfide, Creosote, Guaiacolsulfonate, Levoverbenone, Mucolytics, Acetylcysteine, Bromhexine, Carbocisteine, Eprazinone, Mesna, Ambroxol, Sobrerol, Domiodol, Letosteine, Stepronin, Tiopronin, Dornase alfa (desoxyribonuclease), Neltenexine, Erdosteine, Opium alkaloids and derivatives, Ethylmorphine, Hydrocodone, Codeine, Opium alkaloids with morphine, Normethadone, Noscapine, Pholcodine, Dextromethorphan, Thebacon, Dimemorfan, Acetyldihydrocodeine, Benzonatate, Benproperine, Clobutinol, Isoaminile, Pentoxyverine, Oxolamine, Oxeladin, Clofedanol, Pipazetate, Bibenzonium bromide, Butamirate, Fedrilate, Zipeprol, Dibunate, Droxypropine, Prenoxdiazine, Dropropizine, Cloperastine, Meprotixol, Piperidione, Tipepidine, Morclofone, Nepinalone, Levodropropizine, Dimethoxanate. Antihistamine active substances; Aminoalkyl ethers, Bromazine, Diphenhydramine, Clemastine, Chlorphenoxamine, Diphenylpyraline, Carbinoxamine, Doxylamine, Substituted alkylamines, Brompheniramine, Dexchlorpheniramine, Dimetindene, Chlorphenamine, Pheniramine, Dexbrompheniramine, Talastine, Substituted ethylene diamines, Mepyramine, Histapyrrodine, Chloropyramine, Tripelennamine, Methapyrilene, Thonzylamine, Phenothiazine derivatives, Alimemazine, Promethazine, Thiethylperazine, Methdilazine, Hydroxyethylpromethazine, Thiazinam, Mequitazine, Oxomemazine, Isothipendyl, Piperazine derivatives, Buclizine, Cyclizine, Chlorcyclizine, Meclozine, Oxatomide, Cetirizine, Levocetirizine, Bamipine, Cyproheptadine, Thenalidine, Phenindamine, Antazoline, Triprolidine, Pyrrobutamine, Azatadine, Astemizole, Terfenadine, Loratadine, Mebhydrolin, Deptropine, Ketotifen, Acrivastine, Azelastine, Tritoqualine, Ebastine, Pimethixene, Epinastine, Mizolastine, Fexofenadine, Desloratadine, Rupatadine, Other respiratory system active substances; Lung surfactants, Colfosceril palmitate, Natural phospholipids, Respiratory stimulants, Doxapram, Nikethamide, Pentetrazol, Etamivan, Bemegride, Prethcamide, Almitrine, Dimefline, Mepixanox, Nitric oxide.
Other active substances; Antidotes, Ipecacuanha, Nalorphine, Edetates, Pralidoxime, Prednisolone and promethazine, Thiosulfate, Sodium nitrite, Dimercaprol, Obidoxime, Protamine, Naloxone, Methylthioninium chloride, Potassium permanganate, Physostigmine, Copper sulfate, Potassium iodide, Amyl nitrite, Acetylcysteine, Digitalis antitoxin, Flumazenil, Methionine, 4-dimethylaminophenol, Cholinesterase, Prussian blue, Glutathione, Hydroxocobalamin, Fomepizole, Iron chelating agents, Deferoxamine, Deferiprone, Deferasirox, Polystyrene sulfonate, Sevelamer, Lanthanum carbonate, Mesna, Dexrazoxane, Calcium folinate, Calcium levofolinate, Amifostine, Sodium folinate, Rasburicase, Palifermin, Glucarpidase, Sodium cellulose phosphate, Diazoxide.
In specific embodiments, the active substance is for cardiac therapy including e.g. cardiac glycosides, antiarrhythmics, cardiac stimulants, vasodilators, antihypertensives, diuretics, vasoprotectives, beta blockers, calcium channel blockers, agents acting on the rennin-angiotensin system, lipid modifying agents.
In specific embodiments, the active substance is from the therapeutic classes including antiemetics, antinauseants, antiobesity and anabolic agents.
In specific embodiments, the active substance is from the therapeutic classes including antiinflammatory and antiinfective agents, corticosteroids, non-steroids anti-inflammatory and antirheumatic agents.
In specific embodiments, the active substance is from the therapeutic classes including decongestants, adrenergics, expectorants, cough suppressant and antihistamines.
In specific embodiments, the active substance is from the therapeutic classes including anesthetics, analgesics, opioids, antipyretics, antimigraine agents, antiepileptics, anti-parkinson agents, dopaminergic agents, antipsychotics, anxiolytics, sedatives, antidepressants, psychostimulants agents used for ADHD and nootropics, agents used in addictive disorders.
In specific embodiments, the active substance is from the therapeutic classes including anaesthetics, centrally-acting analgesics, sedative-hypnotics, anxiolytics; appetite suppressants, decongestants, antitussives, antihistamines, antiemetics, antidiarrheals, and drugs used to treat narcolepsy and attention deficit hyperactivity disorder.
In specific embodiments, the active substance is associated with abuse syndromes include opioids, CNS depressants, CNS stimulants, cannabinoids, nicotine-like compounds, glutamate antagonists and N-methyl-D-aspartate (NMDA) antagonists.
In specific embodiments, the active substance is buprenorphine, codeine, dextromoramide, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, morphine, pentazocine, oxycodeine, oxycodone, oxymorphone and tramadol.
The active substance can be in various forms, such as uncharged or charged molecules, molecular complexes, crystalline forms, amorphous form, polyamorphous form, polymorphous form, complexes, solvates, anhydrates, if relevant isomers, enantiomers, racemic mixtures and pharmacologically acceptable salts such as e.g. hydrochloride, hydrobromide, sulfate, laurylate, palmitate, phosphate, nitrite, nitrate, citrate, borate, acetate, maleate, tartrate, oleate, and salicylate. For acidic active substance, salts of metals e.g. alkali metal salts such as, e.g., sodium or potassium salts, alkaline earth metal salts such as, e.g., calcium and magnesium salts, amines amino acids or organic cations, quaternary ammoniums, can be used. Derivatives of active substances such as esters, ethers and amides which have solubility characteristics suitable for use herein can be used alone or mixed with other drugs. After release of the derivative from the drug delivery system it may be converted by enzymes, hydrolysed by body pH or other metabolic processes to the parent drug or to another biologically active form.
A pharmaceutical composition of the invention may in addition be suitable for the delivery of peptides, polypeptides or proteins, for example hormones, enzymes such as lipases, proteases, carbohydrates, amylases, lactoferrin, lactoperoxidases, lysozymes, nanoparticles, etc., and antibodies. The composition may also be employed for the delivery of microorganisms, either living, attenuated or dead, for example bacteria, e.g. gastrointestinal bacteria such as streptococci, e.g. S. faecium, Bacillus spp. such as B. subtilis and B. licheniformis, lactobacteria, Aspergillus spp., bifidogenic factors, or viruses such as indigenous vira, enterovira, bacteriophages, e.g. as vaccines, and fungi such as baker's yeast, Saccharomyces cerevisiae and fungi imperfecti.
In an embodiment of the invention, the active substance is a pharmaceutically active powder. The powder typically has a particle size of from about 0.1 μm to about 500 μm, typically from about 0.5 μm to about 300 μm, more typically from about 1 μm to about 200 μm, especially from about 5 μm to about 100 μm.
In an embodiment of the invention, the active substance is a pharmaceutically active crystal. The crystal typically has a particle size of from about 0.1 μm to about 1000 μm such as, e.g., about 0.1 μm to about 750 μm, about 0.1 μm to about 500 μm, typically from about 0.5 μm to about 500 μm, more typically from about 1 μm to about 500 μm, especially from about 5 μm to about 500 μm.
In another embodiment of the invention, a composition comprises active substance that at least partially is present in amorphous form with a mean particle size of at least about 0.01 μm such as, e.g., from about 0.01 μm to about 500 μm, from about 0.05 μm to about 500 μm, from about 0.1 μm to about 500 μm, from about 0.5 μm to about 500 μm, about 1 μm to about 500 μm, typically from about 0.5 μm to about 300 μm, more typically from about 1 μm to about 200 μm, especially from about 1 μm to about 100 μm.
The at least one therapeutically, prophylactically and/or diagnostically and/or biologically active substance will suitably be present in an amount of up to about 80%, typically up to about 70%, up to about 60% or up to about 50%, such as, e.g., from 0.1% to 80%, such as from 0.25% to 75%, such as from 0.5% to 60%, such as from 0.75% to 50%, such as from 1% to 40%, such as from 1.5% to 35%, such as from 1.75% to 30% by weight of the composition or layer. With respect to situations where one or more active substances are contained in one of the layers or coat, a content of about 60-80% w/w is contemplated to be the maximum content, which still allows for a sufficient content of the polymer and, when relevant, a pharmaceutically acceptable excipient in the composition. The active substance may, on the other hand, be present in the composition in much smaller amounts, depending on the nature and potency of the active substance in question.
A composition according to the invention containing a drug substance is typically for oral administration. Due to the possibility of controlling the release rate of the active substance the composition may be adapted for oral administration 1-6 times a day, normally 1-4 times daily such as 1-3 times, 1-2 times or 1 times daily. The technology may also provide compositions for administration only once or twice daily. In the present context the term “once daily” is intended to mean that it is only necessary to administer the pharmaceutical composition once a day in order to obtain a suitable therapeutic and/or prophylactic response; however, any administration may comprise co-administration of more than one dosage unit, such as, e.g. 2-4 dosage units if the amount of active substance required may not be formulated in only one composition or if a composition of a smaller size is preferred.
The dosage of the active substance depends on the particular substance, the age, weight condition etc. of the human or animal that will be treated with the composition etc. All such factors are well known to a person skilled in the art.
Stability
With respect to the fixed-dosed combination formulation stability is employed to encompass one or more of the following;
    • 1) Stability with respect to the physical stability of the composition (appearance, color, strength, etc.)
    • 2) Stability with respect to in vitro dissolution behavior of the active substance from the composition
      Stability of the Individual Components;
    • 3) Stability with respect to the chemical stability of the active substance (degradation of the active substance to other—normally—unwanted products)
    • 4) Stability with respect to the form the active substance has in the composition; if the active substance is dissolved (molecularly dispersed) in the polymer as a solid dispersion. In such cases precipitation or otherwise formation of crystals of the active substance in the composition is an indication of a stability problem.
    • 5) Physical and chemical stability of the pharmaceutically acceptable polymer and excipients employed
In particular, the active substance or substances maybe stabilized in the dosage form in its amorphous form. The amorphous state and/or the solid dispersion is stabilized either by a very careful choice of the concentration of the active substance in the composition and/or by addition of suitable stabilizing agents acting by stabilizing one or more of the conditions mentioned above under items 1) to 5).
In regards to condition 4) the stability may be retrieved by several mechanisms of which the most important are
    • a) Physical stabilization by decreasing the molecular mobility of the components, i.e. suitable excipients and the active substance of the formulation
    • b) Chemical stabilization by increasing the apparent solubility of the active substance in the matrix formulation.
Thus a stabilizing agent may serve more than one purpose, it may stabilize the amorphous state of the active substance in the composition in order to avoid, reduce or delay any recrystallization, it may stabilize the active substance or other ingredients towards proteolytic or oxidative degradation or it may have an anti-plasticizing effect.
A stabilizing agent may also contribute to an improved solubility of the active substance. Without being bound to any theory it may be assumed that the stabilizing agent together with the polyethylene glycol and/or polyethylene oxide represent the dispersion medium wherein the solubility of the active substance may be higher than in the polyethylene glycol and/or polyethylene oxide alone. The same may apply with respect to the stability of the amorphous form of the active substance.
Pharmaceutically Acceptable Excipients
The composition may also contain other excipients as well, e.g. in order to improve the technical properties of the composition so that it may be easier to produce or in order to improve the properties of the composition such as release rate of the active substance, stability of the active substance or of the composition itself etc.
A suitable pharmaceutically acceptable excipient for use in a composition of the invention may be selected from the group consisting of fillers, diluents, disintegrants, glidants, pH-adjusting agents, viscosity adjusting agents, solubility increasing or decreasing agents, osmotically active agents and solvents.
Suitable excipients include conventional tablet or capsule excipients. These excipients may be, for example, diluents such as dicalcium phosphate, calcium sulfate, lactose or sucrose or other disaccharides, cellulose, cellulose derivatives, kaolin, mannitol, dry starch, glucose or other monosaccharides, dextrin or other polysaccharides, sorbitol, inositol or mixtures thereof; binders such as alginic acid, calcium alginate, sodium alginate, starch, gelatin, saccharides (including glucose, sucrose, dextrose and lactose), molasses, panwar gum, ghatti gum, mucilage of isapol husk, carboxymethylcellulose, methylcellulose, veegum, larch arabolactan, polyethylene glycols, ethylcellulose, water, alcohols, waxes, polyvinylpyrrolidone such as, e.g., PVP K90 or mixtures thereof; lubricants such as talc, silicium dioxide, magnesium stearate, calcium stearate, stearic acid, hydrogenated vegetable oils, sodium benzoate, sodium chloride, leucine, carbowax 4000, magnesium lauryl sulfate, Sodium laurilsulfate, Stearyl alcohol, Polysorbate 20, Polysorbate 60, Polysorbate 80, Macrogol stearate, Macrogol lauryl ether, Stearoyl macrogolglycerides, Sorbitan stearate, Sorbitan laurate, Macrogol glycerol hydroxystearat, colloidal silicon dioxide and mixtures thereof, disintegrants such as starches, clays, cellulose derivatives including microcrystalline cellulose, methycellulose, carboxymethycellulose calcium, carboxymethylcellulose sodium, cellulose, crosscarmellose sodium, gums, aligns, various combinations of hydrogencarbonates with weak acids (e.g. sodium hydrogencarbonate/tartaric acid or citric acid) crosprovidone, sodium starch glycolate, agar, alginic acid, calcium alginate, sodium alginate, chitosan, colloidal silicon dioxide, docusate sodium, guar gum, low-substituted hydroxypropyl cellulose, hydroxypropyl starch, magnesium aluminium silicate, polacrilin potassium, povidone, sodium starch glycolate, pregelatinized starch, cation exchange resins, citrus pulp, veegum, glycollate, natural sponge, bentonite, sucralfate, calcium hydroxyl-apatite or mixtures thereof, effervescent agents (carbonate release) such as citric acid, anhydrous, citric acid, monohydrate, dextrates, fumaric acid, potassium bicarbonate, sodium bicarbonate, sodium citrate, dehydrate, tartaric acid or mixtures thereof.
Furthermore, the composition may comprise one or more agents selected from the group consisting of sweetening agents, flavouring agents and colouring agents, in order to provide an elegant and palatable preparation. Examples are maltol, citric acid, water soluble FD&C dyes and mixtures thereof with corresponding lakes and direct compression sugars such as Di-Pac from Amstar. In addition, coloured dye migration inhibitors such as tragacanth, acacia or attapulgite talc may be added. Specific examples include Calcium carbonate, 1,3,5-trihydroxybenzene, Chromium-cobalt-aluminium oxide, ferric ferrocyanide, Ferric oxide, Iron ammonium citrate, Iron (III) oxide hydrated, Iron oxides, Carmine red, Magnesium carbonate and Titanium dioxide.
Plasticizer may be incorporated in the composition. A suitable plasticizer is selected from such as e.g. mono- and di-acetylated monoglycerides, diacetylated monoglycerides, acetylated hydrogenated cottonseed glyceride, glyceryl cocoate, Polyethylene glycols or polyethylene oxides (e.g. with a molecular weight of about 1,000-500,000 daltons), dipropylene glycol salicylate glycerin, fatty acids and esters, phthalate esters, phosphate esters, amides, diocyl phthalate, phthalyl glycolate, mineral oils, hydrogenated vegetable oils, vegetable oils, acetylated hydrogenated soybean oil glycerides, Castor oil, acetyl tributyl citrate, acetyl triethyl citrate, methyl abietate, nitrobenzene, carbon disulfide, β-naphtyl salicylate, sorbitol, sorbitol glyceryl tricitrate, fatty alcohols, cetostearyl alcohol, cetyl alcohol, stearyl alcohol, oleyl alcohol, myristyl alcohol, sucrose octaacetate, alfa-tocopheryl polyethylene glycol succinate (TPGS), tocopheryl derivative, diacetylated monoglycerides, diethylene glycol monostearate, ethylene glycol monostearate, glyceryl monooleate, glyceryl monostearate, propylene glycol monostearate, macrogol esters, macrogol stearate 400, macrogol stearate 2000, polyoxyethylene 50 stearate, macrogol ethers, cetomacrogol 1000, lauromacrogols, nonoxinols, octocinols, tyloxapol, poloxamers, polyvinyl alcohols, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, polysorbate 85, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, sorbitan sesquioleate, sorbitan trioleate, sorbitan tristearate and sucrose esters, amyl oleate, butyl oleate, butyl stearate, diethylene glycol monolaurate, glycerol tributyrate, Cumar W-1, Cumar MH-1, Cumar V-1, Flexol B-400, monomeric polyethylene ester, Piccolastic A-5, Piccalastic A-25, Beckolin, Clorafin 40, acetyl tributyl citrate, acetyl triethyl citrate, benzyl benzoate, butoxyethyl stearate, butyl and glycol esters of fatty acids, butyl diglycol carbonate, butyl ricinoleate, butyl phthalyl butyl glycolate, camphor, dibutyl sebacate, dibutyl tartrate, diphenyl oxide, glycerine, HB-40, hydrogenated methyl ester of rosin, methoxyethyl oleate, monoamylphthalate, Nevillac 10, Paracril 26, technical hydroabietyl alcohol, triethylene glycol dipelargonate, solid aliphatic alcohols, nitrobenzene, carbon disulfide, β-naphtyl salicylate, phthalyl glycolate, dioctyl phthalate. and mixtures thereof. Other suitable plasticizers appear from EP-B-0 746 310 to which reference is made.
The use of a plasticizer will often be desirable in order to improve the processibility of the coating. The plasticizer may also be a non-ionic surfactant, e.g. a non-ionic surfactant as the one mentioned above.
Preferred stabilizers (chemical) include TPG e.g. in the form of TPGS due to surfactant properties, BHA, BHT, t-butyl hydroquinone, calcium ascorbate, gallic acid, hydroquinone, maltol, octyl gallate, sodium bisulfite, sodium metabisulfite, tocopherol and derivates thereof, citric acid, tartaric acid, and ascorbic acid. Other stabilisers include trivalent phosphorous like e.g. phosphite, phenolic antioxidants, hydroxylamines, lactones such as substituted benzofuranones. Hindered phenols, thiosynergists and/or hindered amines, acids (ascorbic acid, erythorbic acid, etidronic acid, hypophosphorous acid, nordihydroguaiaretic acid, propionic acid etc.), phenols, dodecyl gallate, octyl gallate, 1,3,5-trihydroxybenzene, organic and inorganic salts (calcium ascorbate, sodium ascorbate, sodium bisulphite, sodium metabisulfite, sodium sulfite, potassium bisulphite, potassium metabisulphite), esters (calcium ascorbate, dilauryl thiodipropionate, dimyristyl thiodipropionate, distearyl thiodipropionate), pyranon (maltol), and vitamin E (tocopherol, D-α-tocopherol, DL-α-tocopherol, tocopheryl acetate, d-α-tocopheryl acetate, dl-α-tocopheryl acetate. However, other anti-oxidative agents known in the art may be used according to the present invention. Other suitable stabilizer is selected from such as e.g. sorbitol glyceryl tricitrate, sucrose octaacetate.
Modifier may be incorporated in the composition. A suitable modifier is selected from such as e.g. fatty acids and esters, fatty alcohols, cetyl alcohol, stearyl alcohol, mineral oils, hydrogenated vegetable oils, vegetable oils, acetylated hydrogenated soybean oil glycerides, Castor oil, phosphate esters, amides, phthalate esters, glyceryl cocoate oleyl alcohol, myristyl alcohol, sucrose octaacetate, diacetylated monoglycerides, diethylene glycol monostearate, ethylene glycol monostearate, glyceryl monooleate, glyceryl monostearate, propylene glycol monostearate, macrogol esters, macrogol stearate 400, macrogol stearate 2000, polyoxyethylene 50 stearate, macrogol ethers, cetomacrogol 1000, lauromacrogols, poloxamers, polyvinyl alcohols, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, sorbitan sesquioleate, sorbitan trioleate, sorbitan tristearate, ethylcellulose, cellulose acetate, cellulose propionate, cellulose nitrate, cellulose derivative selected from the group consisting of methylcellulose, carboxymethylcellulose and salts thereof, cellulose acetate phthalate, microcrystalline cellulose, ethylhydroxyethylcellulose, ethylmethylcellulose, hydroxyethylcellulose, hydroxyethylmethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxymethylcellulose and hydroxymethylpropylcellulose, cellulose acetate, polylactic acid or polyglycolic acid and copolymers thereof, methacrylates, a co-polymer of methacrylate-galactomannan etc., Polyvinyl alcohols, glycerinated gelatin, cocoa butter
Other suitable modifier may be selected from the group consisting of inorganic acids, inorganic bases, inorganic salts, organic acids or bases and pharmaceutically acceptable salts thereof, saccharides, oligosaccharides, polysaccharides, polyethylene glycol derivatives and cellulose and cellulose derivatives.
Alternatively or additionally, a suitable pharmaceutically acceptable excipient is a mono-, di-, oligo, polycarboxylic acid or amino acids such as, e.g. acetic acid, succinic acid, citric acid, tartaric acid, acrylic acid, benzoic acid, malic acid, maleic acid, sorbic acid etc., aspartic acid, glutamic acid etc.
Examples of suitable organic acids include acetic acid/ethanoic acid, adipic acid, angelic acid, ascorbic acid/vitamin C, carbamic acid, cinnamic acid, citramalic acid, formic acid, fumaric acid, gallic acid, gentisic acid, glutaconic acid, glutaric acid, glyceric acid, glycolic acid, glyoxylic acid, lactic acid, levulinic acid, malonic acid, mandelic acid, oxalic acid, oxamic acid, pimelic acid, and pyruvic acid.
Examples of suitable inorganic acids include pyrophosphoric, glycerophosphoric, phosphoric such as ortho and meta phosphoric, boric acid, hydrochloric acid, and sulfuric acid.
Examples of suitable inorganic compounds include aluminium.
Examples of organic bases are p-nitrophenol, succinimide, benzenesulfonamide, 2-hydroxy-2cyclohexenone, imidazole, pyrrole, diethanolamine, ethyleneamine, tris(hydroxymethyl) aminomethane, hydroxylamine and derivates of amines, sodium citrate, aniline, hydrazine.
Examples of inorganic bases include aluminium oxide such as, e.g., aluminium oxide trihydrate, alumina, sodium hydroxide, potassium hydroxide, calcium carbonate, ammonium carbonate, ammonium hydroxide, KOH and the like.
Suitable pharmaceutically acceptable salts of an organic acid is e.g. an alkali metal salt or an alkaline earth metal salt such as, e.g. sodium phosphate, sodium dihydrogenphosphate, disodium hydrogenphosphate etc., potassium phosphate, potassium dihydrogenphosphate, potassium hydrogenphosphate etc., calcium phosphate, dicalcium phosphate etc., sodium sulfate, potassium sulfate, calcium sulfate, sodium carbonate, sodium hydrogencarbonate, potassium carbonate, potassium hydrogencarbonate, calcium carbonate, magnesium carbonate etc., sodium acetate, potassium acetate, calcium acetate, sodium succinate, potassium succinate, calcium succinate, sodium citrate, potassium citrate, calcium citrate, sodium tartrate, potassium tartrate, calcium tartrate etc.
A suitable inorganic salt for use in a matrix composition of the invention is sodium chloride, potassium chloride, calcium chloride, magnesium chloride etc.
Saccharides such as glucose, ribose, arabinose, xylose, lyxose, xylol, allose, altrose, inosito, glucose, sorbitol, mannose, gulose, Glycerol, idose, galactose, talose, mannitol, erythritol, ribitol, xylitol, maltitol, isomalt, lactitol, sucrose, fructose, lactose, dextrin, dextran, amylose, xylan.
Polyethylene glycol derivatives such as e.g. polyethylene glycol di(2-ethyl hexoate), polyethylene glycols (200-600 daltons) or polyethylene oxides, e.g. with a molecular weight of about 800-500,000 daltons, typically about 1,000-100,000 daltons, more typically 1,000-50,000 daltons, especially about 1,000-10,000 daltons, in particular about 1,500-5,000 daltons, and mixtures thereof.
Cellulose and cellulose derivative selected from the group consisting of methylcellulose, carboxymethylcellulose and salts thereof, microcrystalline cellulose, ethylhydroxyethylcellulose, ethylcellulose, cellulose acetate, cellulose proprionate, cellulose nitrate, cellulose acetate phthalate, ethylmethylcellulose, hydroxyethylcellulose, hydroxyethylmethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxymethylcellulose and hydroxymethylpropylcellulose.
Preparation of a Composition of the Present Invention
A composition of the invention may be produced by various methods which are either known per se in the pharmaceutical industry or which, for example, are used in the production of polymer-based materials, depending upon the desired embodiment and the materials employed in the composition in question. One advantage of the composition according to the invention is that it may be produced by methods, which are relatively simple and inexpensive.
Suitable preparation methods for compositions according to the invention include extrusion, injection moulding, tabletting, capsule filling, thermoforming, spray coating, micro encapsulation and other methods suitable for preparation of controlled release compositions. Compositions according to the invention may be prepared in numerous ways giving rise to different release mechanisms. Particularly the composition may be prepared by 1, 2 or multiple component injection mouldings, by conventional tablet compression, by tablet compression and afterward temperature curing, by micro encapsulation, by 1, 2 or multiple component extrusions, by capsule filling or by thermoforming. In cases were a preparation is needed in order to make the controlled release properties before/after the above mentions preparation steps, the preparation may also comprise separate steps as for example wet granulation, dry granulation, melt granulation, pelletizing, roller compaction, spray coating, electrostatic coating or other forms of controlled release preparation methods.
In a particular example the composition is prepared by two/three component injection moulding of a matrix and a coat partly covering the matrix and exposing two ends of the composition for erosion governed release.
During the injection moulding process it is possible to place separately prepared components and include these in the final product by insert-moulding or similar methods. Further separately prepared components from injection moulding or other processes e.g. tablets, pellets etc. can be assembled in a separate, automated assembly process.
A composition may also be produced by, for example, injection moulding, co-extrusion of the coating with the matrix composition and the active substance, extrusion and dip coating, injection moulding and dip coating, or by extrusion or injection moulding and solvent coating by spraying or dipping, electrostatic coating. Multiple component injection moulding, or a combination of these methods.
The injection moulding technique have the advantage of simultaneous mixing and heating the components during increased pressure in a one step procedure without exposure to air and moisture because the injection moulding is performed in a single closed compartment from the time the blend has entered the machine to the final pharmaceutical units are ejected ready for packaging.
In a further aspect of the invention, the blending process may be followed by an extrusion step for obtaining pellets suitable for feeding of the injection moulding machines. The extruding step may secure a more intimate blending and thereby higher reproducibility of the final pharmaceutical product.
It should also be mentioned that the present technology also can be applied when it is desired to have an amorphous form of the active substance in the composition, because the most convenient process for the preparation of a composition of the invention involves heating of the polymer together with the active substance and the conversion from the crystalline state to the amorphous state requires addition of energy (heating).
Normally, when preparing a composition according to the invention heating is employed for e.g. an injection moulding process. During heating it has been observed that PEO in various qualities forms free radicals that results in the formation of inter alia formaldehyde and formic acid. These products may often lead to further degradation e.g. of the active substance present in the composition and it is therefore necessary to take the necessary precautions in this respect. Oxidative free radicals degradation by hydroperoxides can be catalysed by certain transition metal ions, especially those of copper, cobalt and manganese. Thus, employment of PEO qualities devoid of or only containing a very small amount of such transition metal ions may improve stability. Another possibility is to use component in a quality that ensures that free radicals formed, if any, do not significantly increase the degradation of the active substance in the composition. Such a quality could e.g. be a quality containing an antioxidant that functions by preventing the formation of free radical during heating or by scavenging any free radicals formed. Another possibility is to add such antioxidant to the formulation before any heating takes place.
A composition according to the invention may therefore further comprise one or more antioxidants that inhibits the formation of peroxides and/or inactivates any peroxides present.
Suitable antioxidants for use includes beta-caroten (a vitamin A precursor), ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, monothioglycerol, potassium metabisulfite, sodium metabisulfite, propyl gallate, sodium formaldehylde sulfoxylate, sodium thiosulfate, sulfur dioxide, tocopherol, tocopherol acetate, tocopherol hemisuccinate, TPGS or other tocopherol derivatives, sulfides, phosphine etc. Other suitable antioxidants are described herein.
It is believed that the amorphous state of the active substance is furthermore favoured by the processing procedures of the preparation of the product according to the present invention, which in a preferred embodiment involves injection moulding of the pharmaceutical units.
For further details reference is made to the experimental section herein.
Other Specific Embodiments of the Invention
In the following is described various embodiments of the present invention. These embodiments illustrate the flexibility of the technology to obtain different release patterns and the flexibility with respect to including two or more, the same or different, active substances in a composition of the invention in order to obtain a composition that releases the active substance in a different manner dependent on in which layer the active substance is present. Accordingly, a composition of the present invention can be designed to have release properties including burst release (very fast release of substantially the whole content in that part of the composition), controlled release (typically prolonged or extended release), delayed release (i.e. release only after a certain lag time) and immediate release (relatively fast release). Thus, the following types can be obtained:
If only one active substance is present in the composition:
  • Delayed release—immediate release
  • Delayed release—controlled release
  • Burst release—delayed release—immediate release
  • Burst release—delayed release—controlled release
  • Burst release—immediate release
  • Burst release—controlled release
  • Controlled release—Immediate release
  • Controlled release—controlled release
If e.g. two different active substances (S1 and S2) are present, the following can be designed:
  • Delayed release for S1, but controlled release for S2—immediate release for S1
  • Delayed release for S1, but controlled release for S2—controlled release for S1
  • Burst release for S1 and/or S2—delayed release for S1, but controlled release for S2—immediate release S1
  • Burst release for S1 and/or S2—delayed release for S1, but controlled release for S2—controlled release for S1.
  • Burst release for S1 and/or S2—immediate release for S1 and/or S2
  • Burst release for S1 and/or S2—controlled release for S1 and/or S2 from multiple units
  • Controlled release for S1 and/or S2—Immediate release for S1 and/or S2
  • Controlled release for S1 and/or S2—controlled release for S1 and/or S2 from multiple units
A person skilled in the art will know how to obtain other combinations in view of the guidelines given herein.
In a specific embodiment, the present invention provides a composition for controlled delivery of at least one active substance. It is possible to include two or more different active substances in the composition of the invention, adapted to enable release at different concentrations, intervals and/or release rates.
Apart from the content of an active substance in the inner layer, the same and/or a different active substance (second active substance) can be substantially homogeneously dispersed in the outer layer (the polymer matrix), in which case a substantially zero order release of the second active substance is obtained. Alternatively or in addition, a burst release of the same or a different active substance may be obtained in a composition of the invention which comprises alternating layers. In a composition comprising alternating layers, the alternating layers may comprise, respectively, none, one, two or more different active substances.
As described in detail above, an inner layer comprises a quick release function obtained by e.g. fast disintegration, exploding and/or effervescent effects.
The first fraction comprises
    • a) a disintegration agent, an exploding agent, an effervescent agent or a mixture thereof
    • b) optionally, an active substance
    • c) optionally, multiple units comprising an active substance and,
    • d) optionally, one or more pharmaceutically acceptable excipients
The outer layers (matrix compositions) comprise
    • a) a polymer or a mixture of polymers,
    • b) optionally, an active substance and,
    • c) optionally, multiple units comprising an active substance and,
    • d) optionally, one or more pharmaceutically acceptable excipients.
A third component may also be present comprising
    • a) a polymer or a mixture of polymers,
    • b) optionally, one or more pharmaceutically acceptable excipients.
Due to the nature of the composition of the invention, it is possible to obtain a substantially controlled pulsatile/burst release, optionally in combination with a constant rate of release of the active substance over a specific period of time. The amount of drug release corresponds to the dosage necessary for the treatment in question, so that adherence to a strict dosage regimen, e.g. requiring administration of a drug at set intervals up to several times a day, may be dispensed with. It is possible to combine two or more active substances each following and independent release pattern however the release pattern of such substances may also be identical.
The matrix of the outer layer of a pharmaceutical composition of the invention may be designed to release an active substance, if any, in a controlled manner such as by a zero order release mechanism. Accordingly, the composition is also suitable for controlled release of an active substance, i.e. first a controlled release of an active substance (from the matrix, layer B) and then a relatively fast release of the same or different active substance (from the Layer A) or other suitable release combinations. In the present context the term “controlled release” is used to designate a release a desired rate during a predetermined release period. Terms like “modified”, “delayed”, “sustained”, “prolonged”, “extended” etc. release are in the present context synonyms to the term “controlled release”. Normally, the term relates to compositions that have a slower release of the active ingredient than that of a plain tablet or a tablet designed for immediate release. A person skilled in the art knows of these terms.
In order to more detailed explain the invention; reference is made to (EP 0406315, EP 0493513, WO 2006/128471) herein although the invention is not limited to this type and shape of the composition. However, the general idea is to have a layered composition, wherein the layers are separate layers.
However, a person skilled in the art will understand that other forms may fulfil the same objective. The most simplified versions of the pharmaceutical composition according to the invention are either a sphere or an oval shaped first fraction surrounded by a sphere or an oval shaped second fraction, reference is made to (EP 0406315, EP 0493513, WO 2006/128471).
In one embodiment of the invention a double burst unit is presented by having a layered composition placed inside an immediate release tablet matrix in such a way that the outer matrix is eroded or disintegrated, exposing the layered composition, as shown in FIG. 1.
In one embodiment of the invention, the inner layer of a composition according to the invention comprises an active substance. The release of the active substance is delayed because the outer layer must erode before the first fraction is exposed to the gastrointestinal fluids after oral administration.
In one embodiment of the invention it is possible to obtain a substantially controlled burst release, optionally in combination with a constant rate of release over a specific period of time. It is possible to combine two or more active substances each following and independent release pattern however the release pattern of such substances may also be identical. It may in certain cases be desirable to incorporate a mixture of two active substances into the matrix in order to release both active substances in the matrix with the same release rate. In other cases it is desirable to have different release rates of the two active substances. In such cases the composition may be composed of two different matrixes, each with different release characteristics. In yet another case the release of the active substances may be sequential, such that during the initial dissolution phase one active substance S1 is released and then the other S2. In this case the second release is onset after a lag defined by the first release.
More specifically, without limiting the invention thereto, the invention is illustrated by the embodiments mentioned below. Various different formulations of layers A) and B) are given and any combination of layers A) and B) is contemplated (i.e. any of the layer B) of 1, 2, 5-9 may be combined with any of layer A) 3, 4, 10-14, and the multiple unit formulations 15 or 16 may be part of either layer A) or B), and the coat formulations 17 or 18 may be applied to any of the combined formulations):
1. A Burst Release Layer B) or Multiple Units:
Ingredient % w/w
Homopolymer (e.g. 20,000-100,000 daltons 5-70
PEO)
Co-polymer (e.g. 1,000-16,000 daltons 5-70
Poloxamer)
Active substance 0.1-80
Filler Up to 100%
2. A Controlled Release Layer B) or Multiple Units:
Ingredient % w/w
Homopolymer (e.g. 100,000-700,000 daltons 5-70
PEO)
Co-polymer (e.g. 1,000-30,000 daltons 5-70
Poloxamer)
Active substance 0.1-80
Filler Up to 100%
3. A Burst Release Inner Layer A):
Ingredient % w/w
Homopolymer (e.g. 1,000-16,000 daltons 5-70
PEO)
Co-polymer (e.g. 2,000-30,000 daltons 5-70
Poloxamer)
Swelling agent 5-80%
Active substance 0.1-80
Filler Up to 100%
4. A Burst Release Inner Layer A):
Ingredient % w/w
Homopolymer (e.g. 1,000-16,000 daltons 5-70
PEO)
Co-polymer (e.g. 2,000-30,000 daltons 5-70
Poloxamer)
Effervescent agent 5-80%
Active substance 0.1-80
Filler Up to 100%
5. A Burst Release Layer B):
Ingredient % w/w
PEO
100 000 5
Poloxamer 188 5
Maltitol 15
Active substance 75
6. A Controlled Release Layer B):
Ingredient % w/w
PEO
200 000 25
Poloxamer 338 25
Xylitol 10
Active substance 40
7. A Controlled Release Layer B):
Ingredient % w/w
PEO 500 000 20
Poloxamer 407 50
Mannitol 2
Active substance 28
8. A Controlled Release Layer B):
Ingredient % w/w
PEO 700 000 20
Poloxamer 407 50
Sorbitol 2
Active substance 28
9. A Controlled Release Layer B):
Ingredient % w/w
PEO
100 000 52
PoloXamer188 10
Eudragit RL 10
Active substance 28
10. A Burst Release Inner Layer A):
Ingredient % w/w
Croscarmellose
20
Lactose 20
PEO 100 000 5
Poloxamer 188 5
Active substance 50
11. A Burst Release Inner Layer A):
Ingredient % w/w
Starch
20
Lactose 20
PEG 1500 5
Poloxamer 188 5
Active substance 50
12. A Burst Release Inner Layer A):
Ingredient % w/w
PEO
100 000 5
Poloxamer 188 5
Citric Acid 10
NaHCO 3 10
Active substance 70
13. A Burst Release Inner Layer A):
Ingredient % w/w
PEO
100 000 5
Poloxamer 188 5
Povidone 2
Citric Acid 10
NaHCO 3 10
Active substance 68
14. A Burst Release Inner Layer A):
Ingredient % w/w
PEO
100 000 5
Poloxamer 188 5
Povidone 2
Citric Acid 10
NaHCO 3 10
Active substance 68
15. Burst Release Multiple Units:
Ingredient % w/w
PEO
100 000 5
Poloxamer 188 5
Povidone 20
Active substance 70
16. Controlled Release Multiple Units:
Ingredient % w/w
PEO
100 000 5
Poloxamer 407 15
Ethylcellulose 70
Active substance 10
17. Controlled Release Multiple Units Coated with Eudragit RL 30D/RS 30D:
Ingredient % w/w
PEO
100 000 5
Poloxamer 188 5
Povidone 20
Active substance 70
18. Coat with a Solid Content of 20%
Ingredient % w/w
Eudragit RL 30D 3.9
Eudragit RS 30D 35.3
Talc 5.9
Triethyl citrate 2.33
Water 52.5
In the appended FIGS. 15-24 are given release profiles obtainable by compositions of the present invention.
Other specific embodiments are listed in the following:
  • 1. A layered pharmaceutical composition comprising A) a solid inner layer comprising
  • i) a substantially water soluble and/or crystalline polymer or a mixture of substantially water soluble and/or crystalline polymers, the polymer being a polyglycol in the from of one of a) a homopolymer having a MW of at the most about 16,000 daltons, and b) a copolymer having a MW of at the most about 30,000 daltons, and
  • ii) an active substance,
    the solid inner core being sandwiched between two outer layers B1 and B2), each outer layer comprising
  • iii) a substantially water soluble and/or crystalline polymer or a mixture of substantially water soluble and/or crystalline polymers, the polymer being a polyglycol in the from of one of c) a homopolymer having a MW of at least about 100,000 daltons, and d) a copolymer having a MW of at least about 2,000 daltons,
  • and i) of layer A being different from iii) of layer B,
    the layered composition being coated with a coating C) that has at least one opening exposing at least one surface of said outer layer, the coating being substantially insoluble in and impermeable to fluids and comprising a polymer.
  • 2. A composition according to item 1, wherein A) further comprises one or more disintegration/exploding agents, one of more effervescent agents or a mixture thereof
  • 3. A composition according to item 2, wherein the disintegrant/exploding is Sodium starch glycolate, Povidone, Sodium alginate, Alginic acid, Calcium alginate, Carboxymethylcellulose calcium, Carboxymethylcellulose sodium, Powdered cellulose, Chitosan, Croscarmellose sodium, Crospovidone, Hydroxypropyl starch, Hydroxypropyl cellulose low-substituted, Magnesium aluminium silicate, Methylcellulose, Microcrystalline cellulose, pregelatinized starch, Docusae sodium, Guar gum, Polacrilin potassium or the like.
  • 4. A composition according to item 2, wherein the effervescent agent is Effer-Soda, Citric acid, Citric acid, monohydrate, Dextrates, Fumaric acid, Potassium bicarbonate, Sodium bicarbonate, Sodium citrate dehydrate, Tartaric acid or the like.
  • 5. A composition according to any of the preceding items, wherein the outer layer B1 and/or B2 when exposed to an aqueous medium erodes at a substantially constant rate.
  • 6. A composition according to any of the preceding items, wherein the active substance in A) is subject to release after a lag time corresponding to the erosion time of the layer B1 and/or B2.
  • 7. A composition according to any of the preceding items, wherein the inner layer A) without B) and C) disintegrates within at the most 60 min such as, e.g., at the most about 30 min or at the most about 15 min, when subjected to a disintegration test according to Ph. Eur.
  • 8. A composition according to any of the preceding items having a cylindrical shape optionally with one or more tapered ends.
  • 9. A composition according to any of the preceding items, wherein the coating C) appears as a substantially intact empty shell when the composition has been subjected to a dissolution test according to Ph. Eur. by which the outer layer B) erodes and the inner layer A) disappears from the composition optionally by means of one or more disintegration agents, explosion agents, effervescent agents or a mixture thereof.
  • 10. A composition according to any of the preceding items, wherein the polymers i) and iii), and the polymer contained in the coating C) are thermoplastic.
    Inner Layer
  • 11. A composition according to any of the preceding items, wherein polymer i) comprises a homopolymer having a MW of at least about 1,000 daltons such as, e.g., a homopolymer having a MW in a range from about 1,000 to about 15,000 daltons, from about 1,000 to about 12,000 daltons, from about 1,500 to about 10,000 daltons, from about 1,500 to about 8,000 daltons.
  • 12. A composition according to any of the preceding items, wherein polymer i) comprises a copolymer having a MW of at the most about 25,000 daltons such as, e.g., at the most about 20,000 daltons, at the most about 15,000 daltons, at the most about 10,000 daltons, at the most about 5,000 daltons, at the most about 2,000 daltons.
  • 13. A composition according to any of the preceding items, wherein the active substance in A) is present at least partly in solid or dissolved form.
  • 14. A composition according to any of the preceding items, wherein the active substance in A) is present in form of pellets, beads, flakes, mini-tablets, granules, microspheres, nanoparticle, crystals or the like.
  • 15. A composition according to claim 14, wherein the active substance containing pellets, beads, flakes, mini-tablets, granules, microspheres, nanoparticles, crystal or the like are dispersed in the polymer i).
  • 16. A composition according to any of the preceding items, wherein the concentration of the polymer i) in inner layer A) is from about 5% w/w to about 100% w/w.
  • 17. A composition according to any of the preceding items 2-16, wherein the concentration of the one or more disintegration/exploding agent, if present, is from about 5% w/w to about 80% w/w such as, e.g., from about 10% w/w to about 70% w/w, from about 15% w/w to about 60% w/w or from about 20% w/w to about 50% w/w.
  • 18. A composition according to any of the preceding items, wherein the concentration of the one or more effervescent agent, if present, is from about 5% w/w to about 80% w/w such as, e.g., from about 10% w/w to about 70% w/w, from about 15% w/w to about 60% w/w or from about 20% w/w to about 50% w/w.
    Outer Layer
  • 19. A composition according to any of the preceding items, wherein polymer iii) comprises one or more of a polyethylene glycol, a polyethylene oxide and/or a copolymer of ethylene oxide and propylene oxide including poly(ethylene-glycol-b-(DL-lactic acid-co-glycolic acid)-b-ethylene glycol (PEG-PLGA PEG), poly((DL-lactic acid-co-glycolic acid)-g-ethylene glycol) (PLGA-g-PEG), and polyethylene oxide-polypropylene oxide (PEO-PPO).
  • 20. A composition according to item 19, wherein the polyethylene glycol or a polyethylene oxide has a molecular weight from about 100,000 to about 700,000.
  • 21. A composition according to item 19, wherein the copolymer of ethylene oxide and propylene oxide comprises up to about 30% w/w of the propylene oxide based block, and has a molecular weight of from about 5,000 to about 15,000 daltons.
  • 22. A composition according to any of the preceding items, wherein the concentration of polymer iii) in layer B) is from about 5% w/w to about 100% w/w.
  • 23. A composition according to any of the preceding items, wherein layer B1) and/or B2) contain a second active substance.
  • 24. A composition according to item 23, wherein the release of the second active substance follows a zero order release pattern at least up to 80% w/w release of the total content of second active substance in layer B).
    Coating
  • 25. A composition according to any of the preceding items, wherein the polymer comprised in the coating is selected from the group consisting of ethylcellulose, cellulose acetate, cellulose propionate, cellulose nitrate, polyamide, polyethylene, polyethylene terephtalate, polypropylene, polyurethane, polyvinyl acetate, polyvinyl chloride, silicone rubber, latex, polyhydroxybutyrate, polyhydroxyvalerate, teflon, polylactic acid or polyglycolic acid and copolymers thereof, copolymers including ethylene vinyl acetate, styrene-butadienstyrene and styrene-isoprene-styrene.
  • 26. A composition according to any of the preceding items, wherein the coating does not completely crumble or erode before the layer B) has completely eroded and the layer A) is released.
The invention is further illustrated in the following non-limiting examples.
EXAMPLES Dissolution Method for Testing Dosage Units According to the Invention
Dissolution testing is performed according to USP 30, NF 25 (711), and apparatus 2 (paddle method). The dissolution medium may consist of 0.1 M HCl or phosphate buffer e.g. pH 6.8, pH 6.8 & 40% ethanol or pH 7.2. The volume of dissolution medium is typically 900 ml or 1000 ml and the paddle speed is 50 rpm. Samples are withdrawn at suitable time points and analysed for content of active substance by means of on-line UV detection or HPLC with UV detection.
Methods
A general method for preparation dosage unit is described below.
Preparation of a Matrix Composition
An accurate amount of the polymer is loaded into a MTI mixer followed by an accurate amount of the active substance and of the pharmaceutically acceptable excipients(s), if any. The mixing is performed at 900-2000 rpm and at a time period up to 20 min. At the start of the mixing the temperature is about 19-21° C. and the final temperature of the mixture is about 30-50° C. The mixture is then allowed to cool to room temperature and is ready to be fed into an injection moulding machine.
Preparation of the Coating Composition
The coating composition is prepared by first adding the Ethylcellulose then Cetostearyl alcohol, and finally the Titanium dioxide to an MTI-Mixer at a temperature about 19-21° C. Mixing rate is 1000 rpm. The mixer is stopped when the temperature reaches 40-50° C. and the adhered material is manually incorporated into the mixture. The mixture is left to cool for about 10 minutes. The mixing is then finalized with a short high-speed mix in order to minimize lumps formation. The mixture is then allowed to cool to room temperature, after which it has a suitable consistency for being fed into an injection moulding machine.
Example of a Coat Composition;
Batch: 58-014-01-013 Batch: 08-0017-058
Material %(w/w) %(w/w)
Ethylcellulose 79 86.5
Cetostearyl alcohol 20 12.5
Titanium dioxide 1 1

Small Scale Preparation
A mixture may be prepared by simple volumetric mixing of the components. 3 g of the mixture is then feeded into a table top injection molding machine (Haake MiniJet II, Thermo Electron, Karlsruhe, Germany) and molded directly into a pre-molden shell and/or matrix. Typical settings in the MiniJet are: Temperature 90-120° C. and pressure 600-800 bar.
Preparation of Dosage Unit
The final dosage units may be prepared according to two different methods. In one method, the coat and the matrix are moulded individually followed by a manually incorporation of the moulded matrix plug into the moulded coat. The injection moulding machine used is an Arburg Allrounder 220 S 250/60. In the second method, the coat and matrix are moulded in one process where the coat is moulded in a first step and the matrix is moulded directly into the coat in a second step (co-moulding or 2-component moulding). The injection moulding machine used is Arburg Allrounder 420 V 800-60/35.
Preparation 1
Pellets for the Inner Layer A of a Dosage Unit According to the Invention (PHH 0120-063)
Pellets were prepared by mixing Poloxamer 188 (48% w/w), Eudragit RL (24% w/w) and Hydrocortisone (28% w/w) in a beaker on a heat stage set at 150° C. The melt was applied to a punched plate (hole size 1 mm) and pellets of diameter 1 mm was formed. The pellets disintegrated in cold MQ water in less than 1 h.
Preparation 2
An Inner Layer a for a Dosage Unit According to the Invention Prepared by Direct Compression (PHH-0120-061-2)
Pellets (batch 108-009-05-001C) comprising Hydrocortison (55% w/w), PEG 8000 (40% w/w) and PVP C15 (5% w/w) was prepared by hot melt extrusion followed by grinding. The pellets were sieved to reach a final size of 1000 μm-1200 μm. 35-37 mg pellets were mixed with 206-230 mg filler material comprising Lactose (StarLac®). The material was placed in an IR-tablet preparing device and compressed at a pressure of 5 metric tons.
Dissolution shows that the tablet is completely disintegrated after 18 minutes leaving the pellets for slower dissolution. Upon testing with an USP 2 apparatus using 900 ml phosphate buffered media, pH 6.8 and 50 RPM the following release profile was obtained.
Time (min) Release (%)
 50 min 50
245 min 80
490 min 90

Preparation 3
An Inner Layer A for a Dosage Unit According to the Invention Prepared by Direct Compression (PHH-0120-062-4)
Pellets (batch 108-009-05-001C) comprising Hydrocortison (55% w/w), PEG 8000 (40% w/w) and PVP C15 (5% w/w) was prepared by hot melt extrusion followed by grinding. The pellets were sieved to reach a final size of 1000 μm-1200 μm. 35-37 mg pellets were mixed with 165-336 mg filler material comprising Lactose (StarLac®):NaHCO3:Citric Acid (1497:333:272% w/w). The material was placed in an IR-tablet preparing device and compressed at a pressure of 5 metric tons.
Dissolution shows that the tablet disintegrates immediately leaving the pellets for slower dissolution. Upon testing with an USP 2 apparatus using 900 ml phosphate buffered media, pH 6.8 and 50 RPM the following release profile was obtained.
Time (min) Release (%)
 40 min 50
185 min 80
435 min 90

Preparation 4
A dosage unit exhibiting Burst-controlled behaviour (MQV batch 1047-041, 1047-042 & 1047-044), see FIG. 2. As both Morphine and Hydrocodone absorb at the same wave length, it has been necessary to conduct two parallel experiments—each experiment applying a dosage unit with active substance combined with placebo. The dosage units consisted of two plugs, one containing the active substance, one being a placebo-formulation. Finally the results from the two experiments were pooled, thereby simulating one dosage unit consisting of the two active substances, one plug which exhibits burst release of Hydrocodone and the other controlled release of Morphine.
The shell was produced by injection moulding. The plugs were injection moulded using the mini jet at applying a temperature 110° C., a pressure of 800 bar and a cycle time of 20 s. The thickness and the diameter of the plug was 4.5 mm diameter. The exposed area of the matrix (i.e. two ends) is 35.04 mm2 and the length of the dosage unit is 9 mm.
Preparation of a Controlled Release Plug:
The active plug comprised: PoloXamer 188, PEO 300 000, Morphine Sulphate pentahydrate and Mannitol, which were mixed. Afterwards the powder mixture fed to the injection moulding machine.
The inactive (placebo) plug comprised: PoloXamer 407, PEO 300 000, which were mixed. Then the powder mixture was fed to the injection moulding machine.
Preparation of a Burst Release Plug:
The active plug comprised: Hydrocodone bitartarte, PEG 3350S, Sodium hydrogen carbonate and Citric acid, which were mixed. Afterwards the powder mixture fed to the injection moulding machine.
The inactive (placebo) plug comprised: PEG 3350S, Sodium hydrogen carbonate and Citric acid, which were mixed. Then the powder mixture was fed to the injection moulding machine.
The Controlled Release Plug has the Composition:
Content % (w/w)
Active plug
Morphine sulphate pentahydrate 53
Mannitol 3
PEO 300 000 35
PoloXamer 188 9
Inactive (placebo) plug
PEO
300 000 85
PoloXamer 407 15
The Burst Release Plug has the Composition:
Content % (w/w)
Active plug
Hydrocodone bitartrate 53
PEG 3350S 41
Sodium hydrogen carbonate 3
Citric acid 3
Inactive (placebo) plug
PEG 3350S 94
Sodium hydrogen carbonate 3
Citric acid 3
Shell
Ethylcellulose 86.5
Cetostearyl alcohol 12.5
Titanium dioxide 1.0
The dissolution behaviour as tested by USP 2 apparatus, (pH 6.8, 900 ml phosphate buffered media, 50 RPM), see FIG. 3.
Preparation 5
A dosage unit exhibiting Controlled-controlled behaviour (MQV batch 1047-041), see FIG. 2. As both active substances Morphine and Oxycodone absorb at the same wave length, it has been necessary to conduct two parallel experiments—each experiment applying a dosage unit with active substance combined with placebo. The dosage units consisted of two plugs, one containing the active substances, one being a placebo-formulation. Finally the results from the two experiments were pooled, thereby simulating one dosage unit consisting of Morphine and Oxycodone, both exhibiting controlled release beheveour.
The shell was produced by injection moulding. The plugs were injection moulded using the mini jet at applying a temperature 110° C., a pressure of 800 bar and a cycle time of 20 s. The thickness and the diameter of the plug was 4.5 mm diameter. The exposed area of the matrix (i.e. two ends) is 35.04 mm2 and the length of the dosage unit is 9 mm.
Preparation of Plug (for Controlled Release of Morphine):
The active plug comprised: PoloXamer 188, PEO 300 000, Morphine Sulphate pentahydrate and Mannitol, which were mixed. Afterwards the powder mixture fed to the injection moulding machine.
Preparation of Plug (for Controlled Release of Oxycodone):
The active plug comprised: Oxycodone hydrochloride, PEO 200 000, Mannitol, PoloXamer 407, which were mixed. Afterwards the powder mixture fed to the injection moulding machine.
In both cases the inactive (placebo) plug comprised: PoloXamer 407, PEO 300 000, which were mixed. Then the powder mixture was fed to the injection moulding machine.
The dosage form (controlled release) consists of an active plug and a placebo plug, the composition is given below:
Content % (w/w)
Active plug
Morphine sulphate pentahydrate 53
Mannitol 3
PEO 300 000 35
PoloXamer 188 9
Active plug
Oxycodone hydrochloride 53
Mannitol 5
PEO 200 000 17
PoloXamer 407 25
Placebo plug
PEO
300 000 85
PoloXamer 407 15
Shell
Ethylcellulose 86.5
Cetostearyl alcohol 12.5
Titanium dioxide 1.0
The dissolution behaviour as tested by USP 2 apparatus, (pH 6.8, 900 ml phosphate buffered media, 50 RPM), see FIG. 4.
Example 1
Dissolution of Non-compressed Inner Layer A for a Dosage Unit According to the Invention (PHH-0120-067).
Units were prepared by the following procedure: Pellets comprising Hydrocortison (55% w/w), PEG 8000 (40% w/w) and PVP C15 (5% w/w) was prepared by hot melt extrusion followed by grinding. The pellets were sieved to reach a uniform size. 36-38 mg pellets were mixed with 170-175 mg filler material comprising lactose (StarLac®), NaHCO3 and Citric Acid (18500:825:675% w/w). Shell comprising Ethyl cellulose (89% w/w), Cetostearyl alcohol (10% w/w) and Titanium dioxide (1% w/w) (batch 06-0010-058) was prepared by injection moulding. The dosage unit was hand assembled first with a 2 mm thick delay plug comprising PEO 200 000, the pellet/filler blend was added and then another 2 mm thick delay plug comprising PEO 200 000. The exposed area of the matrix is 77 mm2 and the length of the shell is 22.7 mm.
Dissolution analysis using USP 2 apparatus, pH 6.8, 900 ml phosphate buffered media at 50 RPM showed a delay for more than 4 hours followed by the immediate release of the un-dissolved pellets from the unit into the dissolution media. From the pellets 50% release of Hydrocortison was reached within 4 h from time of onset (end of delay).
Example 2
Dosage Unit According to the Invention Exhibiting Double Burst Behaviours (Batch 05-0126-110/05-0134-110), See FIG. 5.
Shell, end plugs (layer B), delay plugs and centre plug (inner layer A) were prepared by injection moulding and hand assembled. The procedure was as follows:
  • 1 Locate the shell with injection side upward
  • 2 Place the first delay plug with the injection side down word at the top of the shell
  • 3 Gently push the delay plug a few mm into the shell
  • 4 Place the inner plug at the delay plug and push it into the shell also moving the delay plug
  • 5 Place the second delay plug with the injection side upward at the inner plug and push it into the shell
  • 6 One end plug is placed at each end of the shell
    The Dosage Form has the Composition:
Content % (w/w)
End plug
Paracetamol
80
Peg 8000 10
Hard fat 4
Sodium bicarbonate 3.3
Citric acid, monohydrate 2.7
Delay plug
PEO
200 000 99.5
BHT 0.5
Centre plug
Paracetamol 75.2
Peg 8000 9.4
Hard fat 3.8
Sodium bicarbonate 9.1
Citric acid, monohydrate 2.5
Shell
Ethylcellulose 79
Cetostearoyl 20
Titanium dioxide 1
The exposed area of the matrix is 77 mm2 (i.e. sum of surface area of the two ends) and the length of the shell is 22.7 mm.
The dissolution behaviour as tested by USP 2 apparatus, (pH 6.8, 1000 ml phosphate buffered media, 50 RPM) was as follows (see FIG. 6):
Time (min) Release (%)
15 49
155 50
211 70
218 75
241 92
250 94
Example 3
A Dosage Unit According to the Invention Exhibiting Controlled-burst Behaviour (MQV Batch 1047-040), See FIG. 7.
The shell was produced by injection moulding. The injection moulding machine used is a Haake Minijet II. End plugs and centre plug were prepared by hand and hand assembled. Each plug had a thickness of 3 mm.
Preparation of End Plugs (for Controlled Release):
PoloXamer 338, PEO 200 000, Morphine Sulphate pentahydrate and Mannitol were mixed. Afterwards the powder mixture was heated to approximately 110° C. The melt was moulded into a 3 mm thick, and a 4.5 mm diameter, hole metal filter to attain the plugs.
Preparation of Centre Plug (for Burst Release):
Explotab, Sodium Starch Glycolate & Sodium Carboxymethyl Starch, Maize starch and Morphine Sulphate pentahydrate were mixed. Then the powder mixture was compressed to a plug (tablet) by direct compression. Centre plugs of 3 mm thickness and a diameter of 4.5 mm were prepared.
The Procedure was as Follows:
  • 1 Locate the shell with injection side upward
  • 2 Place the first end plug with the injection side down word at the top of the shell
  • 3 Gently push the centre plug into the shell
  • 4 The last end plug is placed at the end of the shell
    The Dosage Form has the Composition:
Content % (w/w)
End plug
Morphine sulphate pentahydrate 16
Mannitol 10
PEO 200 000 34
PoloXamer 338 40
Centre plug
Morphine sulphate pentahydrate 32
Explotab 50
Maize starch 18
Shell
Ethylcellulose 86.5
Cetostearyl alcohol 12.5
Titanium dioxide 1.0
The exposed area of the matrix is 34.72 mm2 (i.e. two ends) and the length of the dosage unit is 9 mm.
The dissolution behaviour as tested by USP 2 apparatus, (pH 6.8, 900 ml phosphate buffered media, 50 RPM), see FIG. 8.
Example 4
A Dosage Unit According to the Invention Exhibiting Controlled-burst Behaviour (MQV Batch 1047-045), See FIG. 7.
The shell was produced by injection moulding. The injection moulding machine used is a Haake Minijet II. End plugs and centre plug were prepared by hand and hand assembled. Each plug had a thickness of 3 mm.
Preparation of End Plugs (for Controlled Release):
PoloXamer 338, PEO 200 000, Morphine Sulphate pentahydrate and Mannitol were mixed. Afterwards the powder mixture was heated to approximately 110° C. The melt was moulded into a 3 mm thick, and a 4.5 mm diameter, hole metal filter to attain the plugs.
Preparation of Centre Plug (for Burst Release):
Sodium hydrogen carbonate, Citric acid and Morphine Sulphate pentahydrate were mixed. Then the powder mixture was compressed to a plug (tablet) by direct compression. Centre plugs of 3 mm thickness and a diameter of 4.5 mm were prepared.
The Procedure was as Follows:
  • 1 Locate the shell with injection side upward
  • 2 Place the first end plug with the injection side down word at the top of the shell
  • 3 Gently push the centre plug into the shell
  • 4 The last end plug is placed at the end of the shell
    The Dosage Form has the Composition:
Content % (w/w)
End plug
Morphine sulphate pentahydrate 16
Mannitol 10
PEO 200 000 34
PoloXamer 338 40
Centre plug
Morphine sulphate pentahydrate 32
Citric acid 34
Sodium hydrogen carbonate 34
Shell
Ethylcellulose 86.5
Cetostearyl alcohol 12.5
Titanium dioxide 1.0
The exposed area of the matrix (i.e. two ends) is 34.72 mm2 and the length of the dosage unit is 9 mm.
The dissolution behaviour as tested by USP 2 apparatus, (pH 6.8, 900 ml phosphate buffered media, 50 RPM), see FIG. 9.
Example 5
A Dosage Unit According to the Invention Exhibiting Controlled-controlled Behaviour (MQV Batch 1047-043), See FIG. 10.
The shell was produced by injection moulding. End plugs and centre plug, comprising pellets, were prepared by hand and hand assembled. Each plug had a thickness of 3 mm.
Preparation of End Plugs (for Controlled Release):
PoloXamer 188, PEO 300 000, Mannitol and Morphine sulphate pentahydrate were mixed. The material was melted to approximately 110° C., and the melt was moulded into a 3 mm thick, and a 4.5 mm diameter, hole metal filter to attain the plugs.
Preparation of Centre Plug (for Controlled Release):
PoloXamer 188, PEO 300 000, Mannitol and Morphine sulphate pentahydrate were mixed and processed on a melt extruder. The extruded strings were cooled and cut into pellets. The pellets were sieved to reach a uniform size. Pellets were mixed with CrosPovidone to attain a centre plug of approximately 3 mm thickness and a 4.5 mm diameter.
The Procedure was as Follows:
  • 1 Locate the shell with injection side upward
  • 2 Place the first end plug with the injection side down word at the top of the shell
  • 3 Pellets and CrosPovidone were added into the shell
  • 4 The last end plug is placed at the end of the shell
    The Dosage Form has the Composition:
Content % (w/w)
End plug
Morphine sulphate pentahydrate 53
Mannitol 3
PEO 300 000 35
PoloXamer 188 9
Pellets
Morphine sulphate pentahydrate 53
Mannitol 3
PEO 300 000 35
PoloXamer 188 9
Centre plug
Pellets and 25% CrossPovidone were added
Shell
Ethylcellulose 86.5
Cetostearyl alcohol 12.5
Titanium dioxide 1.0
The exposed area of the matrix (i.e. two ends) is 34.72 mm2 and the length of the dosage unit is 9 mm.
The dissolution behaviours as tested by USP 2 apparatus, (pH 6.8 and pH 6.8/40% ethanol, 900 ml phosphate buffered media, 50 RPM), see FIG. 11. Furthermore, it is demonstrated that these pellets are abuse resistant as the dissolution rate is significantly lower in alcohol-containing media, see FIG. 12.
Example 6
A Dosage Unit According to the Invention Exhibiting Controlled-controlled Behaviour (MQV Batch 1047-047, See FIG. 10.
The shell was produced by injection moulding. End plugs and centre plug, comprising pellets, were prepared by hand and hand assembled. Each plug had a thickness of 3 mm.
Preparation of End Plugs (for Controlled Release):
Morphine, PEO and PoloXamer 407 were mixed thoroughly and melted to approximately 110° C., and the melt was moulded into a 2 mm thick, and a 4.5 mm diameter, hole metal filter to attain the plugs.
Preparation of Centre Plug (for Controlled Release):
PoloXamer 188, PEO 300 000, Mannitol and Morphine sulphate pentahydrate were mixed and processed on a melt extruder. The extruded strings were cooled and cut into pellets. The pellets were sieved to reach a uniform size. Pellets were mixed with CrosPovidone to attain a centre plug of approximately 3 mm thickness and a 4.5 mm diameter.
The Procedure was as Follows:
1 Locate the shell with injection side upward
2 Place the first end plug with the injection side down word at the top of the shell
3 Pellets and CrosPovidone were added into the shell
4 The last end plug is placed at the end of the shell
The Dosage form has the Composition:
Content % (w/w)
End plug
Morphine sulphate pentahydrate 20
PEO 45
PoloXamer 407 35
Pellets
Morphine sulphate pentahydrate 53
Mannitol 3
PEO 300 000 35
PoloXamer 188 9
Centre plug
Pellets and 25% CrossPovidone were added
Shell
Ethylcellulose 86.5
Cetostearyl alcohol 12.5
Titanium dioxide 1.0
The exposed area of the matrix (i.e. two ends) is 34.72 mm2 and the length of the dosage unit is 9 mm.
The dissolution behaviour as tested by USP 2 apparatus, (pH 6.8, 900 ml phosphate buffered media, 50 RPM, see FIG. 13.
Example 7
A Dosage Unit According to the Invention Exhibiting Burst-controlled Behaviour (MQV Batch 1047-046), See FIG. 10.
The shell was produced by injection moulding. End plugs and centre plug, comprising pellets, were prepared by hand and hand assembled. Each plug had a thickness of 3 mm.
Preparation of End Plugs (for Burst Release):
Morphine sulphate pentahydrate, PEG 3350S, Sodium hydrogen carbonate and Citric acid were mixed and melted to approximately 110° C., and the melt was moulded into a 3 mm thick, and a 4.5 mm diameter, hole metal filter to attain the plugs.
Preparation of Centre Plug (for Controlled Release):
PoloXamer 188, PEO 300 000, Mannitol and Morphine sulphate pentahydrate were mixed and processed on a melt extruder. The extruded strings were cooled and cut into pellets. The pellets were sieved to reach a uniform size. Pellets were mixed with CrosPovidone to attain a centre plug of approximately 3 mm thickness and a 4.5 mm diameter.
The Procedure was as Follows:
  • 1 Locate the shell with injection side upward
  • 2 Place the first end plug with the injection side down word at the top of the shell
  • 3 Pellets and CrosPovidone were added into the shell
  • 4 The last end plug is placed at the end of the shell
    The Dosage Form has the Composition:
Content % (w/w)
End plugs
Morphine sulphate pentahydrate 25
PEG 3350S 65
Sodium hydrogen carbonate 5
Citric acid 5
Pellets
Morphine sulphate pentahydrate 53
Mannitol 3
PEO 300 000 35
PoloXamer 188 9
Centre plug
Pellets and 25% CrossPovidone were added
Shell
Ethylcellulose 86.5
Cetostearyl alcohol 12.5
Titanium dioxide 1.0
The exposed area of the matrix (i.e. two ends) is 34.72 mm2 and the length of the dosage unit is 9 mm.
The dissolution behaviour as tested by USP 2 apparatus, (pH 6.8, 900 ml phosphate buffered media, 50 RPM) see FIG. 14.

Claims (27)

The invention claimed is:
1. A layered pharmaceutical composition for controlled release of an active substance, comprising:
a solid inner layer (A) comprising the active substance and a disintegrant, the solid inner layer (A) being positioned between two outer layers (B1) and (B2),
each outer layer (B1) and (B2) comprising one or more substantially water soluble or crystalline polyethylene oxides (PEOs) having a molecular weight (MW) of about 100,000 daltons or greater, wherein the average molecular weight of the PEO present in each outer layer is about 100,000 daltons or greater, wherein each outer layer is free of the disintegrant, and wherein at least one of the outer layers (B1) and (B2) comprises the active substance, and
a coating (C) forming a shell covering the solid inner layer (A) and partially covering outer layers (B1) and (B2) with two openings exposing a surface of each outer layer (B1) and (B2), wherein the coating (C) comprises a polymer and is substantially insoluble in and impermeable to gastrointestinal fluids;
wherein the solid inner layer (A), without the outer layers (B1) and (B2) and the coating (C), disintegrates within 60 minutes when subjected to a disintegrating test according to the Eur. Ph; and
wherein the release of the active substance contained in at least one of the outer layers (B1) and (B2) follows a zero order release pattern for at least 80% w/w release of the total content of the active substance in the outer layers (B1) and (B2).
2. The pharmaceutical composition of claim 1, wherein the active substance in the solid inner layer (A) is present in the form of a multiple unit formulation.
3. The pharmaceutical composition of claim 2, wherein the multiple unit formulation is a controlled release multiple unit formulation.
4. The pharmaceutical composition of claim 2, wherein the active substance of the solid inner layer (A) is present in a form selected from pellets, beads, flakes, mini-tablets, granules, microspheres, nanoparticles, crystals, and combinations thereof.
5. The pharmaceutical composition of claim 2, wherein the multiple unit formulation of solid inner layer (A) comprises a polymer selected from the group consisting of (i) substantially water soluble or crystalline polyglycol homopolymers having a MW of about 100,000 daltons or greater and (ii) substantially water soluble or crystalline polyglycol copolymers having a MW of about 2,000 daltons or greater.
6. The pharmaceutical composition of claim 1, wherein solid inner layer (A) further comprises a filler.
7. The pharmaceutical composition of claim 1, wherein solid inner layer (A) further comprises a polymer selected from the group consisting of (i) substantially water soluble or crystalline polyglycol homopolymers having a MW of about 16,000 daltons or less and (ii) substantially water soluble or crystalline polyglycol copolymers having a MW of about 30,000 daltons or less.
8. The pharmaceutical composition of claim 7, wherein the polymer of solid inner layer (A) is a substantially water soluble or crystalline polyglycol homopolymer having a MW of between about 1,000 daltons and about 16,000 daltons.
9. The pharmaceutical composition of claim 7, wherein the polymer of the solid inner layer (A) is a substantially water soluble or crystalline polyglycol copolymer having a MW of about 25,000 daltons or less.
10. The pharmaceutical composition of claim 1, wherein the concentration of the disintegrant in the solid inner layer (A) is from about 5% w/w to about 80% w/w.
11. The pharmaceutical composition of claim 1, wherein each of the two outer layers (B1) and (B2) further comprises one or more block copolymers of ethylene oxide and propylene oxide.
12. The pharmaceutical composition of claim 1, wherein the average molecular weight of the PEO present in each outer layer is from about 100,000 daltons to about 700,000 daltons.
13. The pharmaceutical composition of claim 11, wherein the block copolymers of ethylene oxide and propylene oxide have a MW of from about 4,000 daltons to about 15,000 daltons.
14. The pharmaceutical composition of claim 1, wherein the concentration of the polymer in each of the two outer layers (B1) and (B2) is from about 5% w/w to about 100% w/w.
15. The pharmaceutical composition of claim 1, wherein both of outer layers (B1) and (B2) comprise the active substance.
16. The pharmaceutical composition of claim 1, wherein at least one of outer layers (B1) and (B2) comprises a second active substance different from the active substance in the solid inner layer (A).
17. The pharmaceutical composition of claim 16, wherein both of outer layers (B1) and (B2) comprise the second active substance different from the active substance of solid inner layer (A).
18. The pharmaceutical composition of claim 16, wherein the composition exhibits zero order release of the second active substance present in outer layers layer(s) (B1) and/or (B2).
19. The pharmaceutical composition of claim 16, wherein the composition exhibits zero order release of at least 80% w/w of the second active substance present in outer layer(s) (B1) and/or (B2).
20. The pharmaceutical formulation of claim 1, wherein the polymer of the coating (C) is selected from the group consisting of ethylcellulose, cellulose acetate, cellulose propionate, cellulose nitrate, polyamide, polyethylene, polyethylene terephthalate, polypropylene, polyurethane, polyvinyl acetate, polyvinyl chloride, silicone rubber, latex, polyhydroxybutyrate, polyhydroxyvalerate, polytetrafluoroethylene, polylactic acid or polyglycolic acid and copolymers thereof, copolymers including ethylene vinyl acetate, styrene-butadienstyrene and styrene-isoprene-styrene, and combinations thereof.
21. The pharmaceutical formulation of claim 20, wherein the polymer of the coating (C) is polylactic acid.
22. The pharmaceutical formulation of claim 1, wherein, when the formulation is exposed to an aqueous medium, the coating (C) does not completely crumble or erode before at least one of the outer layers (B1) and (B2) has completely eroded and the solid inner layer (A) is exposed.
23. The pharmaceutical formulation of claim 1, wherein, when the formulation is exposed to an aqueous medium, at least one of the outer layers (B1) and (B2) erodes at a substantially constant rate.
24. The pharmaceutical formulation of claim 1, wherein, when the formulation is exposed to an aqueous medium, release of the active substance from the solid inner layer (A) is subject a lag time corresponding to the erosion time of at least one of the outer layers (B1) and (B2).
25. The pharmaceutical formulation of claim 1, wherein the coating (C) is a substantially intact empty shell after the composition has been subjected to dissolution testing according to USP 30, NF 25 (711), apparatus 2 (paddle method), in dissolution medium consisting of 0.1 M HCl or phosphate buffer (pH 6.8, pH 6.8 and 40% ethanol, or pH 7.2) in a dissolution medium volume of 900 ml or 1000 ml at a paddle speed of 50rpm.
26. The pharmaceutical formulation of claim 1, wherein the polymer of each of the two outer layers (B1) and (B2), and the polymer of the coating (C) are thermoplastic.
27. The pharmaceutical composition of claim 1, wherein the disintegrant is selected from the group consisting of sodium starch glycolate, povidone, sodium alginate, alginic acid, calcium alginate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, powdered cellulose, chitosan, croscarmellose sodium, crospovidone, hydroxypropyl starch, hydroxypropyl cellulose low-substituted, magnesium aluminium silicate, methylcellulose, microcrystalline cellulose, pregelatinized starch, docusae sodium, guar gum, polacrilin potassium, and combinations thereof.
US14/446,234 2007-06-04 2014-07-29 Controlled release pharmaceutical compositions for prolonged effect Expired - Fee Related US9642809B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/446,234 US9642809B2 (en) 2007-06-04 2014-07-29 Controlled release pharmaceutical compositions for prolonged effect

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US94184807P 2007-06-04 2007-06-04
DKPA200700816 2007-06-04
DKPA200700816 2007-06-04
DK200700816 2007-06-04
PCT/EP2008/056910 WO2008148798A2 (en) 2007-06-04 2008-06-04 Controlled release pharmaceutical compositions for prolonged effect
US60295310A 2010-06-07 2010-06-07
US14/446,234 US9642809B2 (en) 2007-06-04 2014-07-29 Controlled release pharmaceutical compositions for prolonged effect

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2008/056910 Continuation WO2008148798A2 (en) 2007-06-04 2008-06-04 Controlled release pharmaceutical compositions for prolonged effect
US12/602,953 Continuation US8821928B2 (en) 2007-06-04 2008-06-04 Controlled release pharmaceutical compositions for prolonged effect

Publications (2)

Publication Number Publication Date
US20150024048A1 US20150024048A1 (en) 2015-01-22
US9642809B2 true US9642809B2 (en) 2017-05-09

Family

ID=39226884

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/602,953 Expired - Fee Related US8821928B2 (en) 2007-06-04 2008-06-04 Controlled release pharmaceutical compositions for prolonged effect
US14/446,234 Expired - Fee Related US9642809B2 (en) 2007-06-04 2014-07-29 Controlled release pharmaceutical compositions for prolonged effect

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/602,953 Expired - Fee Related US8821928B2 (en) 2007-06-04 2008-06-04 Controlled release pharmaceutical compositions for prolonged effect

Country Status (8)

Country Link
US (2) US8821928B2 (en)
EP (1) EP2155167A2 (en)
AU (1) AU2008258596B2 (en)
CA (1) CA2687192C (en)
IL (1) IL202103A0 (en)
NZ (1) NZ580972A (en)
WO (1) WO2008148798A2 (en)
ZA (1) ZA200908019B (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019008605A1 (en) * 2017-07-07 2019-01-10 Zim Laboratories Limited Novel pharmaceutical co-crystal of dabigatran etexilate
WO2020021422A1 (en) 2018-07-21 2020-01-30 Berlia Sushma Paul Controlled release formulation comprising flavoxate
WO2021212097A1 (en) * 2020-04-17 2021-10-21 Brendan Patrick Purcell Controlled release hyaluronic acid compositions
US11458104B1 (en) 2018-06-21 2022-10-04 Mission Pharmacal Company Enteric coated tiopronin tablet
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
WO2023089553A1 (en) 2021-11-19 2023-05-25 Berlia Sushma Paul Controlled release formulations of flavoxate and process for preparation thereof

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE602004031096D1 (en) 2003-03-26 2011-03-03 Egalet As MORPHINE SYSTEM WITH CONTROLLED RELEASE
US20050025825A1 (en) 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004032051A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
US20050244495A1 (en) 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20090215898A1 (en) 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US8022106B2 (en) 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
CN101188999B (en) * 2005-06-03 2012-07-18 尹格莱特股份有限公司 A pharmaceutical delivery system for delivering active component dispersed in dispersion medium
SI2049123T2 (en) 2006-08-03 2016-10-28 Horizon Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
WO2008086804A2 (en) * 2007-01-16 2008-07-24 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
DE102007011485A1 (en) 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with more difficult abuse
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US9125836B2 (en) * 2007-06-07 2015-09-08 Sato Pharmaceutical Co., Ltd. Film preparation with rapidly dissolving property and flexibility
JP5965583B2 (en) * 2007-08-13 2016-08-10 インスピリオン デリバリー テクノロジーズ エルエルシー Abuse resistant pharmaceutical composition, method of use and preparation
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
WO2010104494A1 (en) * 2009-03-09 2010-09-16 Theraquest Biosciences, Inc. Modified release pharmaceutical compositions of buprenorphine
WO2009135680A1 (en) 2008-05-09 2009-11-12 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
WO2009148623A2 (en) 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
CA2732931A1 (en) * 2008-08-11 2010-02-18 Ratiopharm Gmbh Amorphous ambrisentan
EP2700400A1 (en) * 2009-01-26 2014-02-26 Egalet Ltd. Controlled release formulation with continuous efficacy
US8603526B2 (en) 2009-02-06 2013-12-10 Egalet Ltd. Pharmaceutical compositions resistant to abuse
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
AU2012258350B2 (en) * 2009-06-24 2014-10-23 Egalet Ltd Controlled release formulations
KR20110001103A (en) * 2009-06-29 2011-01-06 에스케이케미칼주식회사 Transdermal composition containing tolterodine
CN102573805A (en) 2009-07-22 2012-07-11 格吕伦塔尔有限公司 Hot-melt extruded controlled release dosage form
CN102573806B (en) 2009-07-22 2015-02-25 格吕伦塔尔有限公司 Tamper-resistant dosage form for oxidation-sensitive opioids
EP2493456B1 (en) * 2009-10-27 2018-11-21 Lupin Limited Solid dispersion of rifaximin
BR112012013487A2 (en) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc AMANTADINE COMPOSITIONS AND METHODS OF USE
WO2011107427A1 (en) * 2010-03-01 2011-09-09 Ratiopharm Gmbh Dabigatran etexilate-containing oral pharmaceutical composition
EP2594269A4 (en) * 2010-06-16 2013-12-04 Teijin Pharma Ltd Controlled release nucleated tablet
CN103124559B (en) 2010-08-04 2017-03-29 托马斯·朱利叶斯·波洛迪 For the device of the compositionss and its preparation and application and delivering said composition of faecal microbiota implantation
EP2611425B1 (en) * 2010-09-02 2014-07-02 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
WO2012028319A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
AU2011316565A1 (en) * 2010-10-12 2013-05-02 Cerecor Inc. Antitussive compositions comprising memantine
PL2651415T3 (en) 2010-12-13 2021-04-19 Rite-Prep Pty Ltd. Gastric and colonic formulations and methods for making and using them
WO2012090218A1 (en) 2010-12-30 2012-07-05 Zota Health Care Ltd Synergistic effects of the combination of the specific compounds with paracetamol and their effects on various diseases
CA2825014C (en) * 2011-01-19 2019-01-08 John Mckearn Controlled release oral pharmaceutical dosage forms comprising mgbg
EP2677868B1 (en) * 2011-02-21 2020-01-15 Hetero Research Foundation Pharmaceutical compositions of maraviroc and process for the preparation thereof
EP2683390B1 (en) 2011-03-09 2017-05-03 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
KR101298788B1 (en) * 2011-03-15 2013-08-22 보령제약 주식회사 A combined formulation with improved stability
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
AU2012260605B2 (en) * 2011-05-20 2015-02-19 Astrazeneca Uk Limited Pharmaceutical composition of rosuvastatin calcium
US9186350B2 (en) 2011-07-12 2015-11-17 Gdb Patent Holdings, Llc Composition, and method of using the composition, effective for minimizing the harmful effects associated with individuals suffering from alcohol intoxication
CN103841964A (en) 2011-07-29 2014-06-04 格吕伦塔尔有限公司 Tamper-resistant tablet providing immediate drug release
WO2013017242A1 (en) 2011-07-29 2013-02-07 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
WO2013072937A2 (en) * 2011-11-14 2013-05-23 Hetero Research Foundation Fast release solid oral compositions of entecavir
KR101384055B1 (en) * 2012-02-02 2014-04-14 한국원자력연구원 Burst type lagged-release controlled composition and preparation method thereof
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US20130274342A1 (en) * 2012-04-12 2013-10-17 Cerecor, Inc. Compositions and methods for treating cough
TR201815502T4 (en) 2012-04-18 2018-11-21 Gruenenthal Gmbh Tamper or pharmaceutical dosage form that is resistant and resistant to dose discharge.
US20130295170A1 (en) * 2012-05-03 2013-11-07 Kydes Pharmaceuticals Llc Compositions for control of drug abuse
WO2013169925A1 (en) * 2012-05-08 2013-11-14 Metronomx Novel formulations of nitrofurans including nifurtimox with enhanced activity with lower toxicity
CA2870012A1 (en) 2012-05-11 2013-11-14 Grunenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
JP6436580B2 (en) 2012-06-04 2018-12-12 ガウラブ アグラーワル, Compositions and methods for treating Crohn's disease and related conditions and infections
CN104684548A (en) 2012-07-06 2015-06-03 埃格勒特有限责任公司 Abuse deterrent pharmaceutical compositions for controlled release
US10206874B2 (en) 2012-07-20 2019-02-19 Hetero Research Foundation Rufinamide solid dispersion
CN104797244B (en) 2012-07-27 2018-03-09 红山生物医药有限公司 Preparation and preparation of preparation method for colon emptying
US20150224086A1 (en) * 2012-08-23 2015-08-13 Hetero Research Foundation Pharmaceutical Formulations of Rufinamide
WO2014074797A1 (en) 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use
US20150283083A1 (en) * 2012-11-19 2015-10-08 Azanta A/S Dispersible Tablet
US20160000721A1 (en) * 2012-12-21 2016-01-07 Merck Sharp & Dohme Corp. Gastro-retentive formulations
KR102008490B1 (en) * 2013-01-14 2019-08-08 주식회사 바이오파마티스 Controlled release pharmaceutical composition comprising choline alfoscerate or pharmaceutically acceptable salt thereof and method for manufacturing the same
AU2014262125B2 (en) 2013-04-30 2020-02-13 Thomas Julius Borody Compositions and methods for treating microbiota-related psychotropic conditions and diseases
RU2535115C1 (en) * 2013-05-15 2014-12-10 Бости Трейдинг Лтд Pharmaceutical formulation containing botulinum neurotoxin
MX371432B (en) 2013-05-29 2020-01-30 Gruenenthal Gmbh Tamper-resistant dosage form containing one or more particles.
WO2014191396A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
KR20160031526A (en) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
ITMI20131467A1 (en) 2013-09-06 2015-03-07 Sofar Spa USE OF A COMPOSITION INCLUDING MICRO-ORGANISMS TO INCREASE THE INTESTINAL PRODUCTION OF BUTIRRIC ACID, FOLIC ACID OR NIACINE ACID AND / OR TO REDUCE THE INTESTINAL PRODUCTION OF SUCCINIC ACID
MX371372B (en) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling.
IN2013CH05441A (en) * 2013-11-26 2015-05-29 Aurobindo Pharma Ltd
MX2016007848A (en) 2013-12-16 2016-09-07 Gruenenthal Gmbh Tamper resistant dosage form with bimodal release profile manufactured by co-extrusion.
KR101556568B1 (en) * 2013-12-17 2015-10-01 주식회사 대웅제약 Film coated tablet containing choline alfoscerate and process for preparing the same
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
MA39710A (en) 2014-04-23 2015-10-29 Sofar Spa Topical composition for use in the treatment of inflammatory bowel disease
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
WO2015181059A1 (en) 2014-05-26 2015-12-03 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
DK3169315T3 (en) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Liquid-filled dosage form to prevent immediate release abuse
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US10729685B2 (en) * 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
TW201613565A (en) * 2014-10-15 2016-04-16 Bio Peptide Enhancer Tech Co Ltd Controlled release sealing capsule in stomach, duodenum, jejunum, ileum and colon
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
AU2016206950B2 (en) * 2015-01-12 2021-05-06 Enteris Biopharma, Inc. Solid oral dosage forms
JP2018503693A (en) 2015-02-03 2018-02-08 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Anti-modified dosage form containing polyethylene glycol graft copolymer
EA035434B1 (en) 2015-04-24 2020-06-15 Грюненталь Гмбх Tamper-resistant dosage form with immediate release and resistance against solvent extraction
CN107949391B (en) 2015-05-14 2021-11-09 克雷斯顿沃控股公司 Compositions for fecal flora transplantation and methods for making and using them and devices for delivering them
US20160339015A1 (en) * 2015-05-20 2016-11-24 Lupin Inc. Oral pharmaceutical composition of methylergonovine
NZ737786A (en) 2015-05-22 2022-07-01 Univ Minnesota Methods for treating autism spectrum disorder and associated symptoms
WO2017010938A1 (en) * 2015-07-16 2017-01-19 National University Of Singapore Printing drug tablets with fully customizable release profiles for personalized medicine
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US11214773B2 (en) 2015-09-24 2022-01-04 San Diego State University (Sdsu) Foundation Antibacterial and protective bacteriophage formulations and methods for making and using them
BR112018068665B1 (en) 2016-03-15 2023-12-26 Acer Therapeutics Inc PHARMACEUTICAL COMPOSITION OF SODIUM PHENYLBUTYRATE, PRODUCTION METHOD AND ITS USES
MA45327A (en) 2016-05-13 2019-03-20 Sofar Spa USE OF PROBIOTICS TO IMPROVE PROTEIN ABSORPTION
MA45288A (en) 2016-06-08 2019-04-17 Sofar Spa New medical use of probiotics
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
IT201600122724A1 (en) 2016-12-02 2018-06-02 Sofar Spa EXOPOLYSACCHARIDES AND USES THEREOF
IT201600127498A1 (en) 2016-12-16 2018-06-16 Sofar Spa PROBIOTICS FOR USE IN DIVERTICULOSIS AND DIVERTICULAR DISEASE
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
CA3058818A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating parkinson's disease (pd) and related disorders
US11890306B2 (en) 2017-05-26 2024-02-06 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
WO2019023346A1 (en) * 2017-07-25 2019-01-31 Altibio, Inc. Modified-release bucillamine compositions, kits, and methods for treating cystinuria, arthritis, gout, and related disorders
CN111328284A (en) 2017-08-07 2020-06-23 芬奇治疗公司 Compositions and methods for maintaining and restoring a healthy intestinal barrier
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
WO2020069280A1 (en) 2018-09-27 2020-04-02 Crestovo Holdings Llc Compositions and methods for treating epilepsy and related disorders
CN111374942B (en) * 2018-12-30 2022-09-13 鲁南制药集团股份有限公司 Steroid muscle relaxant injection and preparation method thereof
TR201914416A1 (en) * 2019-09-23 2021-04-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Effervescent formulations of sapropterin dihydrochloride
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
US20230201215A1 (en) * 2020-04-29 2023-06-29 Systamedic Inc. Drug combinations for inhibiting infectivity of influenza and corona viruses
CN111821283B (en) * 2020-07-23 2021-11-30 华侨大学 Zinc glutamate-coated Prussian blue nanoparticles loaded with triphenylphosphine-lonidamine and wrapped by cancer cell membrane and preparation method of zinc glutamate-coated Prussian blue nanoparticles
WO2023009457A1 (en) * 2021-07-26 2023-02-02 Ahmed Suzanne Drug delivery platform for delivery of therapeutics and methods of use and manufacture thereof
CA3228464A1 (en) * 2021-08-11 2023-02-16 Theravida, Inc. Pharmaceutical compositions and methods for treating hyperhidrosis
WO2023225633A1 (en) * 2022-05-19 2023-11-23 Cedars-Sinai Medical Center Rifaximin and n-acetyl cysteine formulations
WO2024010935A1 (en) * 2022-07-07 2024-01-11 Vitalis Analgesics LLC Compositions of aspirin and ketamine

Citations (316)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2685553A (en) 1951-03-30 1954-08-03 Winthrop Stearns Inc Cement coated tablets
US3835221A (en) 1970-03-05 1974-09-10 Hoechst Ag Orally administrable drug dosage form having delayed action
GB1430684A (en) 1972-06-26 1976-03-31 Lowey H Prolonged release lozenges
US3957523A (en) 1973-04-02 1976-05-18 Shinetsu Chemical Company Coating compositions for solid medicines
US4034758A (en) 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US4330338A (en) 1978-10-02 1982-05-18 Purdue Research Foundation Pharmaceutical coating composition, and preparation and dosages so coated
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4404183A (en) 1979-07-05 1983-09-13 Yamanouchi Pharmaceutical Co., Ltd. Sustained release pharmaceutical composition of solid medical material
US4449983A (en) 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4503067A (en) 1978-04-13 1985-03-05 Boehringer Mannheim Gmbh Carbazolyl-(4)-oxypropanolamine compounds and therapeutic compositions
JPS60255719A (en) 1984-06-01 1985-12-17 Takada Seiyaku Kk Preparation of nifedipine sustained release pharmaceutical
GB2170104A (en) 1985-01-30 1986-07-30 Warner Lambert Co Coated pharmaceutical dosage forms
WO1986004817A1 (en) 1985-02-19 1986-08-28 Key Pharmaceuticals, Inc. Controlled release potassium chloride
GB2182559A (en) 1983-11-02 1987-05-20 Alza Corp Dispenser for thermo-responsive drugs
US4686212A (en) 1985-08-13 1987-08-11 Pharmacontrol Corp. Stable sodium aspirin tablet compositions
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4824675A (en) 1987-07-13 1989-04-25 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US4844984A (en) 1984-03-19 1989-07-04 Alza Corporation Dispensing system with means for increasing delivery of beneficial agent from the system
EP0335560A2 (en) 1988-03-31 1989-10-04 Tanabe Seiyaku Co., Ltd. Controlled release pharmaceutical preparation and method for producing the same
WO1989009066A1 (en) 1988-03-24 1989-10-05 Bukh Meditec A/S Controlled release composition
US4873080A (en) 1983-06-08 1989-10-10 Dr. Karl Thomae Gmbh Oral anti-diabetic pharmaceutical compositions and the preparation thereof
US4892742A (en) 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
US4898733A (en) 1985-11-04 1990-02-06 International Minerals & Chemical Corp. Layered, compression molded device for the sustained release of a beneficial agent
WO1990008536A1 (en) 1989-01-30 1990-08-09 Alza Corporation Dosage form for administering calcium antagonist
WO1991004015A1 (en) 1989-09-22 1991-04-04 Bukh Meditec A/S Controlled release composition
US5019396A (en) 1989-05-12 1991-05-28 Alza Corporation Delivery dispenser for treating cardiac arrhythmias
EP0435726A2 (en) 1989-12-29 1991-07-03 Bristol-Myers Squibb Company Capsule and caplet combination
US5102668A (en) 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
WO1992009270A1 (en) 1990-11-22 1992-06-11 British Technology Group Ltd Controlled release compositions
WO1993010765A1 (en) 1991-11-27 1993-06-10 Euroceltique S.A. Controlled release oxycodone compositions
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5352455A (en) 1991-01-23 1994-10-04 British Technology Group Ltd. Controlled release compositions
JPH07100191A (en) 1993-10-06 1995-04-18 Daikyo Yakuhin Kogyo Kk Sustained release suppository
US5411745A (en) 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5419917A (en) 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US5422123A (en) 1989-12-14 1995-06-06 Jagotec Ag Tablets with controlled-rate release of active substances
WO1995022962A1 (en) 1994-02-23 1995-08-31 Bm Research A/S Controlled release composition
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
WO1996008253A1 (en) 1994-09-16 1996-03-21 Alza Corporation Hydrocodone compositions
US5520931A (en) 1992-07-29 1996-05-28 Gacell Laboratories Ab Controlled release morphine preparation
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
US5614218A (en) 1993-03-30 1997-03-25 Pharmacia & Upjohn Aktiebolag Controlled release preparation
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5656291A (en) 1994-03-16 1997-08-12 Pharmacia & Upjohn Aktiebolag Controlled release preparation
WO1997033566A2 (en) 1996-03-12 1997-09-18 Alza Corporation Composition and dosage form comprising opioid antagonist
US5741524A (en) 1995-01-09 1998-04-21 Edward Mendell Co., Inc. Sustained-release formulations utilizing pharmaceutical excipient having improved compressibility
WO1999005105A1 (en) 1997-07-22 1999-02-04 Roche Diagnostics Gmbh Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it
US5869097A (en) 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
US5879705A (en) 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5882682A (en) 1991-12-27 1999-03-16 Merck & Co., Inc. Controlled release simvastatin delivery device
EP0908181A1 (en) 1996-05-20 1999-04-14 Otsuka Pharmaceutical Co., Ltd. Remedy for rosacea
US5914131A (en) 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
WO1999044591A1 (en) 1998-03-06 1999-09-10 Alza Corporation Extended release dosage form
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6066339A (en) 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US6077533A (en) 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US6103261A (en) 1993-07-01 2000-08-15 Purdue Pharma Lp Opioid formulations having extended controlled release
EP1027888A2 (en) 1999-02-10 2000-08-16 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
US6117453A (en) 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
US6183778B1 (en) 1993-09-21 2001-02-06 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
US6225343B1 (en) 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
WO2001035958A1 (en) 1999-11-15 2001-05-25 Smithkline Beecham Corporation Carvedilol methanesulfonate
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
WO2001051035A1 (en) 2000-01-14 2001-07-19 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
WO2001051036A1 (en) 2000-01-14 2001-07-19 Osmotica Corp. Osmotic device within an osmotic device
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6267981B1 (en) 1995-06-27 2001-07-31 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
US6277384B1 (en) 1997-12-22 2001-08-21 Euro-Celtique S.A. Opioid agonist/antagonist combinations
WO2001074357A1 (en) 2000-04-03 2001-10-11 F. Hoffmann-La Roche Ag Hydrophilic molecular disperse solutions of carvedilol
US20010036960A1 (en) 2000-04-03 2001-11-01 Silke Decker Carvedilol-lipophilic solutions
US20010053791A1 (en) 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
US6348216B1 (en) 1996-06-10 2002-02-19 Knoll Pharmaceutical Company Ibuprofen and narcotic analgesic compositions
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US20020054911A1 (en) 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
US6395299B1 (en) 1999-02-12 2002-05-28 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
US6399096B1 (en) 1995-09-22 2002-06-04 Euro-Celtique S.A. Pharmaceutical formulation
US6403579B1 (en) 1998-11-27 2002-06-11 Hoffman-La Roche Inc. Pharmaceutical compositions containing carvedilol and hydrochlorothiazide
EP1213014A2 (en) 2000-12-07 2002-06-12 Warner-Lambert Company Process and system for controlled-release drug delivery
WO2002056861A2 (en) 2001-01-19 2002-07-25 Intellipharmaceutics Corp. Syntactic deformable foam compositions and methods for making
US20020107434A1 (en) 2000-07-06 2002-08-08 Algodyne, Ltd. Objective pain measurement system and method
WO2002065834A2 (en) 2000-10-24 2002-08-29 Smithkline Beecham Corporation Novel formulations of carvedilol
US6458824B1 (en) 1999-11-30 2002-10-01 Dainippon Pharmaceutical Co., Ltd. Solid preparation
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
WO2002087512A2 (en) 2001-05-02 2002-11-07 Euro-Celtique, S.A. Once-a-day oxycodone formulations
US6482437B2 (en) 1998-02-16 2002-11-19 Laboratoires Des Produits Ethiques Ethypharm Morphine sulfate microgranules, manufacturing process and pharmaceutical preparations
WO2002092078A1 (en) 2001-05-17 2002-11-21 Sun Pharamceutical Industries Limited Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6488963B1 (en) 1996-06-26 2002-12-03 The University Of Texas System Hot-melt extrudable pharmaceutical formulation
US6517866B1 (en) 1997-07-01 2003-02-11 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
US6534085B1 (en) 1999-09-23 2003-03-18 Bioresponse L.L.C. Phytochemicals for promoting weight loss
US6543085B2 (en) 2000-02-17 2003-04-08 Emerson Electric Co. Vacuum appliance having push and pull handles
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
US20030091635A1 (en) 2001-09-26 2003-05-15 Baichwal Anand R. Opioid formulations having reduced potential for abuse
WO2003039521A1 (en) 2001-11-09 2003-05-15 Farmatron Ltd. Solid, stabilized, prompt- and/or modified-release therapeutical systems for the oral administration of liquid active principles, excipients or foodstuffs
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
US20030133976A1 (en) 1998-04-29 2003-07-17 Pather S. Indiran Effervescent drug delivery system for oral administration
US6599531B2 (en) 1996-06-12 2003-07-29 Knoll Pharmaceutical Company Method of making ibuprofen and narcotic analgesic compositions
US6607751B1 (en) 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US6632832B1 (en) 2002-09-10 2003-10-14 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
US20030203055A1 (en) 2002-03-15 2003-10-30 Cypress Bioscience, Inc. Methods of treating visceral pain syndromes
WO2003092648A1 (en) 2002-04-29 2003-11-13 Alza Corporation Methods and dosage forms for controlled delivery of oxycodone
US20030224051A1 (en) 2002-05-31 2003-12-04 Fink Tracy A. Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
EP1371360A1 (en) 1993-03-11 2003-12-17 Taro Pharmaceutical Industries Ltd. Device for containing a pharmaceutical composition
US6673816B1 (en) 1998-09-30 2004-01-06 Angelika Esswein Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders
WO2004002447A2 (en) 2002-06-26 2004-01-08 Alza Corporation Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
US6685964B1 (en) 1999-01-18 2004-02-03 Gruenenthal Gmbh Opioid analgesics with controlled active substance release
US20040028733A1 (en) 2002-02-08 2004-02-12 Alkermes Controlled Therapeutics, Inc. Polymer-based compositions for sustained release
US6709678B2 (en) 1996-08-15 2004-03-23 Losan Pharma Gmbh Easy to swallow oral medicament composition
US6730326B2 (en) 1997-07-22 2004-05-04 Roche Diagnostics Gmbh Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3[2-(2-methoxyphenoxy)-ethylamino]-2-propanol process for its preparation and pharmaceutical compositions containing it
US6733783B2 (en) 2000-10-30 2004-05-11 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20040102476A1 (en) 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
US20040115262A1 (en) 2002-07-29 2004-06-17 Frank Jao Formulations and dosage forms for controlled delivery of topiramate
WO2004054542A2 (en) 2002-12-13 2004-07-01 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
WO2004056337A2 (en) 2002-12-18 2004-07-08 Pain Therapeutics Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US20040151772A1 (en) 2002-11-08 2004-08-05 Egalet A/S Controlled release carvedilol compositions
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20040213849A1 (en) 2001-09-28 2004-10-28 Sowden Harry S. Modified release dosage forms
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US6837696B2 (en) 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
WO2005000310A1 (en) 2003-06-27 2005-01-06 Euro-Celtique S.A. Multiparticulates
US20050020613A1 (en) 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
WO2005007074A2 (en) 2003-07-21 2005-01-27 Bio-Dar Ltd. Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention
US20050019399A1 (en) 2001-09-21 2005-01-27 Gina Fischer Controlled release solid dispersions
US6852337B2 (en) 1998-04-09 2005-02-08 Roche Diagnostics Gmbh Carvedilol-galenics
WO2005016313A1 (en) 2003-08-06 2005-02-24 Grünenthal GmbH Dosage form that is safeguarded from abuse
WO2005016314A1 (en) 2003-08-06 2005-02-24 Grünenthal GmbH Form of administration secured against misuse
US20050053655A1 (en) 2003-09-05 2005-03-10 Pharmaceutical Industry Technology And Development Center Rapid disintegrating tablets (RDTs) for pharmaceutical use and method for preparing the same
WO2005027878A1 (en) 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Delayed released dosage forms
US20050074493A1 (en) 2003-10-03 2005-04-07 Mehta Atul M. Extended release formulations of opioids and method of use thereof
US20050089570A1 (en) 2003-09-26 2005-04-28 Evangeline Cruz Oros push-stick for controlled delivery of active agents
US20050089569A1 (en) 1998-04-03 2005-04-28 Bm Research A/S Controlled release composition
US20050095295A1 (en) 2002-03-12 2005-05-05 Lauretta Maggi Therapeutic system for the controlled release of active ingredients
US20050106249A1 (en) 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
WO2005053587A1 (en) 2003-11-26 2005-06-16 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
WO2005063214A1 (en) 2003-12-24 2005-07-14 Grünenthal GmbH Method for the production of an administration form which is secured against misuse
WO2005063206A1 (en) 2003-12-23 2005-07-14 Alza Corporation Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
US20050158382A1 (en) 2003-09-26 2005-07-21 Evangeline Cruz Controlled release formulations of opioid and nonopioid analgesics
US20050163837A1 (en) 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone formulations
US20050236741A1 (en) 2004-04-22 2005-10-27 Elisabeth Arkenau Process for the production of an abuse-proofed solid dosage form
US6960357B2 (en) 2001-05-25 2005-11-01 Mistral Pharma Inc. Chemical delivery device
WO2005102286A1 (en) 2004-04-22 2005-11-03 Grünenthal GmbH Method for the production of an abuse-proof, solid form of administration
US20060002860A1 (en) 2004-07-01 2006-01-05 Johannes Bartholomaus Abuse-proofed oral dosage form
WO2006002883A1 (en) 2004-07-01 2006-01-12 Grünenthal GmbH Method for producing a solid dosage form, which is safeguarded against abuse, while using a planetary gear extruder
WO2006002886A1 (en) 2004-07-01 2006-01-12 Grünenthal GmbH Oral dosage form safeguarded against abuse containing (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
WO2006002884A1 (en) 2004-07-01 2006-01-12 Grünenthal GmbH Oral dosage form safeguarded against abuse
US20060039864A1 (en) 2004-07-01 2006-02-23 Johannes Bartholomaus Abuse-proofed oral dosage form
WO2006026504A2 (en) 2004-08-27 2006-03-09 Spherics, Inc. Mucoadhesive oral formulations of high permeability, high solubility drugs
WO2006030402A2 (en) 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Dual compartment osmotic delivery device
WO2006031209A1 (en) 2003-05-28 2006-03-23 Monosolrx Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US20060110327A1 (en) 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
WO2006058249A2 (en) 2004-11-24 2006-06-01 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US7060293B1 (en) 1994-05-25 2006-06-13 Purdue Pharma Powder-layered oral dosage forms
US7063864B1 (en) 1999-06-09 2006-06-20 Laboratoires Des Products Ethiques Ethypharm Morphine sulphate microgranules, method for preparing same and compositions containing same
US20060165790A1 (en) 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
US20060177507A1 (en) 2003-05-22 2006-08-10 Joaquina Faour Controlled release device containing lercanidipine
WO2006088305A1 (en) 2005-02-15 2006-08-24 Chong Kun Dang Pharmaceutical Corp. Gastric-retentive controlled release mono-matrix tablet
US20060188447A1 (en) 2005-02-04 2006-08-24 Elisabeth Arkenau-Maric Process for the production of an abuse-proofed dosage form
WO2006089843A2 (en) 2005-02-08 2006-08-31 Flamel Technologies Anti-misuse microparticulate oral drug form
US20060193914A1 (en) 2005-02-04 2006-08-31 Judy Ashworth Crush resistant delayed-release dosage forms
US20060193912A1 (en) 2005-02-28 2006-08-31 Penwest Pharmaceuticals Co. Controlled release O-desmethylvenlafaxine formulations
WO2006103551A1 (en) 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Controlled release formulations of oxycodone
WO2006103418A1 (en) 2005-03-28 2006-10-05 Orexo Ab New pharmaceutical compositions useful in the treatment of pain
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US20070004797A1 (en) 2005-06-29 2007-01-04 Weyers Richard G Methods and dosage forms for reducing side effects of carbamate compounds
US20070003617A1 (en) 2003-03-26 2007-01-04 Egalet A/S Morphine controlled release system
US20070020331A1 (en) 2005-07-25 2007-01-25 Gold Thomas B Coated tablet with zero-order of near zero-order release kinetics
US20070042044A1 (en) 2003-03-26 2007-02-22 Egalet A/S Matrix compositions for controlled delivery of drug substances
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
WO2007030754A2 (en) 2005-09-09 2007-03-15 Monosolrx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20070065364A1 (en) 2003-04-21 2007-03-22 Benjamin Oshlack Tamper resistant dosage form comprising co-extruded, sequestered adverse agent particles and process of making same
US20070122455A1 (en) 2001-10-12 2007-05-31 Monosolrx, Llc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
WO2007085024A2 (en) 2006-01-21 2007-07-26 Abbott Gmbh & Co. Kg Dosage form and method for the delivery of drugs of abuse
WO2007082757A2 (en) 2006-01-18 2007-07-26 Wick, Immunologische Diagnostik U. Beratung Kg Test systems for the analysis of polypeptides and cells adhering to silicones
WO2007106550A2 (en) 2006-03-15 2007-09-20 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20070224129A1 (en) 2005-11-10 2007-09-27 Flamel Technologies, Inc. Anti-misuse microparticulate oral pharmaceutical form
WO2007112285A2 (en) 2006-03-24 2007-10-04 Auxilium Pharmaceuticals, Inc. Process for the preparation of a hot-melt extruded laminate
WO2007112286A2 (en) 2006-03-24 2007-10-04 Auxilium Pharmaceuticals, Inc. Stabilized compositions containing alkaline labile drugs
US20070231268A1 (en) 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20070259045A1 (en) 2005-01-28 2007-11-08 Euro-Celtique S.A. Alcohol Resistant Dosage Forms
US20070259033A1 (en) 2003-09-26 2007-11-08 Evangeline Cruz Controlled release formulations exhibiting an ascending rate of release
US20070264326A1 (en) 2005-05-24 2007-11-15 Flamel Technologies Anti-misuse oral microparticle medicinal formulation
US20070264346A1 (en) 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
WO2007133583A2 (en) 2006-05-09 2007-11-22 Mallinckrodt Inc. Zero-order modified release solid dosage forms
US20070275062A1 (en) 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
WO2007135193A2 (en) 2006-05-24 2007-11-29 Flamel Technologies Sustained-release alcohol-resistant multimicroparticulate oral pharmaceutical form comprising anti-misuse means
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
WO2007150075A2 (en) 2006-06-23 2007-12-27 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
WO2007150074A2 (en) 2006-06-23 2007-12-27 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20080031901A1 (en) 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US20080044454A1 (en) 2002-04-11 2008-02-21 Monosolrx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
WO2008023261A1 (en) 2006-08-25 2008-02-28 Purdue Pharma L.P. Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
WO2008027442A2 (en) 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
WO2008028047A2 (en) 2006-08-30 2008-03-06 Lab International Srl Bioadhesive film drug delivery system
US20080063725A1 (en) 2006-05-24 2008-03-13 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US20080075771A1 (en) 2006-07-21 2008-03-27 Vaughn Jason M Hydrophilic opioid abuse deterrent delivery system using opioid antagonists
US20080102121A1 (en) 1998-11-02 2008-05-01 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
US20080113025A1 (en) 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
WO2008068471A1 (en) 2006-12-04 2008-06-12 Orexo Ab New non-abusable pharmaceutical composition comprising opioids
US20080152595A1 (en) 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080166407A1 (en) 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
US7399488B2 (en) 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20080193540A1 (en) 2004-11-23 2008-08-14 Flamel Technologies Solid, Oral Drug Form Which Has Been Designed to Prevent Misuse
US20080200493A1 (en) 2005-01-18 2008-08-21 Euro-Celtique S.A. Use of Oxycodone for Treating Visceral Pain
WO2008107149A2 (en) 2007-03-07 2008-09-12 Grünenthal GmbH Pharmaceutical form with impeded abuse
US20080311205A1 (en) 2006-09-15 2008-12-18 Cima Labs, Inc. Abuse resistant drug formulation
US20090011016A1 (en) 2006-03-01 2009-01-08 Ethypharm Sa Crush-Resistant Oxycodone Tablets Intended For Preventing Accidental Misuse And Unlawful Diversion
US20090022798A1 (en) 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20090022790A1 (en) 2003-12-09 2009-01-22 Flath Robert P Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
WO2009035474A1 (en) 2007-09-13 2009-03-19 Cima Labs Inc. Abuse resistant drug formulation
US7510727B2 (en) 1994-11-04 2009-03-31 Purdue Pharma L.P. Melt-extrusion multiparticulates
US20090099151A1 (en) 2005-06-29 2009-04-16 Panacea Biotec Ltd. Modified Release Pharmaceutical Compositions and Processes Thereof
US20090123386A1 (en) 2005-04-06 2009-05-14 Victor Morrison Young Abuse Resistant Capsules
WO2009075782A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
WO2009076236A2 (en) 2007-12-06 2009-06-18 Pain Therapeutics, Inc. Micronized opioid compositions, formulations and dosage forms and methods of making same
US20090155357A1 (en) 2005-08-01 2009-06-18 Alpharma Inc. Alcohol Resistant Pharmaceutical Formulations
WO2009076764A1 (en) 2007-12-17 2009-06-25 Labopharm Inc. Misuse preventative, controlled release formulation
WO2009092601A1 (en) 2008-01-25 2009-07-30 Grünenthal GmbH Pharmaceutical dosage form
WO2009104838A1 (en) 2008-02-18 2009-08-27 Hana Pharm. Co. Ltd. Sustained release solid formulations and methods of manufacturing the same
US20090221621A1 (en) 2005-10-31 2009-09-03 Alza Corporation Methods of Reducing Alcohol-Induced Dose Dumping for Opioid Sustained Release Oral Dosage Forms
US20090232887A1 (en) 2006-05-12 2009-09-17 Isa Odidi Pharmaceutical composition having reduced abuse potential
WO2009114648A1 (en) 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US20090274759A1 (en) 2005-06-03 2009-11-05 Egalet A/S Solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
US20090317355A1 (en) 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
WO2010017821A1 (en) 2008-08-14 2010-02-18 Daniel Bar-Shalom Coated tablets with a remaining degradation surface over the time8
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
WO2010032128A1 (en) 2008-09-18 2010-03-25 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(e-caprolactone)
US20100099696A1 (en) 2008-10-16 2010-04-22 Anthony Edward Soscia Tamper resistant oral dosage forms containing an embolizing agent
WO2010066034A1 (en) 2008-12-12 2010-06-17 Paladin Labs Inc. Methadone formulation
WO2010069050A1 (en) 2008-12-16 2010-06-24 Labopharm Inc. Misuse preventative, controlled release formulation
US20100172989A1 (en) 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US7771707B2 (en) 2004-06-12 2010-08-10 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US20100204259A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
US20100203129A1 (en) 2009-01-26 2010-08-12 Egalet A/S Controlled release formulations with continuous efficacy
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US7790215B2 (en) 2002-03-26 2010-09-07 Purdue Pharma Lp Sustained-release gel coated compositions
US20100291205A1 (en) 2007-01-16 2010-11-18 Egalet A/S Pharmaceutical compositions and methods for mitigating risk of alcohol induced dose dumping or drug abuse
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
WO2010140007A2 (en) 2009-06-05 2010-12-09 Euro-Celtique S.A. Dosage form
WO2010151741A1 (en) 2009-06-25 2010-12-29 Elite Laboratories, Inc. Abuse resistant oral dosage forms
WO2011009602A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Hot-melt extruded controlled release dosage form
US20110020451A1 (en) 2009-07-22 2011-01-27 Grunenthal Gmbh Tamper-resistant dosage form for oxidation-sensitive opioids
US7883772B2 (en) 2005-06-24 2011-02-08 North Carolina State University High strength, durable fabrics produced by fibrillating multilobal fibers
US7906143B1 (en) 1998-10-05 2011-03-15 Intellipharmaceutics Corp Controlled release pharmaceutical delivery device and process for preparation thereof
US20110077238A1 (en) 2009-09-30 2011-03-31 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US7943174B2 (en) 1999-10-29 2011-05-17 Purdue Pharma L.P. Controlled release hydrocodone formulations
WO2011079248A1 (en) 2009-12-24 2011-06-30 Acura Pharmaceuticals, Inc. Pharmaceutical compositions for deterring misuse, abuse, and diversion
US20110159100A1 (en) 2009-06-24 2011-06-30 Egalet A/S Formulations and methods for the controlled release of active drug substances
US20110195989A1 (en) 2010-02-09 2011-08-11 Rudnic Edward M Controlled Release Formulations of Opioids
US20110200715A1 (en) 2002-10-11 2011-08-18 Monosol Rx, Llc Multi-layer films having uniform content
WO2011106416A2 (en) 2010-02-24 2011-09-01 Cima Labs Inc. Abuse-resistant formulations
US8017150B2 (en) 2002-04-11 2011-09-13 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US20110229533A1 (en) 1998-03-06 2011-09-22 Alza Corporation Extended release dosage form
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US8114384B2 (en) 2004-07-01 2012-02-14 Gruenenthal Gmbh Process for the production of an abuse-proofed solid dosage form
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
WO2012028319A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
WO2012028317A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
WO2012040651A2 (en) 2010-09-24 2012-03-29 QRxPharma Ltd. Controlled release formulations of opioids
WO2012061779A1 (en) 2010-11-04 2012-05-10 Abbott Gmbh & Co. Kg Drug formulations
WO2012076907A2 (en) 2010-12-09 2012-06-14 Euro-Celtique S.A. Dosage form
WO2012080833A2 (en) 2010-12-13 2012-06-21 Purdue Pharma L.P. Controlled release dosage forms
WO2012085656A2 (en) 2010-12-22 2012-06-28 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
WO2012085657A2 (en) 2010-12-23 2012-06-28 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
US8246986B2 (en) 2003-09-26 2012-08-21 Alza Corporation Drug coating providing high drug loading
WO2012112952A1 (en) 2011-02-17 2012-08-23 QRxPharma Ltd. Technology for preventing abuse of solid dosage forms
US20120225122A1 (en) 2009-12-17 2012-09-06 Cima Labs Inc. Abuse-Resistant Formulations
WO2012131463A2 (en) 2011-03-25 2012-10-04 Purdue Pharma L.P. Controlled release pharmaceutical dosage forms
US8329720B1 (en) 2007-05-22 2012-12-11 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting abuse deterrent and anti-dose dumping properties
US20120321674A1 (en) 2011-02-17 2012-12-20 Michael Vachon Technology for Preventing Abuse of Solid Dosage Forms
US20120321713A1 (en) 2008-03-11 2012-12-20 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8338444B1 (en) 2007-05-22 2012-12-25 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties
US20130011479A1 (en) 2010-03-24 2013-01-10 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A Double-layer pharmaceutical formulations containing opioid agonists and antagonists
US20130022646A1 (en) 2010-02-09 2013-01-24 Rudnic Edward M Controlled Release Formulations of Opioids
US20130030561A1 (en) 2010-04-09 2013-01-31 Toshiba Mitsubishi-Electric Industrial Systems Corporation Rolled material cooling control apparatus, rolled material cooling control method, and rolled material cooling control program
US20130028177A1 (en) 2011-07-28 2013-01-31 Renesas Mobile Corporation Network Controlled Filtering Over Wireless Device Communications
US20130028970A1 (en) 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
US20130028972A1 (en) 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
US8383155B2 (en) 2004-05-11 2013-02-26 Egalet A/S Swellable dosage form comprising gellan gum
US8394407B2 (en) 2003-04-24 2013-03-12 Jagotec Ag Delayed release tablet with defined core geometry
WO2013038268A1 (en) 2011-09-16 2013-03-21 Purdue Pharma L.P. Tamper resistant immediate release formulations
WO2013038267A1 (en) 2011-09-16 2013-03-21 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
WO2013050539A2 (en) 2011-10-06 2013-04-11 Grünenthal GmbH Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist
WO2013057570A2 (en) 2011-10-18 2013-04-25 Purdue Pharma L.P. Acrylic polymer formulations
US20130129826A1 (en) 2011-11-17 2013-05-23 Gruenenthal Gmbh Tamper-resistant oral pharmaceutical dosage form comprising opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer
WO2013077851A1 (en) 2011-11-22 2013-05-30 Watson Pharmaceuticals, Inc. Immediate release abuse deterrent tablet
WO2013084059A1 (en) 2011-12-09 2013-06-13 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly (epsilon- caprolactone) and polyethylene oxide
US8465776B2 (en) 2006-08-04 2013-06-18 Ethypharm Granule and orally disintegrating tablet comprising oxycodone
US8486423B2 (en) 2007-08-21 2013-07-16 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
US8491935B2 (en) 2006-03-16 2013-07-23 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US8529848B2 (en) 2010-06-28 2013-09-10 Ronald Danehy Systems and methods for transfer of liquid samples
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US20130251806A1 (en) 2012-03-23 2013-09-26 Pharma73, S.A. Natural biocomposite powder prepared from pichia pastoris biomass, method of preparation and its use as excipient
US20130273162A1 (en) 2012-04-12 2013-10-17 Michael Hsin Chwen LI Oral Film Containing Opiate Enteric-Release Beads
US20130280176A1 (en) 2012-04-18 2013-10-24 Mallinckrodt Llc Immediate Release Pharmaceutical Compositions with Abuse Deterrent Properties
US20130280338A1 (en) 2012-04-18 2013-10-24 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US8603526B2 (en) 2009-02-06 2013-12-10 Egalet Ltd. Pharmaceutical compositions resistant to abuse
US8703189B2 (en) 2001-05-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Medicinal composition
US20140155388A1 (en) 2012-11-30 2014-06-05 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US8765178B2 (en) 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
US20140221416A1 (en) 2013-02-05 2014-08-07 Purdue Pharma L.P. Tamper Resistant Pharmaceutical Formulations
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
US20140275143A1 (en) 2013-03-15 2014-09-18 Mallinckrodt Llc Compositions Comprising An Opioid And An Additional Active Pharmaceutical Ingredient For Rapid Onset And Extended Duration Of Analgesia That May Be Administered Without Regard To Food
US20140271896A1 (en) 2013-03-15 2014-09-18 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US20140271848A1 (en) 2013-03-15 2014-09-18 Purdue Pharma L.P. Abuse-deterrent dosage forms
US9044402B2 (en) 2012-07-06 2015-06-02 Egalet Ltd. Abuse-deterrent pharmaceutical compositions for controlled release

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US268553A (en) * 1882-12-05 Die for forging fifth-wheels

Patent Citations (534)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
US2685553A (en) 1951-03-30 1954-08-03 Winthrop Stearns Inc Cement coated tablets
US3835221A (en) 1970-03-05 1974-09-10 Hoechst Ag Orally administrable drug dosage form having delayed action
GB1430684A (en) 1972-06-26 1976-03-31 Lowey H Prolonged release lozenges
US3957523A (en) 1973-04-02 1976-05-18 Shinetsu Chemical Company Coating compositions for solid medicines
US4034758A (en) 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US4503067A (en) 1978-04-13 1985-03-05 Boehringer Mannheim Gmbh Carbazolyl-(4)-oxypropanolamine compounds and therapeutic compositions
US4330338A (en) 1978-10-02 1982-05-18 Purdue Research Foundation Pharmaceutical coating composition, and preparation and dosages so coated
US4404183A (en) 1979-07-05 1983-09-13 Yamanouchi Pharmaceutical Co., Ltd. Sustained release pharmaceutical composition of solid medical material
US4449983A (en) 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4389393B1 (en) 1982-03-26 1985-10-22
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4873080A (en) 1983-06-08 1989-10-10 Dr. Karl Thomae Gmbh Oral anti-diabetic pharmaceutical compositions and the preparation thereof
GB2182559A (en) 1983-11-02 1987-05-20 Alza Corp Dispenser for thermo-responsive drugs
US4844984A (en) 1984-03-19 1989-07-04 Alza Corporation Dispensing system with means for increasing delivery of beneficial agent from the system
JPS60255719A (en) 1984-06-01 1985-12-17 Takada Seiyaku Kk Preparation of nifedipine sustained release pharmaceutical
GB2170104A (en) 1985-01-30 1986-07-30 Warner Lambert Co Coated pharmaceutical dosage forms
WO1986004817A1 (en) 1985-02-19 1986-08-28 Key Pharmaceuticals, Inc. Controlled release potassium chloride
US4686212A (en) 1985-08-13 1987-08-11 Pharmacontrol Corp. Stable sodium aspirin tablet compositions
US4898733A (en) 1985-11-04 1990-02-06 International Minerals & Chemical Corp. Layered, compression molded device for the sustained release of a beneficial agent
US4892742A (en) 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4824675A (en) 1987-07-13 1989-04-25 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
WO1989009066A1 (en) 1988-03-24 1989-10-05 Bukh Meditec A/S Controlled release composition
US5618560A (en) 1988-03-24 1997-04-08 Bm Research A/S Controlled release erodible composition
US5068112A (en) 1988-03-31 1991-11-26 Tanabe Seiyaku Co., Ltd. Controlled release pharmaceutical preparation and method for producing the same
EP0335560A2 (en) 1988-03-31 1989-10-04 Tanabe Seiyaku Co., Ltd. Controlled release pharmaceutical preparation and method for producing the same
WO1990008536A1 (en) 1989-01-30 1990-08-09 Alza Corporation Dosage form for administering calcium antagonist
US5019396A (en) 1989-05-12 1991-05-28 Alza Corporation Delivery dispenser for treating cardiac arrhythmias
US5213808A (en) * 1989-09-22 1993-05-25 Buhk Meditec A/A Controlled release article with pulsatile release
WO1991004015A1 (en) 1989-09-22 1991-04-04 Bukh Meditec A/S Controlled release composition
US5422123A (en) 1989-12-14 1995-06-06 Jagotec Ag Tablets with controlled-rate release of active substances
EP0435726A2 (en) 1989-12-29 1991-07-03 Bristol-Myers Squibb Company Capsule and caplet combination
US5102668A (en) 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
WO1992009270A1 (en) 1990-11-22 1992-06-11 British Technology Group Ltd Controlled release compositions
US5352455A (en) 1991-01-23 1994-10-04 British Technology Group Ltd. Controlled release compositions
US5549912A (en) 1991-11-27 1996-08-27 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5508042A (en) 1991-11-27 1996-04-16 Euro-Celtigue, S.A. Controlled release oxycodone compositions
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
WO1993010765A1 (en) 1991-11-27 1993-06-10 Euroceltique S.A. Controlled release oxycodone compositions
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US6572885B2 (en) 1991-12-24 2003-06-03 Euro-Celtique, S.A. Orally administrable opioid formulations having extended duration of effect
US6294195B1 (en) 1991-12-24 2001-09-25 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US7270831B2 (en) 1991-12-24 2007-09-18 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5882682A (en) 1991-12-27 1999-03-16 Merck & Co., Inc. Controlled release simvastatin delivery device
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5520931A (en) 1992-07-29 1996-05-28 Gacell Laboratories Ab Controlled release morphine preparation
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
US5869097A (en) 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
EP1371360A1 (en) 1993-03-11 2003-12-17 Taro Pharmaceutical Industries Ltd. Device for containing a pharmaceutical composition
US5614218A (en) 1993-03-30 1997-03-25 Pharmacia & Upjohn Aktiebolag Controlled release preparation
US5952005A (en) 1993-03-30 1999-09-14 Pharmacia & Upjohn Aktiebolag Controlled release preparation for administering morphine
US20130012533A1 (en) 1993-06-18 2013-01-10 Purdue Pharma L.P. Controlled release oxycodone compositions
US20070275062A1 (en) 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US6103261A (en) 1993-07-01 2000-08-15 Purdue Pharma Lp Opioid formulations having extended controlled release
US6143328A (en) 1993-07-27 2000-11-07 Euro-Celtique, S.A. Sustained release compositions and a method of preparing pharmaceutical compositions
US5879705A (en) 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US6183778B1 (en) 1993-09-21 2001-02-06 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
JPH07100191A (en) 1993-10-06 1995-04-18 Daikyo Yakuhin Kogyo Kk Sustained release suppository
US5672360A (en) 1993-11-23 1997-09-30 Purdue Pharma, L.P. Method of treating pain by administering 24 hour oral opioid formulations
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5419917A (en) 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US6787156B1 (en) 1994-02-23 2004-09-07 Bm Research A/S Controlled release composition
WO1995022962A1 (en) 1994-02-23 1995-08-31 Bm Research A/S Controlled release composition
US20050019405A1 (en) 1994-02-23 2005-01-27 Bm Research A/S Controlled release composition
US20080254124A1 (en) 1994-02-23 2008-10-16 Bm Research A/S Controlled release composition
US5656291A (en) 1994-03-16 1997-08-12 Pharmacia & Upjohn Aktiebolag Controlled release preparation
US7060293B1 (en) 1994-05-25 2006-06-13 Purdue Pharma Powder-layered oral dosage forms
US6077533A (en) 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US5411745A (en) 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
WO1996000066A1 (en) 1994-06-27 1996-01-04 Alza Corporation Composition comprising morphine, polypyrrolidone and a polyalkyleneoxide
US5667805A (en) 1994-06-27 1997-09-16 Alza Corporation Morphine therapy
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5593695A (en) 1994-06-27 1997-01-14 Alza Corporation Morphine therapy
US5914131A (en) 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
WO1996008253A1 (en) 1994-09-16 1996-03-21 Alza Corporation Hydrocodone compositions
US5866161A (en) 1994-09-16 1999-02-02 Alza Corporation Hydrocodone therapy
US6491945B1 (en) 1994-09-16 2002-12-10 Alza Corporation Hydrocodone therapy
US20030077320A1 (en) 1994-09-16 2003-04-24 Childers Jerry D. Hydrocodone therapy
US7510727B2 (en) 1994-11-04 2009-03-31 Purdue Pharma L.P. Melt-extrusion multiparticulates
US5741524A (en) 1995-01-09 1998-04-21 Edward Mendell Co., Inc. Sustained-release formulations utilizing pharmaceutical excipient having improved compressibility
US6117453A (en) 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
US6267981B1 (en) 1995-06-27 2001-07-31 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
US6399096B1 (en) 1995-09-22 2002-06-04 Euro-Celtique S.A. Pharmaceutical formulation
US8506998B2 (en) 1995-09-22 2013-08-13 Euro-Celtique S.A. Pharmaceutical formulation
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
WO1997033566A2 (en) 1996-03-12 1997-09-18 Alza Corporation Composition and dosage form comprising opioid antagonist
US5866164A (en) 1996-03-12 1999-02-02 Alza Corporation Composition and dosage form comprising opioid antagonist
EP0908181A1 (en) 1996-05-20 1999-04-14 Otsuka Pharmaceutical Co., Ltd. Remedy for rosacea
US6348216B1 (en) 1996-06-10 2002-02-19 Knoll Pharmaceutical Company Ibuprofen and narcotic analgesic compositions
US6599531B2 (en) 1996-06-12 2003-07-29 Knoll Pharmaceutical Company Method of making ibuprofen and narcotic analgesic compositions
US6488963B1 (en) 1996-06-26 2002-12-03 The University Of Texas System Hot-melt extrudable pharmaceutical formulation
US6709678B2 (en) 1996-08-15 2004-03-23 Losan Pharma Gmbh Easy to swallow oral medicament composition
US6077538A (en) 1997-02-28 2000-06-20 Alza Corporation Controlled release tablet compositions
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US6284274B1 (en) 1997-02-28 2001-09-04 Alza Corporation Analgesic tablet compositions
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6517866B1 (en) 1997-07-01 2003-02-11 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
WO1999005105A1 (en) 1997-07-22 1999-02-04 Roche Diagnostics Gmbh Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it
US6730326B2 (en) 1997-07-22 2004-05-04 Roche Diagnostics Gmbh Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3[2-(2-methoxyphenoxy)-ethylamino]-2-propanol process for its preparation and pharmaceutical compositions containing it
US6607751B1 (en) 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US7090867B2 (en) 1997-10-10 2006-08-15 Intellipharmaceutical Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US20070065510A1 (en) 1997-10-10 2007-03-22 Isa Odidi Novel controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US6066339A (en) 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US20040220250A1 (en) 1997-11-12 2004-11-04 Boehringer Mannhein Pharmaceutical Corporation Novel oral dosage form for carvedilol
US7172767B2 (en) 1997-12-22 2007-02-06 Purdue Pharma L.P. Opioid agonist / antagonist combinations
US8105631B2 (en) 1997-12-22 2012-01-31 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6475494B2 (en) 1997-12-22 2002-11-05 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US7419686B2 (en) 1997-12-22 2008-09-02 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US6277384B1 (en) 1997-12-22 2001-08-21 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US6696066B2 (en) 1997-12-22 2004-02-24 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US7749542B2 (en) 1997-12-22 2010-07-06 Purdue Pharma Lp Opioid agonist/antagonist combinations
US6482437B2 (en) 1998-02-16 2002-11-19 Laboratoires Des Produits Ethiques Ethypharm Morphine sulfate microgranules, manufacturing process and pharmaceutical preparations
US8524277B2 (en) 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
WO1999044591A1 (en) 1998-03-06 1999-09-10 Alza Corporation Extended release dosage form
US20110229533A1 (en) 1998-03-06 2011-09-22 Alza Corporation Extended release dosage form
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US7883722B2 (en) 1998-04-03 2011-02-08 Egalet Ltd. Controlled release composition
US20050089569A1 (en) 1998-04-03 2005-04-28 Bm Research A/S Controlled release composition
US6852337B2 (en) 1998-04-09 2005-02-08 Roche Diagnostics Gmbh Carvedilol-galenics
US20030133976A1 (en) 1998-04-29 2003-07-17 Pather S. Indiran Effervescent drug delivery system for oral administration
US6673816B1 (en) 1998-09-30 2004-01-06 Angelika Esswein Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders
US7906143B1 (en) 1998-10-05 2011-03-15 Intellipharmaceutics Corp Controlled release pharmaceutical delivery device and process for preparation thereof
US20080102121A1 (en) 1998-11-02 2008-05-01 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
US20080113025A1 (en) 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US6403579B1 (en) 1998-11-27 2002-06-11 Hoffman-La Roche Inc. Pharmaceutical compositions containing carvedilol and hydrochlorothiazide
US6685964B1 (en) 1999-01-18 2004-02-03 Gruenenthal Gmbh Opioid analgesics with controlled active substance release
EP1027888A2 (en) 1999-02-10 2000-08-16 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
US6395299B1 (en) 1999-02-12 2002-05-28 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US20070003620A1 (en) 1999-06-09 2007-01-04 Laboratoires Des Produits Ethiques Ethypharm Morphine sulfate microgranules, method for preparing same and compositions containing same
US7063864B1 (en) 1999-06-09 2006-06-20 Laboratoires Des Products Ethiques Ethypharm Morphine sulphate microgranules, method for preparing same and compositions containing same
US6451848B1 (en) 1999-06-16 2002-09-17 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
US6225343B1 (en) 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
US6534085B1 (en) 1999-09-23 2003-03-18 Bioresponse L.L.C. Phytochemicals for promoting weight loss
US7943174B2 (en) 1999-10-29 2011-05-17 Purdue Pharma L.P. Controlled release hydrocodone formulations
WO2001035958A1 (en) 1999-11-15 2001-05-25 Smithkline Beecham Corporation Carvedilol methanesulfonate
US6458824B1 (en) 1999-11-30 2002-10-01 Dainippon Pharmaceutical Co., Ltd. Solid preparation
WO2001051035A1 (en) 2000-01-14 2001-07-19 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
WO2001051036A1 (en) 2000-01-14 2001-07-19 Osmotica Corp. Osmotic device within an osmotic device
US6543085B2 (en) 2000-02-17 2003-04-08 Emerson Electric Co. Vacuum appliance having push and pull handles
US20010053791A1 (en) 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
US20010036959A1 (en) 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
US20040204474A1 (en) 2000-04-03 2004-10-14 Silke Decker Carvedilol-lipophilic solutions
WO2001074357A1 (en) 2000-04-03 2001-10-11 F. Hoffmann-La Roche Ag Hydrophilic molecular disperse solutions of carvedilol
US20010036960A1 (en) 2000-04-03 2001-11-01 Silke Decker Carvedilol-lipophilic solutions
US20020054911A1 (en) 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US20020107434A1 (en) 2000-07-06 2002-08-08 Algodyne, Ltd. Objective pain measurement system and method
US6757558B2 (en) 2000-07-06 2004-06-29 Algodyne, Ltd. Objective pain measurement system and method
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
WO2002065834A2 (en) 2000-10-24 2002-08-29 Smithkline Beecham Corporation Novel formulations of carvedilol
US7514100B2 (en) 2000-10-30 2009-04-07 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8361499B2 (en) 2000-10-30 2013-01-29 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8231898B2 (en) 2000-10-30 2012-07-31 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8142811B2 (en) 2000-10-30 2012-03-27 Purdue Pharma L.P. Controlled release hydrocodone formulations
US6733783B2 (en) 2000-10-30 2004-05-11 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20020119197A1 (en) 2000-12-07 2002-08-29 Dyar Stephen Craig Process and system for controlled-release drug delivery
EP1213014A2 (en) 2000-12-07 2002-06-12 Warner-Lambert Company Process and system for controlled-release drug delivery
WO2002056861A2 (en) 2001-01-19 2002-07-25 Intellipharmaceutics Corp. Syntactic deformable foam compositions and methods for making
US6800668B1 (en) 2001-01-19 2004-10-05 Intellipharmaceutics Corp. Syntactic deformable foam compositions and methods for making
US7846476B2 (en) 2001-05-02 2010-12-07 Purdue Pharma L.P. Once-a-day oxycodone formulations
WO2002087512A2 (en) 2001-05-02 2002-11-07 Euro-Celtique, S.A. Once-a-day oxycodone formulations
US20030035836A1 (en) 2001-05-17 2003-02-20 Shanghvi Dilip Shantilal Oral controlled release pharmaceutical composition for once-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases
WO2002092078A1 (en) 2001-05-17 2002-11-21 Sun Pharamceutical Industries Limited Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases
US8703189B2 (en) 2001-05-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Medicinal composition
US6960357B2 (en) 2001-05-25 2005-11-01 Mistral Pharma Inc. Chemical delivery device
US8609683B2 (en) 2001-08-06 2013-12-17 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US20120201761A1 (en) 2001-08-06 2012-08-09 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant agent
US8017148B2 (en) 2001-08-06 2011-09-13 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20100168148A1 (en) 2001-08-06 2010-07-01 Curtis Wright Pharmaceutical formulation containing gelling agent
US20130317051A1 (en) 2001-08-06 2013-11-28 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US8337888B2 (en) 2001-08-06 2012-12-25 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US20130303494A1 (en) 2001-08-06 2013-11-14 Purdue Pharmaceuticals L.P. Pharmaceutical Formulation Containing Gelling Agent
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US8389007B2 (en) 2001-08-06 2013-03-05 Purdue Pharma L.P. Pharmaceutical composition containing gelling agent
US20130217716A1 (en) 2001-08-06 2013-08-22 Purdue Pharma L.P. Pharmaceutical Formulation Containing Gelling Agent
US20130261143A1 (en) 2001-08-06 2013-10-03 Purdue Pharma L.P. Pharmaceutical Formulation Containing Gelling Agent
US20130245055A1 (en) 2001-08-06 2013-09-19 Purdue Pharmaceuticals L.P. Pharmaceutical Formulation Containing Gelling Agent
US8524275B2 (en) 2001-08-06 2013-09-03 Purdue Pharma L.P. Pharmaceutical formulations containing opioid agonist, opioid antagonist and gelling agent
US20080234352A1 (en) 2001-09-21 2008-09-25 Egalet A/S Controlled release solid dispersions
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
US8609143B2 (en) 2001-09-21 2013-12-17 Egalet Ltd. Morphine polymer release system
US20140120164A1 (en) 2001-09-21 2014-05-01 Egalet Ltd. Polymer release system
US8808745B2 (en) 2001-09-21 2014-08-19 Egalet Ltd. Morphine polymer release system
US20080254123A1 (en) 2001-09-21 2008-10-16 Egalet A/S Morphine polymer release system
US20080254122A1 (en) 2001-09-21 2008-10-16 Egalet A/S Polymer release system
US20150037417A1 (en) 2001-09-21 2015-02-05 Egalet Ltd. Morphine polymer release system
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US8617605B2 (en) 2001-09-21 2013-12-31 Egalet Ltd. Polymer release system
US20050019399A1 (en) 2001-09-21 2005-01-27 Gina Fischer Controlled release solid dispersions
US20030091635A1 (en) 2001-09-26 2003-05-15 Baichwal Anand R. Opioid formulations having reduced potential for abuse
US7968120B2 (en) 2001-09-28 2011-06-28 Mcneil-Ppc, Inc. Modified release dosage forms
US7972624B2 (en) 2001-09-28 2011-07-05 Shun-Por Li Method of manufacturing modified release dosage forms
US6837696B2 (en) 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
US20040213849A1 (en) 2001-09-28 2004-10-28 Sowden Harry S. Modified release dosage forms
US7897080B2 (en) 2001-10-12 2011-03-01 Monosol Rx, Llc Polyethylene-oxide based films and drug delivery systems made therefrom
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US20070122455A1 (en) 2001-10-12 2007-05-31 Monosolrx, Llc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
WO2003039521A1 (en) 2001-11-09 2003-05-15 Farmatron Ltd. Solid, stabilized, prompt- and/or modified-release therapeutical systems for the oral administration of liquid active principles, excipients or foodstuffs
US20040028733A1 (en) 2002-02-08 2004-02-12 Alkermes Controlled Therapeutics, Inc. Polymer-based compositions for sustained release
US20050095295A1 (en) 2002-03-12 2005-05-05 Lauretta Maggi Therapeutic system for the controlled release of active ingredients
US20030203055A1 (en) 2002-03-15 2003-10-30 Cypress Bioscience, Inc. Methods of treating visceral pain syndromes
US7790215B2 (en) 2002-03-26 2010-09-07 Purdue Pharma Lp Sustained-release gel coated compositions
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US20080044454A1 (en) 2002-04-11 2008-02-21 Monosolrx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8017150B2 (en) 2002-04-11 2011-09-13 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US20050106249A1 (en) 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
US20040010000A1 (en) 2002-04-29 2004-01-15 Ayer Atul D. Methods and dosage forms for controlled delivery of oxycodone
WO2003092648A1 (en) 2002-04-29 2003-11-13 Alza Corporation Methods and dosage forms for controlled delivery of oxycodone
US20030224051A1 (en) 2002-05-31 2003-12-04 Fink Tracy A. Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
WO2003101384A2 (en) 2002-05-31 2003-12-11 Alza Corporation Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20040091529A1 (en) 2002-06-26 2004-05-13 David Edgren Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
WO2004002447A2 (en) 2002-06-26 2004-01-08 Alza Corporation Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
US7399488B2 (en) 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20040115262A1 (en) 2002-07-29 2004-06-17 Frank Jao Formulations and dosage forms for controlled delivery of topiramate
US6632832B1 (en) 2002-09-10 2003-10-14 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
US20050020613A1 (en) 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
US20110200715A1 (en) 2002-10-11 2011-08-18 Monosol Rx, Llc Multi-layer films having uniform content
US20040151772A1 (en) 2002-11-08 2004-08-05 Egalet A/S Controlled release carvedilol compositions
US20080268057A1 (en) 2002-11-08 2008-10-30 Egalet A/S Controlled release carvedilol compositions
US8449914B2 (en) 2002-11-08 2013-05-28 Egalet Ltd. Controlled release carvedilol compositions
US20110136847A1 (en) 2002-11-25 2011-06-09 Tai Wah Chan High Concentration Formulations of Opioids and Opioid Derivatives
WO2004047839A1 (en) 2002-11-25 2004-06-10 Durect Corporation High concentration formulations of opioids and opioid derivatives
US20040102476A1 (en) 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
US20130287845A1 (en) 2002-12-13 2013-10-31 Durect Corporation Oral Drug Delivery System
US20130295168A1 (en) 2002-12-13 2013-11-07 Durect Corporation Oral Drug Delivery System
US8147870B2 (en) 2002-12-13 2012-04-03 Durect Corporation Oral drug delivery system
US8153152B2 (en) 2002-12-13 2012-04-10 Durect Corporation Oral drug delivery system
US8168217B2 (en) 2002-12-13 2012-05-01 Durect Corporation Oral drug delivery system
US8354124B2 (en) 2002-12-13 2013-01-15 Durect Corporation Oral drug delivery system
US8420120B2 (en) 2002-12-13 2013-04-16 Durect Corporation Oral drug delivery system
US20130281480A1 (en) 2002-12-13 2013-10-24 Durect Corporation Oral Drug Delivery System
WO2004054542A2 (en) 2002-12-13 2004-07-01 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
US8133507B2 (en) 2002-12-13 2012-03-13 Durect Corporation Oral drug delivery system
US20040224020A1 (en) 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
WO2004056337A2 (en) 2002-12-18 2004-07-08 Pain Therapeutics Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US20080026052A1 (en) 2002-12-18 2008-01-31 Schoenhard Grant L Oral Dosage Forms with Therapeutically Active Agents In Controlled Release Cores and Immediate Release Gelatin Capsule Coats
US20110287093A1 (en) 2002-12-18 2011-11-24 Schoenhard Grant L Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
US20150079150A1 (en) 2003-03-26 2015-03-19 Egalet Ltd. Morphine controlled release system
US9375428B2 (en) 2003-03-26 2016-06-28 Egalet Ltd. Morphine controlled release system
US20070042044A1 (en) 2003-03-26 2007-02-22 Egalet A/S Matrix compositions for controlled delivery of drug substances
US20070003617A1 (en) 2003-03-26 2007-01-04 Egalet A/S Morphine controlled release system
US20080166405A1 (en) 2003-04-08 2008-07-10 Mehta Atul M Abuse-resistant oral dosage forms and method of use thereof
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
WO2004091512A2 (en) 2003-04-08 2004-10-28 Mehta Atul M Abuse-resistant oral dosage forms and method of use thereof
US20130230596A1 (en) 2003-04-08 2013-09-05 Elite Laboratories, Inc. Abuse-Resistant Oral Dosage Forms And Method Of Use Thereof
US8425933B2 (en) 2003-04-08 2013-04-23 Elite Laboratories, Inc. Abuse-resistant oral dosage forms and method of use thereof
US8182836B2 (en) 2003-04-08 2012-05-22 Elite Laboratories, Inc. Abuse-resistant oral dosage forms and method of use thereof
US20070065364A1 (en) 2003-04-21 2007-03-22 Benjamin Oshlack Tamper resistant dosage form comprising co-extruded, sequestered adverse agent particles and process of making same
US8394407B2 (en) 2003-04-24 2013-03-12 Jagotec Ag Delayed release tablet with defined core geometry
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
US20060177507A1 (en) 2003-05-22 2006-08-10 Joaquina Faour Controlled release device containing lercanidipine
WO2006031209A1 (en) 2003-05-28 2006-03-23 Monosolrx Llc Polyethylene oxide-based films and drug delivery systems made therefrom
WO2005000310A1 (en) 2003-06-27 2005-01-06 Euro-Celtique S.A. Multiparticulates
US20060165790A1 (en) 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
WO2005007074A2 (en) 2003-07-21 2005-01-27 Bio-Dar Ltd. Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention
US8114383B2 (en) 2003-08-06 2012-02-14 Gruenenthal Gmbh Abuse-proofed dosage form
WO2005016313A1 (en) 2003-08-06 2005-02-24 Grünenthal GmbH Dosage form that is safeguarded from abuse
US8420056B2 (en) 2003-08-06 2013-04-16 Grunenthal Gmbh Abuse-proofed dosage form
US20070183980A1 (en) 2003-08-06 2007-08-09 Elisabeth Arkenau-Maric Dosage form that is safeguarded from abuse
US8192722B2 (en) 2003-08-06 2012-06-05 Grunenthal Gmbh Abuse-proof dosage form
US8309060B2 (en) 2003-08-06 2012-11-13 Grunenthal Gmbh Abuse-proofed dosage form
US20120251637A1 (en) 2003-08-06 2012-10-04 Gruenenthal Gmbh Abuse-proofed dosage form
US20130171075A1 (en) 2003-08-06 2013-07-04 Grunenthal Gmbh Abuse-proofed dosage form
US20080247959A1 (en) 2003-08-06 2008-10-09 Grunenthal Gmbh Form of administration secured against misuse
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
WO2005016314A1 (en) 2003-08-06 2005-02-24 Grünenthal GmbH Form of administration secured against misuse
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US20060193782A1 (en) 2003-08-06 2006-08-31 Johannes Bartholomaus Abuse-proofed dosage form
US20050053655A1 (en) 2003-09-05 2005-03-10 Pharmaceutical Industry Technology And Development Center Rapid disintegrating tablets (RDTs) for pharmaceutical use and method for preparing the same
WO2005027878A1 (en) 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Delayed released dosage forms
US20070259033A1 (en) 2003-09-26 2007-11-08 Evangeline Cruz Controlled release formulations exhibiting an ascending rate of release
US20050158382A1 (en) 2003-09-26 2005-07-21 Evangeline Cruz Controlled release formulations of opioid and nonopioid analgesics
US8246986B2 (en) 2003-09-26 2012-08-21 Alza Corporation Drug coating providing high drug loading
US20050089570A1 (en) 2003-09-26 2005-04-28 Evangeline Cruz Oros push-stick for controlled delivery of active agents
US20050074493A1 (en) 2003-10-03 2005-04-07 Mehta Atul M. Extended release formulations of opioids and method of use thereof
WO2005034859A2 (en) 2003-10-03 2005-04-21 Elite Laboratories Inc. Extended release formulations of opioids and method of use thereof
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US7476402B2 (en) 2003-11-26 2009-01-13 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US8101630B2 (en) 2003-11-26 2012-01-24 Acura Pharmaceuticals, Inc. Extended release opioid abuse deterrent compositions and methods of making same
US7981439B2 (en) 2003-11-26 2011-07-19 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof
US7510726B2 (en) 2003-11-26 2009-03-31 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US8409616B2 (en) 2003-11-26 2013-04-02 Acura Pharmaceuticals, Inc. Extended release opioid abuse deterrent compositions and methods of making same
US20130171257A1 (en) 2003-11-26 2013-07-04 Acura Pharmaceuticals, Inc. Extended release opioid abuse deterrent compositions and methods of making same
US8637540B2 (en) 2003-11-26 2014-01-28 Acura Pharmaceuticals Compositions for deterring abuse of opioid containing dosage forms
WO2005053587A1 (en) 2003-11-26 2005-06-16 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20090022790A1 (en) 2003-12-09 2009-01-22 Flath Robert P Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
WO2005063206A1 (en) 2003-12-23 2005-07-14 Alza Corporation Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
US20050169992A1 (en) 2003-12-23 2005-08-04 Frank Jao Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
WO2005063214A1 (en) 2003-12-24 2005-07-14 Grünenthal GmbH Method for the production of an administration form which is secured against misuse
US20090005408A1 (en) 2003-12-24 2009-01-01 Grunenthal Gmbh Process for the production of an abuse-proofed dosage form
US20130320592A1 (en) 2003-12-24 2013-12-05 Grünenthal GmbH Process for the production of an abuse-proofed dosage form
US20070003616A1 (en) 2003-12-24 2007-01-04 Elisabeth Arkenau-Maric Process for the production of an abuse-proofed dosage form
US20050163837A1 (en) 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone formulations
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US20050236741A1 (en) 2004-04-22 2005-10-27 Elisabeth Arkenau Process for the production of an abuse-proofed solid dosage form
US20080317854A1 (en) 2004-04-22 2008-12-25 Grunenthal Gmbh Process for the production of an abuse-proofed solid dosage form
WO2005102286A1 (en) 2004-04-22 2005-11-03 Grünenthal GmbH Method for the production of an abuse-proof, solid form of administration
US8383155B2 (en) 2004-05-11 2013-02-26 Egalet A/S Swellable dosage form comprising gellan gum
US8383154B2 (en) 2004-05-11 2013-02-26 Egalet A/S Swellable dosage form comprising gellan gum
US7771707B2 (en) 2004-06-12 2010-08-10 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US8449909B2 (en) 2004-06-12 2013-05-28 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US8323889B2 (en) 2004-07-01 2012-12-04 Gruenenthal Gmbh Process for the production of an abuse-proofed solid dosage form
US20060002860A1 (en) 2004-07-01 2006-01-05 Johannes Bartholomaus Abuse-proofed oral dosage form
US20060039864A1 (en) 2004-07-01 2006-02-23 Johannes Bartholomaus Abuse-proofed oral dosage form
WO2006002884A1 (en) 2004-07-01 2006-01-12 Grünenthal GmbH Oral dosage form safeguarded against abuse
WO2006002886A1 (en) 2004-07-01 2006-01-12 Grünenthal GmbH Oral dosage form safeguarded against abuse containing (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
WO2006002883A1 (en) 2004-07-01 2006-01-12 Grünenthal GmbH Method for producing a solid dosage form, which is safeguarded against abuse, while using a planetary gear extruder
US20080248113A1 (en) 2004-07-01 2008-10-09 Grunenthal Gmbh Abuse-proofed oral dosage form
US8114384B2 (en) 2004-07-01 2012-02-14 Gruenenthal Gmbh Process for the production of an abuse-proofed solid dosage form
WO2006026504A2 (en) 2004-08-27 2006-03-09 Spherics, Inc. Mucoadhesive oral formulations of high permeability, high solubility drugs
US20070281007A1 (en) 2004-08-27 2007-12-06 Jacob Jules S Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
WO2006030402A2 (en) 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Dual compartment osmotic delivery device
US20080031901A1 (en) 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US20080193540A1 (en) 2004-11-23 2008-08-14 Flamel Technologies Solid, Oral Drug Form Which Has Been Designed to Prevent Misuse
US20130005823A1 (en) 2004-11-24 2013-01-03 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
WO2006058249A2 (en) 2004-11-24 2006-06-01 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20070231268A1 (en) 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20120202839A1 (en) 2004-11-24 2012-08-09 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060110327A1 (en) 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080200493A1 (en) 2005-01-18 2008-08-21 Euro-Celtique S.A. Use of Oxycodone for Treating Visceral Pain
US20070259045A1 (en) 2005-01-28 2007-11-08 Euro-Celtique S.A. Alcohol Resistant Dosage Forms
US20060188447A1 (en) 2005-02-04 2006-08-24 Elisabeth Arkenau-Maric Process for the production of an abuse-proofed dosage form
US20100151028A1 (en) 2005-02-04 2010-06-17 Grunenthal Gmbh Crush resistant delayed-release dosage forms
US20080311187A1 (en) 2005-02-04 2008-12-18 Grunenthal Gmbh Crush resistan delayed-release dosage form
US20060193914A1 (en) 2005-02-04 2006-08-31 Judy Ashworth Crush resistant delayed-release dosage forms
US20080311197A1 (en) 2005-02-04 2008-12-18 Grunenthal Gmbh Process for the production of an abuse-proofed dosage form
US20090041838A1 (en) 2005-02-08 2009-02-12 Flamel Technologies, S.A. Anti-Misuse Microparticulate Oral Drug Form
US20100266701A1 (en) 2005-02-08 2010-10-21 Flamel Technologies, S.A. Anti-misuse microparticulate oral drug form
WO2006089843A2 (en) 2005-02-08 2006-08-31 Flamel Technologies Anti-misuse microparticulate oral drug form
WO2006088305A1 (en) 2005-02-15 2006-08-24 Chong Kun Dang Pharmaceutical Corp. Gastric-retentive controlled release mono-matrix tablet
US20060193912A1 (en) 2005-02-28 2006-08-31 Penwest Pharmaceuticals Co. Controlled release O-desmethylvenlafaxine formulations
US20080248110A1 (en) 2005-03-28 2008-10-09 Anders Pettersson Pharmaceutical Compositions Useful in the Treatment of Pain
WO2006103418A1 (en) 2005-03-28 2006-10-05 Orexo Ab New pharmaceutical compositions useful in the treatment of pain
WO2006103551A1 (en) 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Controlled release formulations of oxycodone
US20090123386A1 (en) 2005-04-06 2009-05-14 Victor Morrison Young Abuse Resistant Capsules
US20070264326A1 (en) 2005-05-24 2007-11-15 Flamel Technologies Anti-misuse oral microparticle medicinal formulation
US20090274759A1 (en) 2005-06-03 2009-11-05 Egalet A/S Solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
US7883772B2 (en) 2005-06-24 2011-02-08 North Carolina State University High strength, durable fabrics produced by fibrillating multilobal fibers
US20090099151A1 (en) 2005-06-29 2009-04-16 Panacea Biotec Ltd. Modified Release Pharmaceutical Compositions and Processes Thereof
US20070004797A1 (en) 2005-06-29 2007-01-04 Weyers Richard G Methods and dosage forms for reducing side effects of carbamate compounds
US20070020331A1 (en) 2005-07-25 2007-01-25 Gold Thomas B Coated tablet with zero-order of near zero-order release kinetics
WO2007014061A2 (en) 2005-07-25 2007-02-01 Metrics, Inc. Coated tables with zero-order or near zero-order release kinetics
US20080166407A1 (en) 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
US20090155357A1 (en) 2005-08-01 2009-06-18 Alpharma Inc. Alcohol Resistant Pharmaceutical Formulations
WO2007030754A2 (en) 2005-09-09 2007-03-15 Monosolrx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20090221621A1 (en) 2005-10-31 2009-09-03 Alza Corporation Methods of Reducing Alcohol-Induced Dose Dumping for Opioid Sustained Release Oral Dosage Forms
US20070224129A1 (en) 2005-11-10 2007-09-27 Flamel Technologies, Inc. Anti-misuse microparticulate oral pharmaceutical form
WO2007082757A2 (en) 2006-01-18 2007-07-26 Wick, Immunologische Diagnostik U. Beratung Kg Test systems for the analysis of polypeptides and cells adhering to silicones
WO2007085024A2 (en) 2006-01-21 2007-07-26 Abbott Gmbh & Co. Kg Dosage form and method for the delivery of drugs of abuse
US20090317355A1 (en) 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US20070190142A1 (en) 2006-01-21 2007-08-16 Abbott Gmbh & Co. Kg Dosage forms for the delivery of drugs of abuse and related methods
US20100172989A1 (en) 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US20070264346A1 (en) 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
US20090011016A1 (en) 2006-03-01 2009-01-08 Ethypharm Sa Crush-Resistant Oxycodone Tablets Intended For Preventing Accidental Misuse And Unlawful Diversion
US8501160B2 (en) 2006-03-01 2013-08-06 Ethypharm Sa Crush-resistant oxycodone tablets intended for preventing accidental misuse and unlawful diversion
WO2007106550A2 (en) 2006-03-15 2007-09-20 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US8491935B2 (en) 2006-03-16 2013-07-23 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
WO2007112286A2 (en) 2006-03-24 2007-10-04 Auxilium Pharmaceuticals, Inc. Stabilized compositions containing alkaline labile drugs
US8173152B2 (en) 2006-03-24 2012-05-08 Auxilium Us Holdings, Llc Stabilized compositions containing alkaline labile drugs
WO2007112285A2 (en) 2006-03-24 2007-10-04 Auxilium Pharmaceuticals, Inc. Process for the preparation of a hot-melt extruded laminate
US20120214777A1 (en) 2006-03-24 2012-08-23 Auxilium U.S. Holdings, LLC Stabilized compositions containing alkaline labile drugs
WO2007133583A2 (en) 2006-05-09 2007-11-22 Mallinckrodt Inc. Zero-order modified release solid dosage forms
US20090232887A1 (en) 2006-05-12 2009-09-17 Isa Odidi Pharmaceutical composition having reduced abuse potential
WO2007135193A2 (en) 2006-05-24 2007-11-29 Flamel Technologies Sustained-release alcohol-resistant multimicroparticulate oral pharmaceutical form comprising anti-misuse means
US20080063725A1 (en) 2006-05-24 2008-03-13 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
WO2007150075A2 (en) 2006-06-23 2007-12-27 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
WO2007150074A2 (en) 2006-06-23 2007-12-27 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US8765178B2 (en) 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
US20080075771A1 (en) 2006-07-21 2008-03-27 Vaughn Jason M Hydrophilic opioid abuse deterrent delivery system using opioid antagonists
US8465776B2 (en) 2006-08-04 2013-06-18 Ethypharm Granule and orally disintegrating tablet comprising oxycodone
WO2008023261A1 (en) 2006-08-25 2008-02-28 Purdue Pharma L.P. Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
US20130260015A1 (en) 2006-08-25 2013-10-03 Purdue Pharma L.P. Tamper resistant dosage forms
US20130259939A1 (en) 2006-08-25 2013-10-03 Purdue Pharma L.P. Tamper resistant dosage forms
US20130259940A1 (en) 2006-08-25 2013-10-03 Purdue Pharma L.P. Tamper resistant dosage forms
US20130251802A1 (en) 2006-08-25 2013-09-26 Purdue Pharma L.P. Tamper resistant dosage forms
US20130251799A1 (en) 2006-08-25 2013-09-26 Purdue Pharma L.P. Tamper resistant dosage forms
US20130251801A1 (en) 2006-08-25 2013-09-26 Purdue Pharma L.P. Tamper resistant dosage forms
US20140030327A1 (en) 2006-08-25 2014-01-30 Purdue Pharma L.P. Tamper resistant dosage forms
US20130251797A1 (en) 2006-08-25 2013-09-26 Purdue Pharma L.P. Tamper resistant dosage forms
US20090081290A1 (en) 2006-08-25 2009-03-26 Purdue Pharma L.P. Tamper resistant dosage forms
US20130251796A1 (en) 2006-08-25 2013-09-26 Purdue Pharma L.P. Tamper resistant dosage forms
US20130251798A1 (en) 2006-08-25 2013-09-26 Purdue Pharma L.P. Tamper resistant dosage forms
WO2008027442A2 (en) 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
WO2008028047A2 (en) 2006-08-30 2008-03-06 Lab International Srl Bioadhesive film drug delivery system
US20110200681A1 (en) 2006-09-15 2011-08-18 Cima Labs Inc. Abuse Resistant Drug Formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US20130122101A1 (en) 2006-09-15 2013-05-16 Cima Labs Inc. Abuse resistant drug formulation
WO2008033523A1 (en) 2006-09-15 2008-03-20 Cima Labs Inc. Abuse resistant drug formulation
US20130122087A1 (en) 2006-09-15 2013-05-16 Cima Labs Inc. Abuse resistant drug formulation
US20080311205A1 (en) 2006-09-15 2008-12-18 Cima Labs, Inc. Abuse resistant drug formulation
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
WO2008068471A1 (en) 2006-12-04 2008-06-12 Orexo Ab New non-abusable pharmaceutical composition comprising opioids
US20130195982A1 (en) 2006-12-04 2013-08-01 Orexo Ab Non-abusable pharmaceutical composition comprising opioids
US20130195981A1 (en) 2006-12-04 2013-08-01 Orexo Ab Non-abusable pharmaceutical composition comprising opioids
US8470361B2 (en) 2006-12-04 2013-06-25 Orexo Ab Non-abusable pharmaceutical composition comprising opioids
US20100291205A1 (en) 2007-01-16 2010-11-18 Egalet A/S Pharmaceutical compositions and methods for mitigating risk of alcohol induced dose dumping or drug abuse
WO2008100375A2 (en) 2007-02-13 2008-08-21 Monosol Rx Llc Polymer-based films and drug delivery systems made therefrom
WO2008107149A2 (en) 2007-03-07 2008-09-12 Grünenthal GmbH Pharmaceutical form with impeded abuse
US20090004267A1 (en) 2007-03-07 2009-01-01 Gruenenthal Gmbh Dosage Form with Impeded Abuse
US8367693B1 (en) 2007-05-22 2013-02-05 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting anti-abuse anti-dose dumping properties
US8338444B1 (en) 2007-05-22 2012-12-25 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties
US8476291B1 (en) 2007-05-22 2013-07-02 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting anti-abuse and anti-dumping properties
US8329720B1 (en) 2007-05-22 2012-12-11 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting abuse deterrent and anti-dose dumping properties
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
US20110229526A1 (en) 2007-07-20 2011-09-22 Joerg Rosenberg Formulations of nonopioid and confined opioid analgesics
US20130344143A1 (en) 2007-07-20 2013-12-26 AbbVie Deutschland GmbH & Co. KG Formulations of nonopioid and confined opioid analgesics
US20090022798A1 (en) 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US8486423B2 (en) 2007-08-21 2013-07-16 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
WO2009035474A1 (en) 2007-09-13 2009-03-19 Cima Labs Inc. Abuse resistant drug formulation
WO2009076236A2 (en) 2007-12-06 2009-06-18 Pain Therapeutics, Inc. Micronized opioid compositions, formulations and dosage forms and methods of making same
US8415401B2 (en) 2007-12-06 2013-04-09 Durect Corporation Oral pharmaceutical dosage forms
US20090298862A1 (en) 2007-12-06 2009-12-03 Su Il Yum Methods useful for the treatment of pain, arthritic conditions or inflammation associated with a chronic condition
WO2009088414A2 (en) 2007-12-06 2009-07-16 Durect Corporation Oral pharmaceutical dosage forms
US20130317049A1 (en) 2007-12-06 2013-11-28 Durect Corporation Methods Useful for the Treatment of Pain, Arthritic Conditions or Inflammation Associated with a Chronic Condition
US20130337060A1 (en) 2007-12-06 2013-12-19 Durect Corporation Oral Pharmaceutical Dosage Forms
US20130337059A1 (en) 2007-12-06 2013-12-19 Durect Corporation Oral Pharmaceutical Dosage Forms
WO2009075782A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US20090169631A1 (en) 2007-12-06 2009-07-02 Pain Therapeutics, Inc. Micronized opioid compositions, formulations and dosage forms and methods of making same
US8486448B2 (en) 2007-12-17 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
US20130344142A1 (en) 2007-12-17 2013-12-26 Paladin Labs Inc. Misuse preventative, controlled release formulation
WO2009076764A1 (en) 2007-12-17 2009-06-25 Labopharm Inc. Misuse preventative, controlled release formulation
US8383152B2 (en) 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
WO2009092601A1 (en) 2008-01-25 2009-07-30 Grünenthal GmbH Pharmaceutical dosage form
US20130251759A1 (en) 2008-01-25 2013-09-26 Gruenenthal Gmbh Pharmaceutical dosage form
US20090202634A1 (en) 2008-01-25 2009-08-13 Grunenthal Gmbh Pharmaceutical dosage form
WO2009104838A1 (en) 2008-02-18 2009-08-27 Hana Pharm. Co. Ltd. Sustained release solid formulations and methods of manufacturing the same
US20110008424A1 (en) 2008-02-18 2011-01-13 Hana Pharm. Co., Ltd. Sustained Release Solid Formulations and Methods of Manufacturing the Same
US8394408B2 (en) 2008-03-11 2013-03-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US20120321713A1 (en) 2008-03-11 2012-12-20 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
WO2009114648A1 (en) 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8377453B2 (en) 2008-03-11 2013-02-19 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US20110142905A1 (en) 2008-08-14 2011-06-16 Bioneer A/S Coated tablets with remaining degradation surface over the time
WO2010017821A1 (en) 2008-08-14 2010-02-18 Daniel Bar-Shalom Coated tablets with a remaining degradation surface over the time8
US20110165248A1 (en) 2008-09-18 2011-07-07 Meridith Lee Machonis Pharmaceutical dosage forms comprising poly(e-caprolactone)
WO2010032128A1 (en) 2008-09-18 2010-03-25 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(e-caprolactone)
US20100099696A1 (en) 2008-10-16 2010-04-22 Anthony Edward Soscia Tamper resistant oral dosage forms containing an embolizing agent
WO2010066034A1 (en) 2008-12-12 2010-06-17 Paladin Labs Inc. Methadone formulation
US8460640B2 (en) 2008-12-12 2013-06-11 Paladin Labs, Inc. Narcotic drug formulations with decreased abuse potential
WO2010069050A1 (en) 2008-12-16 2010-06-24 Labopharm Inc. Misuse preventative, controlled release formulation
US20140004191A1 (en) 2008-12-16 2014-01-02 Paladin Labs Inc. Misuse preventative, controlled release formulation
US8486449B2 (en) 2008-12-16 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
US20100203129A1 (en) 2009-01-26 2010-08-12 Egalet A/S Controlled release formulations with continuous efficacy
WO2010083894A1 (en) 2009-01-26 2010-07-29 Abbott Gmbh & Co., Kg Abuse resistant melt extruded formulation having reduced alcohol interaction
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9168228B2 (en) 2009-02-06 2015-10-27 Egalet Ltd. Pharmaceutical compositions resistant to abuse
US20100204259A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
US20150313997A1 (en) 2009-02-06 2015-11-05 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9358295B2 (en) 2009-02-06 2016-06-07 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US8603526B2 (en) 2009-02-06 2013-12-10 Egalet Ltd. Pharmaceutical compositions resistant to abuse
US20120135075A1 (en) 2009-06-05 2012-05-31 Euro-Celtique S.A. Dosage form
WO2010140007A2 (en) 2009-06-05 2010-12-09 Euro-Celtique S.A. Dosage form
US20110159100A1 (en) 2009-06-24 2011-06-30 Egalet A/S Formulations and methods for the controlled release of active drug substances
US20130287849A1 (en) 2009-06-24 2013-10-31 Egalet A/S Formulations and methods for the controlled release of active drug substances
US9023394B2 (en) 2009-06-24 2015-05-05 Egalet Ltd. Formulations and methods for the controlled release of active drug substances
WO2010151741A1 (en) 2009-06-25 2010-12-29 Elite Laboratories, Inc. Abuse resistant oral dosage forms
US20130084333A1 (en) 2009-06-25 2013-04-04 Elite Laboratories, Inc Abuse resistant oral dosage forms
US20110020451A1 (en) 2009-07-22 2011-01-27 Grunenthal Gmbh Tamper-resistant dosage form for oxidation-sensitive opioids
US20120136021A1 (en) 2009-07-22 2012-05-31 Grunenthal Gmbh Oxidation-stabilized tamper-resistant dosage form
WO2011009604A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US20110038930A1 (en) 2009-07-22 2011-02-17 Grunenthal Gmbh Hot-melt extruded pharmaceutical dosage form
WO2011009603A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Tamper-resistant dosage form for oxidation-sensitive oploids
WO2011009602A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Hot-melt extruded controlled release dosage form
WO2011041414A1 (en) 2009-09-30 2011-04-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US20110077238A1 (en) 2009-09-30 2011-03-31 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
WO2011068723A1 (en) 2009-12-04 2011-06-09 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US20120225122A1 (en) 2009-12-17 2012-09-06 Cima Labs Inc. Abuse-Resistant Formulations
WO2011079248A1 (en) 2009-12-24 2011-06-30 Acura Pharmaceuticals, Inc. Pharmaceutical compositions for deterring misuse, abuse, and diversion
US20120009129A1 (en) 2009-12-24 2012-01-12 Acura Pharmaceuticals, Inc. Pharmaceutical compositions for deterring misuse, abuse, and diversion
US20110195989A1 (en) 2010-02-09 2011-08-11 Rudnic Edward M Controlled Release Formulations of Opioids
US20130022646A1 (en) 2010-02-09 2013-01-24 Rudnic Edward M Controlled Release Formulations of Opioids
US20130209560A1 (en) 2010-02-24 2013-08-15 Cima Labs Inc. Abuse-resistant formulations
WO2011106416A2 (en) 2010-02-24 2011-09-01 Cima Labs Inc. Abuse-resistant formulations
US20130011479A1 (en) 2010-03-24 2013-01-10 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A Double-layer pharmaceutical formulations containing opioid agonists and antagonists
US20130030561A1 (en) 2010-04-09 2013-01-31 Toshiba Mitsubishi-Electric Industrial Systems Corporation Rolled material cooling control apparatus, rolled material cooling control method, and rolled material cooling control program
US8529848B2 (en) 2010-06-28 2013-09-10 Ronald Danehy Systems and methods for transfer of liquid samples
US20120065220A1 (en) 2010-09-02 2012-03-15 Grunenthal Gmbh Tamper Resistant Dosage Form Comprising An Anionic Polymer
US20120059065A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper Resistant Dosage Form Comprising An Anionic Polymer
WO2012028317A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
US20130209557A1 (en) 2010-09-02 2013-08-15 Grunenthal Gmbh Tamper resistant dosage form comprising inorganic salt
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
WO2012028319A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
WO2012040651A2 (en) 2010-09-24 2012-03-29 QRxPharma Ltd. Controlled release formulations of opioids
US20120202838A1 (en) 2010-11-04 2012-08-09 Abbott Laboratories Drug formulations
WO2012061779A1 (en) 2010-11-04 2012-05-10 Abbott Gmbh & Co. Kg Drug formulations
WO2012076907A2 (en) 2010-12-09 2012-06-14 Euro-Celtique S.A. Dosage form
WO2012080833A2 (en) 2010-12-13 2012-06-21 Purdue Pharma L.P. Controlled release dosage forms
WO2012085656A2 (en) 2010-12-22 2012-06-28 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US20120164220A1 (en) 2010-12-22 2012-06-28 Purdue Pharma L.P. Encased Tamper Resistant Controlled Release Dosage Forms
WO2012085657A2 (en) 2010-12-23 2012-06-28 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
US20120321716A1 (en) 2011-02-17 2012-12-20 Michael Vachon Technology for preventing abuse of solid dosage forms
US20120321674A1 (en) 2011-02-17 2012-12-20 Michael Vachon Technology for Preventing Abuse of Solid Dosage Forms
WO2012112952A1 (en) 2011-02-17 2012-08-23 QRxPharma Ltd. Technology for preventing abuse of solid dosage forms
WO2012131463A2 (en) 2011-03-25 2012-10-04 Purdue Pharma L.P. Controlled release pharmaceutical dosage forms
US20130028177A1 (en) 2011-07-28 2013-01-31 Renesas Mobile Corporation Network Controlled Filtering Over Wireless Device Communications
US20130028970A1 (en) 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
US20130028972A1 (en) 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
WO2013017242A1 (en) 2011-07-29 2013-02-07 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
WO2013017234A1 (en) 2011-07-29 2013-02-07 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
WO2013038268A1 (en) 2011-09-16 2013-03-21 Purdue Pharma L.P. Tamper resistant immediate release formulations
WO2013038267A1 (en) 2011-09-16 2013-03-21 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US20140294947A1 (en) 2011-09-16 2014-10-02 Purdue Pharma L.P. Tamper resistant immediate release formulations
US20130090349A1 (en) 2011-10-06 2013-04-11 Grünenthal GmbH Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist
WO2013050539A2 (en) 2011-10-06 2013-04-11 Grünenthal GmbH Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist
WO2013057570A2 (en) 2011-10-18 2013-04-25 Purdue Pharma L.P. Acrylic polymer formulations
US20130129826A1 (en) 2011-11-17 2013-05-23 Gruenenthal Gmbh Tamper-resistant oral pharmaceutical dosage form comprising opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer
WO2013072395A1 (en) 2011-11-17 2013-05-23 Grünenthal GmbH Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer
WO2013077851A1 (en) 2011-11-22 2013-05-30 Watson Pharmaceuticals, Inc. Immediate release abuse deterrent tablet
WO2013084059A1 (en) 2011-12-09 2013-06-13 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly (epsilon- caprolactone) and polyethylene oxide
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US20130251806A1 (en) 2012-03-23 2013-09-26 Pharma73, S.A. Natural biocomposite powder prepared from pichia pastoris biomass, method of preparation and its use as excipient
US20130273162A1 (en) 2012-04-12 2013-10-17 Michael Hsin Chwen LI Oral Film Containing Opiate Enteric-Release Beads
US20130280176A1 (en) 2012-04-18 2013-10-24 Mallinckrodt Llc Immediate Release Pharmaceutical Compositions with Abuse Deterrent Properties
US20130280338A1 (en) 2012-04-18 2013-10-24 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US9044402B2 (en) 2012-07-06 2015-06-02 Egalet Ltd. Abuse-deterrent pharmaceutical compositions for controlled release
US20140155388A1 (en) 2012-11-30 2014-06-05 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US20140221416A1 (en) 2013-02-05 2014-08-07 Purdue Pharma L.P. Tamper Resistant Pharmaceutical Formulations
US20140271848A1 (en) 2013-03-15 2014-09-18 Purdue Pharma L.P. Abuse-deterrent dosage forms
US20140271896A1 (en) 2013-03-15 2014-09-18 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US20140275143A1 (en) 2013-03-15 2014-09-18 Mallinckrodt Llc Compositions Comprising An Opioid And An Additional Active Pharmaceutical Ingredient For Rapid Onset And Extended Duration Of Analgesia That May Be Administered Without Regard To Food

Non-Patent Citations (82)

* Cited by examiner, † Cited by third party
Title
"Ascorbic acid," Wikipedia, http://en.wikipedia.org/wiki/Ascorbic-acid, accessed Jan. 23, 2014.
"Ascorbic acid," Wikipedia, http://en.wikipedia.org/wiki/Ascorbic—acid, accessed Jan. 23, 2014.
Brannan et al., "Affine Geometry," Geometry, 2nd edition, p. 78, 2012.
Bravo et al., "In-vitro studies of diclofenac sodium controlled-release from biopolymeric hydrophilic matrices," J. Pharmaceutical Science, vol. 5, No. 3, pp. 213-219 (2002).
Camu et al., "Pharmacology of systemic analgesics," Best Practice & Research Clinical Anaesthesiology, vol. 16, No. 4, pp. 475-488, 2002.
Dahlstrom et al., "Patient-controlled Analgesic Therapy, Part IV: Pharmacokinectics and Analgesic Plasma Concentration of Morphine," Clinical Pharmacokinectics, vol. 7, pp. 266-279, 1982.
Dontula et al., "Model Elastic Liquids with Water-Soluble Polymers," AlChE Journal, vol. 44, No. 6, pp. 1247-1255, Jun. 1998.
Dubbs et al., "Solubility of Vitamin E (α-Tocopherol) and Vitamin K3 (Menadione) in Ethanol-Water Mixture," J. Chem. Eng. Data, vol. 43, pp. 590-591, 1998.
European Search Report issued on Apr. 11, 2011 in application No. EP 10 18 1692 (corresponding to US 2007/003617).
Fischer et al., "Nonmedical Use of Prescription Opioids: Furthering a Meaningful Research Agenda," The Journal of Pain, vol. 9, No. 6, pp. 490-493, Jun. 2008.
Giunchedi et al., "Hydrophilic matrices for the extended release of a model drug exhibiting pH-dependent solubility," International Journal of Pharmaceutics, vol. 85, pp. 141-147 (1992).
Graves et al., "Relationship between plasma morphine concentrations and pharmacologic effects in postoperative patients using patient-controlled analgesia," Clinical Pharmacy, vol. 4, pp. 41-47, Jan.-Feb. 1985.
Haahr et al., "Drug abuse resistant, controlled release, using Egalet® dosage units," Proceedings of the 34th Annual Meeting Exposition of the Controlled Release Society, Poster, Jul. 7-11, 2007.
Hoshi et al., Cellulose and its Derivatives, pp. 24-25 (1992).
International Search Report issued on Apr. 21, 2010 in application No. PCT/EP2010/00728 (corresponding to US 2010/0204259).
International Search Report issued on Jan. 28, 2009 in application No. PCT/EP2008/056910 (corresponding to US 2010/239667).
International Search Report issued on Jul. 8, 2008 in application No. PCT/DK2008/000016 (corresponding to U.S. Pat. No. 8,603,526).
International Search Report issued on Jun. 2, 2010 in application No. PCT/DK2010/050016 (corresponding to US 2010/203129).
International Search Report issued on May 18, 2010 in application No. PCT/DK2010/00019 (corresponding to U.S. Pat. No. 8,603,526).
International Search Report issued on Oct. 20, 2009 in application No. PCT/DK2009/000192.
Kais Group, "Hydrogentated Palm Kernel Oil," http://kaisgroup.us/our-products/palm-oil-products/hydrogentated-palm-kernel-oil. Published 2011.
Katikaneni et al., "Ethylcellulose matrix controlled release tablets of a water-soluble drug," International Journal of Pharmaceutics, vol. 123, pp. 119-125, 1995.
Krogel et al (Pharmaceutical Research, 1998, vol. 15, pp. 474-481). *
Krogel et al., "Pulsatile Drug Release from an Insoluble Capsule Body Controlled by an Erodible Plug," Pharmaceutical Research, vol. 15, No. 3, pp. 474-481, 1998.
Marvola et al., "Enteric polymers as binders and coating materials in multiple-unit site-specific drug delivery systems," European Journal of Pharmaceutical Sciences, vol. 7, pp. 259-267, 1999.
Merck Index (9th ed.) Entry No. 9681 for Vitamin E, p. 1290, 1976.
Meyer et al., "Awareness Topic: Mitigating the Risks of Ethanol Induced Dose Dumping from Oral Sustained/Controlled Release Dosage Forms," FDA's ACPS meeting, Oct. 2005.
MiraLAX®, "MiraLAX® Drug Description," Oct. 19, 2011.
Miyazaki et al., "In situ-gelling gellan formulations as vehicles for oral drug delivery," J. Control Release, vol. 60, pp. 287-295 (1999).
National Institute on Drug Abuse, "Monitoring the Future: National Results on Adolescent Drug Use," http://www.samhsa.gov, May 2009.
National Institute on Drug Abuse, "Prescription Medications," http://www.nida.nih.gov/drugpages/prescription.html, accessed on Jul. 15, 2008.
Notice of Allowance issued on Apr. 6, 2015 in U.S. Appl. No. 14/249,965 (U.S. Pat. No. 9,044,402).
Notice of Allowance issued on Feb. 12, 2016 in U.S. Appl. No. 14/496,561 (U.S. Pat. No. 9,375,428).
Notice of Allowance issued on Feb. 9, 2016 in U.S. Appl. No. 14/656,016 (U.S. Pat. No. 9,358,295).
Notice of Allowance issued on Jan. 20, 2015 in U.S. Appl. No. 13/928,135 (U.S. Pat. No. 9,023,394).
Notice of Allowance issued on Jan. 23, 2015 in U.S. Appl. No. 12/701,248 (U.S. Pat. No. 9,005,660).
Notice of Allowance issued on Jul. 15, 2016 in U.S. Appl. No. 14/859,800 (US 2016/0074332).
Notice of Allowance issued on Jul. 24, 2013 in U.S. Appl. No. 12/701,429 (U.S. Pat. No. 8,603,526).
Notice of Allowance issued on Jun. 11, 2013 in U.S. Appl. No. 12/823,067 (U.S. Pat. No. 8,563,038).
Notice of Allowance issued on Jun. 23, 2015 in U.S. Appl. No. 14/062,719 (U.S. Pat. No. 9,168,228).
Notice of Allowance issued on May 2, 2014 in U.S. Appl. No. 12/602,953 (U.S. Pat. No. 8,821,928).
Office Action issued on Apr. 24, 2015 in U.S. Appl. No. 11/915,655 (US 2009/0274759).
Office Action issued on Dec. 19, 2013 in U.S. Appl. No. 12/602,953 (U.S. Pat. No. 8,821,928).
Office Action issued on Dec. 4, 2015 in U.S. Appl. No. 13/933,053 (US 2014/0010873).
Office Action issued on Dec. 7, 2015 in U.S. Appl. No. 11/915,655 (US 2009/0274759).
Office Action issued on Feb. 22, 2016 in U.S. Appl. No. 13/974,689 (US 2014-0120164).
Office Action issued on Feb. 25, 2015 in U.S. Appl. No. 13/974,689 (US 2014/0120164).
Office Action issued on Jan. 12, 2016 in U.S. Appl. No. 14/560,579 (US 2015/0150812).
Office Action issued on Jan. 20, 2015 in U.S. Appl. No. 13/933,053 (US 2014/0010873).
Office Action issued on Jan. 8, 2016 in U.S. Appl. No. 12/523,045 (US 2010/0291205).
Office Action issued on Jul. 11, 2016 in U.S. Appl. No. 12/523,045 (US 2014/0120164).
Office Action issued on Jul. 22, 2016 in U.S. Appl. No. 14/331,833 (US 2015/0037417).
Office Action issued on Jul. 25, 2016 in U.S. Appl. No. 13/974,689 (US 2014/0120164).
Office Action issued on Jul. 29, 2015 in U.S. Appl. No. 14/496,561 (US 2015/0079150).
Office Action issued on Jun. 22, 2016 in U.S. Appl. No. 14/560,579 (US 2015/0150812).
Office Action issued on Jun. 23, 2016 in U.S. Appl. No. 13/933,053 (US 2014/0010873).
Office Action issued on Jun. 4, 2015 in U.S. Appl. No. 12/523,045 (US 2010/0291205).
Office Action issued on Mar. 6, 2015 in U.S. Appl. No. 14/331,833 (US 2015/0037417).
Office Action issued on Mar. 7, 2013 in U.S. Appl. No. 12/602,953 (U.S. Pat. No. 8,821,928).
Office Action issued on Oct. 17, 2012 in U.S. Appl. No. 12/701,429 (U.S. Pat. No. 8,603,526).
Office Action issued on Oct. 20, 2015 in U.S. Appl. No. 14/656,016 (US 2015/0313997).
Office Action issued on Oct. 29, 2015 in U.S. Appl. No. 14/331,833 (US 2015/0037417).
Office Action issued on Sep. 9, 2013 in U.S. Appl. No. 12/823,067 (U.S. Pat. No. 8,563,038).
Packer et al., "Molecular Aspects of a-Tocotrienol Antioxidant Action and Cell Signaling," Journal of Nutrition, vol. 131, No. 2, pp. 369S-373S, 2001.
Polysciences, Inc., "Monomers & Polymers," http://www.polysciences.com/Catalog/Department/Product/98/categoryid-298/productid--422/, published Apr. 3, 2004.
Qiu et al., "Design of a core-shelled polymer cylinder for potential programmable drug delivery," International Journal of Pharmaceutics, vol. 219, pp. 151-160, 2001.
Raehal et al., "Mu Opioid 'Receptor' Regulation and Opiate Responsiveness," The AAPS Journal, vol. 7, No. 3, pp. E587-E591, 2005.
Raehal et al., "Mu Opioid ‘Receptor’ Regulation and Opiate Responsiveness," The AAPS Journal, vol. 7, No. 3, pp. E587-E591, 2005.
Roberts et al., "Enterohepatic Circulation: Physiological, Pharmacokinetic and Clinical Implications," Clin. Pharmacokinet., vol. 41, Issue 10, pp. 751-790, 2002.
Rowe et al., "Glycerin," Handbook of Pharmaceutical Excipients, Pharmaceutical Presse, 4th edition, pp. 257-258 (2003).
Soy Info Center, "A Special Report on the History of Soy Oil, Soybean Meal & Modern Soy Protein Products," http://soyinfocenter.com/HSS/hydrogenation2.php, published 2007.
The Condensed Chemical Dictionary, "mixture," 9th edition, p. 584 (1977).
U.S. Appl. No. 13/803,132, filed Aug. 25, 2006, Purdue Pharma C.
U.S. Appl. No. 13/900,933, filed Aug. 25, 2006, Purdue Pharma C.
U.S. Appl. No. 13/949,966, filed Dec. 18, 2002, Pain Therapeutics A.
Varshosaz et al., "Use of enteric polymers for production of microspheres by extrusion-spheronization," Pharmaceutica Acta Helvetiae, vol. 72, pp. 145-152. 1997.
Wanka et al., "Phase Diagrams and Aggregation Behavior of Poly(oxyethylene)-Poly(oxypropylene)-Poly(oxyethylene) Triblock Copolymers in Aqueous Solutions," Macromolecules, vol. 27, pp. 4145-4159, 1994.
Wikipedia, "Phosphoric Acid," http://en.wikipedia.org/wiki/Phosphoric-acid downloaded May 10, 2012.
Wikipedia, "Phosphoric Acid," http://en.wikipedia.org/wiki/Phosphoric—acid downloaded May 10, 2012.
www.wikipedia.org, web page on phosphoric acid, http://en.wikipedia.org/wiki/Phosphoric-acid, May 8, 2007.
www.wikipedia.org, web page on phosphoric acid, http://en.wikipedia.org/wiki/Phosphoric—acid, May 8, 2007.
Yamakita et al., "In Vitro/in Vivo Evaluation of Two Series of TA5707F Controlled Release Matrix Tablets Prepared with Hydroxypropyl Methyl Cellulose Derivatives with Entero-Soluble or Gel-Formation Properties," Biol. Pharm. Bull, vol. 18, No. 10, pp. 1409-1416 (1995).

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019008605A1 (en) * 2017-07-07 2019-01-10 Zim Laboratories Limited Novel pharmaceutical co-crystal of dabigatran etexilate
US11458104B1 (en) 2018-06-21 2022-10-04 Mission Pharmacal Company Enteric coated tiopronin tablet
WO2020021422A1 (en) 2018-07-21 2020-01-30 Berlia Sushma Paul Controlled release formulation comprising flavoxate
US20210299053A1 (en) * 2018-07-21 2021-09-30 Sushma Paul BERLIA Controlled release formulation comprising flavoxate
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
US11813283B2 (en) 2018-08-13 2023-11-14 Viscera Labs, Inc. Therapeutic composition and methods
WO2021212097A1 (en) * 2020-04-17 2021-10-21 Brendan Patrick Purcell Controlled release hyaluronic acid compositions
WO2023089553A1 (en) 2021-11-19 2023-05-25 Berlia Sushma Paul Controlled release formulations of flavoxate and process for preparation thereof

Also Published As

Publication number Publication date
ZA200908019B (en) 2014-04-30
WO2008148798A2 (en) 2008-12-11
NZ580972A (en) 2012-02-24
US8821928B2 (en) 2014-09-02
CA2687192C (en) 2015-11-24
WO2008148798A3 (en) 2009-03-12
IL202103A0 (en) 2010-06-16
CA2687192A1 (en) 2008-12-11
AU2008258596B2 (en) 2013-02-14
US20150024048A1 (en) 2015-01-22
US20100239667A1 (en) 2010-09-23
AU2008258596A1 (en) 2008-12-11
EP2155167A2 (en) 2010-02-24

Similar Documents

Publication Publication Date Title
US9642809B2 (en) Controlled release pharmaceutical compositions for prolonged effect
US10105321B2 (en) Pharmaceutical compositions resistant to abuse
TWI454288B (en) Pharmaceutical dosage form
ES2651016T3 (en) Breaking-resistant delayed-release dosage forms
EA021784B1 (en) Extended-release pharmaceutical formulations
US20040185170A1 (en) Method for coating drug-containing particles and formulations and dosage units formed therefrom
CA2876294C (en) Pharmaceutical form for extended release of active substances
WO2012006963A1 (en) Polymer reinforcing agent in controlled release preparation
JP2010260803A (en) Water-soluble saccharide coated with xanthan gum and compression-molded preparation

Legal Events

Date Code Title Description
AS Assignment

Owner name: U.S. BANK NATIONAL ASSOCIATION, MASSACHUSETTS

Free format text: SECURITY INTEREST;ASSIGNORS:EGALET CORPORATION;EGALET US, INC.;EGALET LTD;REEL/FRAME:039600/0791

Effective date: 20160831

AS Assignment

Owner name: EGALET LTD., UNITED KINGDOM

Free format text: CHANGE OF ADDRESS;ASSIGNOR:EGALET LTD.;REEL/FRAME:040293/0249

Effective date: 20160713

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: ZYLA LIFE SCIENCES US INC., F/K/A EGALET US, INC., PENNSYLVANIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:U.S. BANK NATIONAL ASSOCIATION;REEL/FRAME:053411/0496

Effective date: 20200805

Owner name: EGALET LIMITED, UNITED KINGDOM

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:U.S. BANK NATIONAL ASSOCIATION;REEL/FRAME:053411/0496

Effective date: 20200805

Owner name: ZYLA LIFE SCIENCES, F/K/A EGALET CORPORATION, PENNSYLVANIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:U.S. BANK NATIONAL ASSOCIATION;REEL/FRAME:053411/0496

Effective date: 20200805

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20210509